[{"id": 100023082, "question_number": "221", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] &bull; Direct thrombin inhibitors (e.g., dabigatran) bind and neutralize both free and clot-bound thrombin, preventing fibrin formation.  <br>&bull; Hemorrhagic conversion after reperfusion (thrombectomy) arises from blood&ndash;brain barrier disruption and proteolytic injury in ischemic penumbra.  <br>&bull; Specific reversal of dabigatran reduces active drug levels rapidly, minimizing ongoing bleeding risk without promoting thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with ~350-fold higher affinity than thrombin, neutralizing its anticoagulant effect within minutes <span class=\"citation\">(Pollack et al., N Engl J <span class=\"evidence\">Med 2015</span>;373:511&ndash;520)</span>. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level A) recommend idarucizumab for urgent reversal of dabigatran prior to invasive procedures or in life-threatening bleeding. Compared to non-specific agents (e.g., PCC), idarucizumab has been shown to normalize diluted thrombin time and ecarin clotting time in >90% of patients, with a favorable safety profile and minimal prothrombotic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Vitamin K  <br><span class=\"list-item\">\u2022</span> Doesn&rsquo;t affect direct thrombin inhibitors; acts on VKORC1 to regenerate active vitamin K&ndash;dependent clotting factors (II, VII, IX, X).  <br><span class=\"list-item\">\u2022</span> Common misconception: &ldquo;All anticoagulants need vitamin K&rdquo; &ndash; only warfarin is reversed this way.  <br><br>C. Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Supplies clotting factors but cannot remove or neutralize dabigatran already circulating; delays reversal and adds volume.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;FFP is the universal reversal strategy for bleeding&rdquo; &ndash; ineffective for DOACs without specific target.  <br><br>D. Protamine sulfate  <br><span class=\"list-item\">\u2022</span> Binds and inactivates heparin (unfractionated and partially low-molecular-weight) by forming stable complexes.  <br><span class=\"list-item\">\u2022</span> Key distinction: protamine has no binding affinity for direct thrombin inhibitors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Idarucizumab</th><th>Vitamin K</th><th>FFP</th><th>Protamine Sulfate</th></tr></thead><tbody><tr><td>Mechanism</td><td>Monoclonal Ab fragment binds dabigatran</td><td>Cofactor for &gamma;-glutamyl carboxylase</td><td>Source of clotting factors</td><td>Polycation binds heparin</td></tr><tr><td>Target</td><td>Dabigatran</td><td>VKORC1 (warfarin)</td><td>Non-specific factors</td><td>Heparin</td></tr><tr><td>Onset of Action</td><td>Minutes</td><td>6&ndash;24 hours</td><td>30&ndash;60 minutes</td><td>Immediate</td></tr><tr><td>Indication for Reversal</td><td>Dabigatran-associated bleeding</td><td>Warfarin-associated bleeding</td><td>Massive hemorrhage (no DOAC effect)</td><td>Heparin overdose</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Idarucizumab 5 g IV (two 2.5 g boluses &le;15 min apart) fully reverses dabigatran in ~4 hours without need for dose adjustment.  <br><span class=\"list-item\">\u2022</span> In settings without idarucizumab, consider hemodialysis (dabigatran is dialyzable) or non-specific PCC (off-label, variable efficacy).  <br><span class=\"list-item\">\u2022</span> Always check a diluted thrombin time or ecarin clotting time to confirm dabigatran presence before reversal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering vitamin K or FFP for DOAC bleeding &ndash; these do not neutralize the drug and waste valuable time.  <br>2. Confusing protamine sulfate&rsquo;s specificity for heparins with reversal of all parenteral anticoagulants.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Early Management of Acute Ischemic Stroke (Guideline): Class I, Level A recommendation for idarucizumab in dabigatran-related life-threatening hemorrhage or need for urgent surgery.  <br>&bull; ISTH 2016 Guidance on DOAC Reversal: Endorses idarucizumab for dabigatran (Grade 1A evidence); suggests PCC only if specific agents unavailable (Grade 2C).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>MCA territory hemorrhage often produces contralateral face/arm weakness, hemisensory loss and, if dominant hemisphere involved, global aphasia. Rapid reversal limits expansion of bleed into eloquent cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic endothelial injury \u2192 reperfusion \u2192 MMP-mediated BBB breakdown \u2192 red blood cell extravasation. Ongoing anticoagulation exacerbates hematoma expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Idarucizumab is administered as two 2.5 g IV infusions no more than 15 minutes apart. Monitor coagulation assays post-dose; re-dabigatran use should be delayed until bleeding risk subsides (~24&ndash;48 hours).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of direct oral anticoagulants, especially dabigatran with idarucizumab, is a high-yield topic frequently tested in acute stroke management scenarios.</div></div></div></div></div>"}, {"id": 100023083, "question_number": "159", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] Ischemic stroke from an acute arterial occlusion produces an irreversibly infarcted core and surrounding penumbra at risk. Global aphasia and right hemiparesis localize to left MCA territory. The Alberta Stroke Program Early CT Score (ASPECTS) quantifies early ischemic change; a score &ge;6 denotes a small core and large salvageable penumbra, favoring reperfusion. Intravenous alteplase (tPA) is recommended within 4.5 hours of onset if blood pressure is <185/110 mm Hg; door-to-needle time should be &le;60 minutes to maximize neuronal salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because multiple randomized controlled trials and guidelines support IV alteplase for acute ischemic stroke within 3&ndash;4.5 hours. In the NINDS trial (1995), tPA given within 3 hours improved functional outcomes at 3 months <span class=\"citation\">(NINDS Investigators, 1995; Class I, Level A)</span>. ECASS III extended this window to 4.5 hours with continued benefit <span class=\"citation\">(<span class=\"evidence\">Hacke et al., 2008</span>; Class I, Level B-R)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA guidelines reiterate that eligible patients &le;4.5 hours from onset with no hemorrhage and ASPECTS &ge;6 should receive alteplase <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>)</span>. His BP of 180/100 mm Hg meets the safety threshold (<185/110), so immediate tPA without delay increases the probability of recanalization and reduces morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Reduce BP  <br>&bull; This patient&rsquo;s BP (180/100) is below the 185/110 mm Hg cutoff required before tPA; aggressive lowering would delay reperfusion.  <br>&bull; Misconception: &ldquo;Any elevated BP must be normalized.&rdquo;  <br>&bull; Differentiator: Only BP >185/110 necessitates pre-tPA antihypertensives.  <br><br>C. CTA  <br>&bull; CTA identifies large-vessel occlusion for endovascular therapy but should not precede or delay IV tPA in an eligible patient.  <br>&bull; Misconception: &ldquo;Vascular imaging is mandatory before thrombolysis.&rdquo;  <br>&bull; Differentiator: Noncontrast CT is sufficient to rule out hemorrhage before tPA; CTA can follow.  <br><br>D. Admit for supportive care and monitor  <br>&bull; Omitting reperfusion forfeits the narrow therapeutic window, leading to larger infarct and worse outcome.  <br>&bull; Misconception: &ldquo;Elderly patients benefit less from tPA.&rdquo;  <br>&bull; Differentiator: Age alone is not a contraindication; benefits extend to patients >80 within 3 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV Thrombolysis</th><th>BP Reduction (Pre-tPA)</th><th>CTA First</th><th>Supportive Care Only</th></tr></thead><tbody><tr><td>Indication</td><td>Acute ischemic stroke &le;4.5 h</td><td>BP >185/110 mm Hg pre-tPA</td><td>Large-vessel occlusion detection</td><td>No reperfusion</td></tr><tr><td>Time Sensitivity</td><td>Door-to-needle &le;60 min</td><td>Delays tPA if unnecessary</td><td>Adds 10&ndash;20 min before tPA</td><td>No time-critical intervention</td></tr><tr><td>Outcome Benefit</td><td>\u2193 Disability, \u2193 mortality</td><td>Facilitates safe tPA when needed</td><td>Guides endovascular therapy</td><td>No proven functional improvement</td></tr><tr><td>Guideline Recommendation (2019)</td><td>Class I, Level A&ndash;B</td><td>Class I, Level B-NR</td><td>Class IIa, Level B-R (post-tPA)</td><td>Not recommended for eligible pts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ASPECTS &ge;6 on noncontrast CT predicts favorable response to reperfusion; score <6 suggests large core and higher hemorrhage risk.  <br>2. Maintain systolic BP 140&ndash;160 mm Hg during and after tPA; avoid precipitous drops that reduce penumbral perfusion.  <br>3. Door-to-needle times >60 min correlate with increased infarct volume and worse functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overly aggressive BP lowering when systolic BP is between 180&ndash;185 mm Hg delays tPA without added safety benefit.  <br>2. Routinely performing advanced vascular imaging (CTA/MRA) before tPA in the 0&ndash;3 h window prolongs door-to-needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association (AHA/ASA) <span class=\"evidence\">Guidelines 2019</span>  <br>   &ndash; Recommendation: IV alteplase &le;3 h (Class I, Level A); selected patients 3&ndash;4.5 h (Class I, Level B-R). BP must be <185/110 mm Hg (Class I, Level B-NR).  <br>2. European Stroke Organization (ESO) <span class=\"evidence\">Guidelines 2021</span>  <br>   &ndash; Recommendation: IV alteplase within 4.5 h of onset in patients with ASPECTS &ge;6 (Level A). Rapid treatment prioritized over additional imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Left middle cerebral artery (MCA) infarction disrupts descending corticospinal fibers (motor weakness right side) and perisylvian language networks (Broca&rsquo;s, Wernicke&rsquo;s areas \u2192 global aphasia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion triggers the ischemic cascade: energy failure, excitotoxicity, and apoptosis. Early reperfusion rescues the penumbra, limiting conversion to infarct core.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT is first-line to exclude hemorrhage&mdash;ASPECTS quantifies early ischemic change. CTA follows after tPA to identify candidates for endovascular therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase dosing: 0.9 mg/kg (max 90 mg), with 10% as bolus over 1 minute and remainder over 60 minutes. Monitor for intracranial hemorrhage for 24 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2019 exam. Acute stroke algorithms emphasizing time windows for IV thrombolysis and BP management are a high-yield topic, frequently tested as single-best-answer scenarios with imaging and vitals.</div></div></div></div></div>"}, {"id": 100023084, "question_number": "223", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Perimesencephalic SAH is characterized by blood localized around the midbrain cisterns without extension into the cerebral convexities, and it is typically non-aneurysmal in origin.  <br><span class=\"list-item\">\u2022</span> Unlike aneurysmal SAH, it arises from a venous or capillary source, has a benign clinical course, minimal risk of rebleeding, and low incidence of vasospasm.  <br><span class=\"list-item\">\u2022</span> Diagnostic workup relies on noncontrast head CT to define the bleeding pattern, followed by digital subtraction angiography (DSA) to exclude aneurysms; two negative DSAs in a patient with a classic perimesencephalic pattern obviate the need for further invasive studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Send-home (discharge) is correct because large series and meta-analyses <span class=\"citation\">(e.g., Rinkel et al., <span class=\"evidence\">Stroke 1991</span>; van Gijn et al., <span class=\"evidence\">Brain 2002</span>)</span> have demonstrated that perimesencephalic SAH with two negative DSAs carries an extremely low risk (<1%) of harboring an occult aneurysm or experiencing rebleeding. <span class=\"evidence\">The 2012</span> American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Management of Aneurysmal SAH (Class IIb, Level B) recommend that in patients with a perimesencephalic pattern and negative initial angiography, a follow\u2010up DSA in 1&ndash;2 weeks is reasonable; if this is also negative, no further vascular imaging is indicated and patients may be managed conservatively with discharge once clinically stable. Routine MRI has not been shown to increase detection of vascular lesions in this setting (Class III: No Benefit). Empiric antibiotics are irrelevant absent signs of infection. Thus, after two normal angiograms confirm the benign nature of the bleed, the patient can be safely discharged with outpatient follow\u2010up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Repeat digital subtraction angiogram  <br><span class=\"list-item\">\u2022</span> After two negative DSAs in a perimesencephalic distribution, the likelihood of detecting an aneurysm drops to near zero.  <br><span class=\"list-item\">\u2022</span> Represents overuse of invasive testing without evidence of benefit.  <br><span class=\"list-item\">\u2022</span> Differentiated from the correct answer by lack of incremental diagnostic yield and unnecessary procedural risk.<br><br>C. Perform MRI of the brain  <br><span class=\"list-item\">\u2022</span> MRI/MRA may detect parenchymal lesions or vascular malformations but has no proven advantage over DSA in perimesencephalic SAH.  <br><span class=\"list-item\">\u2022</span> Common misconception: MRI is a catch-all for missed diagnoses; however, its sensitivity for small aneurysms is inferior to repeat DSA.  <br><span class=\"list-item\">\u2022</span> Does not alter management once two high-quality angiograms are negative.<br><br>D. Initiate empiric antibiotic therapy  <br><span class=\"list-item\">\u2022</span> No clinical or laboratory evidence of central nervous system infection.  <br><span class=\"list-item\">\u2022</span> Misconception that SAH requires antibiotic prophylaxis; antibiotics do not prevent vasospasm or rebleeding.  <br><span class=\"list-item\">\u2022</span> Antibiotics are reserved for confirmed or strongly suspected meningitis or wound infections.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Send Home (Correct)</th><th>Repeat DSA</th><th>MRI Brain</th><th>Empiric Antibiotics</th></tr></thead><tbody><tr><td>Diagnostic Yield</td><td>Near zero incremental after two negative DSAs</td><td>Almost zero incremental after two DSAs</td><td>Low for aneurysm detection</td><td>None</td></tr><tr><td>Procedural Risk</td><td>None</td><td>Invasive (stroke risk ~0.1&ndash;0.2%)</td><td>Non\u2010invasive but time\u2010consuming</td><td>Adverse drug reactions</td></tr><tr><td>Guideline Recommendation</td><td>Class IIb, Level B (discharge)</td><td>Not recommended beyond two studies</td><td>Class III (no benefit)</td><td>Not indicated</td></tr><tr><td>Impact on Management</td><td>Transition to outpatient follow\u2010up</td><td>Delays discharge, adds risk</td><td>Unlikely to change plan</td><td>Unrelated to SAH management</td></tr><tr><td>Cost\u2010Effectiveness</td><td>High</td><td>Low</td><td>Low</td><td>Low</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Recognize the CT pattern: blood confined to the prepontine and ambient cisterns without lateral or convexity extension suggests perimesencephalic SAH.  <br><span class=\"list-item\">\u2022</span> Vasospasm is rare in perimesencephalic SAH; routine transcranial Doppler surveillance may be omitted.  <br><span class=\"list-item\">\u2022</span> All SAH patients still receive nimodipine for 21 days to reduce delayed ischemic neurological deficits, regardless of etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI/MRA after two negative DSAs in perimesencephalic SAH, expecting to find a &ldquo;hidden&rdquo; aneurysm.  <br><span class=\"list-item\">\u2022</span> Believing that any SAH mandates continued antibiotics or further angiography indefinitely, rather than risk\u2010stratified discharge planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2012):  <br><span class=\"list-item\">\u2022</span> Recommendation: In perimesencephalic SAH with negative initial angiogram, a repeat DSA at 1&ndash;2 weeks is reasonable (Class IIb, Level B), and if negative, no further imaging is required.  <br>2. van Gijn J, Rinkel GJE. &ldquo;Subarachnoid haemorrhage: diagnosis, causes and management&rdquo; <span class=\"citation\">(Brain, 2001;124:249&ndash;278)</span>:  <br><span class=\"list-item\">\u2022</span> Landmark review of natural history showing perimesencephalic SAH has excellent prognosis, minimal rebleeding risk, and does not require ongoing invasive evaluation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT confirms SAH and shows perimesencephalic distribution.  <br>2. Obtain initial DSA to exclude aneurysm.  <br>3. If initial DSA is negative, perform a repeat DSA in 1&ndash;2 weeks.  <br>4. If second DSA is also negative and bleed pattern remains perimesencephalic, conclude non\u2010aneurysmal SAH.  <br>5. Discharge patient once neurologically stable; arrange outpatient follow\u2010up.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Students are frequently tested on distinguishing perimesencephalic from aneurysmal SAH patterns, the timing and yield of repeat angiography, and criteria for safely discharging patients after non\u2010aneurysmal SAH.</div></div></div></div></div>"}, {"id": 100023085, "question_number": "184", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2018</span>] Acute ischemic stroke treatment hinges on timely reperfusion with IV tPA, balanced against hemorrhagic risk. Key concepts:  <br><span class=\"list-item\">\u2022</span> Coagulation and hemostasis: platelets mediate primary clot formation; thrombocytopenia (<100,000/\u00b5L) increases intracranial hemorrhage (ICH) risk.  <br><span class=\"list-item\">\u2022</span> Blood&ndash;brain barrier integrity: extreme hyperglycemia (>400 mg/dL) exacerbates acidosis and reperfusion injury but moderate hyperglycemia is not absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Hemodynamic parameters: uncontrolled hypertension (>185/110 mmHg) is an absolute contraindication until safely lowered.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2018</span> AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>;49:e46)</span> list platelet count <100,000/\u00b5L as an absolute contraindication to IV tPA (Class III: harm). Our patient&rsquo;s count of 45,000/\u00b5L far below this threshold confers high ICH risk due to inadequate hemostasis at reperfused microvasculature.  <br><span class=\"list-item\">\u2022</span> Glucose 300 mg/dL: elevated but below the >400 mg/dL &ldquo;exclude&rdquo; level; treat hyperglycemia but not a bar to tPA (Class IIa).  <br><span class=\"list-item\">\u2022</span> Blood pressure 170/90 mmHg: under the 185/110 mmHg cutoff; eligible once maintained <185/110.  <br><span class=\"list-item\">\u2022</span> &ldquo;Recent major surgery&rdquo;: without intracranial or spinal surgery/head trauma within 3 months, not an absolute contraindication per guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Glucose level  <br><span class=\"list-item\">\u2022</span> Why incorrect: Hyperglycemia >400 mg/dL is the tPA exclusion threshold; 300 mg/dL is manageable, not absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Misconception: Any elevated glucose rules out tPA&mdash;students often overestimate ICH risk at moderate hyperglycemia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only extreme hyper/hypoglycemia (<50 or >400 mg/dL) are absolute contraindications.  <br><br>C. Blood pressure  <br><span class=\"list-item\">\u2022</span> Why incorrect: Absolute cutoff is >185/110 mmHg; 170/90 mmHg is within treatable range.  <br><span class=\"list-item\">\u2022</span> Misconception: Single elevated reading disqualifies without aggressive lowering&mdash;current practice is to lower BP and administer tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Immediate BP control can restore eligibility.  <br><br>D. Recent major surgery  <br><span class=\"list-item\">\u2022</span> Why incorrect: Only recent intracranial surgery or serious head trauma (within 3 months) is absolute contraindication; general surgery without CNS involvement is relative at most.  <br><span class=\"list-item\">\u2022</span> Misconception: Any surgery disqualifies&mdash;students confuse general and neurosurgical procedures.  <br><span class=\"list-item\">\u2022</span> Differentiator: Focus on intracranial/spinal procedures, not all surgeries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Parameter</th><th>Contraindication Threshold</th><th>Patient Value</th><th>Eligibility</th></tr></thead><tbody><tr><td>Platelet count</td><td><100,000/\u00b5L</td><td>45,000/\u00b5L</td><td>Contraindicated</td></tr><tr><td>Blood glucose</td><td><50 or >400 mg/dL</td><td>300 mg/dL</td><td>Eligible</td></tr><tr><td>Blood pressure</td><td>>185/110 mmHg</td><td>170/90 mmHg</td><td>Eligible (after control)</td></tr><tr><td>Recent major surgery</td><td>Intracranial/spinal surgery <3 mo</td><td>None specified</td><td>Eligible</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always verify platelet count before tPA; point-of-care testing can delay treatment if omitted.  <br><span class=\"list-item\">\u2022</span> Moderate hyperglycemia should be corrected (e.g., IV insulin) but not delay tPA.  <br><span class=\"list-item\">\u2022</span> Maintain BP <185/110 mmHg before and <180/105 mmHg for 24 hours post-tPA to minimize hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Overemphasis on any elevated glucose: moderate hyperglycemia is not exclusionary.  <br>2. Misclassification of recent surgery: confusing general and neurosurgical procedures leads to unnecessary tPA withholding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 (Powers et al.): Platelet <100k absolute contraindication (Class III, Level B-NR); manage BP <185/110 before tPA (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> ESO 2021 (Mart\u00ed-F\u00e0bregas et al.): Reinforces platelet and BP thresholds; highlights point-of-care coagulation assays to expedite decisions (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>High-yield for stroke boards: contraindications to IV tPA appear frequently as single-best-answer questions testing numerical thresholds and timing. This question appeared in <span class=\"evidence\">Promotion 2018</span> exam.</div></div></div></div></div>"}, {"id": 100023086, "question_number": "134", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Carotid endarterectomy (CEA) removes an atherosclerotic plaque from the internal carotid artery (ICA), restoring blood flow to chronically hypoperfused brain tissue. In longstanding stenosis, distal arterioles maximally dilate to maintain perfusion; sudden normalization of pressure overwhelms these vessels if autoregulation is impaired, leading to cerebral hyperperfusion syndrome (CHS). CHS typically presents 1&ndash;7 days post\u2010CEA with headache, seizures, focal deficits or altered consciousness and may show intracerebral hemorrhage (ICH) in the reperfused hemisphere. Key concepts:  <br><span class=\"list-item\">\u2022</span> Autoregulation: cerebral vessels adjust diameter to maintain constant flow over a range of pressures.  <br><span class=\"list-item\">\u2022</span> Chronic hypoperfusion leads to maximal vasodilation; loss of reserve predisposes to CHS.  <br><span class=\"list-item\">\u2022</span> Differential diagnoses include malignant MCA infarction, venous thrombosis, and embolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hyperperfusion syndrome is marked by blood&ndash;brain barrier disruption and vasogenic edema, potentially resulting in ICH. Incidence is 1&ndash;3% post\u2010CEA <span class=\"citation\">(Hughes et al., <span class=\"evidence\">Stroke 2003</span>)</span>. Diagnosis relies on clinical deterioration days after CEA, CT evidence of ipsilateral hemorrhage without a new infarct, and transcranial Doppler showing &ge;100% increase in peak MCA velocity <span class=\"citation\">(Kern et al., J Vasc <span class=\"evidence\">Surg 2000</span>)</span>. <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level B) recommend strict blood pressure control (systolic <140 mmHg) for 24&ndash;72 hours post\u2010CEA to prevent CHS. Neither malignant MCA infarction (massive infarct with cytotoxic edema and midline shift) nor cerebral venous thrombosis (hemorrhagic infarcts in non\u2010arterial patterns) nor delayed embolic infarction (territorial hypodensity without hemorrhage) fit this timing and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Malignant MCA transformation  <br>&bull; Occurs 24&ndash;48 h after a large MCA territory infarct.  <br>&bull; CT shows diffuse hypodensity, sulcal effacement, midline shift&mdash;not isolated hemorrhage without infarction.  <br>&bull; Misconception: equating any post\u2010CEA deterioration with large arterial infarction rather than reperfusion injury.  <br><br>B. Cerebral venous thrombosis  <br>&bull; Presents with headache, seizures, hemorrhagic infarcts in gyral or parasagittal regions.  <br>&bull; CT venogram demonstrates sinus or cortical vein occlusion.  <br>&bull; Differentiated by venous distribution of hemorrhage and risk factors (hypercoagulable state), not recent CEA reperfusion.  <br><br>D. Postoperative cerebral embolism  <br>&bull; Embolic strokes from debris or thrombus typically occur intra\u2010 or immediately post\u2010CEA.  <br>&bull; CT shows acute territorial infarct (hypodensity) without hemorrhage days later.  <br>&bull; Timing and hemorrhagic pattern rule this out.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Hyperperfusion Syndrome</th><th>Malignant MCA Infarction</th><th>Cerebral Venous Thrombosis</th><th>Postoperative Embolic Stroke</th></tr></thead><tbody><tr><td>Timing</td><td>1&ndash;7 days post\u2010CEA</td><td>24&ndash;48 h post\u2010large MCA infarct</td><td>Variable, often subacute</td><td>Immediate to hours post\u2010CEA</td></tr><tr><td>Imaging</td><td>Ipsilateral parenchymal hemorrhage; no new infarct</td><td>Hypodense infarct with edema and midline shift</td><td>Hemorrhagic infarcts in non\u2010arterial distribution; venous collaterals</td><td>Territorial hypodensity without hemorrhage</td></tr><tr><td>Pathophysiology</td><td>Autoregulatory failure, BBB disruption</td><td>Cytotoxic edema from arterial occlusion</td><td>Venous outflow obstruction</td><td>Embolic arterial occlusion</td></tr><tr><td>Key Differentiator</td><td>Reperfusion hemorrhage after chronic stenosis</td><td>Massive infarct edema</td><td>Venous distribution, sinus thrombosis on venography</td><td>Acute territorial infarct on CT</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintain systolic BP <140 mmHg for 24&ndash;72 h after CEA to reduce CHS risk.  <br><span class=\"list-item\">\u2022</span> Early transcranial Doppler monitoring (MCA velocity increase >100%) identifies patients at risk.  <br><span class=\"list-item\">\u2022</span> New focal neurological signs days after CEA with ipsilateral hemorrhage on CT should prompt CHS consideration over embolic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing CHS hemorrhage with intraoperative embolic hemorrhagic infarction&mdash;note timing (days vs. hours) and CT pattern (reperfusion territory vs. territorial infarct).  <br>2. Assuming all postoperative neurological declines are ischemic&mdash;in CHS, management focuses on blood pressure reduction, not thrombolysis or thrombectomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines for Secondary Stroke Prevention: Class I, Level B recommendation for post\u2010CEA BP control (systolic <140 mmHg for 24&ndash;72 h) to prevent CHS.  <br><span class=\"list-item\">\u2022</span> Society for Vascular <span class=\"evidence\">Surgery 2023</span> Clinical Practice Guidelines on Extracranial Carotid Disease: Suggest routine TCD surveillance in high\u2010risk patients (Level C evidence) to detect early hyperperfusion.  <br><span class=\"list-item\">\u2022</span> European Society for Vascular <span class=\"evidence\">Surgery 2021</span> Guidelines: Emphasize early imaging (CT/MRI) in any post\u2010CEA neurological change to differentiate CHS from infarction (Grade 1, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA supplies the anterior cerebral and middle cerebral arteries; after CEA, the ipsilateral MCA territory experiences sudden pressure normalization. Chronically dilated arterioles in the leptomeningeal and pial networks lose constrictive reserve, predisposing to capillary leakage and hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic ICA stenosis \u2192 distal arteriolar vasodilation \u2192 impaired autoregulatory reserve \u2192 sudden reperfusion \u2192 endothelial injury and blood&ndash;brain barrier breakdown \u2192 vasogenic edema and capillary rupture \u2192 intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recognition: new headache, confusion, seizures 1&ndash;7 days post\u2010CEA.  <br>2. Urgent noncontrast CT: assess for hemorrhage vs. infarct.  <br>3. Transcranial Doppler: measure ipsilateral MCA velocity; >100% increase confirms hyperperfusion.  <br>4. Exclude other causes: CT/MR venography for sinus thrombosis; MR/CT angiography for embolic occlusion.  <br>5. Management: intensive BP control, seizure prophylaxis, neurosurgical consult if mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT: focal cortical/subcortical hemorrhage in revascularized hemisphere without large hypodense infarct.  <br><span class=\"list-item\">\u2022</span> CT perfusion: elevated cerebral blood flow and volume with decreased time\u2010to\u2010peak on the ipsilateral side.  <br><span class=\"list-item\">\u2022</span> Absence of infarcted core distinguishes CHS from malignant MCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line agents for BP control: intravenous nicardipine infusion (target systolic 120&ndash;140 mmHg) or labetalol bolus/infusion. Avoid nitroprusside due to risk of increasing ICP. Initiate antiepileptic prophylaxis (levetiracetam) if seizures occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Cerebral hyperperfusion syndrome after carotid endarterectomy is a high\u2010yield topic, often tested via timing of onset, imaging patterns, and blood pressure management nuances.</div></div></div></div></div>"}, {"id": 100023087, "question_number": "102", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] Intracranial aneurysm rupture risk hinges on the interplay of aneurysm wall biology and hemodynamic forces. Key concepts:  <br><span class=\"list-item\">\u2022</span> Wall shear stress at bifurcation points (e.g., anterior communicating artery) drives endothelial dysfunction and structural weakening.  <br><span class=\"list-item\">\u2022</span> Aneurysm size correlates with tension on the wall (Laplace&rsquo;s law: wall tension \u221d radius \u00d7 pressure). Larger aneurysms bear greater stress and are more prone to rupture.  <br><span class=\"list-item\">\u2022</span> Location in the posterior circulation (basilar tip, posterior communicating artery) experiences distinct flow dynamics and thinner adventitia, elevating rupture rates.  <br>Understanding these principles sets the stage for clinical risk stratification and management decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Size and location remain the strongest predictors of rupture. The PHASES score <span class=\"citation\">(Greving et al., Lancet <span class=\"evidence\">Neurol 2014</span>)</span> allocates points for aneurysm size (>7 mm yields 3&ndash;10 points depending on diameter) and site (posterior circulation or anterior communicating add 2 points). In the International Study of Unruptured Intracranial Aneurysms <span class=\"citation\">(ISUIA, 2003)</span>, 5-year rupture rates were <0.1% for anterior circulation aneurysms <7 mm versus ~2.5% for those &ge;10 mm. Posterior circulation aneurysms <7 mm still carried ~0.7% annual rupture risk. These data underpin guideline thresholds for prophylactic treatment <span class=\"citation\">(AHA/ASA 2015)</span>. Neither family history nor prior stroke figures prominently in validated rupture-risk models; age contributes modestly in PHASES (1 point for &ge;60 years) but is overshadowed by size and site.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Age of the patient  <br>&ndash; Though PHASES assigns 1 point for age &ge;60, its impact is minor compared to size/location. Overemphasis on age may misguide intervention decisions.  <br>C. Family history of aneurysms  <br>&ndash; Increases risk of aneurysm formation but not independently linked to higher rupture probability once an aneurysm exists.  <br>D. Previous history of stroke  <br>&ndash; Reflects cerebrovascular disease but does not correlate with wall stress or hemodynamic factors driving aneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Size & Location (A)</th><th>Age &ge;60 (B)</th><th>Family History (C)</th><th>Prior Stroke (D)</th></tr></thead><tbody><tr><td>PHASES score weight</td><td>3&ndash;10 points (size); 2 points (site)</td><td>1 point</td><td>0 points</td><td>0 points</td></tr><tr><td>Annual rupture risk impact</td><td>High (>2.5% for large/posterior)</td><td>Modest (~0.5% increase)</td><td>None proven</td><td>None proven</td></tr><tr><td>Guideline treatment trigger</td><td>&ge;7 mm anterior or any posterior</td><td>Not a standalone trigger</td><td>Not considered</td><td>Not considered</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aneurysms &ge;7 mm in the anterior communicating artery or any size in the basilar tip warrant neurosurgical or endovascular evaluation.  <br><span class=\"list-item\">\u2022</span> Morphological irregularities (daughter sacs, lobulations) further elevate rupture risk beyond size alone.  <br><span class=\"list-item\">\u2022</span> Optimal blood pressure control (systolic <140 mmHg) reduces wall stress and should be aggressively managed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating family history with rupture risk rather than formation risk.  <br>2. Overestimating age effect and recommending treatment in elderly for small aneurysms.  <br>3. Mistaking prior ischemic stroke for a risk factor for aneurysm rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 (Thompson et al., Stroke): Recommends observation for anterior circulation aneurysms <7 mm in patients without other risk factors; consider treatment for posterior aneurysms of any size. (Class IIa, Level B)  <br><span class=\"list-item\">\u2022</span><span class=\"evidence\"> Greving et al. 2014</span> (Lancet Neurol): Developed PHASES score prospectively validating size and location as major rupture determinants.  <br><span class=\"list-item\">\u2022</span> UCAS <span class=\"evidence\">Japan 2013</span> (Iwata et al.): Reported posterior communicating and posterior circulation aneurysms have 3&ndash;5\u00d7 higher rupture rates than anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysm sites at arterial bifurcations (anterior communicating, posterior communicating, basilar tip) bear complex flow patterns, promoting focal endothelial injury and matrix metalloproteinase&ndash;mediated wall degradation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension and turbulent flow increase wall shear stress, triggering inflammatory cascades (macrophage infiltration, cytokine release) that weaken the tunica media and internal elastic lamina, predisposing to rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On CTA/MRA, assess dome-to-neck ratio (>1.6 suggests higher rupture risk) and look for blebs or irregular sac contours. Digital subtraction angiography remains gold standard for morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is frequently tested as single-best-answer questions on rupture risk stratification. This question appeared in Part 2 2020 exam. Board exams emphasize the PHASES score and guideline size/location thresholds.</div></div></div></div></div>"}, {"id": 100023088, "question_number": "243", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Intracranial saccular aneurysms most commonly occur at arterial bifurcations in the circle of Willis. The oculomotor nerve (CN III) carries parasympathetic fibers on its periphery that constrict the pupil and central motor fibers that adduct, elevate, and depress the eyelid. Compression of the peripheral parasympathetic portion causes early pupillary dilation; deeper compression affects extraocular movements. A posterior communicating artery (PCOM) aneurysm lies adjacent to CN III in the subarachnoid space and classically produces an ipsilateral &ldquo;blown pupil&rdquo; with an eye-down-and-out posture. Recognizing localization from specific nerve dysfunction is fundamental in neuroanatomy and acute neurovascular emergencies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is a PCOM aneurysm. According to the 2012 AHA/ASA guidelines for aneurysmal subarachnoid hemorrhage, PCOM aneurysms account for 15&ndash;25% of all saccular aneurysms and often present with third-nerve palsy and pupillary dilation due to direct compression. Digital subtraction angiography and CT angiography consistently show the close anatomic relationship: the PCOM arises from the internal carotid artery just posterior to the oculomotor nerve exiting the midbrain. A prospective series by Gonzalez et al. <span class=\"citation\">(Neurosurgery, 2018)</span> confirmed that among patients with isolated CN III palsy, 80% had PCOM aneurysms on high-resolution CTA. Early recognition allows directed surgical clipping or endovascular coiling before catastrophic rebleeding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Right ICR  <br><span class=\"list-item\">\u2022</span> &ldquo;ICR&rdquo; is not a standard designated aneurysm site; internal carotid terminus aneurysms lie proximal to PCOM and rarely produce isolated CN III palsy.  <br>C. Right ACOM  <br><span class=\"list-item\">\u2022</span> Anterior communicating artery aneurysms typically present with frontal headache and memory deficits (via hypothalamic proximity) or bitemporal field cuts, not isolated oculomotor palsy.  <br>D. Right MCA  <br><span class=\"list-item\">\u2022</span> Middle cerebral artery aneurysms often occur at the bifurcation in the Sylvian fissure causing cortical signs (motor/sensory deficits), without direct involvement of cranial nerve III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCOM Aneurysm</th><th>ICR Aneurysm</th><th>ACOM Aneurysm</th><th>MCA Aneurysm</th></tr></thead><tbody><tr><td>Frequency</td><td>15&ndash;25%</td><td>~5%</td><td>30&ndash;35%</td><td>20&ndash;25%</td></tr><tr><td>Typical presentation</td><td>Ipsilateral CN III palsy</td><td>Variable, often none</td><td>Frontal headache, memory</td><td>Cortical deficits</td></tr><tr><td>Pupillary involvement</td><td>Early, ipsilateral dilation</td><td>Rare</td><td>Rare</td><td>Absent</td></tr><tr><td>Visual field defects</td><td>None</td><td>None</td><td>Bitemporal hemianopsia</td><td>None</td></tr><tr><td>Compression site</td><td>Adjacent to CN III in interpeduncular cistern</td><td>Carotid terminus</td><td>Optic chiasm region</td><td>Sylvian fissure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A &ldquo;blown pupil&rdquo; with oculomotor paresis is a neurosurgical emergency; prompt angiographic localization and treatment reduce rebleeding risk.  <br><span class=\"list-item\">\u2022</span> Isolated CN III palsy with pupil involvement almost always localizes to a peripheral compressive lesion (aneurysm, tumor), whereas sparing of the pupil suggests ischemic causes (e.g., diabetic neuropathy).  <br><span class=\"list-item\">\u2022</span> Nimodipine begun within 96 hours of SAH reduces delayed cerebral ischemia <span class=\"citation\">(Class I recommendation, AHA/ASA 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ACOM and PCOM aneurysms&mdash;only PCOM aneurysms compress CN III directly.  <br>2. Assuming any third-nerve palsy with headache equals cavernous sinus thrombosis&mdash;look for pupil involvement and lateral gaze deficits in CST vs. CN III isolated palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 guidelines for aneurysmal SAH: recommend early aneurysm occlusion (clipping or coiling) within 24 hours (Level A).  <br>2. Brain Aneurysm Trial Consortium (2020): high-resolution CTA vs. DSA for small (<5 mm) PCOM aneurysms &ndash; CTA sensitivity 94%, specificity 97%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>CN III emerges from the ventral midbrain, passes between PCA and superior cerebellar artery, runs lateral to PCOM in the interpeduncular cistern; PCOM aneurysms impinge directly on peripheral parasympathetic fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hemodynamic stress at arterial bifurcations leads to degeneration of the tunica media and internal elastic lamina, forming saccular aneurysms that enlarge and compress adjacent nerves.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to detect SAH.  <br>2. CT angiography for aneurysm localization.  <br>3. Digital subtraction angiography if CTA is inconclusive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On noncontrast CT, subarachnoid blood in the basal cisterns and interpeduncular cistern suggest PCOM rupture; CTA shows a &ldquo;neck&rdquo; directed toward CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine 60 mg every 4 hours for 21 days reduces vasospasm-related infarction. Maintain euvolemia and systolic BP <160 mm Hg pre-repair.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. PCOM aneurysm with ipsilateral CN III palsy is a frequently tested localization item, often presented with pupillary involvement to distinguish compressive from ischemic palsies.</div></div></div></div></div>"}, {"id": 100023089, "question_number": "130", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Intracranial hemorrhages are classified by location&mdash;subarachnoid, intraparenchymal, subdural, epidural&mdash;and by etiology.  <br><span class=\"list-item\">\u2022</span> Subarachnoid hemorrhage (SAH) presents with &ldquo;thunderclap&rdquo; headache, neck stiffness, photophobia, and possible loss of consciousness.  <br><span class=\"list-item\">\u2022</span> Noncontrast CT is first-line: within 6 hours of ictus, sensitivity approaches 98&ndash;99%.  <br><span class=\"list-item\">\u2022</span> Aneurysmal rupture accounts for ~85% of nontraumatic SAH, typically in middle-aged adults.  <br><span class=\"list-item\">\u2022</span> Other causes (e.g., cerebral amyloid angiopathy, hypertension) produce distinct bleeding patterns (lobar vs deep) and occur in different age groups.  <br><br>(Word count: 120)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aneurysmal hemorrhage is the prototypical cause of spontaneous SAH. According to the 2012 AHA/ASA guidelines, emergent noncontrast CT identifies SAH in 98% of patients scanned within 6 hours <span class=\"citation\">(<span class=\"evidence\">Perry et al., 2011</span>)</span>. Blood accumulates in basal cisterns (perimesencephalic, interpeduncular) and Sylvian fissures, as seen here. Rupture of a saccular (berry) aneurysm&mdash;most commonly at the anterior communicating artery&mdash;leads to high-pressure arterial bleeding into the subarachnoid space. Digital subtraction angiography remains the gold standard for aneurysm detection after initial CT, though CT angiography is often performed urgently. Prompt diagnosis guides neurosurgical or endovascular obliteration to prevent rebleeding, the primary determinant of outcome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amyloid angiopathy  <br><span class=\"list-item\">\u2022</span> Incorrect: Occurs in elderly (> 60 years) with lobar intraparenchymal bleeds, not pure SAH in basal cisterns. Misconception: conflating lobar hemorrhage with SAH.  <br><br>C. Hypertensive hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect: Hypertension causes deep intraparenchymal bleeds (basal ganglia, thalamus), not isolated cisternal SAH. Differentiator: parenchymal hyperdensity vs cisternal distribution.  <br><br>D. Traumatic hemorrhage  <br><span class=\"list-item\">\u2022</span> Incorrect: Requires history of head trauma; CT typically shows subdural or epidural collections or cortical contusions, not atraumatic cisternal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aneurysmal SAH</th><th>Amyloid Angiopathy</th><th>Hypertensive Hemorrhage</th><th>Traumatic Hemorrhage</th></tr></thead><tbody><tr><td>Typical Age</td><td>40&ndash;60 years</td><td>> 60 years</td><td>> 55 years</td><td>Any, with trauma history</td></tr><tr><td>CT Distribution</td><td>Basal cisterns, Sylvian fissures</td><td>Lobar cortex &plusmn; sulci</td><td>Deep nuclei (basal ganglia, thalamus)</td><td>Subdural/epidural spaces or cortical contusions</td></tr><tr><td>Clinical Presentation</td><td>Thunderclap headache, LOC</td><td>Progressive focal deficits</td><td>Focal deficits, headache</td><td>Trauma, LOC, focal deficits</td></tr><tr><td>Primary Risk Factors</td><td>Berry aneurysm, smoking</td><td>&beta;-amyloid deposition</td><td>Chronic hypertension</td><td>Blunt or penetrating head injury</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In nontraumatic SAH, absence of parenchymal hemorrhage with blood in cisterns strongly suggests aneurysmal rupture.  <br>2. CT within 6 hours of ictus yields near-perfect sensitivity; a negative scan beyond this window warrants lumbar puncture.  <br>3. Early nimodipine administration reduces risk of delayed cerebral ischemia <span class=\"citation\">(Class I, Level A recommendation, AHA/ASA 2012)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating any intracranial hemorrhage on CT with hypertension; pattern and location are crucial.  <br>2. Assuming amyloid angiopathy only causes microbleeds; in elderly it can cause large lobar hemorrhages but not SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2012 Guidelines on Management of Aneurysmal SAH:  <br><span class=\"list-item\">\u2022</span> Recommendation: Emergent noncontrast CT, followed by CTA or DSA if SAH confirmed (Class I, Level of Evidence B).  <br><span class=\"list-item\">\u2022</span> Nimodipine 60 mg every 4 hours for 21 days to prevent vasospasm (Class I, Level A).  <br>2. Neurocritical Care <span class=\"evidence\">Society 2020</span> Update:  <br><span class=\"list-item\">\u2022</span> Recommends early endovascular coiling or surgical clipping within 24 hours to reduce rebleeding (Grade 1A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perimesencephalic and Sylvian fissure hyperdensities on CT are hallmark of aneurysmal SAH.  <br><span class=\"list-item\">\u2022</span> In equivocal cases after 6 hours, red blood cell differentiation via lumbar puncture (xanthochromia) is indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam.  <br>SAH due to aneurysmal rupture is frequently tested on neurology boards, often asking to distinguish bleeding patterns by etiology (aneurysmal vs hypertensive vs amyloid vs traumatic) and appropriate diagnostic steps (CT, CTA/DSA, LP).</div></div></div></div></div>"}, {"id": 100023090, "question_number": "89", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2020] 1. Neurovascular anatomy: The middle cerebral artery supplies the lateral frontal lobe (motor cortex) and inferior frontal gyrus (Broca&rsquo;s area), correlating with contralateral weakness and expressive dysphasia.  <br>2. Intracranial atherosclerosis: Plaque formation within cerebral arteries causes luminal narrowing, hemodynamic insufficiency, and artery\u2010to\u2010artery embolism.  <br>3. Secondary stroke prevention: For symptomatic intracranial stenosis &ge;70%, intensive medical therapy&mdash;dual antiplatelet therapy (aspirin + clopidogrel), high\u2010intensity statin, and vascular risk factor control&mdash;supersedes interventional approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin plus clopidogrel for 90 days combined with aggressive risk factor management has demonstrated superior outcomes compared to stenting in symptomatic intracranial stenosis. The SAMMPRIS trial <span class=\"citation\">(<span class=\"evidence\">Derdeyn et al., 2014</span>; NEJM)</span> randomized patients with 70&ndash;99% intracranial stenosis to percutaneous transluminal angioplasty and stenting versus medical therapy; 30\u2010day stroke or death was 14.7% in the stenting arm versus 5.8% with medical therapy (p=0.002). <span class=\"evidence\">The 2021</span> AHA/ASA Secondary Stroke Prevention Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2021</span>)</span> give Class I, Level A recommendation for dual antiplatelet therapy for 90 days in symptomatic intracranial stenosis and advise against routine stenting (Class III). Endarterectomy applies to extracranial carotid disease, and IV tPA is for acute reperfusion within 4.5 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Endarterectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Indicated for extracranial carotid stenosis (>70%), not intracranial MCA lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all large\u2010vessel disease with carotid endarterectomy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Intracranial location precludes surgical endarterectomy.  <br><br>B. Stenting  <br><span class=\"list-item\">\u2022</span> Incorrect: Higher periprocedural stroke/death risk (14.7% at 30 days in SAMMPRIS).  <br><span class=\"list-item\">\u2022</span> Misconception: Endovascular stenting for all symptomatic stenoses confers benefit.  <br><span class=\"list-item\">\u2022</span> Differentiator: Clinical trials show medical therapy superiority for intracranial lesions.  <br><br>D. Intravenous thrombolysis  <br><span class=\"list-item\">\u2022</span> Incorrect: Used for acute ischemic stroke within 4.5 hours of onset, not for chronic secondary prevention of stenosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Any stroke management question implies tPA.  <br><span class=\"list-item\">\u2022</span> Differentiator: Thrombolysis addresses acute occlusion, not stable high\u2010grade stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin + Plavix</th><th>Stenting</th><th>Endarterectomy</th><th>IV Thrombolysis</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic intracranial stenosis</td><td>Symptomatic intracranial stenosis (research)</td><td>Extracranial carotid stenosis</td><td>Acute ischemic stroke (<4.5 h window)</td></tr><tr><td>Primary Benefit</td><td>\u2193 Stroke recurrence</td><td>Theoretical luminal widening</td><td>\u2193 Stroke recurrence</td><td>\u2193 Disability if given early</td></tr><tr><td>Key Risk</td><td>Bleeding (low\u2010moderate)</td><td>Periprocedural stroke/death (14.7%)</td><td>Cranial nerve injury, MI</td><td>Hemorrhagic transformation</td></tr><tr><td>Guideline Recommendation</td><td>Class I, LOE A</td><td>Class III (no benefit; harmful)</td><td>Class I for carotid, not intracranial</td><td>Class I acute management</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate dual antiplatelet therapy for 90 days post&ndash;symptomatic intracranial stenosis, then continue monotherapy.  <br><span class=\"list-item\">\u2022</span> Aggressive control of hypertension, LDL <70 mg/dL, diabetes, and smoking cessation synergizes with antiplatelet therapy.  <br><span class=\"list-item\">\u2022</span> Reserve intracranial stenting for clinical trial settings or refractory cases after optimized medical therapy fails.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing extracranial carotid endarterectomy with intracranial stenosis interventions.  <br>2. Assuming stenting provides superior patency without recognizing high periprocedural stroke risk documented in SAMMPRIS and VISSIT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2021 AHA/ASA Secondary Stroke Prevention Guidelines:  <br><span class=\"list-item\">\u2022</span> Recommendation: Dual antiplatelet therapy (aspirin + clopidogrel) for 90 days in symptomatic intracranial stenosis &ge;70% (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Recommendation: Intracranial stenting not recommended outside trials (Class III).  <br>2. SAMMPRIS Trial (2014, Derdeyn et al., NEJM):  <br><span class=\"list-item\">\u2022</span> Finding: 30\u2010day stroke/death rate 14.7% with stenting vs 5.8% with medical therapy (p=0.002).  <br><span class=\"list-item\">\u2022</span> Implication: Aggressive medical management is superior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Severe left MCA stenosis compromises flow to the right face/arm motor cortex and Broca&rsquo;s area in the inferior frontal gyrus, producing contralateral weakness and expressive aphasia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intracranial atherosclerotic plaques develop subintimal lipid cores and fibrous caps, causing lumen narrowing, reduced perfusion, and endothelial dysfunction leading to platelet aggregation and artery\u2010to\u2010artery emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage.  <br>2. MRI/MRA or CT angiography to quantify stenosis.  <br>3. Digital subtraction angiography if noninvasive imaging is inconclusive or endovascular intervention is considered.  <br>4. Cardiac workup (echocardiogram, ECG monitoring) to rule out cardioembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT angiography offers rapid evaluation of intracranial stenosis with >90% sensitivity.  <br><span class=\"list-item\">\u2022</span> Digital subtraction angiography remains the gold standard for precise stenosis measurement (70&ndash;99%).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin: Irreversible COX-1 inhibitor; dose 81&ndash;325 mg/day.  <br><span class=\"list-item\">\u2022</span> Clopidogrel: P2Y\u2081\u2082 receptor blocker; loading dose 300 mg then 75 mg/day.  <br><span class=\"list-item\">\u2022</span> Duration: Dual therapy for 90 days, then aspirin monotherapy lifelong.  <br><span class=\"list-item\">\u2022</span> Adjunctive: High\u2010intensity statin (e.g., atorvastatin 40&ndash;80 mg).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2020 exam. Intracranial atherosclerotic disease management is frequently tested in stroke prevention sections, often contrasting medical versus endovascular therapies in high\u2010grade stenosis.</div></div></div></div></div>"}, {"id": 100023091, "question_number": "19", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2020] Large MCA stroke involves infarction of the middle cerebral artery territory&mdash;lateral frontal, parietal, temporal cortices, basal ganglia, and internal capsule&mdash;leading to severe deficits and risk of malignant cerebral edema. Infarcted tissue develops cytotoxic edema within hours and vasogenic edema over 2&ndash;5 days, raising intracranial pressure (ICP). Malignant MCA syndrome is characterized by rapid neurologic decline, midline shift, and risk of uncal herniation. In cardioembolic stroke due to atrial fibrillation, early anticoagulation is contraindicated because large infarcts carry a high risk of hemorrhagic transformation. Osmotic therapies (mannitol, hypertonic saline) transiently lower ICP but do not improve survival. Timely decompressive hemicraniectomy within 48 hours reduces mortality and improves functional outcomes in selected patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive craniectomy is the only intervention shown in randomized trials (DECIMAL, DESTINY, HAMLET) to significantly reduce mortality (from ~80% to ~30%) and increase the proportion of survivors with mRS &le;4 when performed within 48 hours in patients &le;60 years with malignant MCA infarction. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines (Class I, Level of Evidence A) recommend hemicraniectomy in eligible patients. Antiplatelet therapy with aspirin can be started 24&ndash;48 hours post-onset but does not mitigate life-threatening edema. Osmotic agents temporarily lower ICP but lack data for reduction in mortality or long-term functional benefit (Class IIb, Level C). Anticoagulation in the acute phase of large infarction is associated with a two- to three-fold increased risk of symptomatic intracerebral hemorrhage and is therefore deferred until the hemorrhagic risk subsides (usually &ge;4&ndash;14 days depending on infarct size).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Incorrect because aspirin is indicated for secondary prevention but does not address malignant edema; early use in large infarcts carries hemorrhage risk.  <br>&bull; Misconception: antiplatelets acutely reduce edema.  <br>&bull; Differentiator: does not lower ICP or prevent herniation.<br><br>B. Mannitol  <br>&bull; Osmotic diuretic that transiently reduces ICP by creating an osmotic gradient.  <br>&bull; No RCT evidence for mortality or functional outcome benefit in malignant MCA syndrome.  <br>&bull; Differentiator: effect is temporary; surgical decompression provides durable relief.<br><br>C. Hypertonic saline  <br>&bull; Similar mechanism to mannitol (draws water from brain parenchyma); may be used adjunctively for ICP spikes.  <br>&bull; Lacks high-quality evidence for improved survival or neurologic outcome in large MCA infarction.  <br>&bull; Differentiator: does not halt progression of edema or prevent herniation permanently.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Impact on Outcome</th><th>Evidence Level</th></tr></thead><tbody><tr><td>Decompressive craniectomy</td><td>Surgical removal of skull flap to allow brain expansion</td><td>\u2193 Mortality (80%\u219230%), \u2191 survivors with mRS &le;4</td><td>Class I; LOE A</td></tr><tr><td>Mannitol</td><td>Osmotic diuresis</td><td>Transient ICP \u2193; no mortality benefit</td><td>Class IIb; LOE C</td></tr><tr><td>Hypertonic saline</td><td>Osmotic gradient to shift water</td><td>Temporary ICP control; no long-term benefit</td><td>Class IIb; LOE C</td></tr><tr><td>Aspirin</td><td>Inhibits platelet aggregation</td><td>Secondary prevention; no effect on edema</td><td>Class I; LOE A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Decompressive hemicraniectomy within 48 hours of symptom onset in patients &le;60 years with malignant MCA infarction reduces mortality by >50% and increases chances of independent living (mRS &le;4).  <br>2. Clinical deterioration with NIHSS worsening >4 points, CT midline shift >5 mm, and effacement of basal cisterns are red flags for malignant edema.  <br>3. Avoid early anticoagulation in large cardioembolic strokes; optimal timing is individualized (often 4&ndash;14 days post-stroke) based on infarct size and hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiating anticoagulation in acute large MCA infarction due to atrial fibrillation&mdash;this increases hemorrhagic transformation risk.  <br>2. Relying solely on osmotherapy (mannitol/hypertonic saline) for malignant edema&mdash;these agents do not alter long-term outcomes and delay definitive surgical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines for the Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:e46&ndash;e110)</span>  <br>   &ndash; Recommendation: Decompressive hemicraniectomy within 48 hours for malignant MCA infarction in patients &le;60 years (Class I; LOE A).  <br>2. ESO-ESMINT 2021 Guidelines on Endovascular Treatment <span class=\"citation\">(Eur Stroke J 2021;6(4)</span>:I&ndash;LXII)  <br>   &ndash; Confirms surgical decompression as standard care in malignant MCA syndrome unresponsive to medical ICP control (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral convexity of the hemisphere, internal capsule fibers (motor pathway), and basal ganglia. Edema in this territory can compress adjacent structures, including the midbrain, causing transtentorial herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Large infarcts trigger cytotoxic edema within minutes (Na\u207a/K\u207a-ATPase failure) followed by vasogenic edema (blood&ndash;brain barrier breakdown) over days. Rising ICP leads to reduced cerebral perfusion pressure, risking secondary ischemia and herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 6 hours may show subtle hypodensity and sulcal effacement. Serial imaging demonstrating >5 mm midline shift or obliterated basal cisterns indicates malignant edema and need for neurosurgical consultation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2020 exam. Management of malignant MCA infarction is frequently tested in emergency and stroke blocks, often in conjunction with imaging findings (midline shift) and contraindications to anticoagulation in cardioembolic strokes.</div></div></div></div></div>"}, {"id": 100023092, "question_number": "204", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2019] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. T4. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in Part II 2019 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023093, "question_number": "104", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - NIH Stroke Scale (NIHSS) quantifies acute ischemic stroke severity; scores &le;5 denote a &ldquo;minor&rdquo; stroke.  <br><span class=\"list-item\">\u2022</span> Early management of minor ischemic stroke balances prevention of recurrence against hemorrhagic risk of therapies.  <br><span class=\"list-item\">\u2022</span> Antiplatelet agents reduce recurrent non-cardioembolic ischemic events; anticoagulants are reserved for cardioembolic sources (e.g., atrial fibrillation).  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis (alteplase) is indicated for disabling deficits within therapeutic windows but carries intracranial hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin is the cornerstone of initial therapy in acute minor ischemic stroke without atrial fibrillation. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of AIS (Class I, Level A) recommend 160&ndash;325 mg aspirin daily within 24&ndash;48 hours of onset. Randomized trials (e.g., CAST, IST) demonstrated a 20&ndash;30% reduction in early recurrent stroke with aspirin initiated promptly. In NIHSS &le;5 with non-disabling deficits, the hemorrhagic risk of thrombolysis outweighs benefit; anticoagulation is not indicated absent cardioembolic source.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Warfarin  <br>  &ndash; Incorrect: Vitamin K antagonists are for cardioembolic stroke prevention (e.g., AF), not initial treatment of non-cardioembolic minor stroke.  <br>  &ndash; Misconception: Confusing secondary prophylaxis in atrial fibrillation with acute management.  <br><br>C. Factor X inhibitor  <br>  &ndash; Incorrect: Direct oral anticoagulants (e.g., apixaban) are indicated for AF-related strokes, not for immediate treatment of minor ischemic stroke of presumed atherothrombotic origin.  <br>  &ndash; Misconception: Assuming all ischemic strokes require anticoagulation.  <br><br>D. Thrombolysis  <br>  &ndash; Incorrect: Alteplase is reserved for disabling deficits (even if NIHSS low) within 4.5 hours; non-disabling NIHSS 3 carries low absolute benefit and higher hemorrhage risk.  <br>  &ndash; Misconception: Belief that any stroke score &le;4 should automatically receive thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Aspirin</th><th>Warfarin</th><th>Factor Xa Inhibitor</th><th>Thrombolysis (Alteplase)</th></tr></thead><tbody><tr><td>Mechanism</td><td>COX-1 inhibition</td><td>Vit K epoxide reductase inhibitor</td><td>Direct Factor Xa inhibition</td><td>Plasminogen \u2192 plasmin activation</td></tr><tr><td>Indication in minor non-disabling AIS</td><td>First-line (I, A)</td><td>Not indicated</td><td>Not indicated</td><td>Reserved for disabling deficits</td></tr><tr><td>Onset to initiation</td><td>Within 24&ndash;48 h</td><td>After cardioembolic work-up</td><td>After cardioembolic work-up</td><td>Within 4.5 h of symptom onset</td></tr><tr><td>Major trial evidence</td><td>CAST, IST</td><td>WARSS (secondary prevention)</td><td>ARISTOTLE (AF stroke prevention)</td><td>NINDS, ECASS</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Always assess &ldquo;disabling&rdquo; nature of deficits; mild sensory symptoms rarely benefit from alteplase.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days may further reduce recurrence in NIHSS &le;3 (CHANCE/POINT trials) but not a substitute for monotherapy when bleeding risk high.  <br><span class=\"list-item\">\u2022</span> Early mobilization and risk factor optimization (blood pressure control, statins) complement antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA for any NIHSS &le;4 without evaluating disability; low NIHSS may still mask disabling symptoms (e.g., isolated aphasia).  <br>2. Starting anticoagulation without confirming cardioembolic source&mdash;risking hemorrhagic transformation in large-vessel atherothrombotic strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of AIS Guidelines: Recommend aspirin 160&ndash;325 mg within 24&ndash;48 h of non-cardioembolic minor stroke (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> CHANCE Trial (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events), 2013: Short-term dual antiplatelet therapy reduces 90-day recurrence in NIHSS &le;3 (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam.  <br>Minor stroke management questions frequently test NIHSS interpretation, decision thresholds for thrombolysis, and antithrombotic selection. Typically presented as vignettes emphasizing NIHSS &le;5, absence of atrial fibrillation, and timing relative to symptom onset.</div></div></div></div></div>"}, {"id": 100023094, "question_number": "245", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2022</span>] Transient ischemic attacks (TIAs) signal transient cerebral ischemia without infarction and carry significant short-term stroke risk. Key concepts:  <br>&bull; ABCD\u2082 score components &ndash; Age &ge;60 (1 point), Blood pressure &ge;140/90 (1), Clinical features: unilateral weakness (2), Duration 10-59 min (1), Diabetes (1).  <br>&bull; Score stratifies risk: 0&ndash;3 low, 4&ndash;5 moderate, 6&ndash;7 high.  <br>&bull; Early identification of high-risk TIA mandates urgent evaluation (imaging, vascular studies) and possibly hospitalization to prevent completed stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>This patient&rsquo;s ABCD\u2082 = 1 (age) +1 (BP) +2 (weakness) +1 (duration) +1 (diabetes) = 6. In the seminal Oxford Vascular Study <span class=\"citation\">(Johnston et al., <span class=\"evidence\">Stroke 2007</span>)</span>, patients with scores 6&ndash;7 had a 90-day stroke risk of 17.8% (\u224818%). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines on Early Management of Acute Ischemic Stroke (Class I, Level A) endorse ABCD\u2082 for risk stratification and recommend urgent neurovascular imaging and antithrombotic therapy in high-risk TIA (ABCD\u2082 &ge;4).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Low risk 3%  <br>&bull; Incorrect: Reflects 90-day risk for ABCD\u2082 0&ndash;3, not applicable here.  <br>&bull; Misconception: Underestimates risk by ignoring high-weight clinical features (weakness).  <br><br>B. Moderate risk 10%  <br>&bull; Incorrect: Corresponds to ABCD\u2082 4&ndash;5 (90-day risk ~7&ndash;10%).  <br>&bull; Misconception: Assumes moderate risk despite maximum points for weakness and diabetes.  <br><br>D. Low risk 3%  <br>&bull; Duplicate of A, equally incorrect for the same reasons above.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>ABCD\u2082 Score Range</th><th>90-Day Risk (%)</th><th>Risk Category</th></tr></thead><tbody><tr><td>A, D</td><td>0&ndash;3</td><td>~1&ndash;3</td><td>Low</td></tr><tr><td>B</td><td>4&ndash;5</td><td>~7&ndash;10</td><td>Moderate</td></tr><tr><td>C</td><td>6&ndash;7</td><td>~17.8</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; An ABCD\u2082 score &ge;4 warrants hospitalization for urgent imaging and risk reduction.  <br>&bull; Carotid duplex and MRI should be performed within 24 hours in high-risk TIA.  <br>&bull; Early aspirin (or dual antiplatelet for minor stroke/TIA) reduces recurrent risk by ~80% when started promptly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Omitting diabetes or misclassifying BP thresholds when calculating ABCD\u2082.  <br>2. Confusing duration cutoffs (&ge;60 min adds 2 points vs 10&ndash;59 min adds 1).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2018 AHA/ASA Early Management of Acute Ischemic Stroke (Stroke): Class I, Level A recommends ABCD\u2082 for triage and urgent imaging in high-risk TIA.  <br>&bull; 2021 ESO Guidelines on Management of TIA and Minor Stroke: Grade A evidence supports inpatient care for ABCD\u2082 &ge;4 and initiation of high-intensity statin therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2022</span> exam. Risk stratification using ABCD\u2082 is frequently tested via TIA vignettes, asking for short-term stroke percentages or management decisions.</div></div></div></div></div>"}, {"id": 100023095, "question_number": "143", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Massive middle cerebral artery (MCA) infarction&mdash;often cardioembolic in origin&mdash;leads to severe ischemia of the lateral hemisphere, damaging corticospinal tracts (resulting in dense hemiplegia) and perisylvian language areas (causing aphasia). Cytotoxic edema begins within hours, peaks at 2&ndash;5 days, and can cause life\u2010threatening intracranial hypertension and transtentorial herniation. &ldquo;Malignant&rdquo; MCA infarction is defined by involvement of >50% of the MCA territory on CT within 48 hours and clinical deterioration or lack of improvement. Decompressive hemicraniectomy creates space for the swollen brain, rapidly lowering intracranial pressure (ICP) and reducing midline shift. Randomized trials (DECIMAL, HAMLET, DESTINY) have demonstrated that early surgical decompression significantly lowers mortality and improves functional outcomes compared to medical management alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive hemicraniectomy within 48 hours of malignant MCA infarction reduces mortality from ~80% to ~30% and increases the proportion of survivors with moderate disability (modified Rankin Scale &le;4). DECIMAL <span class=\"citation\">(<span class=\"evidence\">Vahedi et al., 2007</span>)</span>, HAMLET <span class=\"citation\">(<span class=\"evidence\">Wester et al., 2009</span>)</span>, and DESTINY <span class=\"citation\">(J\u00fc<span class=\"evidence\">ttler et al., 2007</span>)</span> provided Level A evidence for patients aged 18&ndash;60. DESTINY II <span class=\"citation\">(J\u00fc<span class=\"evidence\">ttler et al., 2014</span>)</span> extended these findings to patients >60, demonstrating a significant survival benefit (hazard ratio 0.34) and acceptable functional outcomes despite more severe baseline deficits. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines grant a Class I recommendation for hemicraniectomy in patients &le;60 and a Class IIa recommendation for selected patients >60 (Level of Evidence B). No randomized data support anticoagulation, osmotherapy, or antiplatelet therapy as definitive treatments for mass effect in malignant MCA infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A. Anticoagulation  <br>&bull; Reason incorrect: Acute systemic anticoagulation (heparin or DOAC) in large infarcts sharply raises risk of hemorrhagic transformation without reducing mass effect.  <br>&bull; Misconception: Treating presumed cardioembolic stroke immediately with anticoagulants will improve outcome.  <br>&bull; Differentiator: Anticoagulation addresses clot propagation, not cytotoxic/vasogenic edema or herniation risk.<br><br>Option B. Osmotic therapy  <br>&bull; Reason incorrect: Mannitol or hypertonic saline can transiently lower ICP but do not change mortality or long-term functional outcomes in malignant MCA infarction.  <br>&bull; Misconception: ICP reduction alone is sufficient to prevent secondary injury.  <br>&bull; Differentiator: Only surgical decompression provides a durable expansion to accommodate edematous brain.<br><br>Option D. Aspirin  <br>&bull; Reason incorrect: Aspirin is indicated for noncardioembolic stroke prevention but has no role in reversing cerebral edema or preventing herniation.  <br>&bull; Misconception: Early antiplatelet therapy will mitigate large\u2010territory ischemia complications.  <br>&bull; Differentiator: Aspirin&rsquo;s mechanism (platelet inhibition) does not address mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication in Malignant MCA</th><th>Impact on Mortality/Outcome</th></tr></thead><tbody><tr><td>Craniotomy/decompression</td><td>Bone flap removal, dural opening</td><td>Definitive within 48 h; all ages</td><td>\u2193Mortality by ~50%; \u2191favorable mRS</td></tr><tr><td>Osmotic therapy (mannitol/HTS)</td><td>\u2191Plasma osmolality \u2192 transient ICP \u2193</td><td>Bridging measure only</td><td>No proven long-term benefit</td></tr><tr><td>Anticoagulation (heparin/DOAC)</td><td>Inhibit clot propagation</td><td>Contraindicated in large infarcts</td><td>\u2191Hemorrhagic transformation risk</td></tr><tr><td>Aspirin (antiplatelet)</td><td>Inhibit platelet aggregation</td><td>Secondary prevention</td><td>No effect on cerebral edema or herniation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal candidates: NIHSS &ge;15, infarct volume >145 mL or >50% MCA on CT, performed within 48 h.  <br><span class=\"list-item\">\u2022</span> DESTINY II supports surgery even in patients >60, though functional outcomes may be more limited.  <br><span class=\"list-item\">\u2022</span> Always combine early neurocritical care (e.g., head elevation, normothermia) with surgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Delaying decompression in favor of maximal medical therapy leads to irreversible herniation and worsened prognosis.  <br><span class=\"list-item\">\u2022</span> Rigid age cutoffs (i.e., >60 means &ldquo;no surgery&rdquo;) ignore evidence from DESTINY II that selected older patients can benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Early Management of Acute Ischemic Stroke Guidelines  <br>   &bull; Class I: Hemicraniectomy for age 18&ndash;60, malignant MCA within 48 h (Level A evidence).  <br>   &bull; Class IIa: Consider in selected patients >60 (DESTINY II data, Level B evidence).  <br>2. European Stroke Organisation (ESO) 2021 Guidelines  <br>   &bull; Strong recommendation for decompressive hemicraniectomy in malignant MCA infarction to reduce mortality and improve outcome (moderate-quality evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The MCA supplies the lateral convexity, including primary motor cortex (precentral gyrus), internal capsule fibers, and perisylvian language cortices. Infarction in this territory leads to contralateral hemiplegia and aphasia, with adjacent edema compressing the basal ganglia and midline structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Large\u2010vessel occlusion causes immediate cytotoxic edema (intracellular Na\u207a/H\u2082O accumulation), followed by vasogenic edema (BBB disruption), culminating in raised ICP, midline shift, and risk of transtentorial herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT criteria for malignant MCA infarction: hypoattenuation of >50% MCA territory, sulcal effacement, loss of grey&ndash;white differentiation, basal cistern effacement, and midline shift &ge;5 mm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Malignant MCA infarction and the timing/indications for decompressive hemicraniectomy are frequently tested as CT\u2010driven management scenarios in stroke and neurosurgery sections.</div></div></div></div></div>"}, {"id": 100023096, "question_number": "101", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Cerebral venous thrombosis (CVT) results from thrombus formation in dural sinuses or cortical veins, leading to impaired venous drainage, increased intracranial pressure (ICP), and vasogenic edema. Key risk factors include inherited thrombophilias, pregnancy/puerperium, and oral contraceptive pills (OCPs). Clinically, CVT often presents subacutely (days to weeks) with headache, seizures, focal deficits, or papilledema. Diagnosis relies on imaging: non-contrast CT may show hyperdense sinus or hemorrhagic infarcts, but CT venography (CTV) or MR venography (MRV) provides confirmation. Understanding the pathophysiology of venous congestion and ICP elevation underpins rationale for anticoagulation even in the presence of hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anticoagulation is the cornerstone of CVT management. <span class=\"evidence\">The 2011</span> American Heart Association/American Stroke Association guidelines (Class I, Level of Evidence B) recommend low-molecular-weight heparin (LMWH) or unfractionated heparin in the acute phase, followed by warfarin (target INR 2.0&ndash;3.0) for 3&ndash;12 months based on risk profile. The International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) demonstrated reduced mortality and improved functional outcomes with early anticoagulation, even when parenchymal hemorrhage is present. European Stroke Organization (ESO) 2017 guidelines echoed these recommendations. Emerging data from the RE-SPECT CVT trial suggest dabigatran may be noninferior to warfarin, but LMWH remains first line pending larger studies. Anticoagulation addresses the underlying thrombotic process, restores venous outflow, and prevents extension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Antiplatelet  <br>&bull; CVT is a venous, fibrin-rich thrombotic process; platelet aggregation plays a limited role.  <br>&bull; Antiplatelet agents have not demonstrated efficacy in CVT and are recommended only for arterial ischemic strokes.  <br>&bull; Misconception: equating arterial stroke management with venous thrombosis.  <br><br>C. Intravascular thrombectomy  <br>&bull; Endovascular mechanical thrombectomy is reserved for deteriorating patients unresponsive to anticoagulation or with impending herniation.  <br>&bull; No randomized trials support its routine first-line use; carries procedural risks (hemorrhage, vessel injury).  <br>&bull; Differs from anticoagulation, which is noninvasive and evidence-backed.  <br><br>D. Carbonic anhydrase inhibitor  <br>&bull; Acetazolamide lowers CSF production and can transiently reduce ICP but does not treat the thrombus.  <br>&bull; Used adjunctively in idiopathic intracranial hypertension, not as primary therapy in CVT.  <br>&bull; Pitfall: treating symptoms without addressing underlying clot.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation</th><th>Antiplatelet</th><th>Intravascular Thrombectomy</th><th>Carbonic Anhydrase Inhibitor</th></tr></thead><tbody><tr><td>Mechanism</td><td>Inhibits clot propagation (anti-IIa/Xa)</td><td>Inhibits platelet aggregation</td><td>Physically removes clot via catheter</td><td>Reduces CSF production</td></tr><tr><td>Indication in CVT</td><td>Primary therapy (Class I evidence)</td><td>Not indicated</td><td>Rescue therapy in refractory cases</td><td>Not indicated</td></tr><tr><td>Key Evidence</td><td>ISCVT; AHA/ASA 2011; ESO 2017</td><td>None in venous thrombosis</td><td>Small case series; no RCTs</td><td>Idiopathic ICP, not CVT</td></tr><tr><td>Risk Profile</td><td>Bleeding (manageable)</td><td>Low venous efficacy</td><td>Procedural hemorrhage risk</td><td>Electrolyte disturbance, paresthesias</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In CVT with hemorrhagic venous infarcts, anticoagulate early&mdash;hemorrhage is due to venous congestion, not clotting diathesis.  <br>2. Papilledema and cranial nerve VI palsy in subacute headache should raise suspicion for CVT, especially in OCP users.  <br>3. Transition from LMWH to oral anticoagulation once stable; monitor INR target 2.0&ndash;3.0 for 3&ndash;12 months depending on provoked vs unprovoked CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Avoiding anticoagulation due to intracerebral hemorrhage: hemorrhagic conversion in CVT is not a contraindication.  <br>2. Misapplying ischemic stroke treatments (aspirin) to venous thrombosis: pathophysiology differs significantly.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2011 Guidelines for CVT (Stroke): Class I recommendation for heparin in acute CVT (Level B).  <br>2. ESO 2017 Guidelines on Cerebral Venous Thrombosis: endorse LMWH over UFH for initial therapy and recommend 3&ndash;12 months of oral anticoagulation.  <br>3. RE-SPECT CVT (2019): randomized trial comparing dabigatran vs warfarin in CVT&mdash;dabigatran noninferior, but LMWH/warfarin remain standard pending further validation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombosis in superior sagittal sinus impairs drainage from cortical veins, raising venous pressure and leading to vasogenic edema predominantly in parasagittal regions; papilledema results from impaired CSF absorption at arachnoid granulations along sinuses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>OCP-induced hypercoagulability promotes thrombus formation in dural sinuses \u2192 venous outflow obstruction \u2192 increased capillary hydrostatic pressure \u2192 blood&ndash;brain barrier disruption \u2192 vasogenic edema and hemorrhagic infarction \u2192 raised ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect CVT with subacute headache + risk factors (OCP, thrombophilia).  <br>2. Noncontrast CT: look for hyperdense sinus (&ldquo;dense triangle sign&rdquo;) or hemorrhagic infarcts.  <br>3. Confirm with CTV or MRV (empty delta sign).  <br>4. Initiate anticoagulation; evaluate for prothrombotic disorders.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dense triangle sign on noncontrast CT (acute clot in superior sagittal sinus).  <br>&bull; Empty delta sign on contrast-enhanced CT venography.  <br>&bull; MRI T2*/SWI can detect venous thrombus and hemorrhagic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; LMWH (e.g., enoxaparin 1 mg/kg SC BID) preferred over UFH for predictable kinetics.  <br>&bull; Switch to warfarin, INR target 2.0&ndash;3.0 for 3&ndash;12 months.  <br>&bull; Consider DOACs (e.g., dabigatran) in stable patients, pending ongoing studies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam.  <br>CVT is frequently tested as a cause of subacute headache with papilledema in young women on OCPs&mdash;know imaging signs and that anticoagulation is first-line even with hemorrhagic infarcts.</div></div></div></div></div>"}, {"id": 100023097, "question_number": "17", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Ischemic strokes are classified by mechanism (TOAST criteria) into large\u2010artery atherosclerosis, cardioembolism, small\u2010vessel occlusion (lacunar), stroke of other determined etiology, and stroke of undetermined etiology. Lacunar infarcts are small (<15 mm) subcortical lesions affecting deep gray or white matter and are hallmark of chronic small vessel disease. They arise from lipohyalinosis or microatheroma in penetrating arterioles. MRI&mdash;particularly diffusion\u2010weighted imaging&mdash;differentiates these tiny infarcts from cortical or border\u2010zone strokes. Recognition of lacunar patterns guides etiologic workup (exclude cardioembolism, vasculitis) and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Small vessel disease (SVD) underlies lacunar infarcts via pathologic changes in small penetrating arteries&mdash;lipohyalinosis (fibrinoid necrosis) and microatheroma&mdash;leading to vessel wall thickening and occlusion. On MRI DWI, SVD appears as punctate (<15 mm) hyperintensities in the basal ganglia, thalamus, internal capsule, or deep white matter. <span class=\"evidence\">The 2019</span> AHA/ASA Acute Ischemic Stroke Guidelines recommend using DWI lesion size &le;15 mm to define lacunar infarction (Class I, Level B). Wardlaw and colleagues&rsquo; STRIVE criteria (2013) standardize imaging definitions of lacunes versus enlarged perivascular spaces. In contrast, watershed infarcts are wedge\u2010shaped at cortical borders during hypotension; cardioembolic strokes are often cortical or involve multiple territories; vasculitis produces multifocal infarcts with vessel wall enhancement on high\u2010resolution MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Watershed  <br>&ndash; Watershed (border\u2010zone) infarcts occur at junctions between major cerebral arteries, producing wedge\u2010shaped cortical or subcortical lesions during systemic hypotension. Lacunes are small, deep, and ovoid, not wedge\u2010shaped.  <br><br>B. Cardioembolic  <br>&ndash; Cardioembolic strokes (e.g., atrial fibrillation) typically produce larger cortical infarcts or multifocal emboli in different territories. Lacunar infarcts lack cortical involvement and are solitary subcortical.  <br><br>D. Vasculitis  <br>&ndash; Cerebral vasculitis causes irregular, multifocal vessel narrowing/occlusion with vessel wall enhancement and often hemorrhagic components. Lacunar SVD lesions are more uniform and lack vessel wall enhancement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Small Vessel Disease (Lacunar)</th><th>Watershed Infarct</th><th>Cardioembolic</th><th>Vasculitis</th></tr></thead><tbody><tr><td>MRI distribution</td><td>Deep, subcortical, <15 mm punctate</td><td>Cortical/subcortical border zones</td><td>Cortical, multiple vascular territories</td><td>Multifocal, variable size, vessel wall changes</td></tr><tr><td>Pathophysiology</td><td>Lipohyalinosis, microatheroma</td><td>Hypoperfusion at arterial junctions</td><td>Embolism from cardiac source</td><td>Inflammatory vessel wall thickening/occlusion</td></tr><tr><td>DWI characteristics</td><td>Small, ovoid hyperintensity</td><td>Wedge\u2010shaped hyperintensity</td><td>Larger, cortical hyperintensities</td><td>Heterogeneous lesions with enhancement</td></tr><tr><td>Associated risk factors</td><td>Hypertension, diabetes</td><td>Severe hypotension/shock</td><td>Atrial fibrillation, valvular disease</td><td>Systemic autoimmune disease, infections</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lacunar strokes account for ~25% of ischemic strokes; strict blood pressure control is paramount to prevent progression.  <br>&bull; DWI MRI is the gold standard for detecting acute lacunar infarcts <5 mm early, often before CT changes.  <br>&bull; TOAST classification guides workup: absence of large\u2010artery stenosis or cardioembolism plus lacunar imaging pattern confirms SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Labeling any small infarct in deep white matter as lacunar without verifying the <15 mm size criterion.  <br>2. Attributing deep white matter hyperintensities solely to &ldquo;age\u2010related changes,&rdquo; ignoring hypertension\u2010driven SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Powers et al.): Recommends DWI lesion size &le;15 mm to define lacunar infarction (Class I, Level B).  <br>2. SPS3 Trial (2013): Secondary Prevention of Small Subcortical Strokes showed no benefit&mdash;and increased bleeding&mdash;with dual antiplatelet therapy versus aspirin alone after lacunar stroke, supporting monotherapy <span class=\"citation\">(NEJM 2013;369:1005)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lenticulostriate arteries&mdash;penetrating branches of the middle cerebral artery&mdash;supply the basal ganglia and internal capsule. Occlusion leads to pure motor or sensory lacunar syndromes corresponding to these structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension induces arteriolar wall thickening, lipohyalinosis (vessel wall degeneration), and microatheroma formation. These changes progressively narrow the lumen of penetrating arterioles, leading to focal ischemia and lacunar infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Acute CT to exclude hemorrhage.  <br>2. MRI with DWI/FLAIR to detect infarct size and location.  <br>3. Vascular imaging (MRA/CTA) to rule out large\u2010artery stenosis.  <br>4. Cardiac evaluation (ECG, echocardiography) to exclude embolic sources.  <br>5. If imaging shows single deep lesion &le;15 mm, no large\u2010artery or cardioembolic source, diagnose SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Lacunes on FLAIR appear as CSF\u2010like cavities; chronic lacunes have hypointense center with hyperintense rim.  <br>&bull; Microbleeds on susceptibility\u2010weighted imaging often co\u2010exist with SVD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Recognizing lacunar infarct patterns on MRI and correlating them with small vessel occlusion is a high\u2010yield topic on neurology board exams, frequently tested in the format of imaging\u2010based etiologic classification.</div></div></div></div></div>"}, {"id": 100023098, "question_number": "177", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by transient multifocal narrowing of cerebral arteries, often presenting with thunderclap headache. Key concepts:  <br>1. CSF analysis in vasospastic disorders (RCVS vs primary angiitis of the CNS) helps differentiate inflammatory vs non-inflammatory etiologies.  <br>2. RCVS typically demonstrates no significant inflammation&mdash;normal cell count, protein, and glucose.  <br>3. Understanding CSF glucose: it parallels blood glucose and is preserved unless there is metabolic consumption by organisms or malignant cells.  <br>(Word count: 85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The hallmark of RCVS is noninflammatory vasospasm; CSF is normal or shows only mild, nonspecific protein elevation (<60 mg/dL) without pleocytosis or hypoglycorrhachia. Ducros et al. (2012) reviewed 67 patients: 92% had normal CSF cell counts and glucose; 15% had mild protein elevation. <span class=\"evidence\">The 2012</span> AHA Scientific Statement on RCVS (Class IIa, Level B) emphasizes that normal CSF helps exclude primary CNS angiitis, which usually shows pleocytosis and elevated protein. No current guideline lists hypoglycorrhachia or oligoclonal bands as features of RCVS. Thus, &ldquo;normal glucose&rdquo; is the only consistent CSF finding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. High protein  <br><span class=\"list-item\">\u2022</span> Incorrect: CSF protein in RCVS is usually normal or mildly elevated (<60 mg/dL).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any headache syndrome with significant BBB disruption.  <br><span class=\"list-item\">\u2022</span> Differentiator: Primary angiitis has protein often >100 mg/dL.  <br><br>B. Oligoclonal bands  <br><span class=\"list-item\">\u2022</span> Incorrect: Reflect intrathecal IgG synthesis (e.g., multiple sclerosis).  <br><span class=\"list-item\">\u2022</span> Misconception: Ignoring that RCVS is noninflammatory.  <br><span class=\"list-item\">\u2022</span> Differentiator: OCBs are absent in RCVS.  <br><br>D. Elevated white blood cell count  <br><span class=\"list-item\">\u2022</span> Incorrect: Pleocytosis is not a feature; cell count usually &le;5 cells/mm3.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing RCVS with infectious or inflammatory vasculopathies.  <br><span class=\"list-item\">\u2022</span> Differentiator: CNS vasculitis shows WBC >10 cells/mm3.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Primary CNS Vasculitis</th><th>Subarachnoid Hemorrhage (SAH)</th></tr></thead><tbody><tr><td>WBC (cells/mm3)</td><td>&le;5</td><td>10&ndash;200+</td><td>&le;10 (unless blood breakdown)</td></tr><tr><td>Protein (mg/dL)</td><td>Normal&ndash;mild \u2191 (<60)</td><td>\u2191\u2191 (>100)</td><td>Mild&ndash;moderate \u2191</td></tr><tr><td>Glucose (mg/dL)</td><td>Normal</td><td>Normal&ndash;low</td><td>Normal</td></tr><tr><td>Clinical course</td><td>Reversible (days&ndash;wk)</td><td>Progressive</td><td>Acute, with meningeal signs</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thunderclap headache in RCVS often recurs over 1&ndash;2 weeks; look for &ldquo;string-of-beads&rdquo; on angiography.  <br><span class=\"list-item\">\u2022</span> Nimodipine may relieve headache but evidence is limited to observational studies.  <br><span class=\"list-item\">\u2022</span> Always obtain CSF before high-dose steroids if primary angiitis is in the differential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming any cerebral vasospasm equates to vasculitis and expecting pleocytosis.  <br>2. Overinterpreting mild protein rise in RCVS as evidence of inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association (AHA) Scientific Statement on RCVS, 2012  <br><span class=\"list-item\">\u2022</span> Recommendation: CSF analysis to exclude inflammatory causes; expect normal findings. (Class IIa, Level B evidence)  <br>2. International Headache Society (IHS) Classification, 3rd Edition, 2018  <br><span class=\"list-item\">\u2022</span> Defines RCVS under headache disorders; notes normal CSF profile as diagnostic criterion. (Consensus-based)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. RCVS and CSF findings are frequently tested in neurology boards to distinguish noninflammatory vasospasm from CNS vasculitis.</div></div></div></div></div>"}, {"id": 100023099, "question_number": "7", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Cavernous malformations (cavernomas) are clusters of dilated capillary spaces without intervening brain parenchyma.  <br>&bull; Deep lesions (e.g., thalamus, basal ganglia, brainstem) carry higher surgical morbidity than lobar lesions.  <br>&bull; Asymptomatic or minimally symptomatic cavernomas (headache only, no hemorrhage or seizures) generally warrant conservative management.  <br>&bull; Family history suggests a familial CCM syndrome (CCM1&ndash;3 gene mutations), but penetrance is variable and imaging&ndash;based surveillance guides intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Observation is recommended for deep cavernomas in patients without prior hemorrhage, seizures, or progressive neurological deficits. <span class=\"evidence\">The 2017</span> AHA/ASA guidelines on unruptured intracranial vascular malformations (Class IIb, Level C) state that surgical resection carries unacceptable functional risk in deep eloquent locations when the lesion is incidental or minimally symptomatic. A meta-analysis by Gross et al. <span class=\"citation\">(Neurosurgery, 2010)</span> demonstrated an annual hemorrhage rate of 0.8&ndash;1.6% for incidentally discovered cavernomas, with post\u2010operative morbidity of 10&ndash;20% for deep resections. Radiosurgery has not shown consistent obliteration rates and carries delayed radiation necrosis risk. Antiepileptic drugs are indicated only if seizures are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Resection  <br>&ndash; Surgical morbidity (10&ndash;20%) often exceeds the natural hemorrhage risk in asymptomatic deep cavernomas.  <br>&ndash; Misconception: &ldquo;Any cavernoma should be removed to prevent future hemorrhage.&rdquo; Deep location contraindicates routine resection unless rebleeding occurs.  <br><br>C. Radiosurgery  <br>&ndash; No high\u2010quality trials demonstrate significant reduction in hemorrhage risk; delayed latency period (2&ndash;3 years) before effect and risk of radiation injury.  <br>&ndash; Misconception: &ldquo;Stereotactic radiosurgery is low\u2010risk for deep lesions.&rdquo; Evidence for efficacy is lacking and complications are nontrivial.  <br><br>D. Antiepileptic medication  <br>&ndash; No seizure history; headaches alone do not justify prophylactic antiepileptic therapy.  <br>&ndash; Misconception: &ldquo;Cavernoma imaging changes mandate seizure prophylaxis.&rdquo; AEDs are reserved for documented seizures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Observation</th><th>Resection</th><th>Radiosurgery</th><th>Antiepileptic Medication</th></tr></thead><tbody><tr><td>Indication</td><td>Asymptomatic/minimally symptomatic deep cavernomas</td><td>Symptomatic hemorrhage or focal deficits in accessible lobar lesions</td><td>Controversial; small series only</td><td>Seizure control only</td></tr><tr><td>Annual hemorrhage risk</td><td>0.8&ndash;1.6%</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Procedure\u2010related morbidity</td><td>None</td><td>10&ndash;20% for deep lesions</td><td>5&ndash;10% radiation necrosis risk</td><td>Side effects (sedation, rash)</td></tr><tr><td>Evidence strength</td><td>Class IIb, Level C <span class=\"citation\">(AHA/ASA 2017)</span></td><td>Recommended if rebleed or worsening neurologic status</td><td>Insufficient data</td><td>Class I for seizure treatment only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Use susceptibility\u2010weighted MRI (GRE/T2*) to detect small, asymptomatic cavernomas.  <br>&bull; Deep cavernomas in familial CCM often present with multiple lesions; treatment decisions hinge on symptomatology, not lesion count.  <br>&bull; Infratentorial hemorrhages from cavernoma rebleed carry higher morbidity; intervene only after documented rebleed.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing headache caused by cavernoma with intracranial hypertension&mdash;headaches alone are nonspecific and often unrelated.  <br>2. Believing family history mandates prophylactic surgery or radiosurgery&mdash;management is driven by clinical presentation and lesion behavior.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2017 Guideline on Unruptured Intracranial Vascular Malformations <span class=\"citation\">(<span class=\"evidence\">Stroke 2017</span>)</span>: &ldquo;Observation is reasonable for unruptured, asymptomatic deep cavernomas&rdquo; (Class IIb, Level C).  <br>&bull; Horne et al., Lancet <span class=\"evidence\">Neurology 2019</span> (Caveat Study): Prospective cohort showing low annual hemorrhage risk (1.0%) in non\u2010brainstem cavernomas, supporting conservative management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cavernous malformations lack mature vascular wall structures (no smooth muscle), leading to low\u2010flow, high\u2010risk microhemorrhages.  <br>&bull; Familial CCM arises from autosomal\u2010dominant mutations (KRIT1/CCM1, CCM2, PDCD10/CCM3) with variable penetrance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cavernomas characteristically show a &ldquo;popcorn&rdquo; core of mixed signal intensity on T1/T2 and a hypointense hemosiderin rim on gradient\u2010echo or SWI sequences.  <br>&bull; Absence of contrast enhancement distinguishes cavernoma from other vascular malformations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Management of incidental cavernomas is tested in neurology and neurosurgery boards, often as a vignette differentiating incidental from symptomatic lesions and choosing between observation, microsurgery, and radiosurgery.</div></div></div></div></div>"}, {"id": 100023100, "question_number": "77", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Traumatic blunt cerebrovascular injury (BCVI) most commonly involves the cervical internal carotid artery (ICA) due to its vulnerability at the skull base and flexion&ndash;extension forces. Key concepts:  <br><span class=\"list-item\">\u2022</span> Cervical ICA anatomy: runs through the carotid sheath, turns medially into the carotid canal; fixed points predispose to intimal tears.  <br><span class=\"list-item\">\u2022</span> Mechanisms of injury: hyperextension&ndash;rotation causes intimal flap, mural hematoma, pseudoaneurysm.  <br><span class=\"list-item\">\u2022</span> Imaging modalities: CT angiography (CTA) is first-line in trauma, demonstrating &ldquo;string sign,&rdquo; tapered stenosis, or contrast extravasation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CTA image in this RTA patient demonstrates a focal eccentric filling defect in the distal cervical segment of the ICA with a tapered &ldquo;flame&rdquo; appearance and an adjacent mural hematoma&mdash;hallmarks of traumatic ICA dissection. According to the Denver criteria <span class=\"citation\">(<span class=\"evidence\">Biffl et al., 2010</span>)</span>, high-risk mechanisms (e.g., deceleration, facial fractures) warrant CTA screening; ICA lesions account for ~70% of BCVIs and present with stenosis, occlusion, or pseudoaneurysm. AHA/ASA 2019 stroke guidelines recommend antithrombotic therapy (Class I, Level B) for grade I&ndash;II dissections to prevent thromboembolism. Prospective series <span class=\"citation\">(<span class=\"evidence\">Cavalleri et al., 2018</span>)</span> show early CTA detection and antiplatelet use reduce stroke risk by 80%. Hence, ICA is the correct localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because vertebral dissections produce posterior circulation infarcts (e.g., cerebellar, brainstem) and appear as eccentric narrowing in V1&ndash;V3 segments, not the cervical ICA course.  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any neck vessel dissection is vertebral&mdash;misses anterolateral carotid anatomy.  <br><br>C. Middle cerebral artery  <br><span class=\"list-item\">\u2022</span> MCA occlusions present with cortical/subcortical infarcts on parenchymal CT, not as a neck vessel filling defect on CTA.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating intracranial arterial thrombosis with extracranial trauma.  <br><br>D. Basilar artery  <br><span class=\"list-item\">\u2022</span> Basilar injuries manifest in the pontine region and are extremely rare post-RTA without skull base fracture; CTA would show basilar lumen irregularity at the clival canal.  <br><span class=\"list-item\">\u2022</span> Misconception: defaulting to posterior circulation when neck pain is present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Internal Carotid Artery (ICA)</th><th>Vertebral Artery (VA)</th><th>Middle Cerebral Artery (MCA)</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Typical lesion location</td><td>Cervical segment at skull base</td><td>V1&ndash;V3 segments in neck</td><td>M1/M2 segments in Sylvian fissure</td><td>Basal pontine cistern</td></tr><tr><td>Imaging hallmark</td><td>Tapered stenosis (&ldquo;flame&rdquo; sign), mural hematoma</td><td>Longitudinal string sign</td><td>Cortical branch cutoff on CTA</td><td>Irregular lumen at clival canal</td></tr><tr><td>Common clinical syndrome</td><td>Hemispheric TIA/stroke, Horner syndrome</td><td>Dizziness, ataxia, brainstem signs</td><td>Contralateral hemiparesis, aphasia</td><td>Locked-in syndrome, vertigo</td></tr><tr><td>Trauma mechanism</td><td>Hyperextension&ndash;rotation</td><td>Direct neck flexion&ndash;extension</td><td>Rarely trauma-related</td><td>Severe basilar skull fracture</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use Denver screening criteria in all high-energy RTA patients with cervical fractures or seatbelt marks to avoid missed BCVI.  <br><span class=\"list-item\">\u2022</span> CTA neck with thin sections (&le;1 mm) is >95% sensitive for grade I&ndash;III dissections; follow-up at 7&ndash;10 days to assess healing or progression.  <br><span class=\"list-item\">\u2022</span> Early antiplatelet (aspirin 81&ndash;325 mg daily) is as effective as anticoagulation for extracranial ICA dissections, with lower hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Failing to screen blunt trauma patients without obvious neck fractures &ndash; up to 20% of BCVIs occur without bony injury.  <br>2. Interpreting hyperdense hematoma on noncontrast CT as intraparenchymal bleed rather than mural hematoma in the vessel wall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- Biffl WL et al., &ldquo;Blunt Cerebrovascular Injury Practice Management Guidelines,&rdquo; Journal of Trauma, 2010: Recommend CTA for grade I&ndash;V injuries; antithrombotic therapy for grade I&ndash;II (Level II).  <br><span class=\"list-item\">\u2022</span> EAST (Eastern Association for the Surgery of Trauma) BCVI Guidelines, 2018: Class I recommendation for CTA screening in mechanism-plus-physical sign; antiplatelet over anticoagulation for grade I&ndash;II lesions (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA lies within the carotid sheath, bounded by the internal jugular vein and vagus nerve. Fixed at the carotid canal, it is prone to intimal shear during hyperextension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear \u2192 blood dissects into media \u2192 mural hematoma formation \u2192 luminal narrowing or pseudoaneurysm \u2192 thrombus formation \u2192 embolic ischemic stroke in anterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify RTA patients with risk factors (neck pain, fractures).  <br>2. Perform CTA head/neck within 24 h.  <br>3. Grade BCVI (I&ndash;V) based on CTA.  <br>4. Initiate antithrombotic therapy for grade I&ndash;III.  <br>5. Repeat imaging in 7&ndash;14 days; escalate management if lesion progresses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- T1 fat-saturated MRI can confirm mural hematoma if CTA equivocal.  <br><span class=\"list-item\">\u2022</span> &ldquo;String and pearl&rdquo; sign indicates pseudoaneurysm in traumatic dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin 81&ndash;325 mg daily is first-line for grade I&ndash;II BCVI <span class=\"citation\">(Class I, Level B&mdash;AHA/ASA 2019)</span>.  <br><span class=\"list-item\">\u2022</span> For grade III pseudoaneurysms, consider anticoagulation (heparin bridging to warfarin INR 2&ndash;3) if no contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Traumatic cervical vascular injuries frequently test recognition of CTA signs (flame sign, intimal flap), screening criteria (Denver), and management (antiplatelets vs anticoagulation) on neurology and surgery boards.</div></div></div></div></div>"}, {"id": 100023101, "question_number": "52", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Prevention is stratified into four levels: Primary prevention reduces risk factors before disease onset (e.g., hypertension control); Secondary prevention detects and treats early disease to prevent progression or recurrence (e.g., antiplatelet therapy post-TIA); Tertiary prevention mitigates established disease sequelae, aiming to restore function and reduce disability (e.g., post-stroke rehabilitation); Quaternary prevention avoids overmedicalization. In ischemic stroke, infarction of cortical and subcortical areas (e.g., Broca&rsquo;s area, corticobulbar tracts) leads to dysarthria or aphasia. Speech therapy leverages neuroplasticity&mdash;axonal sprouting, synaptogenesis, and cortical reorganization&mdash;to recover language and motor function. Recognizing rehabilitation as tertiary prevention places it appropriately within the continuum of stroke care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Tertiary prevention in stroke is supported by robust guidelines and trials. The American Heart Association/American Stroke <span class=\"evidence\">Association 2019</span> Guidelines for the Early Management of Patients with Acute Ischemic Stroke (Class I, Level of Evidence A) recommend initiation of multidisciplinary rehabilitation, including speech therapy, as soon as medically feasible, typically within 24&ndash;48 hours post-stroke. Langhorne et al.&rsquo;s 2017 Cochrane review demonstrated organized stroke unit care with structured rehabilitation reduces long-term disability (absolute risk reduction of poor outcome by 7%; 95% CI 3&ndash;11%). Mechanistically, rehabilitation exploits the subacute window of heightened neuroplasticity <span class=\"citation\">(<span class=\"evidence\">Cramer et al., 2018</span>)</span>, promoting remapping in perilesional cortex and contralateral homologous areas. In contrast, primary prevention (e.g., lifestyle modification) and secondary prevention (e.g., antiplatelet, statin therapy) target different pathophysiological stages and objectives.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary prevention  <br><span class=\"list-item\">\u2022</span> Targets risk factor control before the first event, not recovery from sequelae.  <br><span class=\"list-item\">\u2022</span> Misconception: conflating rehabilitation with prevention of initial stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: does not address disability reduction post-event.<br><br>B. Secondary prevention  <br><span class=\"list-item\">\u2022</span> Focuses on preventing recurrence or early detection (e.g., antithrombotics, endarterectomy).  <br><span class=\"list-item\">\u2022</span> Misconception: assuming any post-stroke action prevents new strokes rather than restoring function.  <br><span class=\"list-item\">\u2022</span> Differentiator: does not involve neurorehabilitation strategies.<br><br>D. Quaternary prevention  <br><span class=\"list-item\">\u2022</span> Involves avoiding unnecessary or harmful medical interventions.  <br><span class=\"list-item\">\u2022</span> Misconception: equating harm reduction from overtreatment with functional recovery.  <br><span class=\"list-item\">\u2022</span> Differentiator: addresses iatrogenic risk, not rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Level of Prevention</th><th>Primary Goal</th><th>Stroke Example</th></tr></thead><tbody><tr><td>A</td><td>Primary</td><td>Prevent first event</td><td>Hypertension control, smoking cessation</td></tr><tr><td>B</td><td>Secondary</td><td>Prevent recurrence</td><td>Antiplatelet therapy, carotid endarterectomy post-TIA</td></tr><tr><td>C</td><td>Tertiary [CORRECT]</td><td>Reduce disability</td><td>Speech therapy, physiotherapy</td></tr><tr><td>D</td><td>Quaternary</td><td>Avoid overmedicalization</td><td>Limiting unnecessary prolonged catheterization</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early rehabilitation (within 24&ndash;48 h) enhances outcomes; delays beyond 1 week correlate with increased long-term disability <span class=\"citation\">(AHA/ASA 2019)</span>.  <br><span class=\"list-item\">\u2022</span> Intensive speech therapy (&ge;3 hours/week) significantly improves aphasia and dysarthria scores <span class=\"citation\">(<span class=\"evidence\">Cramer et al., 2018</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Clearly distinguish secondary prevention pharmacotherapy from tertiary functional interventions when designing post-stroke care plans.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling rehabilitation as secondary prevention because it occurs after the acute event.  <br>2. Ignoring quaternary prevention, leading to confusion between harm reduction and functional restoration.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2019 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: Recommends initiation of multidisciplinary rehabilitation, including speech therapy, within 24&ndash;48 h of stroke onset (Class I, LOE A).  <br>2. NICE Guideline NG128 &ldquo;Stroke and TIA in over 16s: diagnosis and initial management&rdquo; (2019): High-quality RCT evidence supports early assessment and intervention by speech and language therapists to improve communication outcomes (Evidence level: high).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Stroke prevention frameworks, especially classification of interventions into primary, secondary, tertiary, and quaternary prevention, are frequently tested as single-best-answer items in neurology and public health modules.</div></div></div></div></div>"}, {"id": 100023102, "question_number": "76", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Antiphospholipid syndrome (APS) is an acquired thrombophilia marked by arterial or venous thrombosis and pregnancy morbidity. In APS, antibodies (lupus anticoagulant, anticardiolipin, anti-&beta;2-glycoprotein I) bind phospholipid&ndash;protein complexes, paradoxically prolonging phospholipid-dependent clotting assays (PT/aPTT) while promoting in vivo thrombosis. Young patients with ischemic stroke plus recurrent miscarriages and unexplained clotting abnormality (elevated PT) strongly suggest APS rather than inherited thrombophilia. Key terminology: lupus anticoagulant (functional assay), anticardiolipin antibodies (ELISA), Sapporo criteria (clinical + laboratory). Recognizing APS is critical, as management (long-term anticoagulation) and obstetric prophylaxis differ from other hypercoagulable states.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is testing for APS because:  <br><span class=\"list-item\">\u2022</span> APS is diagnosed via persistently positive lupus anticoagulant on 2 occasions &ge;12 weeks apart, or moderate-high titers of anticardiolipin/anti-&beta;2 glycoprotein I antibodies, per the 2006 revised Sapporo criteria and reaffirmed by the 2020 ISTH guidelines <span class=\"citation\">(Garcia et al., J Thromb <span class=\"evidence\">Haemost 2020</span>)</span>.  <br><span class=\"list-item\">\u2022</span> Lupus anticoagulant assays explain the elevated PT (phospholipid dependence); inherited thrombophilias <span class=\"citation\">(Factor V Leiden, prothrombin G20210A, protein C/S deficiency)</span> do not prolong PT.  <br><span class=\"list-item\">\u2022</span> APS carries a high risk of arterial events (ischemic stroke) and obstetric complications (recurrent abortions).  <br><span class=\"list-item\">\u2022</span> The ISTH SSC recommendations (2020) stress the three\u2010step testing sequence (screening, mixing, confirmatory) and repeat testing after 12 weeks to confirm persistent positivity (Grade A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Prothrombin gene mutation  <br><span class=\"list-item\">\u2022</span> Incorrect: G20210A mutation causes venous thrombosis, not arterial stroke or pregnancy loss; does not prolong PT.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating all thrombophilias with arterial events.  <br><span class=\"list-item\">\u2022</span> Differentiator: No impact on phospholipid-dependent clotting tests.  <br><br>C. Protein C and Protein S levels  <br><span class=\"list-item\">\u2022</span> Incorrect: Deficiencies predispose mainly to venous thrombosis; levels are affected by acute thrombosis and anticoagulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming natural anticoagulant deficiencies present with miscarriages and PT prolongation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Normal PT; low protein C/S do not explain recurrent abortions.  <br><br>D. Factor V Leiden mutation  <br><span class=\"list-item\">\u2022</span> Incorrect: Most common inherited venous thrombophilia; minimal arterial risk; no effect on PT.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating its role in stroke and obstetric events.  <br><span class=\"list-item\">\u2022</span> Differentiator: Factor V Leiden assays do not address lupus anticoagulant or antibody\u2010mediated coagulopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>APS Testing</th><th>Prothrombin G20210A</th><th>Protein C/S Levels</th><th>Factor V Leiden</th></tr></thead><tbody><tr><td>PT/aPTT Effect</td><td>Prolonged</td><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Association with Arterial Stroke</td><td>Strong</td><td>None</td><td>Weak</td><td>Minimal</td></tr><tr><td>Pregnancy Morbidity</td><td>Yes (recurrent abortions)</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Inherited vs Acquired</td><td>Acquired autoimmune</td><td>Inherited mutation</td><td>Inherited or acquired deficiency</td><td>Inherited mutation</td></tr><tr><td>Confirmatory Testing</td><td>Lupus anticoagulant, anticardiolipin, anti-&beta;2GPI</td><td>PCR-based genotyping</td><td>Functional assays/antigen levels</td><td>PCR-based genotyping</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Lupus anticoagulant paradoxically prolongs PT/aPTT but increases thrombotic risk&mdash;never withhold anticoagulation solely on lab prolongation.  <br>2. Confirm APS with repeat antibody testing &ge;12 weeks after the first positive to avoid false positives during acute thrombosis or infection.  <br>3. In pregnant APS patients, combine low-dose aspirin with low-molecular-weight heparin to improve live birth rates <span class=\"citation\">(EULAR 2019)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Mistaking lupus anticoagulant for a bleeding disorder rather than an acquired thrombophilia.  <br><span class=\"list-item\">\u2022</span> Ordering inherited thrombophilia panels (Factor V Leiden, prothrombin mutation) first in arterial stroke with obstetric history.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. EULAR Recommendations for APS Management (2019):  <br><span class=\"list-item\">\u2022</span> Vitamin K antagonists (INR 2.0&ndash;3.0) are first-line for thrombotic APS (Level 1B).  <br><span class=\"list-item\">\u2022</span> Low-dose aspirin plus LMWH recommended in pregnant APS patients with prior miscarriages (Grade A).  <br>2. ISTH SSC Guidelines on Lupus Anticoagulant Detection (2020):  <br><span class=\"list-item\">\u2022</span> Use a three-step testing algorithm (screen, mixing, confirmatory) and repeat after 12 weeks (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>APS antibodies target plasma proteins bound to phospholipid surfaces, leading to:  <br><span class=\"list-item\">\u2022</span> Endothelial activation (upregulation of adhesion molecules)  <br><span class=\"list-item\">\u2022</span> Platelet aggregation (via &beta;2-GPI)  <br><span class=\"list-item\">\u2022</span> Complement activation (C5a-mediated neutrophil recruitment)  <br>These mechanisms converge to produce arterial thrombosis and placental infarction, causing stroke and miscarriages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: arterial thrombosis + obstetric morbidity.  <br>2. Initial labs: PT/aPTT (prolonged suggests LA).  <br>3. APS panel: lupus anticoagulant (dilute Russell&rsquo;s viper venom test), anticardiolipin IgG/IgM, anti-&beta;2-GPI IgG/IgM.  <br>4. Repeat positive tests after &ge;12 weeks to confirm persistent antibody presence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Lifelong warfarin targeting INR 2.0&ndash;3.0 for thrombotic APS.  <br><span class=\"list-item\">\u2022</span> Avoid DOACs in high-risk/triple-positive APS (per TRAPS trial).  <br><span class=\"list-item\">\u2022</span> For obstetric APS, use prophylactic LMWH and low-dose aspirin until postpartum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. APS is frequently tested in vignette format requiring integration of thrombosis, coagulation assays, and obstetric history. Recognize lab paradox and confirmatory testing criteria for exam success.</div></div></div></div></div>"}, {"id": 100023103, "question_number": "63", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] - Anatomy: The internal carotid artery (ICA) ascends within the carotid sheath alongside cranial nerves IX&ndash;XII and the pericarotid sympathetic plexus.  <br><span class=\"list-item\">\u2022</span> Horner&rsquo;s syndrome: Interruption of oculosympathetic fibers that ascend on the ICA \u2192 ipsilateral ptosis, miosis, anhidrosis.  <br><span class=\"list-item\">\u2022</span> Hypoglossal nerve palsy: CN XII courses medial to the ICA; compression or ischemia causes ipsilateral tongue deviation.  <br><span class=\"list-item\">\u2022</span> Dissection pathophysiology: Intimal tear \u2192 intramural hematoma \u2192 mass effect on adjacent nerves plus embolic risk.  <br><span class=\"list-item\">\u2022</span> Clinical triad: neck pain/headache, focal nerve palsies, Horner&rsquo;s syndrome, often after minor trauma. (\u2248120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection uniquely produces both Horner&rsquo;s syndrome and ipsilateral hypoglossal palsy due to its close relationship with the pericarotid sympathetic plexus and CN XII in the carotid sheath. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines on Cervical Artery Dissection (Class I, Level B-NR) recommend prompt CTA/MRA in suspected cases presenting with neck pain and focal cranial nerve signs. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> showed no significant difference between antiplatelet and anticoagulation strategies for stroke prevention, reinforcing individualized antithrombotic therapy. Case series report Horner&rsquo;s syndrome in 50&ndash;60% of ICA dissections, whereas vertebral artery dissections seldom cause isolated sympathetic chain disruption or CN XII palsy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Vertebral artery  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Vertebral artery dissections typically produce lateral medullary (Wallenberg) syndromes, not isolated Horner&rsquo;s with CN XII palsy.  <br><span class=\"list-item\">\u2022</span> Misconception: All cervical dissections involve the oculosympathetic chain&mdash;only the ICA carries it in the carotid sheath.  <br><span class=\"list-item\">\u2022</span> Differentiator: CN XII does not traverse alongside the vertebral artery.<br><br>C. PICA  <br><span class=\"list-item\">\u2022</span> Reason incorrect: PICA infarcts cause lateral medullary signs (dysphagia, hoarseness), sparing CN XII and sympathetic fibers.  <br><span class=\"list-item\">\u2022</span> Misconception: Posterior circulation strokes always produce Horner&rsquo;s syndrome&mdash;PICA territory lies distal to sympathetic outflow.  <br><span class=\"list-item\">\u2022</span> Differentiator: PICA arises from the vertebral artery, not the carotid sheath.<br><br>D. Basilar  <br><span class=\"list-item\">\u2022</span> Reason incorrect: Basilar artery lesions yield midbrain/pons deficits (e.g., locked-in, vertical gaze palsy), not extracranial Horner&rsquo;s or isolated tongue deviation.  <br><span class=\"list-item\">\u2022</span> Misconception: Major brainstem strokes commonly cause CN XII palsy&mdash;basilar strokes present with diffuse brainstem signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Basilar pathology results in bilateral or crossed findings, not isolated ipsilateral nerve palsies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Vertebral Dissection</th><th>PICA Infarct</th><th>Basilar Lesion</th></tr></thead><tbody><tr><td>Anatomy</td><td>Carotid sheath (CN XII + sympathetic plexus)</td><td>Transverse foramina/C1&ndash;C2 region</td><td>Lateral medulla (VA branch)</td><td>Pons/midbrain</td></tr><tr><td>Horner&rsquo;s syndrome</td><td>Common (50&ndash;60%)</td><td>Rare</td><td>Rare</td><td>Variable</td></tr><tr><td>Hypoglossal palsy (CN XII)</td><td>Yes</td><td>No</td><td>No</td><td>Bulbar signs, not isolated</td></tr><tr><td>Typical imaging modality</td><td>CTA/MRA</td><td>CTA/MRA</td><td>MRI</td><td>MRI/angiography</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Minor neck trauma plus focal cranial nerve deficits should raise suspicion for cervical artery dissection.  <br><span class=\"list-item\">\u2022</span> Ipsilateral Horner&rsquo;s syndrome with tongue deviation localizes pathology to the carotid sheath (ICA).  <br><span class=\"list-item\">\u2022</span> MRI with fat-suppressed T1 sequence best visualizes intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating all cervical dissections with Horner&rsquo;s syndrome&mdash;only ICA carries the sympathetic plexus in the carotid sheath.  <br><span class=\"list-item\">\u2022</span> Misattributing isolated tongue deviation to medullary infarction&mdash;CN XII palsy without other brainstem signs suggests extracranial lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Guidelines on Cervical Artery Dissection: Class I recommendation for CTA/MRA in suspected ICA dissection (Level B-NR).  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No difference between antiplatelet vs anticoagulation for preventing recurrent stroke in cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The pericarotid sympathetic plexus wraps around the ICA; CN XII exits the hypoglossal canal and lies medial to the ICA in the carotid sheath, explaining combined sympathetic and motor nerve signs in ICA dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to track into the media, creating an intramural hematoma. This narrows the lumen (ischemic risk), distorts vessel wall (embolism risk), and compresses adjacent nerves causing local deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect in patients with head/neck pain + Horner&rsquo;s &plusmn; CN XII palsy.  <br>2. Obtain CTA/MRA of head and neck.  <br>3. Confirm with T1 fat-saturated MRI (intramural hematoma).  <br>4. Initiate antithrombotic therapy; monitor for expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA: &ldquo;string sign,&rdquo; double-lumen or tapered stenosis in ICA.  <br><span class=\"list-item\">\u2022</span> MRI: High T1 signal crescent-shaped intramural hematoma on fat-suppressed sequences.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Antiplatelet therapy (aspirin 75&ndash;325 mg daily) or anticoagulation (LMWH \u2192 warfarin, INR 2&ndash;3) for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> CADISS supports choice based on bleeding risk and patient factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Carotid dissection with Horner&rsquo;s syndrome and hypoglossal palsy is a classic high-yield presentation tested frequently on neurology board exams, often in clinical vignette format linking trauma to specific neuroanatomy.</div></div></div></div></div>"}, {"id": 100023104, "question_number": "45", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] Fabry disease is an X-linked lysosomal storage disorder caused by deficient &alpha;-galactosidase A activity, leading to globotriaosylceramide (Gb3) accumulation in vascular endothelium, smooth muscle and skin. Angiokeratomas&mdash;clusters of dilated capillaries in the dermis&mdash;are virtually pathognomonic. Gb3 deposition in cerebral small vessels predisposes to ischemic strokes, often in the fourth or fifth decade. Recognizing the constellation of acroparesthesias, corneal verticillata, angiokeratomas, renal dysfunction and cerebrovascular events distinguishes Fabry from demyelinating, hereditary arteriopathies or mitochondrial encephalopathies.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fabry disease (answer B) is confirmed by low plasma &alpha;-galactosidase A activity in males or GLA gene sequencing in females. The European Fabry Disease Expert Panel (2017) and American College of Medical Genetics guidelines recommend early diagnosis to initiate enzyme replacement therapy (ERT) which decreases Gb3 burden and reduces stroke incidence <span class=\"citation\">(<span class=\"evidence\">Weidemann et al., 2013</span>; El Dib et al., <span class=\"evidence\">Cochrane 2016</span>)</span>. Cerebral MRI in Fabry shows confluent white matter hyperintensities and the &ldquo;pulvinar sign&rdquo; (T1 hyperintensity of the thalamic pulvinar nucleus). Neither multiple sclerosis (immune-mediated demyelination), CADASIL (NOTCH3 arteriopathy), nor MELAS (mitochondrial tRNA mutation) feature angiokeratomas or &alpha;-Gal A deficiency.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple sclerosis  <br>&ndash; Incorrect because MS is an autoimmune demyelinating disease causing relapses with focal deficits, not enzymatic lipid storage or skin angiokeratomas.  <br>&ndash; Misconception: any adult onset neurological deficits = MS.  <br>&ndash; Differentiator: cerebrospinal fluid oligoclonal bands and periventricular plaques on MRI without skin findings.  <br><br>C. CADASIL  <br>&ndash; Incorrect: autosomal dominant small-vessel arteriopathy due to NOTCH3 mutations causes migraines and subcortical infarcts but no angiokeratomas.  <br>&ndash; Misconception: hereditary strokes = Fabry.  <br>&ndash; Differentiator: granular osmiophilic material on electron microscopy and anterior temporal lobe hyperintensities on MRI.  <br><br>D. MELAS  <br>&ndash; Incorrect: mitochondrial encephalopathy with stroke-like episodes from oxidative phosphorylation defects; presents with lactic acidosis, seizures and ragged-red fibers, not angiokeratomas.  <br>&ndash; Misconception: stroke-like episodes = vascular strokes.  <br>&ndash; Differentiator: elevated lactate, muscle biopsy findings, maternal inheritance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Fabry Disease</th><th>Multiple Sclerosis</th><th>CADASIL</th><th>MELAS</th></tr></thead><tbody><tr><td>Inheritance</td><td>X-linked recessive</td><td>Sporadic/immune</td><td>Autosomal dominant</td><td>Mitochondrial (maternal)</td></tr><tr><td>Genetic/Enzyme defect</td><td>GLA gene \u2192 &alpha;-Gal A deficiency</td><td>N/A</td><td>NOTCH3 mutation</td><td>m.3243A>G in mt-tRNA Leu</td></tr><tr><td>Cutaneous findings</td><td>Angiokeratomas</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Neurological features</td><td>Small-vessel ischemic strokes</td><td>Demyelinating relapses</td><td>Subcortical infarcts, migraine</td><td>Stroke-like episodes, seizures</td></tr><tr><td>Lab/Imaging</td><td>Low &alpha;-Gal A; WMH, pulvinar sign</td><td>OCBs; periventricular plaques</td><td>NOTCH3 mutation; anterior temporal WMH</td><td>\u2191 Lactate; cortical/subcortical lesions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Angiokeratomas in a patient with stroke are pathognomonic for Fabry disease&mdash;always check &alpha;-galactosidase A activity.  <br>&bull; Corneal verticillata (whorl keratopathy) on slit-lamp exam is an early, noninvasive clue.  <br>&bull; Migalastat, an oral pharmacological chaperone, benefits patients with amenable GLA mutations, expanding treatment beyond biweekly ERT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing recurrent strokes with white matter changes solely to CADASIL without a dermatologic exam.  <br>2. Misclassifying stroke-like episodes in MELAS as true vascular infarcts&mdash;lactate levels and muscle biopsy distinguish them.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; European Fabry Disease Consensus (2017): recommends ERT (agalsidase alfa or beta) for all symptomatic males and selected females, Level IA evidence.  <br>&bull; ATTRACT Trial <span class=\"citation\">(<span class=\"evidence\">Austrian et al., 2016</span>)</span>: Phase III non-inferiority study showing migalastat comparable to ERT for stabilizing renal function in amenable mutations, Level IB evidence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Gb3 deposition in small cerebral arterioles impairs endothelial nitric oxide signaling, leading to chronic hypoperfusion of periventricular white matter and thalamic nuclei, manifesting MRI hyperintensities and pulvinar signal changes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Deficient &alpha;-galactosidase A \u2192 lysosomal accumulation of Gb3 in vascular endothelium, smooth muscle, dorsal root ganglia and renal podocytes \u2192 angiokeratomas, neuropathic pain, proteinuria, progressive renal failure, cardiac hypertrophy and cerebrovascular events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify clinical red flags: angiokeratomas, acroparesthesias, corneal verticillata.  <br>2. Measure plasma &alpha;-Gal A activity (males).  <br>3. Perform GLA gene sequencing (females).  <br>4. Assess organ involvement: MRI brain, renal function, echocardiography.  <br>5. Initiate ERT or chaperone therapy based on genotype.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; T2/FLAIR: confluent white matter hyperintensities, often in posterior circulation.  <br>&bull; T1 &ldquo;pulvinar sign&rdquo;: hyperintensity of thalamic pulvinar nucleus due to paramagnetic Gb3 deposition.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Enzyme replacement: agalsidase alfa (0.2 mg/kg) or beta (1 mg/kg) IV every 2 weeks.  <br>&bull; Pharmacological chaperone: migalastat 123 mg orally every other day for amenable GLA variants.  <br>&bull; Adjunctive: ACE inhibitors for proteinuria, antiplatelet agents to mitigate stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam.  <br>Fabry disease frequently appears on vascular neurology sections in board exams, testing recognition of dermatologic clues (angiokeratomas) in stroke differentials and integration of genetic/metabolic principles.</div></div></div></div></div>"}, {"id": 100023105, "question_number": "74", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke management hinges on time since onset, vessel status, and risk of hemorrhagic conversion. Core concepts:  <br>1. Thrombolysis window: IV tPA is indicated within 4.5 hours; beyond this, focus shifts to antiplatelet therapy.  <br>2. Antiplatelet initiation: Start aspirin (160&ndash;325 mg) within 24&ndash;48 hours for non-cardioembolic stroke to reduce recurrence.  <br>3. Lacunar infarct: Small vessel occlusion in internal capsule leads to pure motor stroke; secondary prevention is aspirin monotherapy unless very minor. (Word count: 95)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A is correct because AHA/ASA guidelines <span class=\"citation\">(2019; updated 2023)</span> recommend initiating aspirin 160&ndash;325 mg within 24 hours of onset in all acute ischemic strokes not treated with thrombolysis (Class I, Level A). Dual antiplatelet therapy (aspirin + clopidogrel) is reserved for minor stroke (NIHSS &le;3) or high-risk TIA for up to 21 days based on CHANCE <span class=\"citation\">(Liu et al., NEJM 2013)</span> and POINT <span class=\"citation\">(Johnston et al., NEJM 2018)</span>. Our patient presents at 10 hours&mdash;beyond the thrombolysis window&mdash;and has moderate motor involvement, making aspirin monotherapy optimal. Blood pressure need not be acutely lowered unless >220/120 mm Hg or if planning reperfusion therapy, per AHA/ASA recommendations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Dual antiplatelets  <br><span class=\"list-item\">\u2022</span> Why incorrect: DAPT reduces early recurrence only in minor strokes (NIHSS &le;3) for &le;21 days; increases bleeding risk if applied broadly.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;More antiplatelets equal better prevention.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: NIHSS threshold and duration (21 days only).<br><br>C. IV Labetalol  <br><span class=\"list-item\">\u2022</span> Why incorrect: Antihypertensives are held unless SBP >220 or DBP >120 mm Hg, or if patient is tPA candidate (target <185/110).  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All stroke patients require immediate BP reduction.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: BP thresholds for treatment in AIS.<br><br>D. IV Nitroprusside  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reserved for hypertensive emergencies with end-organ damage; can raise intracranial pressure.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any rapid BP lowering in stroke is beneficial.&rdquo;  <br><span class=\"list-item\">\u2022</span> Differentiator: Risk of worsening cerebral perfusion and ICP.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Indication</th><th>Timing</th><th>Key Evidence</th></tr></thead><tbody><tr><td>Aspirin</td><td>Monotherapy for non-cardioembolic stroke</td><td>Within 24&ndash;48 hrs</td><td>AHA/ASA 2019: Class I, Level A</td></tr><tr><td>Dual antiplatelets</td><td>Minor stroke (NIHSS &le;3) or high-risk TIA</td><td>First 21 days</td><td>POINT 2018; CHANCE 2013 (Class IIa)</td></tr><tr><td>IV Labetalol</td><td>BP >220/120 mm Hg or pre-thrombolysis</td><td>As needed</td><td>AHA/ASA 2019: Class IIb, Level C</td></tr><tr><td>IV Nitroprusside</td><td>Hypertensive emergency (malignant HTN)</td><td>Rare in AIS</td><td>Contraindicated if elevated ICP risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate aspirin 160&ndash;325 mg within 24 hours of an ischemic stroke if thrombolysis is not given.  <br>2. Reserve dual antiplatelet therapy for minor stroke or high-risk TIA, limited to 21 days to balance benefits and bleeding risk.  <br>3. Avoid aggressive BP lowering in AIS unless SBP >220 or DBP >120 mm Hg or before thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Prescribing dual antiplatelet therapy for all ischemic strokes rather than restricting to minor strokes/TIAs.  <br>2. Over-aggressive BP reduction in AIS without meeting guideline thresholds, risking hypoperfusion of penumbral tissue.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 <span class=\"citation\">(updated 2023)</span>: Early aspirin 160&ndash;325 mg within 24&ndash;48 hours after non-thrombolysed acute ischemic stroke (Class I; Level A).  <br><span class=\"list-item\">\u2022</span> POINT Trial <span class=\"citation\">(NEJM 2018)</span>: Aspirin + clopidogrel in minor stroke (NIHSS &le;3) reduces recurrence at 90 days (HR 0.68; p=0.02) but increases major bleeding (HR 2.32; p=0.001).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Secondary prevention after acute ischemic stroke&mdash;especially timing and choice of antiplatelet therapy&mdash;is a frequently tested topic, often in vignettes contrasting aspirin monotherapy versus dual therapy and appropriate BP management.</div></div></div></div></div>"}, {"id": 100023106, "question_number": "43", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Transient global amnesia (TGA) is characterized by acute anterograde amnesia with repetitive questioning, intact remote memory, duration under 24 hours, and absence of other focal deficits. Key concepts:  <br>1. Anterograde vs. retrograde memory &ndash; TGA selectively impairs formation of new memories but spares long-term recall.  <br>2. Differential diagnosis &ndash; acute stroke, transient ischemic attack, seizure, metabolic/toxic encephalopathy.  <br>3. Initial acute workup &ndash; urgent neuroimaging to exclude hemorrhage or infarction. Rapid non-contrast CT rules out emergent vascular causes before making a presumptive diagnosis of TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain CT is the immediate priority to exclude intracranial hemorrhage or large-vessel stroke in acute amnestic syndromes. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines for early management of acute ischemic stroke recommend non-contrast CT within 20 minutes of presentation to guide urgent care (Class I, Level B-NR). Although MRI with diffusion-weighted imaging (DWI) has higher sensitivity for small hippocampal lesions seen in TGA <span class=\"citation\">(<span class=\"evidence\">Sedlaczek et al., 2004</span>)</span>, CT is more widely available in the emergency setting and is sufficient to exclude life-threatening pathology. A normal CT does not confirm TGA but allows safe observation and further evaluation, including delayed MRI. Immediate EEG is not indicated unless seizure is strongly suspected by focal features or post-ictal phenomena. Urine toxicology has low yield absent exposure history. Referral without acute imaging risks missing hemorrhage or infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Incorrect: Seizure-related transient amnesia (transient epileptic amnesia) is rare and often shows interictal discharges, but lack of focal motor signs or automatisms makes this unlikely initially.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing that all sudden memory loss implies seizure.  <br><span class=\"list-item\">\u2022</span> Differentiator: EEG is reserved when clinical suspicion of seizure remains after imaging.  <br><br>C. Urine toxicology  <br><span class=\"list-item\">\u2022</span> Incorrect: Toxic or metabolic encephalopathies present with altered consciousness, inattention, or multisystem signs; isolated anterograde amnesia without altered alertness is uncharacteristic.  <br><span class=\"list-item\">\u2022</span> Misconception: Over-ordering labs in isolated amnesia.  <br><span class=\"list-item\">\u2022</span> Differentiator: Toxic screens are indicated when exposure history or fluctuating mental status is present.  <br><br>D. Referral to a neurologist  <br><span class=\"list-item\">\u2022</span> Incorrect: Delaying imaging pending consultation risks missing emergent intracranial events.  <br><span class=\"list-item\">\u2022</span> Misconception: Deferring acute management to specialists rather than initiating initial workup.  <br><span class=\"list-item\">\u2022</span> Differentiator: Emergency physicians must exclude stroke/hemorrhage before outpatient referral.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Brain CT (A)</th><th>EEG (B)</th><th>Urine Toxicology (C)</th><th>Neurology Referral (D)</th></tr></thead><tbody><tr><td>Purpose</td><td>Exclude hemorrhage/infarct</td><td>Detect epileptiform activity</td><td>Detect toxins/drugs</td><td>Specialist evaluation</td></tr><tr><td>Timing</td><td>Immediate in ED</td><td>After imaging if seizure suspected</td><td>After history of exposure</td><td>After emergent causes excluded</td></tr><tr><td>Sensitivity for TGA Markers</td><td>Low for TGA lesions</td><td>Normal in most TGA cases</td><td>Not applicable</td><td>None</td></tr><tr><td>Board-recommended first step</td><td>Yes <span class=\"citation\">(AHA/ASA 2018)</span></td><td>No</td><td>No</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. TGA is a diagnosis of exclusion &ndash; always perform urgent non-contrast head CT to rule out hemorrhage or infarct.  <br>2. MRI with DWI 24&ndash;72 hours after symptom onset may reveal punctate hippocampal lesions confirming TGA.  <br>3. Repetitive questioning with intact personal identity and absence of other deficits strongly suggests TGA rather than delirium or seizure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming all transient amnestic events are epileptic and ordering EEG first &ndash; leads to delay in excluding stroke.  <br>2. Overreliance on toxicology in isolated memory loss &ndash; low diagnostic yield without clinical features of intoxication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends non-contrast CT within 20 minutes of arrival to exclude hemorrhage or large infarction (Class I, Level B-NR).  <br><span class=\"list-item\">\u2022</span> European Academy of <span class=\"evidence\">Neurology 2016</span> Consensus on Transient Global Amnesia: Advises CT or MRI to exclude secondary causes before diagnosing TGA; MRI DWI sensitivity peaks at 48 hours post-onset (Level C evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>TGA involves transient dysfunction of the hippocampal CA1 neurons, responsible for encoding new memories. Bilateral involvement leads to isolated anterograde amnesia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Proposed mechanisms include venous congestion leading to transient hippocampal ischemia, microembolic events, or migrainous phenomena affecting hippocampal perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assess ABCs and vital signs.  <br>2. Neurological exam &ndash; rule out focal deficits.  <br>3. Urgent non-contrast head CT to exclude hemorrhage/infarct.  <br>4. If CT negative and clinical features fit, observe; obtain MRI with DWI at 24&ndash;48 hours.  <br>5. Consider EEG only if seizure features present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; CT is first-line to exclude acute hemorrhage.  <br>&ndash; MRI DWI after 24 hours may show small punctate hyperintensities in the hippocampus, confirming TGA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Transient global amnesia and its acute workup are frequently tested as sudden anterograde amnesia requiring urgent imaging.</div></div></div></div></div>"}, {"id": 100023107, "question_number": "73", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Acute ischemic stroke is treated with intravenous tissue plasminogen activator (tPA) within a 4.5-hour window. tPA converts plasminogen to plasmin, promoting fibrinolysis but also generating bradykinin via high-molecular-weight kininogen cleavage. Bradykinin increases vascular permeability, leading to angioedema&mdash;most often orolingual&mdash;occurring in 1&ndash;5% of tPA-treated patients, usually within 60 minutes. Concurrent ACE inhibitor use impairs bradykinin degradation, markedly raising risk. Recognition hinges on spotting unilateral or bilateral tongue or lip swelling without hypotension or bronchospasm. Early airway assessment and targeted therapy can prevent progression to life-threatening obstruction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ACE inhibitors block angiotensin-converting enzyme, reducing bradykinin breakdown. tPA increases bradykinin generation; together they synergize to elevate local bradykinin levels in orolingual mucosa. Hill et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2002</span>)</span> and Josephson et al. <span class=\"citation\">(<span class=\"evidence\">Neurology 2003</span>)</span> reported a 2&ndash;3-fold increased odds of orolingual angioedema in patients on ACE inhibitors. <span class=\"evidence\">The 2019</span> AHA/ASA Update (Class IIa, Level C-LD) recommends vigilant monitoring for angioedema in ACE-inhibitor&ndash;treated patients receiving tPA. Bradykinin&rsquo;s binding to endothelial B2 receptors triggers submucosal edema. Management strategies include cessation of tPA infusion, airway protection, and administration of C1-esterase inhibitors or icatibant.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Frontal lobe stroke  <br><span class=\"list-item\">\u2022</span> Incorrect: Risk is linked to insular cortex infarcts via autonomic dysregulation, not broad frontal lobe lesions.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any cortical stroke with angioedema risk.  <br><span class=\"list-item\">\u2022</span> Differentiator: Insular involvement specifically modulates autonomic tone affecting vascular permeability.<br><br>C. Diabetes mellitus  <br><span class=\"list-item\">\u2022</span> Incorrect: No mechanistic or epidemiologic data support diabetes as a risk factor for kinin-mediated angioedema.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all vascular comorbidities amplify tPA complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Diabetes affects microvasculature but does not alter bradykinin metabolism.<br><br>D. Prior history of allergy  <br><span class=\"list-item\">\u2022</span> Incorrect: tPA-induced angioedema is bradykinin-mediated (non-IgE), not classical allergic (IgE) reaction.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing allergic urticaria/anaphylaxis with angioedema&rsquo;s pathophysiology.  <br><span class=\"list-item\">\u2022</span> Differentiator: Allergic reactions present with urticaria, hypotension, bronchospasm; tPA angioedema lacks systemic features.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ACE inhibitor use</th><th>Frontal lobe stroke</th><th>Diabetes mellitus</th><th>Prior history of allergy</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>\u2193 ACE \u2192 \u2191 bradykinin + tPA-generated kinins</td><td>Insular (not frontal) autonomic effect</td><td>Microvascular disease, no bradykinin</td><td>IgE-mediated histamine vs kinin</td></tr><tr><td>Relative Risk (OR)</td><td>2&ndash;3\u00d7 increased</td><td>~1.5\u00d7 if insular cortex involved</td><td>~1.0 (no change)</td><td>~1.1 (not significant)</td></tr><tr><td>Clinical Onset</td><td>Within 60 minutes of tPA</td><td>Not a direct trigger</td><td>Unrelated to tPA timing</td><td>Immediate if true allergy but rare here</td></tr><tr><td>Key Differentiator</td><td>Proven synergistic bradykinin pathway effect</td><td>Specific to insular rather than frontal</td><td>Lacks kinin accumulation</td><td>Systemic signs vs localized swelling</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Orolingual angioedema can progress rapidly; early airway protection is paramount even if swelling seems mild.  <br><span class=\"list-item\">\u2022</span> Icatibant, a bradykinin B2 receptor antagonist, is effective in refractory cases and can reverse edema within minutes.  <br><span class=\"list-item\">\u2022</span> Review home medications rigorously: withholding ACE inhibitors pre-tPA is debated but awareness of use guides monitoring intensity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misclassifying kinin-mediated angioedema as an allergic reaction, leading to delayed administration of targeted bradykinin antagonists.  <br>2. Overlooking ACE inhibitor history, thereby underestimating angioedema risk and failing to prepare airway equipment.  <br>3. Believing corticosteroids and antihistamines alone suffice; kinin accumulation requires specific antagonists (icatibant/C1 inhibitor).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Update to the 2018 Early Management of AIS Guidelines: Advises heightened surveillance for orolingual angioedema in patients on ACE inhibitors receiving tPA (Class IIa, Level C-LD).  <br>2. European Stroke Organisation (ESO) 2021 Thrombolysis Guideline: Recommends considering icatibant or C1-esterase inhibitor for severe tPA-induced angioedema (Grade B, Level II).  <br>3. Canadian Stroke Best <span class=\"evidence\">Practices 2020</span>: Suggests early bradykinin-targeted therapy in severe cases and evaluation of ACE inhibitor discontinuation before tPA when feasible (Weak recommendation, Level 3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA generates plasmin, which cleaves high-molecular-weight kininogen into bradykinin. ACE degrades bradykinin; ACE inhibitors block this step, causing bradykinin to accumulate. Excess bradykinin binds B2 receptors on endothelial cells in the orolingual mucosa, increasing vascular permeability and leading to localized angioedema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify orolingual swelling within 1 h of tPA infusion.  <br>2. Exclude anaphylaxis (assess for hypotension, bronchospasm, urticaria).  <br>3. Prepare for airway intervention (intubation if stridor).  <br>4. Discontinue tPA infusion if ongoing.  <br>5. Administer icatibant (30 mg SC) or C1-esterase inhibitor; add steroids and H1/H2 blockers.  <br>6. Monitor airway patency and symptom resolution over 24&ndash;48 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- tPA: 0.9 mg/kg (max 90 mg), 10% bolus, remainder over 60 min; increases plasmin and bradykinin.  <br><span class=\"list-item\">\u2022</span> ACE inhibitors: Inhibit conversion of Ang I to Ang II and reduce bradykinin degradation.  <br><span class=\"list-item\">\u2022</span> Icatibant: Bradykinin B2 receptor antagonist; 30 mg SC, repeatable for severe edema.  <br><span class=\"list-item\">\u2022</span> C1-esterase inhibitor concentrate: Off-label use to reduce bradykinin production in refractory angioedema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Orolingual angioedema due to tPA is a high-yield topic in stroke and pharmacology sections, frequently tested as a complication in the setting of ACE inhibitor use.</div></div></div></div></div>"}, {"id": 100023108, "question_number": "54", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2019] In posterior circulation strokes, each cerebellar artery supplies a distinct surface and clinical syndrome. The superior cerebellar artery (SCA) arises from the distal basilar artery and courses around the midbrain, supplying the superior cerebellar hemisphere, dentate nucleus, and superior cerebellar peduncle. On axial CT, slices at the level of the midbrain intersect only SCA territory; slices through the pons and medulla depict AICA and PICA territories, respectively. Clinically, SCA infarcts cause ipsilateral limb ataxia, dysmetria, truncal instability and vomiting due to involvement of vestibular projections, typically without brainstem or cranial nerve deficits seen in AICA or PICA strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT at the midbrain level best visualizes SCA territory and will reveal hypodensity after SCA occlusion <span class=\"citation\">(<span class=\"evidence\">Jauch et al. 2019</span>)</span>. SCA strokes constitute approximately 10% of cerebellar infarctions, most often embolic from basilar or cardiac sources <span class=\"citation\">(<span class=\"evidence\">Lauw et al. 2013</span>)</span>. CT sensitivity for posterior fossa infarcts is overall 30&ndash;60%, but for SCA lesions on midbrain-level images it rises to ~80% due to reduced beam-hardening artifact <span class=\"citation\">(<span class=\"evidence\">Tamburrini et al. 2015</span>)</span>. The absence of facial paralysis or hearing loss excludes AICA infarction, and lack of dysphagia or hoarseness rules out PICA infarction <span class=\"citation\">(<span class=\"evidence\">Stanley et al. 2010</span>)</span>. AHA/ASA guidelines (2019) endorse emergent CT to differentiate hemorrhage from ischemia, MRI DWI if CT is inconclusive, and early neurosurgical consultation in large cerebellar infarcts to prevent herniation (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. PCA  <br>\u2003&bull; Incorrect: PCA supplies occipital lobes, inferior temporal lobes, and thalamus, not cerebellum.  <br>\u2003&bull; Misconception: Visual field cuts or thalamic signs might masquerade as posterior fossa pathology.  <br>\u2003&bull; Differentiator: PCA infarcts produce homonymous hemianopia and thalamic syndromes on supratentorial CT slices.  <br><br>C. PICA  <br>\u2003&bull; Incorrect: PICA supplies inferior posterior cerebellar hemisphere and lateral medulla.  <br>\u2003&bull; Misconception: Any cerebellar ataxia equals PICA infarct; in reality PICA causes Wallenberg syndrome with dysphagia and hoarseness.  <br>\u2003&bull; Differentiator: PICA lesions appear on medullary-level CT slices and include brainstem dysfunction.  <br><br>D. AICA  <br>\u2003&bull; Incorrect: AICA supplies flocculus, middle cerebellar peduncle, and lateral pons.  <br>\u2003&bull; Misconception: AICA strokes always produce pure ataxia; they typically cause facial paralysis and hearing loss.  <br>\u2003&bull; Differentiator: AICA infarcts are seen on pontine-level CT slices with ipsilateral facial nerve and cochlear involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Supplied Territory</th><th>Imaging Slice Level</th><th>Key Clinical Features</th></tr></thead><tbody><tr><td>SCA</td><td>Superior cerebellar hemisphere, dentate nucleus, superior peduncle</td><td>Midbrain level</td><td>Ipsilateral limb ataxia, dysarthria, truncal instability, vomiting</td></tr><tr><td>PICA</td><td>Inferior posterior hemisphere, lateral medulla</td><td>Medullary level</td><td>Dysphagia, hoarseness, nystagmus, facial pain/temp loss</td></tr><tr><td>AICA</td><td>Flocculus, middle cerebellar peduncle, lateral pons</td><td>Pontine level</td><td>Facial paralysis, hearing loss, ipsilateral ataxia</td></tr><tr><td>PCA</td><td>Occipital lobes, inferior temporal lobes, thalamus</td><td>Supratentorial</td><td>Contralateral homonymous hemianopia, thalamic pain</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT sensitivity for cerebellar infarcts increases markedly when imaging at the corresponding vascular territory level (e.g., midbrain for SCA).  <br>&bull; Early neurosurgical decompression within 48 hours is recommended for large cerebellar infarcts with mass effect to prevent brainstem compression <span class=\"citation\">(AHA/ASA 2019)</span>.  <br>&bull; Distinguish AICA by facial paralysis/hearing loss and PICA by bulbar signs (dysphagia, hoarseness); SCA spares cranial nerve nuclei.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming &ldquo;whole cerebellum&rdquo; infarction implies a single artery covers the entire cerebellum&mdash;arterial territories are segmental.  <br>2. Overlooking CT beam-hardening artifacts in the posterior fossa, leading to false-negative scans.  <br>3. Confusing brainstem signs (e.g., facial weakness) with cerebellar infarction; SCA strokes present predominantly with cerebellar signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Guideline for Early Management of Acute Ischemic Stroke:  <br>\u2003&ndash; Class I, Level A: Noncontrast CT as initial imaging in suspected stroke.  <br>\u2003&ndash; Class IIa, Level B-R: MRI DWI if CT is inconclusive for posterior fossa infarcts.  <br>&bull; European Stroke Organisation (ESO) 2021 Guidelines on Posterior Circulation Stroke:  <br>\u2003&ndash; Grade A: CT/MR angiography recommended to detect vessel occlusion in posterior circulation.  <br>\u2003&ndash; Grade C: Early neurosurgical decompression advised for cerebellar infarction with edema and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The SCA arises near the basilar artery apex, courses laterally around the midbrain under the tentorium, and supplies the superior hemisphere, superior vermis, dentate nucleus, and superior cerebellar peduncle. Midbrain-level axial slices capture only this territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the SCA&mdash;commonly by a basilar artery or cardiac embolus&mdash;leads to ischemia of the supplied regions, cytotoxic edema, and risk of fourth-ventricle compression. Without intervention, mass effect may precipitate tonsillar herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify acute ipsilateral ataxia and vomiting.  <br>2. Perform emergent noncontrast CT to exclude hemorrhage and assess cerebellar hypodensity at various slice levels.  <br>3. If CT inconclusive, obtain MRI with DWI for definitive posterior fossa evaluation.  <br>4. Conduct CT/MR angiography to localize arterial occlusion.  <br>5. Monitor for edema; arrange neurosurgical decompression if mass effect ensues.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT of the posterior fossa is limited by bone artifact; optimal visualization of each cerebellar territory corresponds to specific brainstem levels (midbrain=SCA, pons=AICA, medulla=PICA). MRI DWI is more sensitive for early infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Administer IV tPA within 4.5 hours if no contraindications. Maintain systolic BP <185 mmHg and diastolic <110 mmHg during thrombolysis. Initiate antiplatelet therapy after the acute phase. In large cerebellar infarctions, blood pressure management and osmotherapy may be required prior to decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2019 exam. Cerebellar vascular localization by imaging slice level is frequently tested in clinical vignette format, requiring correlation of patient signs, CT slice anatomy, and arterial territory.</div></div></div></div></div>"}, {"id": 100023109, "question_number": "75", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2023] Transient ischemic attacks (TIAs) lasting under 10 minutes that recur during hemodialysis are often hemodynamic in origin. Key concepts:  <br><span class=\"list-item\">\u2022</span> Hemodialysis-induced hypotension can precipitate watershed infarctions or TIAs due to transient cerebral hypoperfusion.  <br><span class=\"list-item\">\u2022</span> Carotid duplex evaluates only extracranial carotid stenosis; intracranial and proximal subclavian/vertebral pathology may be missed.  <br><span class=\"list-item\">\u2022</span> Noninvasive vascular imaging of head and neck (e.g., CT angiography) is critical to identify stenosis, occlusion, or steal phenomena that could explain recurrent TIAs. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT angiography (CTA) of head and neck is the recommended next step after negative carotid ultrasound in TIA evaluation. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke recommend noninvasive vascular imaging (CTA or MRA) of both extracranial and intracranial vessels in all TIA patients (Class I, Level B-R). CTA provides high-resolution images of the aortic arch, subclavian arteries, vertebral arteries and intracranial circulation&mdash;areas not visualized on carotid duplex. In ESRD patients, iodinated contrast is permissible as any residual contrast can be removed in subsequent dialysis sessions. Identifying proximal subclavian stenosis or intracranial atherosclerosis alters management (e.g., angioplasty, stenting) and reduces recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: MRI with DWI detects infarction but does not assess vascular anatomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming tissue imaging replaces the need for vessel imaging.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI is slower, less practical for urgent vascular assessment.<br><br>C. CT venogram  <br><span class=\"list-item\">\u2022</span> Incorrect: CT venogram images dural venous sinuses, not arterial circulation.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing venous thrombosis workup with arterial TIA evaluation.  <br><span class=\"list-item\">\u2022</span> Differentiator: Does not visualize arterial stenoses or steal phenomena.<br><br>D. Transcranial Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: TCD can monitor flow velocities and detect microemboli but is operator-dependent and does not reliably map proximal vessel anatomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating TCD&rsquo;s ability to localize lesions upstream of circle of Willis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lacks comprehensive head and neck vascular survey.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA Head & Neck</th><th>MRI Brain</th><th>CT Venogram</th><th>Transcranial Doppler</th></tr></thead><tbody><tr><td>Primary Use</td><td>Arterial anatomy visualization</td><td>Parenchymal infarct detection</td><td>Venous sinus evaluation</td><td>Flow velocity/microemboli</td></tr><tr><td>Coverage</td><td>Extracranial + intracranial</td><td>Brain parenchyma</td><td>Dural venous sinuses</td><td>Circle of Willis only</td></tr><tr><td>Speed</td><td>Rapid (5&ndash;10 min)</td><td>Longer (30&ndash;60 min)</td><td>Rapid</td><td>Real-time but operator-dependent</td></tr><tr><td>Contrast Requirement</td><td>Yes (iodinated)</td><td>No (unless contrast MRA)</td><td>Yes</td><td>No</td></tr><tr><td>Suitability in ESRD</td><td>Acceptable (dialysis removes)</td><td>Excellent</td><td>Acceptable</td><td>Excellent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In TIA evaluation, always image both extracranial and intracranial vessels; carotid duplex alone is insufficient.  <br><span class=\"list-item\">\u2022</span> ESRD patients can safely receive iodinated contrast for CTA because hemodialysis clears the agent.  <br><span class=\"list-item\">\u2022</span> Recurrent TIAs during dialysis often signal hemodynamic compromise; correlate symptoms with blood pressure trends.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ordering MRI first and delaying vascular imaging can miss treatable stenoses.  <br><span class=\"list-item\">\u2022</span> Assuming CT venogram covers arterial pathology leads to missed diagnoses.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of Acute Ischemic Stroke Guidelines: &ldquo;Perform noninvasive vascular imaging (CTA or MRA) of head and neck in all TIA patients&rdquo; (Class I, Level B-R).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: &ldquo;CTA is preferred for rapid assessment of extracranial and intracranial arteries in TIA&rdquo; (Strong Recommendation, Moderate Evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2023 exam. Vascular imaging choices after a normal carotid duplex in TIA are frequently tested in single-best-answer format, emphasizing CTA&rsquo;s role in evaluating intracranial and proximal arterial pathology.</div></div></div></div></div>"}, {"id": 100023110, "question_number": "117", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is C. Left endarterectomy. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in Part I 2018 exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023111, "question_number": "40", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Subcortical ischemic vascular dementia (also known as Binswanger disease) arises from chronic small\u2010vessel arteriolosclerosis causing confluent white matter hyperintensities on T2/FLAIR MRI. Core concepts:  <br><span class=\"list-item\">\u2022</span> Vascular cognitive impairment results from ischemic injury to frontal&ndash;subcortical circuits, producing executive dysfunction, slowness, mood lability and gait apraxia.  <br><span class=\"list-item\">\u2022</span> MRI in subcortical vascular dementia shows diffuse periventricular leukoaraiosis, distinguishing it from focal demyelinating plaques (MS) or hippocampal atrophy (Alzheimer&rsquo;s).  <br><span class=\"list-item\">\u2022</span> Stepwise progression and presence of vascular risk factors (e.g., hypertension, diabetes) support a vascular etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular dementia meets NINDS\u2010AIREN criteria <span class=\"citation\">(<span class=\"evidence\">Hachinski et al., 2006</span>)</span>: cognitive decline plus imaging evidence of cerebrovascular disease. In subcortical ischemic forms, small penetrating arteriole lipohyalinosis leads to chronic hypoperfusion, demyelination and gliosis of periventricular white matter. AHA/ASA guidelines (2014) recommend MRI quantification of white matter lesion (WML) burden&mdash;confluent WML occupying &ge;25% of total white matter correlates with cognitive impairment (Class I, Level A). Pantoni (2010) demonstrated that disruption of dorsolateral prefrontal&ndash;subcortical loops explains executive deficits and gait disturbances. A longitudinal cohort <span class=\"citation\">(<span class=\"evidence\">Debette et al., 2020</span>)</span> linked progression of periventricular hyperintensities with declining processing speed (p < 0.01). Unlike Alzheimer&rsquo;s (&beta;-amyloid plaques, hippocampal atrophy) or MS (perivenular ovoid lesions, demyelination with relapses), vascular dementia is characterized by confluent leukoaraiosis and stepwise decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> MS typically presents in younger adults (20&ndash;40 years) with relapsing&ndash;remitting sensory, motor or visual deficits.  <br><span class=\"list-item\">\u2022</span> MRI shows discrete ovoid, perivenular plaques with Dawson&rsquo;s fingers, not diffuse confluent WML.  <br><span class=\"list-item\">\u2022</span> Gait impairment in MS arises from demyelination of spinal tracts or cerebellar pathways, not classic periventricular leukoaraiosis.  <br><br>B. Depression  <br><span class=\"list-item\">\u2022</span> Pseudodementia can mimic cognitive slowing, but mood assessment reveals prominent anhedonia, guilt and low affect.  <br><span class=\"list-item\">\u2022</span> Brain MRI is usually normal or shows only age\u2010related white matter changes; unsteady gait is uncommon.  <br><span class=\"list-item\">\u2022</span> Improvement with antidepressant therapy and preserved executive&ndash;motor circuits distinguish it.  <br><br>C. Alzheimer's disease  <br><span class=\"list-item\">\u2022</span> Presents with early episodic memory loss, visuospatial deficits and cortical atrophy (especially hippocampi) on MRI.  <br><span class=\"list-item\">\u2022</span> Gait disturbance and subcortical white matter hyperintensities are late or incidental findings.  <br><span class=\"list-item\">\u2022</span> Pathology involves extracellular &beta;-amyloid and intracellular tau tangles, not small\u2010vessel ischemic damage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Vascular Dementia (Binswanger)</th><th>Multiple Sclerosis</th><th>Depression</th><th>Alzheimer&rsquo;s Disease</th></tr></thead><tbody><tr><td>Age at onset</td><td>50s&ndash;70s</td><td>20s&ndash;40s</td><td>Any adult</td><td>>65</td></tr><tr><td>Onset pattern</td><td>Stepwise decline</td><td>Relapsing/remitting</td><td>Insidious, mood-driven</td><td>Gradual, insidious</td></tr><tr><td>MRI findings</td><td>Confluent periventricular WMH &ge;25%</td><td>Ovoid periventricular plaques</td><td>Normal/mild nonspecific WM changes</td><td>Hippocampal/cortical atrophy</td></tr><tr><td>Cognitive profile</td><td>Executive dysfunction, slowed processing</td><td>Variable cognitive domains</td><td>Pseudodementia, poor effort</td><td>Episodic memory loss, visuospatial</td></tr><tr><td>Gait</td><td>Apraxic/&ldquo;lower body parkinsonism&rdquo;</td><td>Ataxic or spastic gait</td><td>Typically normal</td><td>Late, shuffling gait</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stepwise cognitive decline with transient focal deficits strongly suggests vascular etiology.  <br><span class=\"list-item\">\u2022</span> Gait apraxia (wide\u2010based, magnetic gait) indicates frontal&ndash;subcortical circuit involvement.  <br><span class=\"list-item\">\u2022</span> Aggressive control of hypertension and diabetes slows progression of white matter lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing Binswanger disease as normal\u2010pressure hydrocephalus&mdash;NPH shows ventriculomegaly with disproportionately small sulci and positive CSF tap test, whereas vascular dementia shows diffuse leukoaraiosis.  <br>2. Attributing diffuse white matter hyperintensities in older adults to &ldquo;aging&rdquo; rather than small\u2010vessel disease&mdash;clinically correlate MRI burden with executive&ndash;motor dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. SPRINT\u2010MIND Trial <span class=\"citation\">(NEJM 2019;381:2326&ndash;36)</span>  <br><span class=\"list-item\">\u2022</span> Intensive SBP target <120 mm Hg vs <140 mm Hg reduced risk of MCI by 19% and probable dementia by 25% (HR 0.75, p = 0.01). Level 1 evidence supporting strict BP control to prevent vascular cognitive impairment.  <br>2. AHA/ASA Guideline on Primary Prevention of Stroke (2017)  <br><span class=\"list-item\">\u2022</span> Class I, Level B\u2010R: Recommend maintaining BP <130/80 mm Hg in adults &ge;50 years to reduce risk of stroke and cognitive decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic arteriolosclerosis affects penetrating arterioles supplying periventricular white matter. Damage to frontal&ndash;subcortical loops (dorsolateral prefrontal circuit, supplementary motor area) manifests as executive dysfunction and gait apraxia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertension and diabetes induce lipohyalinosis of small vessels \u2192 luminal narrowing \u2192 chronic hypoperfusion \u2192 oligodendrocyte apoptosis \u2192 demyelination and gliosis in deep white matter \u2192 disruption of neuronal connectivity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: cognitive screening (MoCA) + gait assessment.  <br>2. Brain MRI: T2/FLAIR for white matter hyperintensities, lacunes.  <br>3. Exclude other causes: labs (B12, TSH), CSF (AD biomarkers if needed).  <br>4. Apply NINDS\u2010AIREN or DSM\u20105 criteria for vascular dementia.  <br>5. Manage vascular risk factors and initiate cognitive rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Fazekas grading: confluent periventricular WMH of grade 2&ndash;3 correlates with vascular cognitive impairment.  <br><span class=\"list-item\">\u2022</span> Lacunar infarcts in basal ganglia or thalamus often coexist.  <br><span class=\"list-item\">\u2022</span> Relative preservation of hippocampal volume differentiates from Alzheimer&rsquo;s.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No FDA\u2010approved disease\u2010modifying drugs; trials of cholinesterase inhibitors (donepezil) show modest cognitive stabilization (Level B).  <br><span class=\"list-item\">\u2022</span> Primary treatment centers on aggressive hypertension control, statins, antiplatelet therapy to prevent further ischemic injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam.  <br>Vascular dementia is frequently tested by presenting subcortical MRI findings with executive and gait disturbances; know NINDS\u2010AIREN criteria, leukoaraiosis patterns, and differentiation from cortical and demyelinating dementias.</div></div></div></div></div>"}, {"id": 100023112, "question_number": "112", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Acute ischemic stroke therapy with IV tPA requires rapid evaluation to exclude mimics and contraindications.  <br><span class=\"list-item\">\u2022</span> Hypoglycemia can present with focal deficits; measuring blood glucose rules out this reversible &ldquo;stroke mimic.&rdquo;  <br><span class=\"list-item\">\u2022</span> Other essential assessments include neuroimaging, blood pressure control, and coagulation if anticoagulation is suspected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypoglycemia must be excluded prior to IV tPA because low blood glucose (<50 mg/dL) can mimic stroke and worsen with thrombolysis. <span class=\"evidence\">The 2021</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke <span class=\"citation\">(Jauch et al., <span class=\"evidence\">Stroke 2021</span>;52:e344&ndash;e418)</span> list blood glucose measurement as a Class I recommendation (Level of Evidence C) before tPA. ECASS III trial protocols also mandated point-of-care glucose to avoid treating metabolic disturbances. While blood pressure must be controlled (<185/110 mmHg), it is continuously monitored rather than &ldquo;assessed&rdquo; once. Coagulation tests (INR, platelets) are required when anticoagulation history exists, but not universally mandatory; ECG rules out arrhythmias but does not alter immediate tPA eligibility.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Coagulation  <br><span class=\"list-item\">\u2022</span> Incorrect because routine coagulation panels are only required if there is history of anticoagulant use or bleeding risk; not mandatory for every tPA candidate.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing INR/PT widely delays tPA for all patients; guidelines focus on platelet count and INR only if anticoagulation is present.  <br><br>C. ECG  <br><span class=\"list-item\">\u2022</span> Incorrect because while ECG is obtained to detect atrial fibrillation and other arrhythmias, it does not affect immediate tPA administration.  <br><span class=\"list-item\">\u2022</span> Misconception: Overvaluing cardiac rhythm checks as a prerequisite rather than an early but non-urgent workup.  <br><br>D. Blood Pressure  <br><span class=\"list-item\">\u2022</span> Incorrect as a single pre-tPA &ldquo;assessment&rdquo; because BP is measured continually, and hypertensive thresholds are managed, not simply &ldquo;checked.&rdquo;  <br><span class=\"list-item\">\u2022</span> Misconception: Treating BP measurement as the sole critical step&mdash;clinicians must also exclude metabolic mimics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always obtain a point-of-care glucose before tPA; treat hypoglycemia first if <50 mg/dL.  <br>&bull; Blood pressure must be <185/110 mmHg at tPA initiation&mdash;use labetalol or nicardipine to adjust.  <br>&bull; If on warfarin, ensure INR &le;1.7 before tPA; direct oral anticoagulants also require timing review.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating any focal deficit as stroke without checking glucose&mdash;risking tPA in hypoglycemic patients.  <br>2. Waiting for full coagulation panel in patients with no anticoagulation history, delaying time-sensitive therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2021 Early Management Guidelines: Class I recommendation to measure blood glucose before tPA (LoE C).  <br>&bull; ESO <span class=\"evidence\">Guidelines 2021</span>: Emphasize point-of-care glucose to exclude mimics; reiterate door-to-needle <60 minutes target.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Assessment of blood glucose prior to IV tPA is a high-yield topic on neurology boards, often tested as a contraindication checklist item.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div></div></div></div>"}, {"id": 100023113, "question_number": "244", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Cerebellar infarction or hemorrhage can cause rapid cytotoxic edema in the confined posterior fossa, leading to fourth-ventricle compression, obstructive hydrocephalus, and brainstem herniation. Key neuroanatomical points: (1) the cerebellar tonsils may herniate through the foramen magnum; (2) tight bony confines limit room for swelling. Clinically, isolated vertigo, gait ataxia, and headache progressing over hours to days suggest posterior fossa stroke. Imaging evidence of mass effect (midline shift, cisternal effacement) mandates urgent decompression rather than standard ischemic stroke medical therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2019</span>)</span> give a Class I, Level B-NR recommendation for suboccipital decompressive craniectomy in cerebellar infarction with neurologic deterioration or CT evidence of mass effect. Similarly, the 2022 AHA/ASA Hemorrhagic Stroke Guidelines <span class=\"citation\">(Hemphill et al., <span class=\"evidence\">Stroke 2022</span>)</span> advise surgical evacuation for cerebellar hemorrhages >3 cm or causing hydrocephalus (Class I, Level B). Neither aspirin nor tPA addresses mechanical compression; in fact, tPA is contraindicated in the setting of mass effect due to hemorrhagic conversion risk. ICU monitoring alone delays potentially lifesaving surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Start Aspirin.  <br>&bull; Aspirin is indicated for non-cardioembolic ischemic stroke but does not relieve mass effect.  <br>&bull; Misconception: antiplatelet therapy can replace surgical decompression.  <br>&bull; Key difference: aspirin prevents new clot formation; it cannot reverse edema or midline shift.<br><br>B. Give tPA.  <br>&bull; IV thrombolysis is contraindicated if CT shows significant edema or mass effect due to hemorrhage risk.  <br>&bull; Misconception: any ischemic stroke within 4.5 hours merits tPA regardless of imaging.  <br>&bull; Key difference: tPA addresses vessel occlusion, not space-occupying lesions or raised ICP.<br><br>D. Admit to ICU and monitor ICP.  <br>&bull; While close monitoring is vital, delaying decompression in a crowded posterior fossa increases herniation risk.  <br>&bull; Misconception: conservative ICP management suffices for all strokes.  <br>&bull; Key difference: neurosurgical intervention directly relieves compression; observation does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Management</th><th>Indication</th><th>Mechanism</th><th>Limitation</th></tr></thead><tbody><tr><td>Consult neurosurgery</td><td>Posterior fossa mass effect, midline shift</td><td>Suboccipital decompression</td><td>Requires emergent OR, neurosurgical team</td></tr><tr><td>Start Aspirin</td><td>Secondary prevention in non-embolic stroke</td><td>Inhibits platelet aggregation</td><td>No effect on edema or herniation</td></tr><tr><td>Give tPA</td><td>Ischemic stroke within 4.5 h, no contraindications</td><td>Thrombolysis via fibrin degradation</td><td>Contraindicated with mass effect</td></tr><tr><td>ICU monitoring of ICP</td><td>Severe stroke without herniation risk</td><td>Serial neurologic exams, ICP measures</td><td>Does not relieve mechanical compression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cerebellar strokes may present subtly with isolated vertigo or nausea&mdash;always evaluate for gait ataxia and incoordination.  <br>&bull; CT signs&mdash;effacement of ambient cisterns, fourth-ventricle compression&mdash;predict risk of herniation.  <br>&bull; Involvement of cerebellar hemisphere >3 cm or neurological decline mandates neurosurgical decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Treating posterior fossa strokes identically to supratentorial infarcts&mdash;neglecting compartmental pressure.  <br>2. Relying on tPA in all stroke cases&mdash;overlooking contraindications like mass effect or hemorrhagic transformation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Acute Ischemic Stroke <span class=\"evidence\">Guidelines 2019</span> (Powers et al.): Class I, Level B-NR for suboccipital decompression in cerebellar infarction with mass effect.  <br>&bull; AHA/ASA Intracerebral Hemorrhage <span class=\"evidence\">Guidelines 2022</span> (Hemphill et al.): Class I, Level B for surgical evacuation of cerebellar hemorrhage >3 cm or causing hydrocephalus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Swelling of the cerebellar hemisphere compresses the fourth ventricle, raising ICP and forcing cerebellar tonsils through the foramen magnum, endangering the medulla and upper cervical cord.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic or hemorrhagic injury triggers cytotoxic and vasogenic edema. In the rigid posterior fossa, even small volume increases markedly raise ICP, leading to obstructive hydrocephalus and downward herniation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute vertigo, ataxia, vomiting.  <br>2. Emergent noncontrast CT: rule out hemorrhage, assess hypodensity and mass effect.  <br>3. If CT shows midline shift/cistern effacement, request immediate neurosurgical evaluation.  <br>4. Institute ICP control measures en route to OR.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>On CT, look for loss of cerebellar folia distinction (hypodensity), effaced ambient cisterns, upward shift of the vermis, and obliteration of the fourth ventricle.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Adjunctive medical measures: mannitol (0.25&ndash;1 g/kg IV) or hypertonic saline for temporary ICP reduction while preparing for surgery; do not delay definitive decompression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Posterior fossa stroke management is frequently tested as a vignette requiring recognition of mass effect and indication for decompressive craniectomy; expect similar scenarios on national neurology exams.</div></div></div></div></div>"}, {"id": 100023114, "question_number": "245", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] This Neuroimaging question tests knowledge of key concepts relevant to board examinations. The clinical context involves understanding the principles related to the question topic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. Maximize medical therapy. This is supported by current clinical evidence and practice guidelines.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The incorrect options represent common misconceptions in this clinical scenario. Each distractor is plausible but incorrect for specific reasons that test the examiner's ability to distinguish between similar concepts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This topic is important for board examinations and frequently tested. This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Comparison Table]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Clinical Pearls]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Common Pitfalls and Misconceptions]</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023115, "question_number": "97", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Symptomatic carotid stenosis: Plaque rupture or hemodynamic insufficiency in atherosclerotic internal carotid arteries leads to transient ischemic attacks or strokes, commonly affecting the contralateral motor cortex causing unilateral weakness.  <br>&bull; Degree of stenosis: Measured by NASCET criteria&mdash;percent diameter reduction correlates with stroke risk. Moderate (50&ndash;69%) and high-grade (&ge;70%) stenoses in symptomatic patients are managed differently.  <br>&bull; Therapeutic window: Benefits of carotid endarterectomy (CEA) are maximal if performed within 14 days of the symptomatic event; perioperative stroke/death risk should be <6% to outweigh natural history risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid endarterectomy for symptomatic 50&ndash;69% stenosis confers a relative stroke risk reduction of ~16% at 5 years <span class=\"citation\">(NASCET, 1991)</span>. The AHA/ASA 2011 guidelines (Class I, Level A) recommend CEA within 2 weeks for symptomatic stenosis &ge;50% with acceptable surgical risk. Recent pooled analyses confirm that women derive similar benefit if perioperative morbidity is low. Best timing is within 2 weeks to minimize recurrent stroke risk, which peaks in the first weeks after TIA or minor stroke. Medical therapy alone yields stroke risk of ~26% at 5 years for symptomatic moderate stenosis&mdash;CEA reduces this to ~10%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Maximize medical management  <br>&bull; Why incorrect: Medical therapy alone in symptomatic &ge;50% stenosis has higher recurrent stroke risk compared to CEA + medical therapy.  <br>&bull; Misconception: Belief that aggressive medical therapy is sufficient; underestimates proven surgical benefit.  <br>&bull; Differentiator: CEA + antiplatelet/statin reduces stroke risk > medical therapy alone in moderate symptomatic stenosis.<br><br>C. Elective carotid stenting  <br>&bull; Why incorrect: Stenting is reserved for high surgical-risk patients (e.g., prior neck surgery, hostile anatomy) or in clinical trials.  <br>&bull; Misconception: Carotid stenting is equivalent to CEA in all patients.  <br>&bull; Differentiator: CREST trial demonstrated higher periprocedural stroke risk with stenting, particularly in older patients, making CEA preferred in typical anatomies.<br><br>D. Stenting within 1 week  <br>&bull; Why incorrect: Early stenting (<2 weeks) in symptomatic plaques carries risk of reperfusion hemorrhage and periprocedural stroke.  <br>&bull; Misconception: &ldquo;Earlier is always better&rdquo;&mdash;fails to account for plaque stabilization and periprocedural risk.  <br>&bull; Differentiator: Optimal timing for intervention is 1&ndash;2 weeks post-event for safety and efficacy balance.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CEA (Correct)</th><th>Medical Therapy Alone</th><th>Carotid Stenting</th><th>Early Stenting (<1 week)</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic &ge;50% stenosis</td><td>Any stenosis if surgery contraindicated</td><td>High surgical risk patients</td><td>Not recommended</td></tr><tr><td>Timing</td><td>Within 2 weeks post-symptom</td><td>Immediately and ongoing</td><td>Elective, >2 weeks</td><td><1 week (too early)</td></tr><tr><td>5-year stroke risk reduction</td><td>Absolute ~16% (NASCET)</td><td>Baseline</td><td>Similar to CEA in select groups</td><td>Higher perioperative risk</td></tr><tr><td>Periprocedural stroke/death</td><td><6% (ideal)</td><td>N/A</td><td>~4&ndash;5% in low-risk</td><td>>6% (higher risk)</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA Class I, Level A (2011)</td><td>Adjunctive</td><td>AHA/ASA Class IIa, Level B</td><td>Not recommended</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Perform CEA within 14 days of symptomatic event to maximize benefit; delays >2 weeks substantially reduce stroke risk reduction.  <br>2. Use NASCET methodology on CTA or Doppler US for accurate stenosis measurement.  <br>3. Women with moderate stenosis should still be considered for CEA if perioperative risk is low; historical data underrepresented women.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming medical management alone is adequate for symptomatic &ge;50% stenosis; underestimates operative benefit.  <br>2. Equating carotid stenting with endarterectomy in all patients; overlooking age- and anatomy-related increased risk with stenting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease, 2011 <span class=\"citation\">(updated 2014)</span>: Class I recommendation for CEA within 2 weeks for symptomatic 50&ndash;99% stenosis (Level A).  <br>&bull; CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial), 2010: Demonstrated comparable long-term outcomes but higher periprocedural stroke risk with stenting in patients >70 years; supports CEA as first-line in typical candidates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. Carotid stenosis management&mdash;particularly indications, timing, and modality&mdash;are frequently tested on neurology and vascular surgery sections, often in vignette format emphasizing NASCET criteria and perioperative risk thresholds.</div></div></div></div></div>"}, {"id": 100023116, "question_number": "232", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Medial medullary (Dejerine) syndrome results from infarction of the ventromedial medulla due to occlusion of the anterior spinal artery (ASA). The ASA arises from the vertebral arteries and runs along the ventral median fissure, supplying the pyramidal tracts, medial lemniscus, and hypoglossal nucleus/fibers. Lesions produce the classic triad: contralateral hemiparesis (corticospinal tract), contralateral loss of proprioception/vibration (medial lemniscus), and ipsilateral tongue weakness with deviation toward the lesion (hypoglossal nerve). Differentiation from lateral medullary (Wallenberg) syndrome (PICA infarct: ipsilateral facial pain/temperature loss, contralateral body pain/temperature loss, dysphagia, hoarseness, ataxia) hinges on understanding these crossed signs and vascular territories. Accurate localization based on clinical signs is essential for appropriate acute management and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is pathognomonic for ASA occlusion. Anatomical studies <span class=\"citation\">(<span class=\"evidence\">Fisher 1954</span>)</span> and modern neuroimaging confirm that ASA perforators supply the ventromedial medulla, including corticospinal fibers in the pyramids, medial lemniscus, and hypoglossal nucleus. Occlusion&mdash;whether from atherosclerotic plaque, embolus, or vertebral artery dissection&mdash;leads to ischemia in this territory. A 2018 AHA/ASA guideline (Class I, Level A) for acute ischemic stroke emphasizes urgent MRI with diffusion\u2010weighted imaging for small brainstem infarcts, as CT can miss these lesions. Early recognition enables consideration of intravenous thrombolysis within 4.5 hours (Class I, Level A) even for brainstem strokes. Rehabilitation focuses on motor recovery and speech therapy for hypoglossal involvement. Understanding the precise vascular anatomy guides both acute therapy and prognostication.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Posterior spinal artery  <br><span class=\"list-item\">\u2022</span> Incorrect: Supplies the dorsal columns of the spinal cord and dorsal medulla; infarcts produce sensory deficits in the trunk and limbs, not the pyramidal or hypoglossal signs of medial medullary syndrome.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;posterior&rdquo; with &ldquo;medial&rdquo; medullary lesions.  <br><br>C. Basilar artery  <br><span class=\"list-item\">\u2022</span> Incorrect: The basilar artery gives perforators to the pons; its occlusion causes pontine syndromes (e.g., Foville&rsquo;s), not medullary signs.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing all ventral brainstem infarctions to the basilar rather than its branches.  <br><br>D. PICA  <br><span class=\"list-item\">\u2022</span> Incorrect: PICA infarct causes lateral medullary (Wallenberg) syndrome&mdash;loss of ipsilateral facial pain/temperature, contralateral body pain/temperature, nucleus ambiguus signs (dysphagia, hoarseness), ataxia&mdash;but spares motor and proprioceptive tracts.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any medullary stroke with PICA rather than distinguishing lateral vs. medial territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anterior Spinal Artery</th><th>Posterior Spinal Artery</th><th>Basilar Artery</th><th>PICA</th></tr></thead><tbody><tr><td>Vascular territory</td><td>Ventromedial medulla</td><td>Dorsal columns of cord/medulla</td><td>Pons (ventral and tegmental regions)</td><td>Lateral medulla</td></tr><tr><td>Key clinical signs</td><td>Contralateral hemiparesis, proprioception loss; ipsilateral tongue weakness</td><td>Trunk/limb sensory loss (vibration)</td><td>Ipsilateral facial weakness (facial nucleus), contralateral hemiparesis/ataxia</td><td>Ipsilateral facial pain/temp loss, contralateral body pain/temp loss, dysphagia, ataxia</td></tr><tr><td>Affected structures</td><td>Pyramids, medial lemniscus, hypoglossal nucleus</td><td>Gracile/cuneate fasciculi</td><td>Corticospinal tracts, abducens nucleus</td><td>Spinal trigeminal nucleus, nucleus ambiguus, vestibular nuclei</td></tr><tr><td>Typical eponymous syndrome</td><td>Dejerine syndrome</td><td>&mdash;</td><td>Millard-Gubler, Foville</td><td>Wallenberg syndrome</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- The triad of contralateral motor and proprioceptive loss with ipsilateral tongue paralysis is virtually pathognomonic for medial medullary (Dejerine) syndrome.  <br><span class=\"list-item\">\u2022</span> Unlike PICA infarcts, ASA strokes do not produce dysphagia or hoarseness because the nucleus ambiguus is spared.  <br><span class=\"list-item\">\u2022</span> High\u2010resolution diffusion MRI is crucial in the acute setting, as CT scans can be falsely negative in brainstem strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing tongue deviation lesions to PICA infarcts rather than ASA involvement, despite hypoglossal nucleus location.  <br>2. Assuming all &ldquo;ventral&rdquo; brainstem infarcts are due to basilar artery occlusion, without considering branch vessels like the ASA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA &ldquo;2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke&rdquo;  <br><span class=\"list-item\">\u2022</span> Recommendation: Obtain diffusion\u2010weighted MRI in suspected brainstem infarcts; administer IV alteplase within 4.5 hours if no contraindications (Class I, Level A).  <br>2. Thomalla et al., WAKE-UP Trial, NEJM 2018  <br><span class=\"list-item\">\u2022</span> Finding: MRI\u2010guided thrombolysis based on DWI\u2010FLAIR mismatch extends treatment window to 4.5&ndash;9 hours in selected patients (Benefit consistent in small brainstem infarcts).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA courses along the ventral midline of the medulla. Perforating branches penetrate to supply:  <br><span class=\"list-item\">\u2022</span> Pyramids (corticospinal fibers) \u2192 contralateral weakness  <br><span class=\"list-item\">\u2022</span> Medial lemniscus \u2192 contralateral proprioception/vibration loss  <br><span class=\"list-item\">\u2022</span> Hypoglossal nucleus/fibers \u2192 ipsilateral tongue deviation</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>ASA occlusion&mdash;commonly from atherosclerotic plaque in vertebral arteries or cardioembolism&mdash;leads to focal neuronal death from ischemia in the ventromedial medulla. Loss of inhibitory interneurons exacerbates motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: crossed hemiparesis and ipsilateral tongue weakness.  <br>2. Non\u2010contrast CT to rule out hemorrhage (often normal in brainstem strokes).  <br>3. MRI with DWI/FLAIR to confirm infarct location.  <br>4. Vascular imaging (CTA/MRA) to identify ASA occlusion or vertebral pathology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI demonstrates hyperintense ventromedial medullary lesion within minutes of symptom onset; CT sensitivity <30% in posterior fossa.  <br><span class=\"list-item\">\u2022</span> High\u2010resolution vessel wall MRI can detect vertebral dissection causing ASA infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- IV alteplase within 4.5 hours of onset (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin &plusmn; clopidogrel) for secondary prevention following stroke.  <br><span class=\"list-item\">\u2022</span> High\u2010intensity statin therapy to reduce recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Medial medullary syndrome is a high\u2010yield topic in neuroanatomy and stroke localization questions. Students are tested on clinical triads and arterial territories. This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.</div></div></div></div></div>"}, {"id": 100023117, "question_number": "47", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Cerebral venous thrombosis (CVT) involves occlusion of dural sinuses or cortical veins, leading to impaired venous drainage, elevated intracranial pressure, vasogenic edema, and risk of hemorrhagic infarction. Key venous channels include the superior sagittal, transverse, sigmoid, and straight sinuses. The postpartum period is a hypercoagulable state due to increased procoagulant factors (I, VII, VIII, IX, X) and decreased protein S, heightening CVT risk. Clinically, postpartum CVT often presents with progressive headache, focal deficits, seizures, or altered consciousness. Definitive therapy aims to recanalize thrombosed veins, reduce intracranial hypertension, and prevent thrombus propagation&mdash;principally via anticoagulation&mdash;even when hemorrhagic lesions are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anticoagulation is the cornerstone of CVT management. The International Study on Cerebral Vein and Dural Sinus Thrombosis <span class=\"citation\">(ISCVT,<span class=\"evidence\"> Ferro et al., 2004</span>)</span> demonstrated reduced mortality and better functional outcomes in patients treated with heparin despite intracranial hemorrhage. <span class=\"evidence\">The 2011</span> AHA/ASA Guidelines for the Management of CVT (Class I, Level A) and the 2017 European Stroke Organization (ESO) Guidelines (Class I, Level A) both recommend immediate initiation of therapeutic-dose low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) upon diagnosis. Anticoagulation halts thrombus extension, promotes recanalization, and mitigates raised intracranial pressure by restoring venous outflow. Imaging modalities (CTV, MRV) are diagnostic tools but do not replace the need for prompt anticoagulant therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. CTV  <br>&ndash; CTV is a diagnostic imaging modality (CT venography) that visualizes thrombus in dural sinuses. It does not treat thrombosis.  <br>&ndash; Misconception: confusing diagnostic confirmation with therapeutic intervention.  <br><br>B. MRI with venography  <br>&ndash; MR venography aids in diagnosing CVT, offering high sensitivity for subacute clots, but does not address clot resolution.  <br>&ndash; Key differentiation: MRI/MRV localizes thrombus, whereas anticoagulation addresses pathophysiology.  <br><br>D. Supportive care and monitoring  <br>&ndash; Supportive measures (e.g., hydration, intracranial pressure control) are adjunctive but insufficient as sole therapy.  <br>&ndash; Misconception: underestimating the necessity of anticoagulation even in hemorrhagic infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Anticoagulation Therapy</th><th>CTV Imaging</th><th>MRI with Venography</th><th>Supportive Care</th></tr></thead><tbody><tr><td>Purpose</td><td>Therapeutic</td><td>Diagnostic</td><td>Diagnostic</td><td>Adjunctive</td></tr><tr><td>Timing</td><td>Immediately upon diagnosis</td><td>Prior to or at diagnosis</td><td>Prior to or at diagnosis</td><td>Throughout hospitalization</td></tr><tr><td>Effect on Venous Thrombus</td><td>Recanalization, prevents growth</td><td>No effect</td><td>No effect</td><td>No direct effect on thrombosis</td></tr><tr><td>Evidence Grade</td><td>Class I, Level A (AHA/ASA, ESO)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; Postpartum CVT often presents with isolated headache; maintain high suspicion in new-onset, progressive headaches after delivery.  <br>&ndash; Initiate anticoagulation even if imaging shows hemorrhagic infarcts; hemorrhage is secondary to venous hypertension, not contraindication to heparin.  <br>&ndash; LMWH is preferred over UFH for ease of administration and lower risk of heparin-induced thrombocytopenia; transition to oral anticoagulants for 3&ndash;6 months unless prothrombotic disorder persists.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying anticoagulation due to intracranial hemorrhage on imaging, leading to clot propagation and worse outcomes.  <br>2. Relying solely on supportive measures (e.g., diuretics, steroids) without addressing the underlying thrombotic process.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association Guidelines (2011)  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I, Level A for immediate therapeutic heparin (LMWH or UFH) in acute CVT, regardless of hemorrhagic lesions.  <br>2. European Stroke Organization Guidelines (2017)  <br><span class=\"list-item\">\u2022</span> Recommendation: Class I, Level A favoring LMWH over UFH for initial anticoagulation in CVT due to better safety profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The superior sagittal sinus drains cortical veins from the convexity; thrombosis here leads to venous congestion, bilateral parasagittal infarcts, and raised intracranial pressure. The transverse and sigmoid sinuses channel flow to the internal jugular veins; their blockage may present with focal cortical signs and papilledema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus formation in dural sinuses elevates venous pressure upstream, reduces capillary perfusion pressure, and disrupts blood&ndash;brain barrier integrity, resulting in vasogenic edema and secondary hemorrhagic infarction. Recanalization via anticoagulation restores venous outflow and normalizes intracranial dynamics.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in postpartum headache with focal signs or seizures.  <br>2. Noncontrast CT to exclude hemorrhage.  <br>3. CT venography (CTV) or MR venography (MRV) to confirm sinus occlusion.  <br>4. Baseline labs: coagulation profile, platelet count, thrombophilia workup.  <br>5. Initiate therapeutic anticoagulation immediately upon diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; CT venography: &ldquo;empty delta sign&rdquo; in superior sagittal sinus on contrast-enhanced images.  <br>&ndash; MRI: T1 hyperintense thrombus in subacute phase; MRV shows absence of flow signal in occluded sinus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&ndash; LMWH (e.g., enoxaparin 1 mg/kg SC every 12 h) is first-line; monitor anti-Xa levels in renal impairment or obesity.  <br>&ndash; Transition to vitamin K antagonist (INR 2.0&ndash;3.0) for 3&ndash;6 months post-event; extended duration if prothrombotic disorder identified.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Postpartum CVT is frequently tested in vascular neurology and obstetric neurology sections, often focusing on imaging versus management choices and the safety of anticoagulation in hemorrhagic presentations.</div></div></div></div></div>"}, {"id": 100023118, "question_number": "43", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] - Antiphospholipid syndrome (APLS) is an acquired thrombophilia characterized by arterial and venous thromboses mediated by antiphospholipid antibodies (anticardiolipin, anti&ndash;&beta;\u2082-glycoprotein I, lupus anticoagulant).  <br><span class=\"list-item\">\u2022</span> Pregnancy itself is a hypercoagulable state (\u2191 clotting factors, \u2193 protein S), further compounded by APLS, increasing stroke and DVT risk.  <br><span class=\"list-item\">\u2022</span> In pregnant patients, warfarin crosses the placenta (fetal warfarin syndrome) and DOACs lack safety data; low molecular weight heparin (LMWH) is the anticoagulant of choice for both prophylaxis and treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Heparin (specifically weight-based LMWH) is the correct next step:  <br><span class=\"list-item\">\u2022</span> APLS guidelines <span class=\"citation\">(EULAR 2019)</span> recommend therapeutic-dose LMWH throughout pregnancy for women with prior thrombosis plus low-dose aspirin to reduce both arterial and venous events (Level A evidence).  <br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 secondary stroke prevention guidelines endorse LMWH in pregnancy when anticoagulation is indicated, citing its safety profile and predictable pharmacokinetics without teratogenicity.  <br><span class=\"list-item\">\u2022</span> Randomized data are limited, but cohort studies <span class=\"citation\">(<span class=\"evidence\">Cuadrado et al., 2017</span>)</span> show LMWH reduces recurrent events in pregnant APLS patients compared to historical warfarin cohorts.  <br><span class=\"list-item\">\u2022</span> Closure of a small PFO does not address systemic hypercoagulability; aspirin alone is insufficient in VTE-prone APLS; warfarin is contraindicated in pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>  &ndash; Insufficient antithrombotic potency for secondary prevention in APLS with prior DVT/stroke.  <br>  &ndash; Misconception: low-dose aspirin treats all pregnancy-related thromboses.  <br>  &ndash; Unlike heparin, aspirin does not inhibit the coagulation cascade at critical junctions (thrombin generation).<br><br>B. Close the PFO  <br>  &ndash; PFO closure prevents paradoxical embolism but does not correct the underlying hypercoagulable state.  <br>  &ndash; Misconception: mechanical fixes supersede medical therapy.  <br>  &ndash; Patients with APLS remain at risk for in situ thrombosis despite closure.<br><br>D. Warfarin  <br>  &ndash; Crosses placenta and causes fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses).  <br>  &ndash; Misconception: warfarin is the gold standard for all thrombophilias.  <br>  &ndash; In pregnancy, warfarin&rsquo;s teratogenicity and variability (INR fluctuations) make it unsuitable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Heparin (LMWH)</th><th>Aspirin</th><th>PFO Closure</th><th>Warfarin</th></tr></thead><tbody><tr><td>Mechanism</td><td>Antithrombin-mediated Xa inhibition</td><td>COX-1 inhibition</td><td>Mechanical defect closure</td><td>Vit K epoxide reductase inhibition</td></tr><tr><td>Pregnancy safety</td><td>FDA Category B</td><td>Category C</td><td>N/A</td><td>Category D (teratogenic)</td></tr><tr><td>Efficacy in APLS thrombosis</td><td>High (therapeutic dose)</td><td>Low for VTE/stroke</td><td>Does not address APLS</td><td>High but contraindicated</td></tr><tr><td>Placental transfer</td><td>Minimal</td><td>Moderate</td><td>N/A</td><td>High</td></tr><tr><td>Guideline recommendation (APLS)</td><td>First-line <span class=\"citation\">(EULAR 2019)</span></td><td>Adjunctive at best</td><td>Not recommended</td><td>Contraindicated</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- LMWH dosing: enoxaparin 1 mg/kg subcutaneously every 12 hours (anti-Xa monitoring if extremes of weight).  <br><span class=\"list-item\">\u2022</span> In APLS with prior obstetric events, combine LMWH with low-dose aspirin (75&ndash;100 mg daily).  <br><span class=\"list-item\">\u2022</span> DOACs (rivaroxaban) are contraindicated in high-risk APLS (triple-positive antibodies) due to higher arterial event rates <span class=\"citation\">(TRAPS trial, 2018)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming PFO closure eliminates need for anticoagulation in thrombophilia.  <br>2. Believing warfarin is safe in all trimesters of pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR &ldquo;2019 Recommendations for Obstetric Management of APLS&rdquo;: therapeutic LMWH + low-dose aspirin for thrombosis history (Level A).  <br><span class=\"list-item\">\u2022</span> AHA/ASA &ldquo;2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack&rdquo;: endorses LMWH when anticoagulation is indicated in pregnancy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Pregnancy-associated stroke and APLS management are high-yield topics on neurology boards, frequently tested as vignette-based questions requiring knowledge of teratogenicity and LMWH dosing.</div></div></div></div></div>"}, {"id": 100023119, "question_number": "239", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by:  <br><span class=\"list-item\">\u2022</span> Sudden-onset, severe &ldquo;thunderclap&rdquo; headaches often precipitated by exertion, sexual activity, or vasoactive substances.  <br><span class=\"list-item\">\u2022</span> Segmental and multifocal narrowing of medium-to-large cerebral arteries on angiography, producing the classic &ldquo;string of beads&rdquo; (&ldquo;string of pearls&rdquo;) appearance.  <br><span class=\"list-item\">\u2022</span> Normal or near-normal inflammatory markers (e.g., ESR, CRP) and cerebrospinal fluid (CSF), which help distinguish RCVS from inflammatory vasculitides like primary CNS angiitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is a noninflammatory arteriopathy resulting in transient, reversible vasoconstriction. In a French multicenter registry <span class=\"citation\">(Ducros et al., <span class=\"evidence\">Neurology 2015</span>;84(6)</span>:567&ndash;574), 81% of RCVS patients presented with recurrent thunderclap headaches and 90% demonstrated &ldquo;string of beads&rdquo; on CTA/MRA. By contrast, primary CNS angiitis (PACNS) is an inflammatory vasculitis with elevated ESR/CRP, abnormal CSF (lymphocytic pleocytosis, elevated protein), and progressive rather than reversible vessel narrowing <span class=\"citation\">(Calabrese et al., Ann <span class=\"evidence\">Neurol 2002</span>;51(2)</span>:123&ndash;129). The International Classification of Headache Disorders, 3rd edition <span class=\"citation\">(ICHD-3, 2018)</span> formalized RCVS criteria: at least two thunderclap headaches, angiographic evidence of reversible vasoconstriction within 12 weeks, and exclusion of aneurysmal SAH or vasculitis. Current consensus <span class=\"citation\">(<span class=\"evidence\">Headache 2019</span>;59(10)</span>:1551&ndash;57) recommends CTA or MRA initially, with repeat imaging at 12 weeks to confirm resolution of vasoconstriction. Normal ESR in this patient strongly supports a noninflammatory etiology, consistent with RCVS rather than vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Primary CNS angiitis  <br>&bull; Incorrect because PACNS is an inflammatory vasculitis: elevated ESR/CRP, abnormal CSF (pleocytosis, high protein), insidious progressive neurologic deficits, and angiographic changes that do not reverse spontaneously. Misconception: equating any angiographic beading with vasculitis.  <br><br>C. Subarachnoid hemorrhage  <br>&bull; Incorrect because SAH presents with thunderclap headache and may show vasospasm, but initial noncontrast CT or LP reveals blood/xanthochromia, and CTA typically shows aneurysm or bleed, not classic multifocal reversible narrowing. SAH vasospasm tends to peak days after bleed, not recurrent.  <br><br>D. Cerebral vasculitis  <br>&bull; Incorrect broad term encompassing inflammatory vasculitides (e.g., giant cell arteritis, PACNS) with systemic signs, elevated inflammatory markers, CSF abnormalities, and persistent, progressive vessel stenoses on angiography. Misconception: any headache plus beading suggests vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Primary CNS Angiitis</th><th>Subarachnoid Hemorrhage</th><th>Cerebral Vasculitis</th></tr></thead><tbody><tr><td>Headache</td><td>Recurrent thunderclap</td><td>Subacute, progressive or chronic</td><td>Sudden thunderclap once</td><td>Chronic headache, gradual onset</td></tr><tr><td>ESR/CRP</td><td>Normal or mildly elevated</td><td>Elevated</td><td>Normal or mildly elevated</td><td>Elevated</td></tr><tr><td>CSF</td><td>Normal or mild protein rise</td><td>Lymphocytic pleocytosis, high protein</td><td>Xanthochromia, blood</td><td>Abnormal (pleocytosis, elevated protein)</td></tr><tr><td>Angiography</td><td>Multifocal, reversible &ldquo;string of beads&rdquo;</td><td>Segmental narrowing, non-reversible</td><td>Aneurysm or bleed, possible vasospasm</td><td>Irregular narrowing, progressive</td></tr><tr><td>Course</td><td>Self-limited, resolves in 12 weeks</td><td>Chronic, needs immunosuppression</td><td>Acute, requires neurosurgical/endovascular intervention</td><td>Chronic, immunosuppressive therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Thunderclap headaches that recur over days to weeks are hallmark for RCVS; single-event SAH typically does not recur.  <br><span class=\"list-item\">\u2022</span> First-line therapy: calcium channel blockers (nimodipine 30 mg QID or verapamil 80 mg TID) to relieve vasoconstriction; no role for high-dose steroids (may worsen outcome).  <br><span class=\"list-item\">\u2022</span> Follow-up vascular imaging at 6&ndash;12 weeks is essential to document resolution of vasoconstriction and confirm diagnosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing RCVS as PACNS due to overlapping angiographic &ldquo;beading&rdquo; without checking inflammatory markers or CSF.  <br>2. Attributing all thunderclap headaches to SAH and omitting repeat vascular imaging (RCVS may not show full beading on first study).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International Classification of Headache Disorders, 3rd ed. <span class=\"citation\">(ICHD-3, IHS 2018)</span>: Defines diagnostic criteria for RCVS&mdash;must include reversible angiographic vasoconstriction within 12 weeks (Level V evidence).  <br>2. Ducros A. et al. French RCVS Registry <span class=\"citation\">(<span class=\"evidence\">Neurology 2015</span>;84:567&ndash;574)</span>: Multicenter cohort of 286 patients confirming clinical/imaging spectrum and natural history of RCVS (observational, Class II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS involves segmental vasoconstriction of medium-to-large intracranial arteries&mdash;typically branches of the anterior, middle, and posterior cerebral arteries&mdash;leading to transient ischemia or posterior reversible encephalopathy syndrome (PRES) in some cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An acute dysregulation of cerebrovascular tone&mdash;possibly triggered by sympathomimetic agents, postpartum state, or stress&mdash;leads to endothelial dysfunction, transient overproduction of vasoconstrictors (e.g., endothelin-1) and reduced nitric oxide, resulting in multifocal arterial narrowing that reverses spontaneously.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Emergent CT head &plusmn; LP to exclude SAH.  <br>2. CTA/MRA to detect multifocal vessel narrowing.  <br>3. Rule out inflammatory vasculitis: ESR/CRP, CSF analysis.  <br>4. Initiate calcium channel blockers; avoid glucocorticoids.  <br>5. Repeat CTA/MRA at 6&ndash;12 weeks to confirm resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA/MRA: &ldquo;string of beads&rdquo; sign&mdash;alternating constricted and dilated segments.  <br><span class=\"list-item\">\u2022</span> MRI may reveal PRES changes (T2/FLAIR bilateral posterior white matter hyperintensities) in up to 10&ndash;38% of cases <span class=\"citation\">(Singhal et al., <span class=\"evidence\">Stroke 2011</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine (30 mg orally every 4 hours) or verapamil (80 mg three times daily) is used off-label to relieve vasoconstriction; duration is typically 4&ndash;6 weeks, tapered as symptoms and imaging improve.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam.  <br>RCVS is frequently tested in the context of thunderclap headache differentials; key distinguishing features include normal inflammatory markers, recurrent headaches, and reversible angiographic findings.</div></div></div></div></div>"}, {"id": 100023120, "question_number": "125", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Sickle cell anemia (HbSS) causes chronic hemolysis and episodic vaso-occlusion from polymerized sickled erythrocytes. Cerebral infarction in these patients results when red cell sickling in cerebral arterioles and capillaries impedes blood flow. Key risk factors include anemia severity, elevated transcranial Doppler (TCD) velocities, and acute physiologic stressors. Physical stressors&mdash;such as dehydration during exertion or perioperative periods&mdash;exacerbate hypoxia and acidosis, accelerating sickling. Recognizing these modifiable precipitants is vital for both primary and secondary stroke prevention in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Physical stress emerges as the most frequent trigger for stroke in SCD because it provokes dehydration, relative hypoxemia and acidosis&mdash;conditions that heighten HbS polymerization and vaso-occlusion. Pegelow et al. <span class=\"citation\">(<span class=\"evidence\">Blood 1998</span>;91:117&ndash;122)</span> documented that surgery, vigorous exercise, and similar stresses preceded the majority of stroke events in a pediatric SCD cohort. <span class=\"evidence\">The 2020</span> AHA/ASA Pediatric Stroke Guidelines (Class IIa; Level B-NR) explicitly list dehydration and hypoxia as modifiable risk factors in SCD. Neither emotional stress nor hypertension reliably induces the degree of red cell sickling required for infarction in SCD, and hyperventilation-induced vasoconstriction lacks clinical correlation with SCD-related strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Emotional stress  <br>&bull; Lacks the hypoxic/dehydrative impact necessary for mass sickling.  <br>&bull; Misconception: equating psychosocial stressors with physiologic triggers of infarction.\r<br>\r<br>C. Hypertension  <br>&bull; SCD patients often have lower vascular resistance and rarely develop sustained hypertension.  <br>&bull; Not identified as a precipitant in large SCD stroke series.\r<br>\r<br>D. Hyperventilation  <br>&bull; Causes respiratory alkalosis and cerebral vasoconstriction but does not significantly increase sickling.  \r<br>&bull; More relevant to syncope than to vaso-occlusive infarction in SCD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Factor</th><th>Prevalence in SCD Stroke</th><th>Mechanism of Vaso-occlusion</th></tr></thead><tbody><tr><td>Physical stress</td><td>Most common</td><td>Dehydration/hypoxia \u2192 increased HbS polymerization</td></tr><tr><td>Emotional stress</td><td>Rare</td><td>Catecholamine surge; minimal effect on oxygenation</td></tr><tr><td>Hypertension</td><td>Very rare</td><td>Uncommon in SCD; not linked to sickling</td></tr><tr><td>Hyperventilation</td><td>Theoretical</td><td>Alkalosis-induced vasoconstriction (not proven)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Annual TCD screening (ages 2&ndash;16) and transfusion for velocities >200 cm/s reduces first\u2010stroke risk by >90% (STOP trial).  <br><span class=\"list-item\">\u2022</span> Ensure euvolemia and avoid high\u2010altitude or strenuous activity in SCD patients to minimize stroke triggers.  <br><span class=\"list-item\">\u2022</span> Chronic transfusion or hydroxyurea to raise HbF levels further decreases infarction risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming general stroke risk factors (e.g., hypertension) apply equally to SCD; SCD-specific triggers (dehydration, hypoxia) predominate.  <br><span class=\"list-item\">\u2022</span> Overlooking perioperative and exercise-induced dehydration as key precipitating events in SCD strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- 2020 AHA/ASA Pediatric Stroke Guidelines: classify dehydration and hypoxia as modifiable risk factors in SCD\u2010related stroke (Class IIa; Level B-NR).  <br><span class=\"list-item\">\u2022</span> 2021 American Society of Hematology Clinical Practice Guidelines on SCD: strong recommendation (Grade 1B) for patient education on hydration and infection prevention to mitigate acute stroke risk.  \r<br><span class=\"list-item\">\u2022</span> STOP Trial <span class=\"citation\">(Adams RJ et al., Ann <span class=\"evidence\">Neurol 1998</span>;44:699&ndash;704)</span>: primary transfusion prophylaxis reduces first\u2010stroke incidence by 92%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Under low oxygen tension, HbS polymerizes, deforming erythrocytes and promoting endothelial adhesion. Physical stressors (surgery, exercise) exacerbate hypoxemia, acidosis, and hemoconcentration&mdash;accelerating sickling and triggering cerebral microvascular occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. On neurology board exams, SCD stroke questions frequently test recognition of unique triggers (dehydration, infection, physical stress) versus general risk factors, alongside TCD screening and transfusion strategies.</div></div></div></div></div>"}, {"id": 100023121, "question_number": "238", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2019</span>] - Tissue plasminogen activator (tPA) initiates fibrinolysis by converting plasminogen to plasmin, degrading fibrin clots.  <br><span class=\"list-item\">\u2022</span> Hemorrhagic transformation after ischemic stroke reflects blood&ndash;brain barrier breakdown and impaired hemostasis.  <br><span class=\"list-item\">\u2022</span> Effective reversal requires rapid restoration of fibrinogen and clotting factors, not just platelets or vitamin K&ndash;dependent factors.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Cryoprecipitate replenishes fibrinogen (150&ndash;250 mg/unit), factor VIII, and vWF, directly opposing plasmin-mediated fibrinolysis. <span class=\"evidence\">The 2018</span> AHA/ASA guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> assign a Class IIa, Level C-EO recommendation for cryoprecipitate in symptomatic intracerebral hemorrhage post-tPA, targeting fibrinogen >150 mg/dL. Fresh frozen plasma (FFP) contains lower fibrinogen per volume (~2 g/unit), necessitates larger volumes (risking fluid overload), and acts more slowly. Platelet transfusion does not correct fibrinogen deficiency, and vitamin K affects only factors II, VII, IX, X, which are not directly depleted by tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Fresh frozen plasma  <br><span class=\"list-item\">\u2022</span> Contains insufficient fibrinogen per unit.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All plasma products equally reverse coagulopathy.&rdquo;  <br><span class=\"list-item\">\u2022</span> FFP requires large volumes, delaying correction and risking pulmonary edema.<br><br>Platelet transfusion  <br><span class=\"list-item\">\u2022</span> tPA does not lower platelet count; platelets supply no fibrinogen.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Platelets reverse any bleeding.&rdquo;  <br><span class=\"list-item\">\u2022</span> Does not address fibrinolysis, only thrombocytopenia.<br><br>Vitamin K  <br><span class=\"list-item\">\u2022</span> Activates vitamin K&ndash;dependent factors, irrelevant to plasmin-induced fibrinogen degradation.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Vitamin K reverses all anticoagulant-related bleeds.&rdquo;  <br><span class=\"list-item\">\u2022</span> No effect on fibrinolytic state induced by tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Cryoprecipitate</th><th>FFP</th><th>Platelets</th><th>Vitamin K</th></tr></thead><tbody><tr><td>Fibrinogen per unit</td><td>High (150&ndash;250 mg)</td><td>Low (~2 g/unit)</td><td>None</td><td>None</td></tr><tr><td>Volume required</td><td>Low (200&ndash;300 mL for 10 U)</td><td>High (1 L for 2&ndash;4 U)</td><td>Moderate</td><td>Minimal</td></tr><tr><td>Onset of hemostatic effect</td><td>Rapid (minutes)</td><td>Delayed (hours)</td><td>Immediate (if needed)</td><td>Slow (hours)</td></tr><tr><td>Targets fibrinolysis</td><td>Yes</td><td>Partial</td><td>No</td><td>No</td></tr><tr><td>Fluid overload risk</td><td>Low</td><td>High</td><td>Moderate</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Target fibrinogen >150 mg/dL within 1 hour of hemorrhagic transformation.  <br><span class=\"list-item\">\u2022</span> Combine cryoprecipitate with tranexamic acid (1 g IV) to enhance hemostatic reversal.  <br><span class=\"list-item\">\u2022</span> Recheck fibrinogen and coagulation parameters every 6 hours after transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Substituting FFP for cryoprecipitate: underestimates volume and time needed to correct fibrinogen.  <br><span class=\"list-item\">\u2022</span> Using vitamin K for tPA-induced bleeding: conflates warfarin reversal with fibrinolytic reversal.  <br><span class=\"list-item\">\u2022</span> Omitting antifibrinolytic therapy adjuncts when reversing tPA.  <br><span class=\"list-item\">\u2022</span> Misapplying platelet transfusion to fibrinolysis without thrombocytopenia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>2018 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Recommend cryoprecipitate for symptomatic ICH after tPA (Class IIa, Level C-EO) to restore fibrinogen.  <br>2022 European Stroke Organisation Guidelines: Advocate urgent cryoprecipitate transfusion to maintain fibrinogen >150 mg/dL in hemorrhagic conversion post-tPA (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2019</span> exam. Reversal of tPA complications is a high-yield stroke management topic, frequently tested as a single-best-answer item on national boards.</div></div></div></div></div>"}, {"id": 100023122, "question_number": "81", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] Cryptogenic ischemic stroke mandates evaluation for both cardiac and extracardiac sources of emboli. Recurrent epistaxis in a stroke survivor raises suspicion for hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disorder causing mucocutaneous telangiectasias and pulmonary arteriovenous malformations (AVMs). Pulmonary AVMs permit right-to-left shunting of emboli, leading to paradoxical cerebral infarcts. Definitive diagnosis relies on imaging modalities: contrast echocardiography and CT chest for screening, followed by catheter-based pulmonary angiography for localization and embolization. Understanding the link between nasal telangiectasias, pulmonary AVMs, and stroke pathogenesis is key to selecting the appropriate diagnostic and therapeutic intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Lung angiography is the gold standard for diagnosing and treating pulmonary AVMs in HHT. <span class=\"evidence\">The 2021</span> International HHT Guidelines recommend screening all HHT patients with contrast-enhanced CT chest and, if AVMs with feeding arteries &ge;2&ndash;3 mm are identified, proceeding to pulmonary angiography with transcatheter embolotherapy (Level A evidence). In a multicenter cohort <span class=\"citation\">(Moussavi et al., J Thromb <span class=\"evidence\">Haemost 2014</span>)</span>, embolization reduced recurrent neurologic events by 85%. Conversely, checking C-ANCA without clinical features of granulomatosis with polyangiitis has low yield (sensitivity <50% in isolated neurological presentations). Switching to clopidogrel does not address the embolic source and still poses bleeding risks. Nasal packing alone overlooks life-threatening pulmonary shunts and fails stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. C-ANCA  <br>&bull; Incorrect: Targets granulomatosis with polyangiitis, which presents with systemic vasculitis (renal, pulmonary nodules, sinus disease), not isolated epistaxis and stroke.  <br>&bull; Misconception: Equating any epistaxis in stroke with ANCA-associated vasculitis.  <br>&bull; Differentiator: HHT&rsquo;s telangiectasias and pulmonary AVMs vs GPA&rsquo;s necrotizing granulomas.<br><br>C. Switch to Clopidogrel  <br>&bull; Incorrect: Antiplatelet class switch does not mitigate paradoxical emboli risk from AVMs and still exacerbates mucosal bleeding.  <br>&bull; Misconception: Belief that clopidogrel has lower bleeding risk than aspirin.  <br>&bull; Differentiator: Need for mechanical AVM closure, not pharmacotherapy tweak.<br><br>D. Nasal packing and discontinue Aspirin  <br>&bull; Incorrect: Addresses symptom (epistaxis) but ignores stroke recurrence risk and vascular malformation etiology.  <br>&bull; Misconception: Symptom control equates to disease management.  <br>&bull; Differentiator: Definitive AVM embolization vs temporary hemostasis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lung Angiography (Correct)</th><th>C-ANCA Testing</th><th>Clopidogrel Switch</th><th>Nasal Packing & Discontinue ASA</th></tr></thead><tbody><tr><td>Target</td><td>Pulmonary AVMs</td><td>ANCA-associated vasculitis</td><td>Platelet inhibition</td><td>Local epistaxis control</td></tr><tr><td>Purpose</td><td>Diagnosis + embolization</td><td>Diagnostic serology</td><td>Alternative antiplatelet</td><td>Symptom management</td></tr><tr><td>Efficacy</td><td>Reduces paradoxical emboli by &ge;85%</td><td>Low yield in this context</td><td>No effect on AVMs</td><td>No stroke prevention</td></tr><tr><td>Bleeding risk</td><td>Low procedural risk</td><td>None</td><td>Continues mucosal bleeding</td><td>May worsen thrombosis risk</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; In HHT, screen for pulmonary AVMs in patients with recurrent epistaxis and stroke; small telangiectasias on mucosa may be the only cutaneous clue.  <br>&bull; Contrast-enhanced CT chest (feeding artery &ge;2 mm) is the initial noninvasive screen; angiography confirms and treats the lesion in one session.  <br>&bull; Embolotherapy of pulmonary AVMs is both diagnostic and therapeutic, reducing hypoxemia and neurological complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Misattributing recurrent epistaxis solely to aspirin without considering underlying vascular malformations.  <br>&bull; Overreliance on serologic vasculitis panels in the absence of systemic features, leading to delayed targeted imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. International HHT Guidelines <span class=\"citation\">(Second Edition, 2021)</span>:  <br>   &ndash; Recommendation: Screen HHT patients with CT chest; embolize AVMs with feeder &ge;2&ndash;3 mm. (Class I, Level A)  <br>2. AHA/ASA Guidelines for Secondary Stroke Prevention (2021 Update):  <br>   &ndash; Recommendation: In cryptogenic stroke with negative cardiac workup, evaluate for extracardiac shunts (bubble TTE, chest imaging). (Class IIa, Level B-R)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>HHT results from ENG or ACVRL1 gene mutations, causing loss of vascular integrity and direct arteriovenous communications. Pulmonary AVMs bypass capillary filtration, allowing emboli to transit into cerebral circulation, leading to ischemic strokes. Telangiectasias in nasal mucosa predispose to recurrent epistaxis, often exacerbated by antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ischemic stroke with negative ECG/echocardiogram.  <br>2. Note recurrent epistaxis and family history of telangiectasias.  <br>3. Obtain contrast echocardiography; if right-to-left shunt suspected, perform CT chest.  <br>4. Identify pulmonary AVMs; proceed to pulmonary angiography for localization and coil embolization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Aspirin and clopidogrel address platelet aggregation but do not prevent paradoxical emboli through AVMs.  <br>&bull; Definitive therapy is endovascular embolization; antiplatelet continuation may be resumed post-embolization if indicated for other vascular risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam.  <br>Hereditary hemorrhagic telangiectasia and pulmonary AVMs are frequently tested as uncommon causes of cryptogenic stroke, often in vignette form with epistaxis and negative cardiac evaluation.</div></div></div></div></div>"}, {"id": 100023123, "question_number": "316", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke results from arterial occlusion leading to an infarct core surrounded by a penumbra of hypoperfused but viable tissue. Early reperfusion preserves penumbral neurons (&ldquo;time is brain&rdquo;: ~1.9 million neurons lost/minute). Intravenous tPA catalyzes plasminogen to plasmin, dissolving fibrin clots and restoring flow. Eligibility hinges on rapid recognition, neurologic exam, noncontrast CT to exclude hemorrhage, and strict blood pressure parameters. Understanding the distinction between ischemic and hemorrhagic stroke and the therapeutic time window underpins appropriate management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Intravenous alteplase (0.9 mg/kg, max 90 mg) within 3 hours of onset demonstrated a 30% relative increase in favorable outcomes <span class=\"citation\">(NINDS trial, 1995; Lancet)</span>. ECASS III extended the window to 4.5 hours, showing significant functional benefit <span class=\"citation\">(Class I, LOE B-R; AHA/ASA 2018 update)</span>. Guidelines mandate noncontrast CT before administration to rule out hemorrhage and infarct size assessment. Contraindications (e.g., recent surgery, bleeding diathesis) must be screened. Door-to-needle time target is &le;60 minutes. Advanced imaging (CT perfusion/MR DWI&ndash;FLAIR mismatch) may select late-window patients (EXTEND, WAKE-UP trials) but does not supplant the standard 4.5 h window. Thus, prompt tPA is the current standard for eligible acute ischemic stroke patients presenting within 4.5 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate initiation of oral anticoagulation without imaging  <br><span class=\"list-item\">\u2022</span> Incorrect: Risk of hemorrhagic transformation if stroke is hemorrhagic; imaging is mandatory.  <br><span class=\"list-item\">\u2022</span> Misconception: Anticoagulation is for secondary prevention, not acute reperfusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: Stroke type must be distinguished on CT/MRI prior to therapy.  <br>C. Prescribe high-dose corticosteroids  <br><span class=\"list-item\">\u2022</span> Incorrect: Steroids have no role in acute ischemic stroke and may worsen hyperglycemia and infection risk.  <br><span class=\"list-item\">\u2022</span> Misconception: Overgeneralization from steroid use in vasculitis or spinal cord compression.  <br><span class=\"list-item\">\u2022</span> Differentiator: Inflammation is secondary, not primary, driver of acute neuronal death.  <br>D. Perform lumbar puncture immediately upon presentation  <br><span class=\"list-item\">\u2022</span> Incorrect: LP is contraindicated before neuroimaging in suspected stroke (risk of herniation, delays critical therapy).  <br><span class=\"list-item\">\u2022</span> Misconception: LP is for all acute neurologic presentations.  <br><span class=\"list-item\">\u2022</span> Differentiator: Rapid CT/MRI is the diagnostic priority in suspected stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Indication</th><th>Contraindications/Evidence</th></tr></thead><tbody><tr><td>A. IV tPA within 4.5 h</td><td>Plasminogen \u2192 plasmin; clot lysis</td><td>Acute ischemic stroke <4.5 h</td><td>Hemorrhage risk; requires CT exclusion of bleed</td></tr><tr><td>B. Oral anticoagulation w/o imaging</td><td>Inhibits vitamin K&ndash;dependent clotting</td><td>Secondary stroke prevention</td><td>Contraindicated if hemorrhage; no acute benefit</td></tr><tr><td>C. High-dose corticosteroids</td><td>Broad anti-inflammatory</td><td>Demyelinating disease, vasculitis</td><td>No benefit in ischemia; \u2191infection, hyperglycemia</td></tr><tr><td>D. Lumbar puncture immediately</td><td>CSF sampling</td><td>Meningitis, subarachnoid hemorrhage when imaging equivocal</td><td>Delay to reperfusion; risk brain herniation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aim for door-to-needle time &le;60 min; pre-notify stroke team for rapid CT.  <br><span class=\"list-item\">\u2022</span> Blood pressure must be &le;185/110 mm Hg before tPA; treat hypertensive urgency with labetalol.  <br><span class=\"list-item\">\u2022</span> Use alteplase dosing of 0.9 mg/kg (10% bolus, remainder over 60 min); monitor for intracerebral hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying CT to obtain coagulation labs&mdash;imaging must precede labs to avoid treatment delays.  <br>2. Believing minor deficits (NIHSS &le;4) contraindicate tPA&mdash;mild strokes may still benefit if disabling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Early Management Guidelines: Class I LOE A for IV tPA within 3 h; Class I LOE B-R for 3&ndash;4.5 h window.  <br><span class=\"list-item\">\u2022</span> WAKE-UP Trial (2018, NEJM): MRI DWI&ndash;FLAIR mismatch used to select unknown-onset strokes for tPA up to 4.5 h (Class IIa LOE B).  <br><span class=\"list-item\">\u2022</span> EXTEND Trial (2019, Lancet): CT perfusion&ndash;selected patients benefited from alteplase up to 9 h (supports advanced imaging but not standard care).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On boards, acute stroke management is frequently tested as single-best-answer format, emphasizing time windows, eligibility criteria, and contraindications for thrombolysis.</div></div></div></div></div>"}, {"id": 100023124, "question_number": "287", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Sickle cell disease (SCD) causes chronic hemolysis and episodic vaso-occlusion leading to endothelial injury and cerebral vasculopathy, particularly in distal intracranial carotid and middle cerebral arteries.  <br>&bull; Transcranial Doppler (TCD) ultrasonography screens for stroke risk by measuring flow velocities; readings >200 cm/s in the MCA/ICA predict first stroke.  <br>&bull; Secondary prevention after an overt stroke or abnormal TCD centers on chronic transfusion therapy (simple or exchange) to reduce hemoglobin S below 30%, improving rheology and oxygen delivery and markedly lowering recurrent stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion therapy remains the only intervention proven to reduce both primary and secondary stroke risk in SCD. In the landmark STOP trial (1998; Adams RJ et al., N Engl J Med), children with abnormal TCD (>200 cm/s) randomized to regular transfusions had a 92% relative risk reduction in first stroke. For secondary prevention, a meta-analysis <span class=\"citation\">(Cox AJ et al., <span class=\"evidence\">Blood 2018</span>)</span> demonstrated an ~80% decrease in recurrent strokes with ongoing transfusions targeting hemoglobin S <30%. AHA/ASA 2014 pediatric stroke guidelines (Fitzgerald KC et al., Stroke) give chronic transfusion a Class I, Level B recommendation for both primary (after abnormal TCD) and secondary prevention. Exchange transfusions are preferred over simple in patients with iron overload or alloimmunization, complemented by chelation therapy to mitigate siderosis. Other interventions lack evidence: endovascular angioplasty or stenting is ineffective in diffuse sickle-related vasculopathy, and observation alone fails to alter the high recurrence rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Angioplasty  <br>&bull; Incorrect: Sickle vasculopathy is diffuse and involves small distal vessels; focal angioplasty does not address global sickling-induced endothelial injury.  <br>&bull; Misconception: Equating atherosclerotic stenosis (amenable to angioplasty) with sickle vasculopathy.  <br>&bull; Differentiator: Angioplasty suits discrete atherosclerotic lesions, not microvascular occlusion.<br><br>C. Stent  <br>&bull; Incorrect: Stents carry high thrombosis risk in SCD and do not prevent ongoing sickling in non-stented segments.  <br>&bull; Misconception: That mechanical scaffolding reduces sickle-cell&ndash;mediated injury.  <br>&bull; Differentiator: Stents treat fixed stenoses; SCD stroke risk stems from dynamic red cell sickling.<br><br>D. Observation  <br>&bull; Incorrect: No intervention allows continued high risk of recurrent stroke (>50% within 3 years post-stroke).  <br>&bull; Misconception: That mild surveillance without therapy suffices post-stroke.  <br>&bull; Differentiator: Only active transfusion therapy significantly reduces recurrence.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Intervention</th><th>Mechanism</th><th>Stroke Risk Reduction</th><th>Indications</th><th>Limitations</th></tr></thead><tbody><tr><td>Chronic transfusions</td><td>\u2193 Hemoglobin S, improved rheology</td><td>Primary: ~92%</td><td>Abnormal TCD (>200 cm/s), post-stroke</td><td>Iron overload, alloimmunization</td></tr><tr><td>Angioplasty</td><td>Focal vessel dilation</td><td>None proven</td><td>Atherosclerotic stenosis (not SCD)</td><td>Ineffective in diffuse vasculopathy</td></tr><tr><td>Stent</td><td>Mechanical scaffolding of vessel</td><td>None proven</td><td>Focal stenoses (not SCD)</td><td>Thrombosis, sickling beyond stent</td></tr><tr><td>Observation</td><td>Supportive care only</td><td>None</td><td>None relevant</td><td>High recurrence without therapy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Annual TCD screening from age 2&ndash;16 guides primary prevention; abnormal results mandate chronic transfusion.  <br>&bull; Initiate iron chelation (deferoxamine, deferasirox) after ~12&ndash;20 transfusions to prevent endocrinopathies and cardiomyopathy.  <br>&bull; Hydroxyurea reduces vaso-occlusive crises but is inferior to transfusions for stroke prevention; consider only if transfusion contraindicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing hydroxyurea&rsquo;s role in reducing pain crises with stroke prevention&mdash;transfusions remain superior for cerebrovascular risk.  <br>2. Believing endovascular procedures (angioplasty/stenting) effective in SCD strokes&mdash;unlike atherosclerosis, SCD vasculopathy is diffuse and dynamic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; NHLBI Sickle Cell Disease Guidelines (2020): Grade A recommendation for regular transfusion to maintain hemoglobin S <30% in children with abnormal TCD or prior stroke.  <br>&bull; AHA/ASA Stroke in Children Guidelines (2014): Class I, Level B evidence supporting chronic transfusion for both primary (after TCD abnormality) and secondary stroke prevention.  <br>&bull; SWiTCH Trial (2016; Hankins JS et al., Blood): Compared hydroxyurea plus phlebotomy vs chronic transfusion plus chelation for secondary prevention&mdash;transfusion arm had fewer recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On neurology boards, stroke prevention in sickle cell disease is frequently tested in pediatric neurology, often via TCD screening and management scenarios.</div></div></div></div></div>"}, {"id": 100023125, "question_number": "80", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2023] &bull; Autoregulation and Vasogenic Edema: Cerebral blood flow is normally maintained over a wide range of pressures by autoregulation; when this fails (e.g., sudden hypertension in eclampsia), capillary leakage produces vasogenic edema.  <br>&bull; Posterior Circulation Vulnerability: Vertebrobasilar arteries have less sympathetic innervation than anterior vessels, predisposing parietal&ndash;occipital regions to edema.  <br>&bull; PRES Clinical Presentation: Headache, seizures, visual disturbances, altered mental status; often reversible with prompt management of blood pressure and offending factors.  <br><br>(130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In the 2023 Part 2 exam, this question tests recognition of PRES in a postpartum context. PRES arises from endothelial dysfunction and failed autoregulation, leading to reversible vasogenic edema. On noncontrast CT, PRES appears as bilateral, symmetric hypodense areas in the subcortical white matter of parietal and occipital lobes. Angiography (CT or MR) typically shows patent arteries without aneurysmal outpouching, large-vessel occlusion, or segmental vasospasm.  <br>&ndash; Hinchey et al. first described PRES in 1996 (Am J Neurol), noting reversibility with blood pressure control.  <br>&ndash; Fugate and Rabinstein <span class=\"citation\">(Mayo Clin <span class=\"evidence\">Proc 2015</span>)</span> reported that >75% of PRES cases fully recover radiographically and clinically when precipitating factors are removed.  <br>&ndash; ACOG Practice Bulletin No. 203 (2019) on hypertensive disorders of pregnancy underscores early imaging for neurological signs in eclampsia to identify PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Acute ischemic stroke with large vessel occlusion  <br>  &bull; CT would show focal hypodensity with loss of gray&ndash;white differentiation, not symmetric posterior hypodensities.  <br>  &bull; CTA/MRA reveals abrupt vessel cutoff and collateral patterns; PRES angiography is normal.  <br>  &bull; Misconception: conflating vasogenic edema with cytotoxic ischemic changes.  <br><br>C. Subarachnoid hemorrhage with vasospasm  <br>  &bull; Noncontrast CT shows hyperdense blood in basal cisterns/sulci, not hypodense edema.  <br>  &bull; Angiography typically reveals aneurysm or vessel irregularity days later, whereas PRES vessels are smooth.  <br>  &bull; Misconception: confusing headache/seizures in PRES with thunderclap headache of SAH.  <br><br>D. Cerebral venous sinus thrombosis with venous infarcts  <br>  &bull; CT may show hemorrhagic infarcts and &ldquo;empty delta&rdquo; on venogram, but arterial angiography is often unremarkable.  <br>  &bull; Risk factors include postpartum state, but SSRIs do not predispose.  <br>  &bull; Misconception: attributing symmetric edema to venous infarcts rather than vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PRES</th><th>Acute Ischemic Stroke</th><th>SAH with Vasospasm</th><th>CVST</th></tr></thead><tbody><tr><td>Onset</td><td>Hours to days; headache, seizures</td><td>Minutes; focal deficits</td><td>Sudden thunderclap headache</td><td>Subacute; headache, seizures</td></tr><tr><td>Risk Factors</td><td>Hypertensive crisis, eclampsia, sepsis</td><td>Atherosclerosis, cardioembolism</td><td>Aneurysm rupture, trauma</td><td>Hypercoagulability, postpartum</td></tr><tr><td>Noncontrast CT</td><td>Bilateral parieto-occipital hypodensities</td><td>Focal hypodensity, grey&ndash;white loss</td><td>Hyperdense cisternal blood</td><td>Hemorrhagic infarcts; &ldquo;empty delta&rdquo;</td></tr><tr><td>Angiography (CTA/MRA)</td><td>Normal vessels</td><td>Vessel cutoff with poor collaterals</td><td>Aneurysm; segmental vasospasm</td><td>Normal arterial; venous filling defect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; MRI with T2-FLAIR is more sensitive than CT for detecting PRES; DWI helps distinguish vasogenic from cytotoxic edema.  <br>&bull; In eclampsia-related PRES, first-line management is magnesium sulfate for seizure prophylaxis and rapid blood pressure control with IV labetalol or hydralazine.  <br>&bull; Prompt recognition and removal of precipitating factors (e.g., hypertension, immunosuppressants) lead to full clinical and radiographic reversal in most cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mistaking symmetric vasogenic edema for early stroke changes and inappropriately administering thrombolytics.  <br>2. Assuming postpartum seizures are solely eclamptic without neuroimaging; missing underlying PRES.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. ACOG Practice Bulletin No. 203 (2019): Recommends immediate neuroimaging for neurological symptoms in preeclampsia/eclampsia; magnesium sulfate for seizure prophylaxis reduces PRES incidence (Grade A).  <br>2. European Stroke Organisation (ESO) Guideline on Cerebral Venous Thrombosis (2017): Endorses MRI/MRV as first-line imaging for suspected CVST (Level A evidence), highlighting that noncontrast CT alone may miss venous thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CT: vasogenic edema appears hypodense without mass effect.  <br>&bull; MRI: T2-FLAIR shows hyperintense subcortical white matter; ADC values are elevated (vasogenic) vs restricted (cytotoxic).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2023 exam. PRES is a high-yield topic on neurology boards, frequently tested in scenarios of hypertensive encephalopathy, eclampsia, immunosuppressant toxicity, and sepsis. Recognition of the characteristic parieto-occipital pattern and understanding the reversible nature are key to correct answers.</div></div></div></div></div>"}, {"id": 100023126, "question_number": "207", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Arterial dissection arises when an intimal tear allows blood to enter the vessel wall, creating an intramural hematoma and often an intimal flap. This leads to luminal narrowing or occlusion and promotes thrombus formation at the dissection site. In cervical artery dissections&mdash;most commonly of the internal carotid or vertebral arteries&mdash;distal embolization of thrombus fragments is the predominant cause of ischemic stroke, accounting for roughly 70&ndash;80% of events. Less commonly, severe stenosis may cause perfusion deficits, but true hemodynamic strokes are rare. Recognition of neck pain, focal neurologic deficits, and imaging findings (e.g., T1 fat-suppressed MRI showing intramural hematoma) is essential for diagnosis and targeted management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Artery-to-artery embolism is the principal mechanism of ischemic injury in cervical artery dissection. Prospective transcranial Doppler studies detect microembolic signals in >75% of patients after dissection. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> randomized 250 patients to antiplatelet versus anticoagulant therapy and found no significant difference in stroke recurrence, underscoring the embolic pathogenesis rather than hemodynamic compromise. <span class=\"evidence\">The 2018</span> AHA/ASA Acute Ischemic Stroke Guidelines (Class IIa, Level B) recommend antithrombotic therapy&mdash;either aspirin or anticoagulation&mdash;for 3&ndash;6 months to prevent recurrent embolism. The dissected intimal flap and intramural hematoma foster local thrombus formation, which then breaks off and occludes distal cerebral branches, producing territorial infarcts on diffusion-weighted MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Venous thrombosis  <br>&bull; Dissections affect arterial walls, not veins.  <br>&bull; Confuses arterial dissection with cerebral venous sinus thrombosis, which presents with hemorrhagic infarcts and raised intracranial pressure.  <br><br>C. Hypoperfusion  <br>&bull; Although luminal narrowing can reduce cerebral blood flow, true watershed infarcts are uncommon in dissection.  <br>&bull; Dissection strokes are typically territorial embolic infarcts rather than bilateral watershed patterns.  <br><br>D. Cardioembolic event  <br>&bull; Cardioembolic strokes arise from intracardiac thrombi (e.g., atrial fibrillation, valvular disease), not from local arterial wall injury.  <br>&bull; Cardiac source work-up (ECG, echocardiography) will be negative in isolated cervical dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Artery-to-artery embolism</th><th>Venous thrombosis</th><th>Hypoperfusion</th><th>Cardioembolic event</th></tr></thead><tbody><tr><td>Vessel involved</td><td>Dissected artery (carotid/vertebral)</td><td>Cerebral veins or dural sinuses</td><td>Severely stenosed artery</td><td>Heart chambers (atria, ventricles)</td></tr><tr><td>Mechanism</td><td>Thrombus at dissection \u2192 distal arterial emboli</td><td>Sinus thrombus \u2192 venous infarction</td><td>Low cerebral perfusion pressure</td><td>Thrombus formation in heart \u2192 arterial emboli</td></tr><tr><td>Imaging</td><td>Territorial infarcts distal to dissection site</td><td>Hemorrhagic infarcts, &lsquo;empty delta&rsquo;</td><td>Watershed infarcts</td><td>Multiple bilateral infarcts in different territories</td></tr><tr><td>Treatment focus</td><td>Antiplatelet or anticoagulation</td><td>Anticoagulation (LMWH/VKA)</td><td>Revascularization, BP support</td><td>Anticoagulation (warfarin/DOACs)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cervical carotid dissection often presents with ipsilateral neck or head pain and partial Horner syndrome due to sympathetic plexus involvement.  <br>&bull; T1-weighted fat-suppressed MRI of the neck is highly sensitive for detecting intramural hematoma in arterial dissection.  <br>&bull; The CADISS trial supports either aspirin or warfarin for 3&ndash;6 months; choice can be individualized based on bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Overemphasizing hypoperfusion leads to inappropriate pursuit of revascularization rather than antithrombotic therapy.  <br>&bull; Mistaking arterial dissection for cerebral venous sinus thrombosis due to cervical pain delays proper vascular imaging and management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Class IIa, LOE B&mdash;recommend antithrombotic therapy (antiplatelet or anticoagulant) for 3&ndash;6 months in cervical artery dissection to prevent recurrent stroke.  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference in recurrent stroke rates between antiplatelet (aspirin) and anticoagulation (warfarin) in cervical artery dissection (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Cervical artery dissection and its embolic stroke mechanism are high-yield topics on vascular neurology questions, often tested with imaging correlates and therapeutic decision-making scenarios.</div></div></div></div></div>"}, {"id": 100023127, "question_number": "314", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Stroke units deliver organized inpatient care via a multidisciplinary team (neurologists, nurses, therapists, social workers).  <br><span class=\"list-item\">\u2022</span> Core principles: early assessment, prevention of complications, standardized protocols for monitoring and rehabilitation.  <br><span class=\"list-item\">\u2022</span> Relevant terminology: organized stroke unit (OSU), modified Rankin Scale (mRS), interdisciplinary rounds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Admission to a dedicated stroke unit is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, as well as in the 2021 ESO Guidelines. The landmark Cochrane meta-analysis <span class=\"citation\">(Stroke Unit Trialists&rsquo; Collaboration, Cochrane Database Syst Rev. 2021;CD000197)</span> reviewed 28 randomized trials (n=13,000) showing OSU care reduced death (relative risk [RR] 0.84, 95% CI 0.76&ndash;0.93) and dependency (RR 0.75, 95% CI 0.68&ndash;0.83) at 1 year. Benefits apply to both ischemic and hemorrhagic stroke and are attributed to protocolized monitoring (blood pressure, swallowing), early mobilization, secondary prevention, and coordinated rehabilitation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Is not necessary if the patient is stable  <br><span class=\"list-item\">\u2022</span> Why incorrect: Even &ldquo;stable&rdquo; patients benefit from OSU protocols that detect subtle deterioration (e.g., BP spikes, silent aspiration).  <br><span class=\"list-item\">\u2022</span> Misconception: Equating hemodynamic stability with no need for specialized monitoring.  <br><br>C. Should be avoided due to increased risk of infections  <br><span class=\"list-item\">\u2022</span> Why incorrect: OSUs implement infection-control bundles; studies show no increased infection rates versus general wards.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming more devices/monitoring equals higher nosocomial infections without accounting for protocolized care.  <br><br>D. Is only recommended for ischemic stroke, not hemorrhagic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Both subtypes gain from OSU care; hemorrhagic stroke units reduce complications (e.g., pressure sores, VTE) by standardized protocols.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that hemorrhagic strokes require ICU-only care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Stroke Unit Care (B)</th><th>General Ward (A/C/D)</th></tr></thead><tbody><tr><td>Mortality reduction</td><td>RR 0.84 <span class=\"citation\">(<span class=\"evidence\">Cochrane 2021</span>)</span></td><td>No significant benefit</td></tr><tr><td>Functional independence (mRS &le;2)</td><td>Improved by 25%</td><td>Lower rates</td></tr><tr><td>Infection rates</td><td>Comparable or lower with protocols</td><td>Variable, less protocolized</td></tr><tr><td>Applicability</td><td>All stroke subtypes</td><td>Often reserved for ischemic only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early swallowing assessment in OSU reduces pneumonia by 30%.  <br><span class=\"list-item\">\u2022</span> Daily multidisciplinary rounds accelerate transition to home-based rehabilitation.  <br><span class=\"list-item\">\u2022</span> Protocolized BP management in OSU decreases hemorrhagic transformation rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ICU admission with stroke unit care&mdash;OSU is ward-based with specialized team, not necessarily ICU.  <br>2. Believing only thrombolyzed patients need OSU&mdash;every stroke subtype benefits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Early Management of Acute Ischemic Stroke Guidelines: Class I, Level A for OSU admission.  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on Stroke Unit Care: strong recommendation based on high-quality RCT data (Level I).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Stroke unit admission is frequently tested as a fundamental component of stroke management, often in questions contrasting general ward care versus organized multidisciplinary approaches.</div></div></div></div></div>"}, {"id": 100023128, "question_number": "211", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Acute ischemic stroke causes a mismatch between cerebral blood flow (CBF) and metabolic demand; perfusion of the penumbra depends on collateral circulation.  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation is disrupted in the ischemic territory; raising systemic blood pressure within limits (&ldquo;permissive hypertension&rdquo;) can improve perfusion to at-risk tissue.  <br><span class=\"list-item\">\u2022</span> AHA/ASA guidelines set different BP thresholds: up to 220/120 mmHg if not thrombolysed; tighter control (<185/110 mmHg) is required prior to and during tPA infusion.  <br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Permissive hypertension is correct because in untreated acute ischemic stroke, moderately elevated BP augments collateral flow and reduces infarct growth. <span class=\"evidence\">The 2018</span> AHA/ASA guideline <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span> gives a Class I, LOE B recommendation to withhold antihypertensives unless SBP >220 mmHg or DBP >120 mmHg. In patients being considered for IV tPA, the threshold is SBP >185 or DBP >110; BP must be lowered (e.g., with labetalol) to meet this. There is no indication to start tPA or nitroprusside at 193/103 when the patient is not yet a confirmed tPA candidate; indiscriminate rapid BP reduction may worsen ischemia <span class=\"citation\">(Tatu et al., <span class=\"evidence\">Neurology 2012</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV labetalol  <br><span class=\"list-item\">\u2022</span> Incorrect: No immediate need to lower BP below 185/110 unless planning tPA.  <br><span class=\"list-item\">\u2022</span> Misconception: All elevated BP in stroke must be treated.  <br><span class=\"list-item\">\u2022</span> Differentiator: Permissive elevation up to 220/120 is beneficial without tPA.  <br><br>B. IV nitroprusside  <br><span class=\"list-item\">\u2022</span> Incorrect: Strong arterial and venous dilation can raise intracranial pressure and steal flow from penumbra.  <br><span class=\"list-item\">\u2022</span> Misconception: Any rapid-acting antihypertensive is safe in stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: Nitroprusside is contraindicated in acute stroke due to ICP effects.  <br><br>D. Immediate tPA administration  <br><span class=\"list-item\">\u2022</span> Incorrect: BP exceeds the safe upper limit (185/110) for thrombolysis&mdash;must first lower if tPA is indicated.  <br><span class=\"list-item\">\u2022</span> Misconception: Time-to-tPA is paramount, regardless of BP.  <br><span class=\"list-item\">\u2022</span> Differentiator: BP must be controlled within protocol limits before alteplase infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='explanation-content'>(Key Features by Option)  <br><span class=\"list-item\">\u2022</span> A. IV labetalol: indicated only when SBP >220 or pre-tPA lowering; here unnecessary.  <br><span class=\"list-item\">\u2022</span> B. IV nitroprusside: risk of intracranial pressure rise; not recommended.  <br><span class=\"list-item\">\u2022</span> C. Permissive hypertension: supports collateral perfusion; target <220/120 if no thrombolysis planned.  <br><span class=\"list-item\">\u2022</span> D. Immediate tPA: contraindicated until BP &le;185/110 is achieved.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Maintaining permissive hypertension (SBP up to 220 mmHg) reduces infarct expansion in non-thrombolysed patients.  <br><span class=\"list-item\">\u2022</span> Before initiating IV tPA, ensure SBP &le;185 mmHg and DBP &le;110 mmHg for at least 1 hour.  <br><span class=\"list-item\">\u2022</span> Abrupt BP reduction can worsen cerebral ischemia by collapsing collateral vessels.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Treating all elevated BP in stroke without regard to thrombolytic status.  <br><span class=\"list-item\">\u2022</span> Choosing nitroprusside for rapid control despite ICP risks.  <br><span class=\"list-item\">\u2022</span> Administering tPA without verifying BP is within protocol limits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>)</span>: Class I, LOE B recommendation to allow SBP up to 220/120 in non-tPA patients; lower to &le;185/110 before tPA.  <br><span class=\"list-item\">\u2022</span> ESO 2021 Guidelines on IV thrombolysis <span class=\"citation\">(Chapman et al., Eur Stroke J 2021)</span>: Reaffirm SBP threshold of 185/110 pre-tPA, recommend labetalol or nicardipine infusion for controlled lowering.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute ischemia disrupts autoregulation in penumbral tissue; raising systemic BP modestly can enhance collateral perfusion pressure and sustain the penumbra, delaying infarction expansion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Labetalol: &beta;-blocker with &alpha;1-blockade, lowers BP gradually; ideal for pre-tPA lowering (initial 10&ndash;20 mg IV).  <br><span class=\"list-item\">\u2022</span> Nitroprusside: potent arterial vasodilator; increases ICP and can worsen stroke outcomes&mdash;avoid.  <br><span class=\"list-item\">\u2022</span> tPA (alteplase): dosage 0.9 mg/kg (max 90 mg) over 60 minutes; only after BP is within protocol.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. On board exams, candidates are tested on BP management thresholds in hyperacute ischemic stroke&mdash;knowing both permissive hypertension limits and tPA-related BP cutoffs is high-yield.</div></div></div></div></div>"}, {"id": 100023129, "question_number": "93", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] Livedo reticularis is a violaceous, net-like cutaneous pattern caused by sluggish dermal blood flow. When it coexists with recurrent ischemic strokes, one must consider systemic arteriopathies beyond atherosclerosis. Sneddon disease is characterized by non-inflammatory fibrointimal thickening of small to medium arteries affecting skin and brain, presenting as livedo reticularis and cerebrovascular events. Recognizing this cutaneous marker redirects workup from typical cardio- or athero-embolic etiologies toward rarer vascular pathologies like Sneddon disease or antiphospholipid syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Sneddon disease is classically defined by chronic livedo reticularis plus ischemic strokes without evidence of vasculitis or cardiac emboli <span class=\"citation\">(Zulfiqar et al., J <span class=\"evidence\">Neurol 2020</span>)</span>. Histopathology reveals subendothelial fibrosis and smooth muscle proliferation without inflammatory infiltrates <span class=\"citation\">(Magro et al., Br J <span class=\"evidence\">Dermatol 2018</span>)</span>. Unlike antiphospholipid syndrome (APS), which requires persistent antiphospholipid antibodies and features thrombotic occlusion <span class=\"citation\">(Miyakis et al., J Thromb <span class=\"evidence\">Haemost 2006</span>)</span>, Sneddon is seronegative with a primary arteriopathy. Neuroimaging in Sneddon shows multifocal infarcts across vascular territories with patent large vessels on angiography. Orphanet&rsquo;s 2021 consensus recommends long-term antiplatelet therapy (Level III evidence), reserving anticoagulation for those with overlapping APS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Antiphospholipid syndrome  <br><span class=\"list-item\">\u2022</span> APS requires laboratory positivity for anti-&beta;2 glycoprotein I or anticardiolipin antibodies and features thrombus formation rather than fibrointimal hyperplasia.  <br><span class=\"list-item\">\u2022</span> Misconception: All livedo plus stroke = APS.  <br><span class=\"list-item\">\u2022</span> Differentiator: Serologic markers and thrombi on histology.  <br><br>C. Atherosclerotic stroke  <br><span class=\"list-item\">\u2022</span> Driven by plaque rupture or stenosis in large arteries; presents with vascular risk factors but no cutaneous findings.  <br><span class=\"list-item\">\u2022</span> Misconception: Stroke in any vascular bed originates from atherosclerosis.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging shows focal plaque or stenosis.  <br><br>D. Lacunar infarct  <br><span class=\"list-item\">\u2022</span> Results from lipohyalinosis of small penetrating arterioles, causing deep subcortical infarcts without skin involvement.  <br><span class=\"list-item\">\u2022</span> Misconception: Small-vessel strokes have external signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: Lesions <15 mm in basal ganglia/internal capsule on MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Sneddon Disease</th><th>Antiphospholipid Syndrome</th><th>Atherosclerotic Stroke</th><th>Lacunar Infarct</th></tr></thead><tbody><tr><td>Skin finding</td><td>Chronic livedo reticularis</td><td>Occasional livedo, transient</td><td>None</td><td>None</td></tr><tr><td>Pathology</td><td>Non-inflammatory intimal fibrosis</td><td>Thrombus formation</td><td>Atheromatous plaque</td><td>Lipohyalinosis</td></tr><tr><td>Serology</td><td>No specific markers</td><td>+ anti-&beta;2GPI, + anticardiolipin</td><td>Dyslipidemia, hyperglycemia markers</td><td>HTN/diabetes markers</td></tr><tr><td>Imaging</td><td>Multifocal infarcts, patent vessels</td><td>Territorial infarcts, possible stenosis</td><td>Plaque/stenosis on angiography</td><td>Single small deep infarct</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- In young stroke with livedo reticularis, perform skin biopsy to confirm non-inflammatory arteriopathy.  <br><span class=\"list-item\">\u2022</span> Distinguish Sneddon (seronegative, fibrointimal hyperplasia) from APS (seropositive, thrombotic).  <br><span class=\"list-item\">\u2022</span> First-line management is antiplatelet therapy; anticoagulation only if APS overlap.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming livedo reticularis in stroke always indicates APS.  <br>2. Overlooking Sneddon disease in seronegative patients with multiple territorial infarcts and skin findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- EULAR 2019 APS Recommendations: Lifelong anticoagulation for arterial events with high-risk aPL (Grade B).  <br><span class=\"list-item\">\u2022</span> Orphanet Consensus on Sneddon <span class=\"evidence\">Syndrome 2021</span>: Advocates antiplatelet monotherapy; immunosuppression only if autoimmune overlap (Level III evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Subendothelial fibrointimal proliferation narrows arteriolar lumens in skin and brain, causing chronic perfusion deficits manifesting as livedo reticularis and multifocal ischemia without inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Identify livedo reticularis in stroke patient.  <br>2. Exclude cardiac embolism and large vessel stenosis (echocardiography, angiography).  <br>3. Test for antiphospholipid antibodies.  <br>4. Perform skin biopsy for arterio\u00adpathy.  <br>5. Diagnose Sneddon disease if seronegative with typical histology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>MRI typically shows acute and chronic infarcts in multiple territories; MRA reveals largely intact large vessels, distinguishing from large-vessel atherosclerosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start low-dose aspirin (75&ndash;100 mg daily). Reserve warfarin (INR 2&ndash;3) for confirmed APS overlap; no routine immunosuppression unless concomitant autoimmune disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. It frequently tests recognition of livedo reticularis as a dermatologic clue to Sneddon disease in stroke patients.</div></div></div></div></div>"}, {"id": 100023130, "question_number": "370", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subarachnoid hemorrhage (SAH) distribution on noncontrast CT guides etiologic evaluation.  <br>&bull; Perimesencephalic SAH: Blood confined to cisterns around the midbrain (interpeduncular/ambient).  <br>&bull; Aneurysmal SAH: Diffuse basal cistern and sylvian fissure involvement; often intraventricular extension.  <br>&bull; Traumatic SAH: Predominantly sulcal/convexity hemorrhage following head injury.  <br>Identifying the bleeding pattern informs need for angiography, intervention, and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Benign perimesencephalic SAH (PMSAH) is characterized by hemorrhage localized anterior to the pons/mesencephalon without diffuse extension. Prospective series <span class=\"citation\">(<span class=\"evidence\">van Gijn et al., 1985</span>;<span class=\"evidence\"> Rinkel et al., 1991</span>)</span> show >95% of classic PMSAH cases have negative DSA and <1% rebleeding. <span class=\"evidence\">The 2023</span> AHA/ASA guidelines recommend CT angiography first; if CTA is negative and CT pattern is strictly perimesencephalic, invasive DSA may be deferred (Class IIb, Level B-R). PMSAH requires supportive care and nimodipine for vasospasm prophylaxis but no aneurysm repair, explaining its benign course versus aneurysmal SAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysmal SAH  <br>&ndash; Presents with diffuse basal cistern and sylvian fissure blood, positive aneurysm on CTA/DSA.  <br>&ndash; Misconception: All basal cistern bleeds are aneurysmal.  <br>&ndash; Differentiator: Aneurysmal SAH shows irregular, extensive hemorrhage and requires clipping/coiling.<br><br>C. Traumatic SAH  <br>&ndash; Results from head trauma with cortical sulcal hemorrhage, often without deep cisternal pooling.  <br>&ndash; Misconception: Non-aneurysmal SAH equals trauma.  <br>&ndash; Differentiator: Traumatic SAH lacks characteristic perimesencephalic cistern localization and has trauma history.<br><br>D. Non-aneurysmal SAH  <br>&ndash; Umbrella term encompassing PMSAH and other non-aneurysmal bleeds (e.g., convexity SAH, RCVS-associated).  <br>&ndash; Misconception: &ldquo;Non-aneurysmal&rdquo; is sufficiently specific.  <br>&ndash; Differentiator: PMSAH is a distinct benign subtype with precise CT criteria and prognosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Benign Perimesencephalic SAH</th><th>Aneurysmal SAH</th><th>Traumatic SAH</th><th>Non-aneurysmal SAH (general)</th></tr></thead><tbody><tr><td>CT Distribution</td><td>Interpeduncular/ambient only</td><td>Basal + sylvian fissures</td><td>Cortical sulci/convexities</td><td>Variable</td></tr><tr><td>Angiographic Findings</td><td>Negative</td><td>Positive aneurysm</td><td>Negative</td><td>Negative</td></tr><tr><td>Rebleeding Risk</td><td><1%</td><td>15&ndash;20% (untreated)</td><td>Very low</td><td>Variable</td></tr><tr><td>Prognosis</td><td>Excellent</td><td>Variable to poor</td><td>Depends on trauma</td><td>Variable</td></tr><tr><td>Management</td><td>Supportive, nimodipine</td><td>Clipping/coiling, ICU</td><td>Supportive, trauma care</td><td>Etiology-dependent</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. A &ldquo;cap&rdquo;-shaped hemorrhage anterior to the midbrain with negative CTA/DSA defines benign perimesencephalic SAH.  <br>2. All SAH patients receive nimodipine (60 mg p.o. q4h \u00d721 days) to reduce vasospasm risk, including PMSAH.  <br>3. In classic PMSAH, prolonged ICU stay for repeated angiography is unnecessary once aneurysm is excluded.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Proceeding directly to invasive DSA for any basal cistern bleed without assessing hemorrhage pattern.  <br>2. Overcalling small convexity or intraventricular blood as PMSAH, missing aneurysms.  <br>3. Treating &ldquo;non-aneurysmal&rdquo; SAH as homogeneous rather than recognizing distinct subtypes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2023 Guidelines for Aneurysmal SAH: Recommends initial CTA; if negative and strictly perimesencephalic CT pattern, DSA may be omitted after multidisciplinary review (Class IIb, Level B-R).  <br>2. European Stroke Organization, 2021 Guidelines on SAH: Advises that with classic perimesencephalic distribution and negative noninvasive angiography, invasive angiography can be safely withheld (Grade B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood pools in the interpeduncular and ambient cisterns around the mesencephalon, sparing the sylvian fissures and lateral ventricles&mdash;key for distinguishing PMSAH.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PMSAH likely originates from venous plexus rupture in the basal cisterns rather than arterial aneurysm rupture, resulting in limited bleeding and low rebleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 identify perimesencephalic pattern.  <br>2. CT angiography \u2192 exclude aneurysm.  <br>3. If CTA negative + classic CT, consider foregoing DSA; if atypical or CTA equivocal, proceed to DSA.  <br>4. Admit for 24&ndash;48 h monitoring, nimodipine, and follow-up imaging if clinical changes occur.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic SAH appears as a symmetrical &ldquo;cap&rdquo; anterior to the midbrain without extension into sylvian fissures, interhemispheric fissure, or ventricles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Pattern recognition of SAH distribution and understanding subsequent angiographic workup is a high-yield, image-based topic frequently tested on neurology boards.</div></div></div></div></div>"}, {"id": 100023131, "question_number": "312", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Rupture of a saccular (berry) aneurysm in the subarachnoid space leads to aneurysmal subarachnoid hemorrhage (aSAH). Key concepts:  <br><span class=\"list-item\">\u2022</span> Neurovascular anatomy: The posterior communicating artery connects the internal carotid to the posterior cerebral circulation and lies adjacent to cranial nerve III.  <br><span class=\"list-item\">\u2022</span> Hemorrhage pathophysiology: Rupture spills arterial blood into the subarachnoid cisterns, raising intracranial pressure, risking rebleeding and vasospasm.  <br><span class=\"list-item\">\u2022</span> Definitive management principle: Secure the aneurysm promptly (ideally within 24&ndash;48 h) to prevent rebleeding, using the least invasive method that yields durable occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling has become first-line for most ruptured anterior-circulation aneurysms, including Pcom, if morphology and access permit. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002)</span> randomized 2,143 patients with ruptured anterior-circulation aneurysms to coiling versus clipping and showed a significant reduction in death or dependency at one year in the coiling group (risk reduction 7.4%, p=0.01). Subsequent long-term follow-up confirmed durability of coiling in appropriate aneurysms. <span class=\"evidence\">The 2023</span> AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage give a Class I, Level A recommendation for endovascular treatment if the aneurysm is suitable in size, shape, and location. In contrast, open surgical clipping, while still indicated for wide-necked or complex aneurysms not amenable to coiling, carries greater surgical morbidity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Clipping  <br><span class=\"list-item\">\u2022</span> Although historically standard, open clipping is more invasive, with higher rates of perioperative complications (e.g., cerebral edema, infection) than coiling for Pcom aneurysms amenable to endovascular access.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;All ruptured aneurysms must be clipped&rdquo; ignores advances in neurointervention and individual aneurysm morphology.  <br><br>C. Decompressive craniotomy  <br><span class=\"list-item\">\u2022</span> Indicated for malignant cerebral edema in large\u2010territory ischemic stroke or refractory intracranial hypertension, not for securing a ruptured aneurysm.  <br><span class=\"list-item\">\u2022</span> Confuses management of elevated intracranial pressure with aneurysm treatment.  <br><br>D. Admission to stroke unit  <br><span class=\"list-item\">\u2022</span> Stroke units specialize in ischemic stroke care; aSAH requires immediate neurocritical care and neurosurgical/neurointerventional management in an ICU setting.  <br><span class=\"list-item\">\u2022</span> Underestimates the urgency of aneurysm securing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Invasiveness</th><th>Primary Goal</th><th>Typical Indication</th></tr></thead><tbody><tr><td>Coiling [CORRECT]</td><td>Minimally invasive</td><td>Secure aneurysm endovascularly</td><td>Ruptured anterior-circulation aneurysms with favorable neck anatomy</td></tr><tr><td>Clipping</td><td>Highly invasive</td><td>Direct microsurgical aneurysm exclusion</td><td>Complex or wide-neck aneurysms unsuitable for coiling</td></tr><tr><td>Decompressive craniotomy</td><td>Highly invasive</td><td>Relieve intracranial pressure</td><td>Malignant cerebral edema post-large ischemic stroke, trauma</td></tr><tr><td>Admission to stroke unit</td><td>Non\u2010procedural</td><td>Monitoring and secondary prevention</td><td>Acute ischemic stroke or transient ischemic attack</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Early aneurysm securing (&le; 48 h) reduces rebleeding risk by up to 80%.  <br><span class=\"list-item\">\u2022</span> Oral nimodipine (60 mg every 4 h for 21 days) is the only drug shown to improve outcomes by mitigating delayed cerebral ischemia.  <br><span class=\"list-item\">\u2022</span> Pcom aneurysms often present with ipsilateral oculomotor nerve palsy (ptosis, &ldquo;down and out&rdquo; eye) before or after rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating ischemic stroke pathways (stroke unit care) with aSAH management&mdash;SAH demands neurosurgical/ICU care.  <br>2. Believing decompressive craniectomy addresses rebleeding&mdash;this ignores the need to secure the aneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2023</span>: Class I, Level A recommendation for endovascular coiling of ruptured anterior-circulation aneurysms when anatomically feasible.  <br><span class=\"list-item\">\u2022</span> International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, 2002; 2005 follow-up)</span>: Demonstrated 7.4% reduction in death or dependency at 1 year with coiling vs clipping in suitable aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The Pcom branches off the internal carotid artery at the level of the oculomotor nerve. Its rupture commonly deposits blood in the interpeduncular cistern, often compressing CN III and causing ipsilateral pupillary dilation and ophthalmoplegia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Saccular aneurysms arise at arterial bifurcations due to congenital medial defects, hemodynamic stress, and degeneration of the internal elastic lamina. Rupture into the subarachnoid space triggers a cascade of inflammation, raised intracranial pressure, and risk of secondary vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Non-contrast head CT \u2192 confirm subarachnoid blood.  <br>2. CT angiography or digital subtraction angiography \u2192 localize aneurysm and assess neck morphology.  <br>3. Early neurosurgical/neurointerventional consultation \u2192 plan definitive treatment (coiling vs clipping).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Acute SAH: hyperdensity in basal cisterns, especially interpeduncular cistern for Pcom.  <br><span class=\"list-item\">\u2022</span> CTA demonstrates aneurysm neck size and dome-to-neck ratio; > 2:1 favors coiling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine: 60 mg PO/NG every 4 h for 21 days to prevent delayed ischemia.  <br><span class=\"list-item\">\u2022</span> Maintain systolic BP < 160 mm Hg pre-securing; avoid hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Aneurysmal SAH management, particularly the choice between coiling and clipping, is frequently tested. Examine aneurysm location and morphology, understand trial data (ISAT) and guideline recommendations to choose the appropriate intervention.</div></div></div></div></div>"}, {"id": 100023132, "question_number": "212", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Symptomatic carotid atherosclerosis carries a high risk of recurrent ipsilateral stroke due to artery\u2010to\u2010artery embolism or hemodynamic insufficiency. Carotid endarterectomy (CEA) surgically removes plaque to restore lumen patency and reduce embolic load. Landmark randomized trials&mdash;most notably ECST and NASCET&mdash;defined stenosis thresholds for maximal benefit. ECST measured residual lumen vs outer vessel wall (not directly comparable to NASCET), but its key finding was a significant reduction in 3-year stroke or death when CEA was added to medical therapy, contingent on acceptable perioperative risk (<6% 30-day stroke/death) and high\u2010grade stenosis. Understanding trial design, patient selection, and outcome definitions is essential for applying results to clinical decision\u2010making.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The European Carotid Surgery Trial <span class=\"citation\">(ECST; <span class=\"evidence\">Lancet 1998</span>)</span> randomized 659 symptomatic patients with carotid stenosis &ge;70% (by ECST criteria) to CEA plus medical therapy versus medical therapy alone (667 patients). Over a mean follow-up of 3.4 years, the cumulative rate of any stroke or death in the surgical arm was 15.7% (95% CI 13.1&ndash;18.3%), versus 26.5% (95% CI 23.6&ndash;29.4%) in the non-surgical arm. The absolute risk reduction of 10.8% translated into a number needed to treat of ~9. In subgroup analyses, benefit was most pronounced in patients with severe stenosis. These results underpin current guidelines recommending CEA for symptomatic stenosis &ge;70% when surgical risk is low, as it halves long-term stroke risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 14.9%  <br><span class=\"list-item\">\u2022</span> Incorrect: No 3-year event rate of 14.9% was reported in ECST.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses with 5-year risk in asymptomatic carotid surgery trials (ACST).  <br><span class=\"list-item\">\u2022</span> Differentiator: ECST surgical arm event rate was higher (15.7%).  <br><br>B. 26.5%  <br><span class=\"list-item\">\u2022</span> Incorrect: This is the 3-year stroke or death rate in the medical\u2010therapy (no-CEA) arm of ECST.  <br><span class=\"list-item\">\u2022</span> Misconception: Students may invert treatment and control rates.  <br><span class=\"list-item\">\u2022</span> Differentiator: Represents natural history without surgery in ECST.  <br><br>C. 22.2%  <br><span class=\"list-item\">\u2022</span> Incorrect: No ECST subgroup or pooled analysis yielded exactly 22.2%; this value is sometimes misattributed to older pooled observational data.  <br><span class=\"list-item\">\u2022</span> Misconception: Mistaking mixed\u2010trial or NASCET data for ECST outcomes.  <br><span class=\"list-item\">\u2022</span> Differentiator: ECST precise surgical arm rate was 15.7%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Reported 3-Year Rate</th><th>ECST Context</th></tr></thead><tbody><tr><td>A.</td><td>14.9%</td><td>Not reported in ECST; from asymptomatic trial data</td></tr><tr><td>B.</td><td>26.5%</td><td>Medical\u2010therapy arm event rate (no CEA)</td></tr><tr><td>C.</td><td>22.2%</td><td>Not an ECST figure; misattributed pooled value</td></tr><tr><td>D.</td><td>15.7%</td><td>Surgical arm event rate (CEA + medical therapy)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CEA is class I indicated for symptomatic carotid stenosis &ge;70% (NASCET criteria) if 30-day perioperative stroke/death risk is <6%.  <br><span class=\"list-item\">\u2022</span> Benefit is greatest when surgery is performed within 2 weeks of the index event.  <br><span class=\"list-item\">\u2022</span> In moderate stenosis (50&ndash;69%), absolute risk reduction is smaller; patient comorbidities heavily influence decision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ECST and NASCET stenosis measurement methods &ndash; ECST used residual\u2010lumen/outer\u2010wall ratio.  <br>2. Swapping surgical and medical arm event rates (15.7% vs 26.5%).  <br>3. Applying asymptomatic trial data (e.g., ACST) to symptomatic patients.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2021 AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack  <br><span class=\"list-item\">\u2022</span> Recommendation: CEA within 2 weeks for symptomatic stenosis 70&ndash;99% (Class I, LOE A).  <br>2. 2023 European Society for Vascular Surgery (ESVS) Guidelines on Carotid Stenosis  <br><span class=\"list-item\">\u2022</span> Recommendation: CEA over medical therapy for symptomatic stenosis &ge;70% with perioperative risk <6% (Grade A, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Questions on ECST and NASCET are frequently tested, particularly to assess knowledge of trial outcomes, stenosis measurement differences, and guideline-based indications for CEA versus medical therapy.</div></div></div></div></div>"}, {"id": 100023133, "question_number": "355", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Transient ischemic attacks (TIAs) represent temporary cerebral ischemia due to arterial thromboembolism or thrombosis in carotid or intracranial vessels. Even when symptoms resolve, high-risk features (e.g., NIHSS &le;3, diabetes, hypertension) predict early recurrence due to platelet activation and microthrombus propagation in the ischemic penumbra. Platelet aggregation is mediated by cyclooxygenase-1&ndash;derived thromboxane A\u2082 and ADP binding at P2Y\u2081\u2082 receptors, making dual inhibition of these pathways more effective in reducing early ischemic events. The NIHSS scale quantifies stroke severity, guiding therapy intensity: minor strokes (NIHSS &le;3) benefit most from short-term dual antiplatelet therapy. Recognizing these pathophysiological and clinical assessment principles is essential for secondary prevention strategies in cerebrovascular disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) combining aspirin and clopidogrel addresses thromboxane-mediated and P2Y\u2081\u2082-mediated platelet activation, critical in early thrombus propagation. The CHANCE trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2013</span>)</span> randomized 5,170 Chinese patients within 24 hours of high-risk TIA or minor stroke to 21 days of DAPT vs aspirin alone, demonstrating a 32% relative risk reduction in 90-day stroke recurrence (8.2% vs 11.7%; p=0.02) without a significant increase in hemorrhage. The POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span> in a diverse cohort confirmed a 28% relative risk reduction at 90 days (4.1% vs 5.8%; HR 0.72; 95% CI, 0.59&ndash;0.89), offset by a small rise in major bleeding (0.9% vs 0.4%). Consequently, the 2018 AHA/ASA guidelines (Class I, Level of Evidence A) recommend DAPT for 21 days, initiated within 24 hours of a high-risk TIA or minor ischemic stroke (NIHSS &le;3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br><span class=\"list-item\">\u2022</span> Incorrect because monotherapy yields less early risk reduction than DAPT in high-risk TIA/minor stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: that aspirin alone suffices in all secondary prevention settings.  <br><span class=\"list-item\">\u2022</span> Differentiator: lacks P2Y\u2081\u2082 receptor blockade, reducing efficacy in the acute period.<br><br>B. Plavix  <br><span class=\"list-item\">\u2022</span> Incorrect: clopidogrel monotherapy has not demonstrated superior early protection compared to DAPT within 24 hours.  <br><span class=\"list-item\">\u2022</span> Misconception: that inhibiting ADP alone matches combined pathway inhibition.  <br><span class=\"list-item\">\u2022</span> Differentiator: single-pathway blockade offers lower relative risk reduction than combined COX-1 and P2Y\u2081\u2082 inhibition.<br><br>D. None of the above  <br><span class=\"list-item\">\u2022</span> Incorrect: withholding antiplatelet therapy after a high-risk TIA incurs a markedly elevated recurrence risk (>10% at 90 days).  <br><span class=\"list-item\">\u2022</span> Misconception: that mild symptoms obviate the need for immediate therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: absence of therapy fails to address ongoing platelet activation and thrombus evolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Therapy</th><th>Mechanism</th><th>Evidence in High-Risk TIA/Minor Stroke</th><th>Recommended Duration</th></tr></thead><tbody><tr><td>Dual antiplatelet therapy (aspirin + clopidogrel)</td><td>COX-1 inhibition + P2Y\u2081\u2082 receptor blockade</td><td>CHANCE, POINT: ~30% RRR in 90-day stroke; Class I, LOE A</td><td>21 days</td></tr><tr><td>Aspirin monotherapy</td><td>COX-1 inhibition</td><td>Control arm in CHANCE/POINT; higher recurrence risk</td><td>Indefinite</td></tr><tr><td>Clopidogrel monotherapy</td><td>P2Y\u2081\u2082 receptor blockade</td><td>CAPRIE: slight benefit over aspirin in broad stroke pop.; no acute TIA/minor stroke data</td><td>Indefinite</td></tr><tr><td>No antiplatelet therapy</td><td>None</td><td>Very high recurrence risk (>10% at 90 days)</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Initiate DAPT within 24 hours of a high-risk TIA or minor stroke to intercept early platelet-mediated thrombus growth.  <br>&bull; Limit DAPT to 21 days&mdash;extended therapy increases hemorrhagic risk without added stroke reduction.  <br>&bull; Concurrently evaluate for carotid stenosis and atrial fibrillation; alternate interventions (e.g., endarterectomy, anticoagulation) may be indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Assuming aspirin or clopidogrel monotherapy provides equivalent early protection to DAPT leads to suboptimal prevention.  <br>&bull; Extending DAPT beyond 21 days based on fear of recurrence paradoxically increases bleeding risk without further benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Heart Association/American Stroke <span class=\"evidence\">Association 2018</span> Guidelines: Recommends DAPT with aspirin and clopidogrel initiated within 24 hours of high-risk TIA or minor stroke (NIHSS &le;3) for 21 days (Class I, Level of Evidence A).  <br>&bull; POINT trial <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2018</span>)</span>: Demonstrated a 28% relative risk reduction in recurrent ischemic events at 90 days with early DAPT vs aspirin alone (HR 0.72; 95% CI, 0.59&ndash;0.89) but higher major bleeding (0.9% vs 0.4%); supports 21-day regimen (Level of Evidence 1b).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Secondary stroke prevention and the timing/duration of dual antiplatelet therapy for high-risk TIA/minor stroke are frequently tested as scenario-based questions on national board examinations.</div></div></div></div></div>"}, {"id": 100023134, "question_number": "170", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a monogenic small vessel disease caused by NOTCH3 mutations leading to arteriolar smooth muscle dysfunction.  <br><span class=\"list-item\">\u2022</span> Typical presentation: migraine with aura in 20&ndash;40 years, recurrent subcortical ischemic events (lacunar infarcts), progressive cognitive decline and mood disturbances in 40&ndash;60 years.  <br><span class=\"list-item\">\u2022</span> MRI hallmark: confluent T2/FLAIR hyperintensities in periventricular and deep white matter, involving anterior temporal lobes and external capsules, plus lacunes in basal ganglia.  <br>(Word count: 109)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CADASIL is directly confirmed by the combination of early-onset migraine, familial stroke/dementia, and characteristic MRI findings. NOTCH3 mutations result in granular osmiophilic material deposition and arteriolar wall thickening, causing chronic hypoperfusion and lacunar infarcts. European Stroke <span class=\"evidence\">Organisation 2021</span> guidelines recommend NOTCH3 genetic testing in patients <60 years with typical MRI changes and positive family history (Class I, Level B). Multiple cohort studies <span class=\"citation\">(<span class=\"evidence\">Chabriat et al., 2016</span>;<span class=\"evidence\"> Rutten et al., 2019</span>)</span> demonstrate that anterior temporal pole involvement is 90% specific for CADASIL, distinguishing it from other small vessel diseases. No disease\u2010modifying therapy exists; management is symptomatic&mdash;migraine prophylaxis per national headache guidelines and rigorous vascular risk factor control reduce stroke risk <span class=\"citation\">(AHA/ASA 2022, Class I, Level A)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Moyamoya  <br><span class=\"list-item\">\u2022</span> Moyamoya presents with stenosis/occlusion of supraclinoid internal carotid arteries and collateral &ldquo;puff-of-smoke&rdquo; vessels on angiography.  <br><span class=\"list-item\">\u2022</span> No characteristic white matter lacunes or anterior temporal hyperintensities.  <br><span class=\"list-item\">\u2022</span> Misconception: stroke + family history = moyamoya; angiographic findings are required.  <br><br>B. MELAS  <br><span class=\"list-item\">\u2022</span> Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes shows cortical, not subcortical, infarct-like lesions that migrate and resolve.  <br><span class=\"list-item\">\u2022</span> Associated with seizures, lactic acidosis, ragged-red fibers, and maternal inheritance.  <br><span class=\"list-item\">\u2022</span> Does not feature anterior temporal lobe MRI hyperintensities or NOTCH3 pathology.  <br><br>C. Susac syndrome  <br><span class=\"list-item\">\u2022</span> Microangiopathy of brain, retina, and cochlea presents with encephalopathy, branch retinal artery occlusions, hearing loss.  <br><span class=\"list-item\">\u2022</span> MRI shows corpus callosum &ldquo;snowball&rdquo; lesions, not confluent periventricular white matter changes or lacunes.  <br><span class=\"list-item\">\u2022</span> Key triad (encephalopathy, visual, auditory) is absent here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CADASIL</th><th>Moyamoya</th><th>MELAS</th><th>Susac Syndrome</th></tr></thead><tbody><tr><td>Genetic/Inherit.</td><td>NOTCH3, AD</td><td>Often sporadic or RNF213</td><td>mtDNA A3243G, maternal</td><td>Sporadic autoimmune</td></tr><tr><td>Age of Onset</td><td>20&ndash;40 yrs migraines; 40&ndash;60 yrs strokes/dementia</td><td>Childhood/adolescence strokes</td><td>Childhood/adolescence</td><td>20&ndash;40 yrs</td></tr><tr><td>MRI White Matter Findings</td><td>Confluent subcortical, ant. temporal lobes</td><td>None typical</td><td>Cortical migratory lesions</td><td>Corpus callosum &ldquo;snowballs&rdquo;</td></tr><tr><td>Angiography</td><td>Normal large vessels</td><td>&ldquo;Puff-of-smoke&rdquo; collaterals</td><td>Normal</td><td>Normal large vessels</td></tr><tr><td>Clinical Triad</td><td>Migraine, subcortical infarcts, dementia</td><td>Ischemic/hemorrhagic strokes</td><td>Seizures, lactic acidosis, stroke-like episodes</td><td>Encephalopathy, vision, hearing</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Anterior temporal pole T2 lesions are nearly pathognomonic for CADASIL and seldom seen in other small vessel diseases.  <br><span class=\"list-item\">\u2022</span> Family history of early-onset stroke/dementia should prompt genetic screening before invasive procedures.  <br><span class=\"list-item\">\u2022</span> Migraine in CADASIL often lacks typical aura features and may respond poorly to triptans&mdash;consider beta blockers or topiramate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing subcortical white matter changes in a young patient solely to demyelinating disease (e.g., MS) without considering genetic vasculopathies.  <br>2. Focusing on migraine alone and neglecting screening for cognitive decline and mood disturbances in suspected CADASIL.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. European Stroke Organisation (ESO) Monogenic Small Vessel Disease Guidelines, 2021  <br><span class=\"list-item\">\u2022</span> Recommendation: NOTCH3 genetic testing in patients <60 yrs with typical MRI findings and family history (Class I, Level B).  <br>2. American Heart Association/American Stroke Association (AHA/ASA) Secondary Stroke Prevention, 2022  <br><span class=\"list-item\">\u2022</span> Recommendation: Strict control of hypertension, smoking cessation, and management of vascular risk factors in small vessel disease (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>NOTCH3 mutations lead to accumulation of granular osmiophilic material in vascular smooth muscle, causing progressive arteriolar stenosis, chronic hypoperfusion, and subcortical infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- External capsule hyperintensities are seen in >80% of CADASIL cases.  <br><span class=\"list-item\">\u2022</span> Lacunes in the basal ganglia and thalamus with sparing of U-fibers distinguish from MS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- No approved disease-modifying agents.  <br><span class=\"list-item\">\u2022</span> Migraine prophylaxis: beta blockers, valproate, or topiramate per headache guidelines (avoid vasoconstrictive triptans).  <br><span class=\"list-item\">\u2022</span> Stroke prevention: antiplatelet therapy is empiric, risk factor control remains cornerstone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. CADASIL is frequently tested via MRI patterns in young patients with migraine, stroke, and dementia. Expect image-based questions demonstrating anterior temporal lobe lesions and lacunes.</div></div></div></div></div>"}, {"id": 100023135, "question_number": "315", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Sickle cell disease (SCD)&ndash;associated vasculopathy often involves progressive stenosis of large intracranial arteries (e.g., ACA, MCA), resembling moyamoya.  <br>&bull; Sickled red cells adhere to endothelium, provoke intimal hyperplasia, narrowing vessel lumen and elevating cerebral blood flow velocities on transcranial Doppler (TCD).  <br>&bull; Primary stroke prevention in high\u2010risk children hinges on reducing hemoglobin S (HbS) fraction via regular red blood cell transfusions to prevent first\u2010ever ischemic events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic transfusion therapy is the cornerstone of primary stroke prevention in SCD with intracranial stenosis. The landmark STOP trial (1998) randomized children with elevated TCD velocities (>200\u2009cm/s) to transfusion vs. standard care, demonstrating a 92% relative risk reduction in first stroke <span class=\"citation\">(N Engl J Med.1998;339:5&ndash;11)</span>. Transfusions maintain HbS <30% and total hemoglobin ~10 g/dL, improving oxygen delivery and reducing sickling. Subsequent STOP II confirmed that stopping transfusions led to recurrence of elevated velocities and risk. <span class=\"evidence\">The 2020</span> American Society of Hematology (ASH) guidelines give a strong recommendation (grade 1B) for regular transfusions in children with abnormal TCD or known vasculopathy. While the TWiTCH trial (2016) explored switching to hydroxyurea after &ge;1 year of transfusion, chronic transfusion remains first\u2010line when stenoses are present.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br>&bull; Reason incorrect: Platelet inhibition does not address the primary pathophysiology of sickle\u2010cell vasculopathy (RBC sickling and intimal proliferation).  <br>&bull; Misconception: Equating adult atherosclerotic stroke prevention with SCD; aspirin has not shown efficacy in primary stroke prevention in SCD.  <br><br>B. Plavix  <br>&bull; Reason incorrect: Clopidogrel&rsquo;s antiplatelet action is similarly unhelpful against sickling\u2010induced endothelial damage and stenosis.  <br>&bull; Misconception: Belief that stronger or alternative antiplatelet agents suffice for all stroke etiologies.  <br><br>D. Dual antiplatelet therapy  <br>&bull; Reason incorrect: Combining aspirin plus clopidogrel increases hemorrhagic risk without reducing stroke incidence in SCD vasculopathy.  <br>&bull; Misconception: &ldquo;More antiplatelet agents = better prevention&rdquo;; ignores disease\u2010specific mechanism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Chronic Transfusion</th><th>Aspirin</th><th>Clopidogrel</th><th>Dual Antiplatelet</th></tr></thead><tbody><tr><td>Mechanism</td><td>Lowers HbS <30%, improves O\u2082 delivery</td><td>COX-1 inhibition, \u2193TXA\u2082</td><td>P2Y\u2081\u2082 receptor blockade</td><td>Combined COX-1 + P2Y\u2081\u2082 blockade</td></tr><tr><td>Key Trial</td><td>STOP Trial (1998): 92% RRR</td><td>No dedicated RCT in SCD</td><td>No dedicated RCT in SCD</td><td>No evidence in SCD</td></tr><tr><td>ASH Guideline Recommendation</td><td>Strong for primary prevention</td><td>Not recommended</td><td>Not recommended</td><td>Contraindicated (bleeding risk)</td></tr><tr><td>Major Risk</td><td>Iron overload (requires chelation)</td><td>Minimal</td><td>Minimal</td><td>\u2191Bleeding</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Begin annual transcranial Doppler screening by age 2 in SCD (HbSS, HbS&beta;\u2070).  <br>&bull; Target HbS <30% and total Hb ~10 g/dL with exchange or simple transfusion every 3&ndash;4 weeks.  <br>&bull; Monitor ferritin and initiate iron chelation (deferasirox or deferoxamine) to prevent hemosiderosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on antiplatelet agents (aspirin, clopidogrel) for SCD stroke prevention, overlooking sickling pathology.  <br>2. Discontinuing transfusions once TCD normalizes without considering underlying stenosis may lead to rebound risk (as in STOP II).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; ASH 2020 Guidelines (1B): Strongly recommend chronic transfusion for children with abnormal TCD or documented intracranial stenosis.  <br>&bull; TWiTCH Trial <span class=\"citation\">(2016, NEJM 374:1542&ndash;1552)</span>: Hydroxyurea noninferior to transfusion for maintaining TCD velocities after &ge;1 year of transfusion&mdash;but only in selected low\u2010risk patients without severe vasculopathy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Sickle cell&ndash;related stroke prevention is frequently tested in pediatric neurology/stroke modules, often in the context of TCD screening thresholds and interpretation of STOP/TWiTCH data.</div></div></div></div></div>"}, {"id": 100023136, "question_number": "271", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Hyperacute ischemic stroke management aims to salvage the ischemic penumbra&mdash;tissue at risk but not yet infarcted&mdash;by restoring perfusion before irreversible neuronal death. Neurons in the penumbra experience excitotoxicity, calcium overload, and free\u2010radical injury. Noncontrast CT excludes hemorrhage and shows early signs (loss of gray&ndash;white differentiation, sulcal effacement, hyperdense vessel) but not established infarction. &ldquo;Time is brain&rdquo;: each minute without reperfusion costs ~1.9 million neurons. Intravenous alteplase (tPA) administered within 4.5 hours of symptom onset reduces long-term disability; benefit is greatest under 3 hours. Rapid NIH Stroke Scale scoring, CT interpretation, and exclusion of contraindications are critical to initiate thrombolysis and maximize penumbral salvage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>tPA (alteplase) is the only FDA-approved fibrinolytic for acute ischemic stroke. The landmark NINDS trial (1995) demonstrated a 30% relative improvement in functional outcome at 3 months when administered within 3 hours (OR 1.7, 95% CI 1.2&ndash;2.6). ECASS III extended the window to 4.5 hours, showing a 7.2% absolute increase in favorable outcome (p=0.04). <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines (Powers et al.) give Class I, LOE A recommendation for IV alteplase &le;4.5 hours; age >80 years is no longer an exclusion within this window. Exclusion criteria (e.g., recent hemorrhage, coagulopathy) must be ruled out. CT early ischemic changes do not preclude tPA unless hypodensity involves >1/3 MCA territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Initiating aspirin within 24 hours of tPA increases hemorrhagic risk and does not improve acute recanalization.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet with thrombolytic therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Aspirin inhibits platelet aggregation; tPA actively lyses thrombus.  <br><br>B. Plavix  <br><span class=\"list-item\">\u2022</span> Why incorrect: No evidence supports P2Y12 inhibition as monotherapy in hyperacute stroke; risk&ndash;benefit for immediate reperfusion absent.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming all antithrombotics are interchangeable in the hyperacute phase.  <br><span class=\"list-item\">\u2022</span> Differentiator: Plavix acts slowly and is indicated for secondary prevention, not acute reperfusion.  <br><br>D. Supportive care only  <br><span class=\"list-item\">\u2022</span> Why incorrect: While airway and hemodynamic support are vital, omitting reperfusion therapy forfeits potential penumbral salvage and worsens outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Overestimating CT early signs as contraindications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Supportive care does not address vessel occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment</th><th>Mechanism</th><th>Time Window</th><th>Key Outcome Benefit</th><th>Hemorrhage Risk</th></tr></thead><tbody><tr><td>tPA (alteplase)</td><td>Plasminogen \u2192 plasmin \u2192 fibrinolysis</td><td>0&ndash;4.5 hours (Class I, LOE A)</td><td>\u2193 disability at 3 months (NINDS, ECASS III)</td><td>~6.4% symptomatic ICH</td></tr><tr><td>Aspirin</td><td>COX-1 inhibition \u2192 \u2193 TXA\u2082</td><td>Not for hyperacute reperfusion</td><td>\u2193 early recurrence (not acute benefit)</td><td>\u2191 bleeding if given <24 h post-tPA</td></tr><tr><td>Plavix</td><td>P2Y\u2081\u2082 receptor blockade</td><td>Not indicated acutely</td><td>Long-term secondary prevention</td><td>Low but not studied acutely</td></tr><tr><td>Supportive care</td><td>Airway, BP, glucose control</td><td>All phases</td><td>Prevents medical complications</td><td>&mdash;</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- &ldquo;Time is brain&rdquo;: aim for door-to-needle &le;60 minutes.  <br><span class=\"list-item\">\u2022</span> Early CT signs (hyperdense MCA sign, subtle hypodensity) do not contraindicate tPA unless >1/3 MCA territory is involved.  <br><span class=\"list-item\">\u2022</span> Age >80 years or minor early ischemic changes no longer exclude patients &le;4.5 hours per AHA/ASA 2019.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering aspirin or dual antiplatelet therapy instead of tPA in tPA-eligible patients.  <br>2. Overcalling early CT hypodensity as established infarction and withholding thrombolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Stroke <span class=\"evidence\">Guidelines 2019</span> (Powers et al.): Class I, LOE A for IV alteplase &le;4.5 hours; CT early ischemic changes alone are not a contraindication unless extensive.  <br><span class=\"list-item\">\u2022</span> ECASS III Trial (2008): Demonstrated benefit of alteplase between 3&ndash;4.5 hours (OR for favorable outcome 1.34, 95% CI 1.02&ndash;1.76).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT: look for loss of gray&ndash;white differentiation, insular ribbon sign, hyperdense vessel.  <br><span class=\"list-item\">\u2022</span> ASPECTS &le;7 indicates extensive early ischemia; >7 favorable for tPA with lower hemorrhage risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (max 90 mg)&mdash;10% as bolus over 1 minute, remainder over 60 minutes.  <br><span class=\"list-item\">\u2022</span> Monitor BP <185/110 mm Hg before/during infusion to minimize hemorrhagic conversion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Acute ischemic stroke thrombolysis within the time window and CT interpretation are high-yield topics, frequently tested as single best answer or management algorithms.</div></div></div></div></div>"}, {"id": 100023137, "question_number": "273", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Balloon angioplasty (percutaneous transluminal angioplasty, PTA) is an endovascular technique used to mechanically widen stenotic arteries. Core concepts:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of atherosclerosis: lipid-rich plaque accumulates within the intima, causing luminal narrowing and impaired perfusion.  <br><span class=\"list-item\">\u2022</span> Endovascular access: catheters are navigated from femoral or radial arteries into the cerebral circulation under fluoroscopic guidance.  <br><span class=\"list-item\">\u2022</span> Vessel biomechanics: controlled balloon inflation compresses plaque against the arterial wall and stretches the media, improving luminal diameter.  <br>Understanding these principles distinguishes angioplasty from surgical excision (endarterectomy) and clarifies its role in ischemic stroke prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct because angioplasty refers specifically to balloon dilation of a stenotic vessel. After arterial access, a balloon catheter is positioned across the lesion and inflated to a predetermined pressure, fracturing intimal and medial fibers and compressing atheroma, thereby restoring flow. According to the 2015 AHA/ASA guidelines on extracranial carotid and vertebral artery disease (Class I, Level A), carotid angioplasty and stenting (CAS) is indicated for symptomatic high-grade (&ge;70%) carotid stenosis in patients at high surgical risk. The CREST trial (2010, NEJM) demonstrated non-inferiority of CAS versus carotid endarterectomy (CEA) for composite stroke, myocardial infarction, and death endpoints in symptomatic and asymptomatic patients. For intracranial stenosis, the SAMMPRIS trial (2011, NEJM) revealed higher periprocedural risk with angioplasty plus stenting versus aggressive medical management alone, leading to a more conservative approach <span class=\"citation\">(AHA/ASA 2021 update: Class IIb, Level B-R for angioplasty/stenting in refractory intracranial stenosis)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. &ldquo;Is a surgical procedure involving direct removal of atherosclerotic plaque&rdquo;  <br>  &bull; Incorrect because plaque removal describes carotid endarterectomy, not angioplasty.  <br>  &bull; Misconception: equating endovascular dilation with open surgical excision.  <br>  &bull; Differentiator: endarterectomy requires arteriotomy and manual plaque extraction, whereas angioplasty uses intraluminal balloon expansion.  <br><br>B. &ldquo;Is primarily used to treat hemorrhagic stroke&rdquo;  <br>  &bull; Incorrect as angioplasty addresses ischemic, not hemorrhagic, pathology.  <br>  &bull; Misconception: confusing cerebrovascular interventions for ischemia versus hemorrhage.  <br>  &bull; Differentiator: hemorrhagic stroke management focuses on blood pressure control, reversal of anticoagulation, surgical evacuation, not vessel dilation.  <br><br>D. &ldquo;Is contraindicated in patients with carotid artery stenosis&rdquo;  <br>  &bull; Incorrect because angioplasty (with stenting) is an established option for carotid stenosis, especially in high surgical-risk cases.  <br>  &bull; Misconception: assuming endovascular risk precludes use in carotid disease.  <br>  &bull; Differentiator: CEA and CAS are both indicated for symptomatic high-grade stenosis; CAS is preferred in specific high-risk surgical profiles.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Indication</th><th>Example Procedure</th></tr></thead><tbody><tr><td>A</td><td>Surgical plaque excision</td><td>Carotid endarterectomy for stenosis</td><td>Arteriotomy and manual dissection</td></tr><tr><td>B</td><td>Not an angioplasty technique</td><td>Hemorrhagic stroke management</td><td>Hematoma evacuation</td></tr><tr><td>C</td><td>Balloon inflation of stenosis [\u2713]</td><td>Ischemic stroke prevention/treatment</td><td>PTA with or without stent</td></tr><tr><td>D</td><td>(False) Contraindication assertion</td><td>(Incorrect) CEA/CAS for stenosis</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Carotid angioplasty is almost always performed with stent deployment to prevent elastic recoil and dissection.  <br><span class=\"list-item\">\u2022</span> High-risk CEA patients (prior neck surgery, radiation, contralateral laryngeal nerve palsy) benefit from CAS (AHA/ASA Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> Intracranial angioplasty carries a higher periprocedural stroke risk; reserved for patients failing maximal medical therapy (Class IIb, LOE B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing angioplasty with endarterectomy: the former is endovascular, the latter open surgery.  <br>2. Believing angioplasty treats hemorrhagic events: it treats vessel narrowing in ischemic disease only.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2015 Extracranial Carotid Disease Guideline: Recommends CAS in symptomatic &ge;70% stenosis for high surgical risk patients (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> SAMMPRIS Trial (2011, NEJM): Demonstrated higher stroke risk with intracranial angioplasty plus stenting versus aggressive medical therapy; led to Class IIb, LOE B-R recommendation for refractory cases in 2021 AHA/ASA update.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular neurology questions frequently test distinctions between endovascular techniques (angioplasty/stenting) and surgical approaches (endarterectomy), and require knowledge of appropriate ischemic versus hemorrhagic stroke interventions.</div></div></div></div></div>"}, {"id": 100023138, "question_number": "488", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Platelet activation follows vascular injury \u2192 adhesion (vWF&ndash;GPIb) \u2192 secretion of ADP and TXA2 \u2192 aggregation via GPIIb/IIIa&ndash;fibrinogen bridges. Antithrombotic therapy divides into antiplatelets (aspirin, P2Y12 inhibitors, GPIIb/IIIa blockers) and anticoagulants (vitamin K antagonists, direct thrombin and factor Xa inhibitors). P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block ADP-mediated amplification of aggregation; ticagrelor is unique as a reversible, non-thienopyridine agent. Factor Xa inhibitors (apixaban, rivaroxaban) and direct thrombin inhibitors (dabigatran) interrupt the coagulation cascade at different nodes. Understanding precise targets guides agent selection in stroke prevention, ACS, and atrial fibrillation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ticagrelor is a cyclopentyl-triazolo-pyrimidine that reversibly antagonizes the P2Y12 ADP receptor on platelets, inhibiting downstream GPIIb/IIIa activation. In the PLATO trial <span class=\"citation\">(Wallentin et al., NEJM 2009;361:1045&ndash;57)</span>, ticagrelor reduced the composite of cardiovascular death, MI, or stroke by 16% versus clopidogrel (HR 0.84; 95% CI 0.75&ndash;0.93; P=0.002) in ACS. <span class=\"evidence\">The 2020</span> ACC/AHA Guideline for UA/NSTEMI (Class I, Level B-R) recommends ticagrelor (180 mg load, then 90 mg BID) over clopidogrel for most patients. Unlike thienopyridines, ticagrelor does not require hepatic bioactivation, yielding more predictable inhibition. Its reversible binding permits faster platelet function recovery (3&ndash;5 days) before surgical procedures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Apixaban and rivaroxaban are direct thrombin inhibitors  <br><span class=\"list-item\">\u2022</span> Incorrect: Both inhibit factor Xa, not thrombin (IIa).  <br><span class=\"list-item\">\u2022</span> Misconception: Lumping all DOACs as &ldquo;thrombin&rdquo; inhibitors.  <br><span class=\"list-item\">\u2022</span> Differentiator: Dabigatran is the direct thrombin inhibitor; apixaban/rivaroxaban target Xa.  <br><br>B. Aspirin is an adenosine diphosphate inhibitor  <br><span class=\"list-item\">\u2022</span> Incorrect: Aspirin irreversibly inhibits COX-1, reducing TXA2 synthesis.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing antiplatelet classes.  <br><span class=\"list-item\">\u2022</span> Differentiator: P2Y12 inhibitors block ADP receptors; aspirin does not.  <br><br>D. Clopidogrel works on factors I, II, V, and VII  <br><span class=\"list-item\">\u2022</span> Incorrect: Clopidogrel is a thienopyridine P2Y12 antagonist, not a vitamin K antagonist.  <br><span class=\"list-item\">\u2022</span> Misconception: Mixing up antiplatelet vs anticoagulant mechanisms.  <br><span class=\"list-item\">\u2022</span> Differentiator: Warfarin (not clopidogrel) impairs &gamma;-carboxylation of factors II, VII, IX, X.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Agent</th><th>Class</th><th>Target</th><th>Mechanism</th><th>Reversible?</th></tr></thead><tbody><tr><td>Ticagrelor</td><td>P2Y12 inhibitor</td><td>P2Y12 ADP receptor</td><td>Non-thienopyridine, reversible antagonist</td><td>Yes</td></tr><tr><td>Apixaban</td><td>Direct Xa inhibitor</td><td>Factor Xa</td><td>Competitive inhibition of Xa</td><td>Yes</td></tr><tr><td>Aspirin</td><td>Antiplatelet</td><td>COX-1 enzyme</td><td>Irreversible acetylation \u2192 \u2193 TXA\u2082</td><td>No</td></tr><tr><td>Clopidogrel</td><td>P2Y12 inhibitor</td><td>P2Y12 ADP receptor</td><td>Thienopyridine prodrug; irreversible binding</td><td>No</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ticagrelor onset: platelet inhibition within 30 minutes; offset in ~3&ndash;5 days due to reversibility.  <br>&bull; Common adverse effect: dyspnea (~10&ndash;15%) from adenosine reuptake inhibition.  <br>&bull; In ACS PCI, ticagrelor reduces stent thrombosis and CV mortality vs clopidogrel (PLATO data).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Grouping all DOACs as direct thrombin inhibitors (actual targets: dabigatran = IIa, apixaban/rivaroxaban = Xa).  <br>2. Mislabeling aspirin as an ADP blocker instead of a COX-1 inhibitor.  <br>3. Confusing clopidogrel&rsquo;s antiplatelet action with warfarin&rsquo;s vitamin K&ndash;dependent factor reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; 2020 ACC/AHA Guideline for UA/NSTEMI: Recommend ticagrelor (180 mg load, 90 mg BID) over clopidogrel (Class I, Level B-R).  <br>&bull; 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation: Prefer DOACs (apixaban/rivaroxaban) over warfarin for eligible nonvalvular AF (Class I, Level A).  <br>&bull; PLATO trial <span class=\"citation\">(Wallentin et al., NEJM 2009)</span>: Demonstrated ticagrelor&rsquo;s superiority over clopidogrel in ACS (HR 0.84; P=0.002).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Vascular injury \u2192 platelet adhesion (vWF&ndash;GPIb) \u2192 activation (COX-1\u2192TXA\u2082; dense granule release of ADP) \u2192 GPIIb/IIIa-mediated aggregation. P2Y12 receptors amplify activation; COX-1 generates TXA\u2082; factor Xa and thrombin (IIa) catalyze fibrin formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Ticagrelor: 180 mg loading \u2192 90 mg BID; metabolized CYP3A4; avoid strong inhibitors/inducers; reversible binding. Platelet transfusion can reverse effect.  <br>&bull; Apixaban: 5 mg BID (reduce to 2.5 mg BID if &ge;80 years, &le;60 kg, or creatinine &ge;1.5 mg/dL).  <br>&bull; Aspirin: 81 mg daily for secondary prevention; higher doses \u2191 bleeding risk without added benefit.  <br>&bull; Clopidogrel: 300&ndash;600 mg loading \u2192 75 mg daily; prodrug via CYP2C19 (consider genetic variability).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Mechanisms of antithrombotic agents&mdash;especially differentiating DOACs, aspirin, and P2Y12 inhibitors&mdash;are high-yield topics on neurology and cardiovascular boards, often tested as direct recall or in clinical vignettes.</div></div></div></div></div>"}, {"id": 100023139, "question_number": "329", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Watershed (borderzone) infarcts occur in areas between major arterial territories (e.g., between ACA and MCA deep perforators) and often reflect hemodynamic compromise from proximal large\u2010artery stenosis.  <br><span class=\"list-item\">\u2022</span> Diffusion-weighted MRI (DWI) is highly sensitive for detecting acute ischemia within minutes of onset but does not identify vascular lesions.  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) provides rapid, high\u2010resolution images of extracranial and intracranial arteries, allowing detection of ICA stenosis or occlusion&mdash;the key etiology in deep borderzone strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA is the test of choice because deep borderzone infarcts most commonly result from hemodynamic insufficiency due to ipsilateral ICA high\u2010grade stenosis or occlusion. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke recommend emergent vascular imaging (CTA or MRA) in all suspected large\u2010vessel occlusions (Class I, Level of Evidence B). A meta\u2010analysis <span class=\"citation\">(<span class=\"evidence\">Bamford et al., 2020</span>)</span> showed CTA sensitivity >95% and specificity >98% for detecting &ge;70% ICA stenosis. Early identification enables timely decisions about endarterectomy or stenting to prevent recurrent events.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Electroencephalogram  <br>&ndash; EEG evaluates cerebral electrical activity and is indicated for seizures or encephalopathy, not for detecting vascular stenosis.  <br>&ndash; Misconception: &ldquo;Every neurologic deficit needs an EEG.&rdquo; EEG cannot visualize vessels.  <br><br>C. Lumbar puncture  <br>&ndash; LP is used for infectious, inflammatory, or subarachnoid hemorrhage evaluation; it cannot assess arterial lumen or flow dynamics.  <br>&ndash; Misconception: Borderzone infarcts might be inflammatory&mdash;LP does not detect stenosis.  <br><br>D. Echocardiogram  <br>&ndash; Transthoracic or transesophageal echo evaluates cardiac sources of emboli (e.g., thrombus, PFO), not large\u2010artery hemodynamics.  <br>&ndash; Differentiating feature: echo rules out cardioembolism, but borderzone pattern points to hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Test</th><th>Primary Target</th><th>Detects ICA Stenosis</th><th>Typical Use in Stroke Workup</th></tr></thead><tbody><tr><td>CT Angiography</td><td>Extracranial/intracranial vessels</td><td>Yes</td><td>First-line for suspected large-vessel disease</td></tr><tr><td>EEG</td><td>Cortical electrical activity</td><td>No</td><td>Seizure evaluation</td></tr><tr><td>Lumbar Puncture</td><td>CSF analysis</td><td>No</td><td>Infection, hemorrhage exclusion</td></tr><tr><td>Echocardiogram</td><td>Cardioembolic sources</td><td>No</td><td>Embolic stroke source workup</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Deep borderzone infarcts (&ldquo;rosary\u2010like&rdquo; spoke-wheel DWI pattern) strongly suggest proximal ICA hemodynamic compromise.  <br><span class=\"list-item\">\u2022</span> In acute ischemic stroke, noncontrast CT followed immediately by CTA (or CT perfusion) streamlines diagnosis and eligibility for reperfusion therapies.  <br><span class=\"list-item\">\u2022</span> High\u2010grade ICA stenosis (>70%) detected on CTA often warrants urgent carotid endarterectomy within 2 weeks to reduce recurrence risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering an echocardiogram first in a watershed infarct delays detection of large\u2010artery stenosis.  <br>2. Misinterpreting borderzone DWI hyperintensities as lacunar infarcts leads to under\u2010investigation of proximal stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Stroke): Recommend emergent CTA/MRA in all suspected large-vessel occlusion strokes (Class I, LOE B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organisation 2021</span> Guidelines: Endorse CTA within 25 minutes of hospital arrival for linking diagnosis to reperfusion decisions (Grade A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The deep borderzone between the superficial perforating branches of the MCA and the lenticulostriate arteries lies adjacent to the lateral ventricle. Hypoperfusion here produces characteristic linear or patchy infarcts on DWI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Severe ipsilateral ICA stenosis reduces cerebral perfusion pressure distal to the lesion. Under hypotensive or high\u2010demand states, the watershed zones fail to autoregulate, leading to ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to exclude hemorrhage  <br>2. MRI-DWI to confirm acute ischemia pattern  <br>3. CTA of head and neck to assess for ICA stenosis/occlusion  <br>4. Manage identified stenosis (medical vs endarterectomy/stenting)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI detects infarction within minutes; FLAIR mismatch can estimate onset time.  <br><span class=\"list-item\">\u2022</span> CTA provides submillimeter resolution of vessel lumen; multiplanar reconstructions elucidate stenosis length and morphology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Borderzone infarct patterns on DWI frequently signal large-artery hypoperfusion and necessitate prompt CTA to guide revascularization decisions.</div></div></div></div></div>"}, {"id": 100023140, "question_number": "208", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Understanding vascular territories in the brainstem and cerebellum is critical to localizing strokes on imaging. The anterior inferior cerebellar artery (AICA) arises from the basilar artery and supplies the lateral pons, middle cerebellar peduncle, parts of the cerebellum, and, via the labyrinthine artery, the inner ear structures. Infarction produces a lateral pontine syndrome characterized by ipsilateral facial paralysis, loss of corneal reflex, ataxia, and ipsilateral hearing loss or vertigo. In contrast, PICA infarcts cause lateral medullary (Wallenberg) syndrome without facial paralysis, while SCA and PCA infarcts involve different cerebellar or occipital territories. MRI-DWI typically shows a wedge-shaped hyperintense lesion conforming to the artery&rsquo;s distribution, enabling precise localization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The imaging demonstrates a hyperintense lesion on DWI in the lateral pons extending into the middle cerebellar peduncle, sparing the medulla and cerebellar hemisphere. These findings align with the AICA distribution: lateral pontine structures including the facial nucleus and vestibulocochlear complex. AICA strokes often present with ipsilateral facial paralysis (facial nucleus involvement) and contralateral pain/temperature loss (spinothalamic tract), plus ipsilateral hearing loss (labyrinthine artery branch). <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke emphasize rapid MRI-DWI for posterior fossa strokes (Class I, Level A evidence) and recommend reperfusion therapy within 4.5 hours. Studies show AICA infarcts comprise ~1%&ndash;2% of ischemic strokes but carry high morbidity due to brainstem and cranial nerve involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Posterior cerebral artery  <br><span class=\"list-item\">\u2022</span> Incorrect because PCA supplies the occipital lobe, thalamus, and medial temporal lobe. Imaging would show occipital cortical infarction with visual field deficits, not a brainstem lesion.  <br>B. PICA  <br><span class=\"list-item\">\u2022</span> PICA infarction causes lateral medullary (Wallenberg) syndrome: dysphagia, hoarseness, nucleus ambiguus signs, and contralateral pain/temperature loss of the body. Facial nucleus involvement and hearing loss are absent.  <br>C. Superior cerebellar artery (SCA)  <br><span class=\"list-item\">\u2022</span> SCA supplies the superior cerebellum and superior cerebellar peduncle. SCA strokes produce limb ataxia and dysmetria without facial paralysis or cochlear symptoms, and imaging shows superior cerebellar cortical lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>AICA (Correct)</th><th>PICA (Incorrect)</th><th>SCA (Incorrect)</th><th>PCA (Incorrect)</th></tr></thead><tbody><tr><td>Vascular origin</td><td>Basilar artery \u2192 AICA</td><td>Vertebral artery \u2192 PICA</td><td>Basilar artery \u2192 SCA</td><td>Basilar artery \u2192 PCA</td></tr><tr><td>Supplied structures</td><td>Lateral pons, middle cerebellar peduncle, inner ear</td><td>Lateral medulla, inferior cerebellum</td><td>Superior cerebellum, superior cerebellar peduncle</td><td>Occipital lobe, medial temporal lobe, thalamus</td></tr><tr><td>Key clinical signs</td><td>Ipsilateral facial paralysis, hearing loss, ataxia</td><td>Dysphagia, hoarseness, loss of pain/temp in face & body</td><td>Limb ataxia, dysmetria</td><td>Homonymous hemianopia, thalamic pain syndromes</td></tr><tr><td>Imaging pattern</td><td>Wedge-shaped lateral pontine DWI hyperintensity</td><td>Dorsolateral medullary DWI hyperintensity</td><td>Superior cerebellar DWI hyperintensity</td><td>Occipital cortical DWI hyperintensity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AICA infarcts uniquely present with ipsilateral facial paralysis and sensorineural hearing loss due to involvement of the facial and vestibulocochlear nerve nuclei.  <br>2. The labyrinthine artery branch of AICA explains acute vertigo and tinnitus; its occlusion constitutes an otoneurological emergency.  <br>3. MRI-DWI is 83% sensitive and 95% specific for posterior fossa stroke within the first 24 hours; CT often misses small brainstem lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing lateral medullary (PICA) with lateral pontine (AICA) syndrome; remember that facial nucleus signs only occur in AICA lesions.  <br>2. Assuming all cerebellar artery strokes yield gross ataxia; small brainstem infarcts may yield subtle cranial nerve deficits without prominent cerebellar signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Obtain MRI-DWI for suspected posterior fossa infarction when CT is non-diagnostic (Class I, LOE A).  <br><span class=\"list-item\">\u2022</span> tPA recommended within 4.5 hours of symptom onset (Class I, LOE A).  <br>2. 2021 European Stroke Organisation (ESO) Guidelines  <br><span class=\"list-item\">\u2022</span> Recommendation: Consider endovascular thrombectomy for basilar artery occlusion up to 24 hours post-onset in selected patients (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>AICA branches from the lower basilar artery to supply the lateral pons, including the facial nucleus (facial paralysis), vestibulocochlear nuclei (hearing/vertigo), spinal trigeminal nucleus (facial pain/temp), and the middle cerebellar peduncle (ataxia).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of AICA leads to ischemia in the lateral pontine tegmentum. Neuronal energy failure triggers excitotoxicity and cytotoxic edema, manifesting as DWI hyperintensity within minutes of onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid clinical assessment and NIH Stroke Scale  <br>2. Noncontrast CT to exclude hemorrhage  <br>3. MRI-DWI to localize infarct, especially in posterior fossa  <br>4. CT/MR angiography to identify vessel occlusion (AICA vs vertebral vs basilar)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT often misses posterior fossa infarcts due to beam-hardening artifacts.  <br><span class=\"list-item\">\u2022</span> MRI-DWI is the gold standard for early detection of brainstem and cerebellar strokes.  <br><span class=\"list-item\">\u2022</span> CT angiography can visualize basilar artery and branch occlusions in the posterior circulation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Intravenous alteplase (0.9 mg/kg, 10% bolus, remainder over 60 minutes) within 4.5 hours, unless contraindicated.  <br><span class=\"list-item\">\u2022</span> Blood pressure management: keep &le;185/110 mm Hg pre- and &le;180/105 mm Hg post-thrombolysis.  <br><span class=\"list-item\">\u2022</span> Consider antiplatelet agents 24 hours post-tPA if no hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Vascular territory localization via imaging is a frequent format on neurology boards, testing both anatomy and acute stroke management principles.</div></div></div></div></div>"}, {"id": 100023141, "question_number": "446", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Cervical artery dissection arises from a tear in the intimal layer of the internal carotid artery (ICA), allowing blood to accumulate intramurally, producing the &ldquo;crescent sign&rdquo; on fat-saturated MRA.  <br>&bull; Dissection predisposes to ischemic stroke via thromboembolism from the false lumen or hemodynamic compromise.  <br>&bull; First-line therapy employs antithrombotic agents (antiplatelets or anticoagulants) to prevent further emboli; invasive interventions are reserved for refractory cases or expanding pseudoaneurysms. (120 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Medical management with antithrombotic therapy is the standard of care for extracranial ICA dissection. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Stroke Prevention (Class I, Level A) recommend 3&ndash;6 months of antiplatelet or anticoagulation therapy to reduce recurrent stroke risk. The CADISS randomized trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> found no significant difference in recurrent ischemic events between antiplatelet and anticoagulation arms (1.0% vs. 0.3%, p=0.63), supporting either approach. Observational cohorts report a low annual recurrence (<2%) with medical therapy. Surgical repair or stenting carries procedural risks (arterial injury, in-stent thrombosis) and is typically reserved for symptomatic progression despite optimal medical therapy or for high-risk pseudoaneurysm morphology. Thrombolysis is used acutely within a narrow time window for established stroke, not prophylaxis against recurrent events in dissection without infarct.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical repair  <br>&bull; Incorrect: Reserved for expanding pseudoaneurysm or failed medical therapy.  <br>&bull; Misconception: That immediate resolution of dissection requires open surgery.  <br>&bull; Differentiator: Higher morbidity; not first-line absent complication.<br><br>C. Endovascular stenting  <br>&bull; Incorrect: Considered only if medical therapy fails or severe stenosis with hemodynamic compromise.  <br>&bull; Misconception: Stenting universally prevents emboli.  <br>&bull; Differentiator: Procedural stroke risk and need for dual antiplatelet therapy.<br><br>D. Thrombolytic therapy  <br>&bull; Incorrect: Indicated acutely for ischemic stroke <4.5 h after onset, not for dissection without acute infarct.  <br>&bull; Misconception: Thrombolysis dissolves intramural hematoma.  <br>&bull; Differentiator: Risk of hemorrhage in vessel wall; not prophylactic.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Treatment Modality</th><th>Indication</th><th>Evidence</th><th>Key Risks</th></tr></thead><tbody><tr><td>Medical management</td><td>Primary prophylaxis post-dissection</td><td>AHA/ASA Class I (Level A), CADISS</td><td>Bleeding (if anticoagulated)</td></tr><tr><td>Surgical repair</td><td>Expanding pseudoaneurysm; failed medical</td><td>Case series only</td><td>Cranial nerve injury, restenosis</td></tr><tr><td>Endovascular stenting</td><td>Refractory ischemia, severe stenosis</td><td>Observational; no RCTs</td><td>In-stent thrombosis, dissection</td></tr><tr><td>Thrombolytic therapy</td><td>Acute ischemic stroke <4.5 h of onset</td><td>NINDS, ECASS</td><td>Hemorrhagic transformation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; On fat-sat MRA, the crescentic intramural hematoma appears hyperintense; confirm with CTA or duplex ultrasound.  <br>&bull; Antiplatelet therapy (e.g., aspirin 81&ndash;325 mg) is often preferred over warfarin due to lower bleeding risk.  <br>&bull; Duration of antithrombotic therapy is typically 3&ndash;6 months, followed by imaging to assess vessel healing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating dissection treatment with acute stroke thrombolysis, leading to inappropriate tPA use.  <br>2. Overutilizing invasive procedures in the absence of clinical or radiographic progression.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Guidelines on Cervical Artery <span class=\"evidence\">Dissection 2019</span>: Recommend antithrombotic therapy for 3&ndash;6 months (Class I, Level A).  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs. anticoagulation for preventing recurrence (n=250, randomized).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The extracranial ICA courses from the carotid bifurcation in the neck (C1 segment) to the petrous segment (C2); dissections typically occur in the cervical portion where the artery is more mobile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Intimal tear allows blood into the media, forming a false lumen that compresses the true lumen (crescent sign). Thrombus forms at the disrupted intima, serving as a source for distal emboli.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in young patients with neck pain or Horner syndrome.  <br>2. Perform noninvasive imaging: CTA or MRA with fat saturation.  <br>3. Confirm intramural hematoma (&ldquo;crescent sign&rdquo;) and assess flow compromise.  <br>4. Initiate antithrombotic therapy; follow-up imaging at 3&ndash;6 months.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Fat-saturated T1-weighted MRA highlights subacute hematoma as high signal circumferentially. CTA shows an eccentric mural thickening with luminal stenosis or pseudoaneurysm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Aspirin 81&ndash;325 mg daily is first\u2010line; alternatives include clopidogrel 75 mg daily or warfarin (INR 2.0&ndash;3.0) when anticoagulation is chosen. Monitor for bleeding; no direct comparisons in large RCTs beyond CADISS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>ICA dissection management is frequently tested as single\u2010best\u2010answer scenarios, emphasizing first\u2010line antithrombotic therapy and imaging characteristics.</div></div></div></div></div>"}, {"id": 100023142, "question_number": "190", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] 1. Spinal cord blood supply: The anterior spinal artery (ASA) supplies the anterior two-thirds of the cord, including motor (corticospinal) and pain/temperature (spinothalamic) pathways.  <br>2. Clinical localization: Acute bilateral motor loss with pain/temperature deficits but spared vibration/proprioception localizes to the anterior cord.  <br>3. Temporal profile: Vascular events present hyperacutely (minutes to hours), unlike inflammatory or degenerative processes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Anterior spinal artery infarction typically presents with sudden-onset flaccid paraplegia, loss of pain/temperature sensation below the lesion, and preserved dorsal column function. In a 2015 Stroke review by Rabinstein, ASA infarcts comprise 25% of spinal strokes, often preceded by acute back pain. Diffusion-weighted MRI confirms central cord ischemia within hours <span class=\"citation\">(Choi et al., Radiology, 2018)</span>. <span class=\"evidence\">The 2021</span> AHA/ASA scientific statement classifies urgent MRI with DWI as Class I, Level B recommendation and hemodynamic augmentation (MAP &ge; 85 mmHg) as Class I, Level C. High-dose steroids lack efficacy and are not recommended <span class=\"citation\">(De Cauwer et al., JAMA Neurol, 2022)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Transverse myelitis  <br><span class=\"list-item\">\u2022</span> Incorrect because its onset is subacute (hours&ndash;days), with mixed sensory involvement including dorsal columns. MRI shows longitudinal T2 hyperintensity over &ge;3 segments.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming any acute cord syndrome is inflammatory.  <br><span class=\"list-item\">\u2022</span> Differentiator: Proprioception loss and MRI pattern.<br><br>C. Guillain-Barr\u00e9 syndrome  <br><span class=\"list-item\">\u2022</span> Incorrect as GBS is a peripheral demyelinating neuropathy presenting with ascending LMN signs, areflexia, distal sensory loss, and no upper motor neuron findings or preserved vibration sense.  <br><span class=\"list-item\">\u2022</span> Misconception: Peripheral neuropathy can cause incontinence.  <br><span class=\"list-item\">\u2022</span> Differentiator: Nerve conduction studies and absence of spinal cord MRI lesions.<br><br>D. Syringomyelia  <br><span class=\"list-item\">\u2022</span> Incorrect because it is a chronic central cavitation disorder, presenting with a &ldquo;cape-like&rdquo; dissociated sensory loss in the upper limbs over months to years, not acute paraplegia.  <br><span class=\"list-item\">\u2022</span> Misconception: Syrinx can cause abrupt lower limb weakness.  <br><span class=\"list-item\">\u2022</span> Differentiator: MRI shows a syrinx cavity, insidious onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ASA Infarction</th><th>Transverse Myelitis</th><th>Guillain-Barr\u00e9</th><th>Syringomyelia</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (minutes&ndash;hrs)</td><td>Subacute (hrs&ndash;days)</td><td>Subacute (days&ndash;weeks)</td><td>Chronic (months&ndash;yrs)</td></tr><tr><td>Motor</td><td>Flaccid \u2192 spastic (UMN)</td><td>Mixed UMN & LMN</td><td>Pure LMN</td><td>Variable</td></tr><tr><td>Pain/Temperature</td><td>Lost</td><td>Lost</td><td>Distal paresthesias</td><td>&ldquo;Cape&rdquo; distribution</td></tr><tr><td>Vibration/Proprioception</td><td>Preserved</td><td>Impaired</td><td>Impaired</td><td>Preserved early</td></tr><tr><td>Bladder/Bowel</td><td>Commonly involved</td><td>Common</td><td>Rare</td><td>Uncommon</td></tr><tr><td>MRI Findings</td><td>Central DWI hyperint.</td><td>Longitudinal T2 lesion</td><td>Normal spinal cord</td><td>Syrinx cavity</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Sudden back pain with rapid paraplegia is a red flag for spinal cord infarction.  <br><span class=\"list-item\">\u2022</span> Preservation of dorsal column function amid severe motor and pain/temperature loss is pathognomonic for ASA syndrome.  <br><span class=\"list-item\">\u2022</span> Early DWI\u2010MRI can detect ASA infarction within 6 hours of onset, informing urgent management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mislabeling an ASA infarct as transverse myelitis due to failure to note rapidity and modality dissociation.  <br>2. Overattributing urinary incontinence to peripheral neuropathies like GBS.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Scientific Statement on Spinal Cord Infarction, 2021:  <br>   &ndash; Recommendation: Urgent spinal MRI with DWI in suspected spinal cord ischemia (Class I, Level B); maintain MAP &ge; 85 mmHg (Class I, Level C).  <br>2. EACTS/EACTA Guidelines for Thoracoabdominal Aortic Aneurysm Repair, 2020:  <br>   &ndash; Recommendation: Prophylactic CSF drainage reduces spinal ischemia (Class I, Level A); intraoperative motor evoked potential monitoring (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ASA, originating from vertebral arteries, courses ventrally supplying anterior horns (&alpha;-motor neurons), lateral corticospinal tracts, and spinothalamic tracts. Dorsal columns, supplied by paired posterior spinal arteries, remain intact in ASA infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the ASA (via hypotension, atherothrombosis, or aortic pathology) leads to ischemic necrosis of anterior cord structures. Motor neurons and spinothalamic fibers are most vulnerable; dorsal columns are spared.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid examination to localize lesion and assess modality involvement.  <br>2. Emergent MRI spine with DWI to confirm ischemia and exclude compression.  <br>3. Vascular imaging (CT angiography) to identify aortic dissection or ASA occlusion.  <br>4. Initiate hemodynamic augmentation and consult relevant specialties.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Diffusion\u2010weighted MRI shows restricted diffusion centrally in the cord within hours; T2-weighted hyperintensity follows. CT angiography can reveal ASA flow interruption or proximal aortic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>No proven neuroprotective drugs. Management centers on supportive care: blood pressure augmentation (target MAP &ge; 85 mmHg), early physical therapy, antiplatelet therapy per stroke protocols. Avoid steroids unless differential suggests inflammation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Spinal cord infarctions are frequently tested via vignettes highlighting dissociated sensory loss (preserved proprioception with motor and pain/temperature deficits) and acute onset.</div></div></div></div></div>"}, {"id": 100023143, "question_number": "406", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] - Ischemic stroke severity is stratified using the NIH Stroke Scale (NIHSS); scores &le;3 define &ldquo;minor&rdquo; strokes.  <br><span class=\"list-item\">\u2022</span> Intravenous thrombolysis (alteplase) is indicated for disabling deficits within 4.5 hours, but may be withheld in non-disabling minor strokes.  <br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) initiated within 24 hours and continued for ~21 days reduces early recurrence in minor non-disabling AIS (POINT, CHANCE trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (DAPT) is correct. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines (Class IIa, LOE B-R) recommend DAPT for 21 days in minor (NIHSS &le;3) non-disabling ischemic stroke when started within 24 hours to prevent recurrence <span class=\"citation\">(<span class=\"evidence\">Johnston et al., 2018</span> POINT trial;<span class=\"evidence\"> Wang et al., 2013</span> CHANCE trial)</span>. In contrast, alteplase is reserved for disabling strokes&mdash;sensory deficits alone and mild facial weakness generally do not qualify as disabling. Mechanical thrombectomy is indicated only for large vessel occlusions within 6 hours (or select patients to 24 hours). Aspirin monotherapy is inferior to DAPT for early secondary prevention in this population.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. tPA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Indicated for disabling deficits; this patient&rsquo;s symptoms (mild sensory loss, facial weakness) are non-disabling.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;Any stroke within window gets tPA&rdquo; ignores disability assessment.  <br><span class=\"list-item\">\u2022</span> Differentiator: Disability vs non-disabling minor deficits.  <br><br>C. Aspirin  <br><span class=\"list-item\">\u2022</span> Why incorrect: Aspirin alone reduces recurrence less effectively than DAPT in first 21 days post&ndash;minor stroke (POINT: HR 0.68 for DAPT).  <br><span class=\"list-item\">\u2022</span> Misconception: Monotherapy sufficient for all AIS.  <br><span class=\"list-item\">\u2022</span> Differentiator: Superior early reduction of recurrence with DAPT.  <br><br>D. Mechanical thrombectomy  <br><span class=\"list-item\">\u2022</span> Why incorrect: Reserved for large vessel occlusion (ICA/M1) with moderate&ndash;severe deficits; minor strokes without imaging evidence of LVO do not qualify.  <br><span class=\"list-item\">\u2022</span> Misconception: All ischemic strokes benefit from mechanical clot retrieval.  <br><span class=\"list-item\">\u2022</span> Differentiator: Vessel occlusion location and NIHSS threshold &ge;6&ndash;8.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT (Correct)</th><th>tPA</th><th>Aspirin Monotherapy</th><th>Thrombectomy</th></tr></thead><tbody><tr><td>Mechanism</td><td>ADP-receptor blockade (clopidogrel) + COX-1 inhibition</td><td>Plasminogen \u2192 plasmin activation</td><td>COX-1 inhibition</td><td>Mechanical clot removal</td></tr><tr><td>Indication</td><td>Minor non-disabling AIS &le;3, within 24 h</td><td>Disabling AIS within 4.5 h</td><td>Secondary prevention (long-term)</td><td>LVO AIS within 6 h (select to 24 h)</td></tr><tr><td>Key Trials/Guidelines</td><td>POINT (2018), CHANCE (2013); AHA/ASA 2019 IIa B-R</td><td>NINDS (1995), ECASS III</td><td>IST (1997)</td><td>MR CLEAN, ESCAPE, SWIFT PRIME</td></tr><tr><td>Duration</td><td>21 days</td><td>Single infusion</td><td>Indefinite</td><td>Single procedure</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate DAPT within 24 hours in minor non-disabling AIS (NIHSS &le;3) for 21 days to halve early recurrence.  <br><span class=\"list-item\">\u2022</span> Assess disability (not just NIHSS score) when deciding on thrombolysis; isolated sensory loss often non-disabling.  <br><span class=\"list-item\">\u2022</span> After 21 days of DAPT, transition to monotherapy (aspirin or clopidogrel) to minimize bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Administering tPA for any stroke within the window without assessing disability.  <br>2. Prescribing aspirin alone for acute minor stroke despite evidence favoring short-term DAPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 Guidelines for Early Management of AIS: Class IIa recommendation (LOE B-R) for DAPT in minor non-disabling stroke within 24 h.  <br><span class=\"list-item\">\u2022</span> POINT trial <span class=\"citation\">(NEJM 2018)</span>: DAPT reduced 90-day recurrent stroke (5.0% vs 6.5%; HR 0.68, 95% CI 0.51&ndash;0.91) when initiated within 12 h.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lesion likely involves the right post-central gyrus (primary somatosensory cortex) causing contralateral hemisensory loss, and adjacent lower precentral gyrus affecting facial motor fibers&mdash;both small cortical branch ischemia of the MCA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute thromboembolic occlusion of a distal MCA branch leads to focal neuronal ischemia. Mild deficits reflect limited penumbral involvement and justify aggressive antiplatelet prophylaxis rather than full-dose fibrinolysis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. NIHSS assessment to quantify severity and disability.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. CT angiography if LVO suspected.  <br>4. Determine reperfusion vs antiplatelet strategy based on disability and vessel status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Early ischemic changes in minor stroke may be subtle on CT; MRI DWI is more sensitive for small cortical infarcts but not required before DAPT initiation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Dosing: Aspirin 75&ndash;100 mg daily + clopidogrel 75 mg daily after 300 mg loading; continue for 21 days, then single-agent therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. It tests recognition of minor non-disabling stroke management per AHA/ASA guidelines and POINT/CHANCE trial data. Frequent in board questions are NIHSS thresholds for therapy, DAPT indications and duration, and distinguishing disabling vs non-disabling deficits.</div></div></div></div></div>"}, {"id": 100023144, "question_number": "9", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2024] Intracerebral hemorrhage (ICH) causes a mass lesion that raises intracranial pressure and promotes hematoma expansion. Key concepts include:  <br><span class=\"list-item\">\u2022</span> Cerebral autoregulation is impaired in perihematomal tissue, so excessive hypertension drives further bleeding.  <br><span class=\"list-item\">\u2022</span> Rapid hematoma growth within the first 6 hours correlates with worse outcome; blood pressure control mitigates this risk.  <br><span class=\"list-item\">\u2022</span> Over\u2010aggressive lowering risks hypoperfusion in areas of shifted autoregulation.  <br>Students must integrate pathophysiology of bleeding, autoregulation curves, and trial data to target an optimal systolic blood pressure (SBP) that balances expansion risk and perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'><span class=\"evidence\">The 2015</span> AHA/ASA ICH guidelines (Class I, Level A) recommend acute lowering of SBP to 140 mmHg for patients presenting with SBP 150&ndash;220 mmHg. The INTERACT2 trial <span class=\"citation\">(n=2839)</span> showed that targeting SBP <140 mmHg was safe and trended toward improved functional outcome (ordinal shift OR 0.87, 95% CI 0.75&ndash;1.01; p=0.06). Although the ATACH-2 trial <span class=\"citation\">(n=1000)</span> found no significant benefit on mortality or disability when targeting 110&ndash;139 mmHg vs 140&ndash;179 mmHg and reported increased renal adverse events in the intensive group, current consensus still favors a goal SBP of 140 mmHg to limit hematoma expansion without provoking ischemia. A diastolic goal of ~90 mmHg aligns with general cerebral perfusion considerations.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. 160/90 &ndash; This higher systolic target was formerly permissive but leaves SBP in a range (150&ndash;160 mmHg) where hematoma expansion risk remains high; INTERACT2 showed better trends at lower SBP.  <br>C. 130/90 &ndash; While lower SBP might seem more protective, neither INTERACT2 nor ATACH-2 demonstrated additional functional benefit below 140 mmHg, and SBP <130 mmHg risks hypoperfusion in perihematomal penumbra.  <br>D. 120/90 &ndash; Targeting SBP this low exceeds the lower limit of autoregulation in injured brain, increasing risk of ischemic injury and worsening neurological outcome; no clinical trial supports such aggressive reduction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>SBP Target (mmHg)</th><th>Guideline Recommendation</th><th>Hematoma Expansion Risk</th><th>Ischemia Risk</th></tr></thead><tbody><tr><td>A. 140/90 (Correct)</td><td><140</td><td>AHA/ASA Class I, Level A</td><td>Minimized</td><td>Low</td></tr><tr><td>B. 160/90</td><td><160</td><td>Older consensus only</td><td>Moderate&ndash;High</td><td>Low</td></tr><tr><td>C. 130/90</td><td><130</td><td>Not supported by trial data</td><td>Low but theoretical</td><td>Moderate</td></tr><tr><td>D. 120/90</td><td><120</td><td>Contraindicated</td><td>Very low</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use titratable agents (e.g., nicardipine infusion) to achieve SBP 140 mmHg within 1 hour, avoiding rapid fluctuations.  <br><span class=\"list-item\">\u2022</span> Continuously monitor end-organ function; acute kidney injury incidence rises with overly aggressive SBP reduction.  <br><span class=\"list-item\">\u2022</span> Maintain cerebral perfusion pressure &ge;60 mmHg; adjust diastolic goals if auto\u2010regulation suggests.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing SBP targets for subarachnoid hemorrhage (often <160 mmHg pre-repair) with ICH guidelines (<140 mmHg).  <br><span class=\"list-item\">\u2022</span> Overshooting SBP reduction below 120 mmHg, leading to perihematomal ischemia and worse functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2015 Guidelines on ICH Management: Class I, Level A recommendation to lower SBP to 140 mmHg for initial ICH with SBP 150&ndash;220 mmHg.  <br>2. ATACH-2 Trial (2016): Intensive SBP lowering to 110&ndash;139 mmHg showed no functional benefit over 140&ndash;179 mmHg and increased renal adverse events (Level B-R evidence), reinforcing cautious targets around 140 mmHg.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2024 exam. Blood pressure targets in acute intracerebral hemorrhage are commonly tested as single best\u2010answer formats, emphasizing the balance between reducing hematoma expansion and preserving cerebral perfusion.</div></div></div></div></div>"}, {"id": 100023145, "question_number": "286", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Borderzone (watershed) infarcts occur at the junctional zones between major cerebral arteries (e.g., ACA&ndash;MCA) due to hypoperfusion or proximal stenosis. ESRD accelerates intracranial atherosclerosis via chronic inflammation and uremia, making intracranial vessel stenosis a leading cause of watershed strokes in this population. Noninvasive vascular imaging modalities differ in territory covered: CTA/MRA visualize intracranial vessels directly, whereas carotid Doppler is limited to extracranial arteries. In hemodynamic infarcts, identifying proximal intracranial stenosis guides further management. ESRD patients on dialysis can generally tolerate iodinated contrast with proper timing and supportive measures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Brain CT angiography (CTA) is the optimal next step because it rapidly and noninvasively depicts intracranial arterial stenoses that underlie hemodynamic (borderzone) infarcts.  <br>&bull; AHA/ASA 2018 Guidelines (Class I, Level B): CTA is recommended as first-line intracranial vascular imaging in acute ischemic stroke to detect large-vessel stenosis or occlusion.  <br>&bull; Wong et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 2007</span>)</span>: ESRD patients have a fourfold increased prevalence of intracranial atherosclerosis versus extracranial disease.  <br>&bull; Digital subtraction angiography (DSA) is the gold standard but is invasive, with higher risk (0.5&ndash;2% risk of stroke), and reserved for interventional planning or inconclusive noninvasive studies (Class IIa).  <br>&bull; Carotid Doppler ultrasound assesses extracranial carotid bifurcation but misses intracranial pathology.  <br>&bull; Cardiac echocardiography evaluates cardioembolic sources but is low yield in purely hemodynamic infarcts.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Conventional angiography  <br>  &ndash; Incorrect: Invasive with procedural stroke risk; reserved when noninvasive CTA/MRA findings are equivocal or intervention is planned.  <br>  &ndash; Misconception: &ldquo;Angiography is always needed for definitive diagnosis.&rdquo; Noninvasive CTA suffices initially.  <br><br>C. Carotid Doppler ultrasound  <br>  &ndash; Incorrect: Only images extracranial carotid and vertebral arteries; cannot detect intracranial MCA/ACA stenosis causing borderzone infarction.  <br>  &ndash; Misconception: &ldquo;All stroke patients need carotid ultrasound first.&rdquo; This overlooks intracranial disease.  <br><br>D. Cardiac echocardiography  <br>  &ndash; Incorrect: Targeted at cardioembolic sources (e.g., atrial thrombus, valvular lesions), but watershed infarcts are usually hemodynamic, not embolic.  <br>  &ndash; Misconception: &ldquo;Stroke workup always begins with echocardiogram.&rdquo; Stroke subtype guides imaging choice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Modality</th><th>Vessels Assessed</th><th>Invasiveness</th><th>Utility for ACA/MCA Borderzone</th><th>Main Risks</th></tr></thead><tbody><tr><td>Brain CT angiography</td><td>Intracranial arteries</td><td>Noninvasive</td><td>Excellent for proximal stenosis</td><td>Contrast nephrotoxicity (manageable in ESRD), radiation</td></tr><tr><td>Conventional angiography</td><td>Intra- & extracranial</td><td>Invasive</td><td>Gold standard resolution; reserved</td><td>Procedural stroke, bleeding</td></tr><tr><td>Carotid Doppler ultrasound</td><td>Extracranial carotids</td><td>Noninvasive</td><td>Cannot assess intracranial stenosis</td><td>Operator-dependent</td></tr><tr><td>Cardiac echocardiography</td><td>Cardiac chambers/valves</td><td>Noninvasive</td><td>Unrelated to hemodynamic stenosis</td><td>None (minimal)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- ESRD patients have higher rates of intracranial rather than extracranial atherosclerosis; prioritize intracranial imaging.  <br><span class=\"list-item\">\u2022</span> Borderzone infarcts classically indicate hemodynamic compromise; noninvasive vascular imaging (CTA/MRA) is the first diagnostic step.  <br><span class=\"list-item\">\u2022</span> Dialysis scheduling around contrast administration can mitigate concerns about contrast-induced nephropathy in ESRD.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering carotid Doppler as a standalone vascular study in watershed infarcts, missing intracranial disease.  <br>2. Proceeding directly to invasive angiography without first using noninvasive CTA/MRA, exposing patients to unnecessary procedural risks.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke: Recommends CTA as first-line vascular imaging (Class I, Level B).  <br>&bull; ESO (European Stroke Organisation) 2021 Guidelines: Endorses noninvasive CTA/MRA for detection of intracranial stenosis over ultrasound in suspected intracranial atherosclerosis (Strong Recommendation, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Watershed zones lie between the distal fields of the ACA and MCA territories, particularly the cortical borderzone over the lateral convexity. Proximal ACA or MCA stenosis reduces perfusion pressure in these distal fields, leading to laminar infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic uremia and dysregulated calcium&ndash;phosphate metabolism in ESRD promote endothelial dysfunction and accelerated intracranial atherosclerosis. Resultant arterial stenoses impair cerebral perfusion reserve; borderline hypotension or reduced cardiac output precipitates watershed infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT/MRI to confirm infarct pattern.  <br>2. Perform noninvasive intracranial vascular imaging (CTA or MRA).  <br>3. If CTA inconclusive or endovascular therapy considered, proceed to conventional angiography.  <br>4. Evaluate extracranial carotids if borderzone infarct accompanied by extracranial symptoms.  <br>5. Reserve echocardiography for patients with lacunar or embolic patterns or when noninvasive vascular studies are unrevealing.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CTA source images can show &ldquo;contrast cutoff&rdquo; at a stenotic segment; multiplanar reconstructions improve visualization in ACA/MCA segments.  <br><span class=\"list-item\">\u2022</span> CT perfusion adjunctively demonstrates prolonged time-to-peak and mean transit time in watershed regions, corroborating hypoperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, watershed infarctions in high-risk populations (e.g., ESRD) are frequently tested to assess understanding of hemodynamic versus embolic stroke mechanisms and appropriate imaging strategies.</div></div></div></div></div>"}, {"id": 100023146, "question_number": "266", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Vascular territories: The PCA supplies the occipital lobes, inferior temporal lobes, thalami, and midbrain.  <br>&bull; Reticular activating system (RAS): Consciousness depends on RAS integrity in the midbrain and thalami.  <br>&bull; Artery of Percheron variant: A single thalamoperforating branch from the PCA can infarct both paramedian thalami, leading to sudden coma.  <br><br>(Word count: 67)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Bilateral paramedian thalamic infarcts due to occlusion of the artery of Percheron, a variant branch of the PCA, classically present with profound unconsciousness. Non-contrast CT may show symmetric hypodensities in both thalami within hours of onset <span class=\"citation\">(<span class=\"evidence\">Schmahmann et al., 2003</span>)</span>. Diffusion-weighted MRI confirms the diagnosis with high sensitivity. The PCA arises from the basilar artery bifurcation and gives off small perforators to the medial thalami and rostral midbrain; occlusion here disrupts the intralaminar nuclei and RAS, causing coma <span class=\"citation\">(Percheron, 1973)</span>. AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Powers et al., 2019</span>; Class I, Level B-R)</span> recommend emergent vascular imaging in unexplained coma to identify posterior circulation occlusions. Early recognition enables timely reperfusion&mdash;IV alteplase within 4.5 hours or endovascular thrombectomy up to 6 hours <span class=\"citation\">(or longer in select posterior strokes per BASICS trial, JAMA <span class=\"evidence\">Neurol 2021</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. MCA  <br>&bull; MCA strokes produce contralateral hemiparesis, hemisensory loss, aphasia or neglect, but spare consciousness since RAS is preserved.  <br>&bull; Misconception: large cortical strokes always cause coma&mdash;only massive hemispheric edema can herniate.  <br><br>C. Anterior choroidal artery  <br>&bull; Supplies posterior limb of internal capsule, optic tract, hippocampus; infarction causes pure motor/sensory or visual field defects, not coma.  <br>&bull; Misconception: &ldquo;choroidal&rdquo; implies deep thalamic involvement; actually spares intralaminar thalamic nuclei.  <br><br>D. Basilar artery  <br>&bull; Basilar occlusion causes coma via brainstem ischemia; however, CT without angiography often appears normal or shows hyperdense basilar sign but not bilateral thalamic hypodensities.  <br>&bull; Differentiating feature: basilar occlusion yields locked-in syndrome or crossed signs, whereas artery of Percheron infarct localizes to thalami.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>PCA (Artery of Percheron)</th><th>MCA</th><th>Anterior Choroidal</th><th>Basilar Artery</th></tr></thead><tbody><tr><td>Territory</td><td>Paramedian thalami, midbrain</td><td>Lateral frontal/parietal lobes</td><td>Posterior limb internal capsule</td><td>Pons, cerebellum, midbrain</td></tr><tr><td>Key clinical sign</td><td>Sudden coma, vertical gaze palsy</td><td>Hemiparesis, aphasia, neglect</td><td>Pure motor/sensory stroke</td><td>Coma &plusmn; locked-in, cranial nerve signs</td></tr><tr><td>CT findings</td><td>Bilateral thalamic hypodensities</td><td>Cortical/subcortical hypodensity</td><td>Internal capsule lacune</td><td>Often normal; hyperdense basilar sign</td></tr><tr><td>Time to reperfusion window</td><td>4.5&ndash;6 hrs (IV tPA, thrombectomy)</td><td>4.5 hrs IV tPA; 6&ndash;24 hrs thrombectomy</td><td>4.5 hrs IV tPA</td><td>Up to 6 hrs, extended in trials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bilateral paramedian thalamic infarcts in an unconscious patient are pathognomonic for an artery of Percheron variant (PCA branch).  <br>&bull; Always perform CT angiography in unexplained coma to detect posterior circulation occlusions, even if non-contrast CT is non-diagnostic.  <br>&bull; Vertical gaze palsy and memory impairment can accompany thalamic strokes&mdash;look beyond motor deficits.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming MCA occlusion causes unconsciousness&mdash;MCA strokes rarely disrupt the RAS.  <br>2. Overlooking artery of Percheron infarction because it lacks cortical signs; absence of hemiparesis does not exclude a devastating stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Acute Ischemic Stroke Guidelines (Powers et al.): Class I, Level B-R recommendation for CTA/MRA in posterior circulation strokes to guide reperfusion.  <br>&bull; BASICS Trial <span class=\"citation\">(JAMA <span class=\"evidence\">Neurol 2021</span>)</span>: Endovascular therapy for basilar artery occlusion showed improved functional outcomes when treated within 6&ndash;24 hours; suggests extended windows for posterior strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Paramedian thalamic perforators from the PCA supply the mediodorsal nucleus and intralaminar nuclei, integral to consciousness. The RAS ascends through these nuclei to the cortex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial occlusion \u2192 loss of thalamic perfusion \u2192 failure of intralaminar nuclei \u2192 disruption of RAS \u2192 sudden coma. Cytotoxic edema ensues within minutes, visible on diffusion MRI.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Unconscious patient \u2192 secure airway, breathing, circulation  <br>2. Non-contrast CT to exclude hemorrhage  <br>3. CT angiography to assess posterior circulation  <br>4. MRI DWI if CT equivocal  <br>5. Initiate IV thrombolysis or thrombectomy per findings</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bilateral symmetric thalamic low attenuation on CT suggests artery of Percheron infarct.  <br>&bull; Hyperdense basilar sign on non-contrast CT indicates basilar thrombosis but requires CTA confirmation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Posterior circulation strokes&mdash;especially artery of Percheron infarctions&mdash;are high-yield for neurovascular localization questions on board exams.</div></div></div></div></div>"}, {"id": 100023147, "question_number": "210", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute ischemic stroke results from an arterial occlusion producing an ischemic core (irreversibly damaged tissue) surrounded by a salvageable penumbra. Intravenous alteplase (tPA) promotes fibrinolysis, restoring perfusion if given within 4.5 hours of symptom onset. Key principles:<br><span class=\"list-item\">\u2022</span> Time is brain: nearly 2 million neurons lost per minute of untreated ischemia.<br><span class=\"list-item\">\u2022</span> Penumbral salvage depends on early reperfusion to limit infarct growth.<br><span class=\"list-item\">\u2022</span> Rapidly improving symptoms raise questions about &ldquo;minor stroke&rdquo; vs. disabling residual deficits; NIH Stroke Scale (NIHSS) helps gauge severity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase within 4.5 hours remains the standard for eligible patients. NINDS trials (1995) demonstrated a 30% greater chance of minimal or no disability at 90 days (OR 1.7, 95% CI 1.2&ndash;2.6). ECASS III extended the window to 4.5 hours, showing 52.4% of treated patients achieved favorable outcome versus 45.2% with placebo (p = 0.04). <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines (Class I, Level A) recommend IV alteplase for patients with disabling deficits, even if partially improving, provided residual deficits impair function. Rapidly improving non-disabling symptoms remain a relative exclusion, but persistent deficits (aphasia, hemiparesis) justify treatment. Alteplase dosing (0.9 mg/kg, max 90 mg, 10% bolus, remainder over 60 minutes) maximizes efficacy while managing hemorrhagic risk (~6% symptomatic ICH).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Administer aspirin  <br>&bull; Why incorrect: Monotherapy with aspirin within the hyperacute window is inferior to tPA for eligible patients; aspirin is contraindicated within 24 hours of tPA.  <br>&bull; Misconception: Belief that antiplatelet therapy substitutes for reperfusion; it only prevents recurrence, not reverse ongoing ischemia.  <br>&bull; Differentiator: Aspirin acts on platelet aggregation, not fibrin clot lysis; benefit accrues over days, not minutes.<br><br>C. Perform a thrombectomy  <br>&bull; Why incorrect: Mechanical thrombectomy is indicated for large-vessel occlusions (e.g., ICA/M1) within 6&ndash;24 hours after CT\u2010perfusion mismatch; first confirm LVO on CTA.  <br>&bull; Misconception: Equating any acute stroke with immediate endovascular therapy; thrombectomy requires imaging confirmation and specialized centers.  <br>&bull; Differentiator: tPA is first-line within 4.5 hours for most strokes; thrombectomy is adjunctive for LVO or tPA-ineligible patients.<br><br>D. Observe and reassess  <br>&bull; Why incorrect: Delaying reperfusion forfeits the narrow therapeutic window; partial improvement does not guarantee complete recovery.  <br>&bull; Misconception: &ldquo;Wait and see&rdquo; avoids hemorrhagic risk; untreated penumbra will infarct.  <br>&bull; Differentiator: Active reperfusion therapy within window improves functional outcome; observation misses this opportunity.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA</th><th>Aspirin Only</th><th>Thrombectomy</th><th>Observe & Reassess</th></tr></thead><tbody><tr><td>Time window</td><td>&le; 4.5 hours (Class I, LOE A)</td><td>Any time (no lysis effect)</td><td>&le; 6 hours (up to 24 h w/ mismatch)</td><td>No active reperfusion</td></tr><tr><td>Mechanism</td><td>Fibrinolysis via plasminogen</td><td>COX-1 inhibition of platelets</td><td>Mechanical clot retrieval</td><td>None</td></tr><tr><td>Key evidence</td><td>NINDS (1995), ECASS III (2008)</td><td>IST-1, Chinese Acute Stroke Study</td><td>MR CLEAN, ESCAPE, REVASCAT</td><td>None</td></tr><tr><td>Hemorrhage risk</td><td>~6% symptomatic ICH</td><td>~1% GI bleed over weeks</td><td>7&ndash;10% vessel injury risk</td><td>Ongoing infarct expansion</td></tr><tr><td>Functional outcome benefit</td><td>\u2191 Independence at 90 days</td><td>\u2193 recurrence long-term</td><td>\u2191 recanalization in LVO</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use NIHSS to quantify deficits; scores &ge; 4 with residual disabling symptoms merit tPA.  <br><span class=\"list-item\">\u2022</span> &ldquo;Rapidly improving&rdquo; excludes only if deficits are non-disabling (e.g., isolated numbness).  <br><span class=\"list-item\">\u2022</span> Maintain BP < 185/110 mm Hg before and during tPA infusion to reduce hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Interpreting any improvement as complete resolution&mdash;some deficits (e.g., mild aphasia) still justify tPA.  <br>2. Substituting aspirin or delaying therapy to &ldquo;see if she improves&rdquo;&mdash;missed window means irreversible infarction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2018 Guidelines on Early Management of Acute Ischemic Stroke <span class=\"citation\">(<span class=\"evidence\">Stroke 2018</span>;49:e46&ndash;e99)</span>  <br>   &ndash; Recommendation: IV alteplase &le; 4.5 hours for disabling deficits (Class I, LOE A).  <br>2. ESO&ndash;ESMINT 2021 Guidelines <span class=\"citation\">(Eur Stroke J 2021;6(2)</span>:I&ndash;LVI)  <br>   &ndash; Endorses alteplase within 4.5 hours and mechanical thrombectomy for anterior LVO &le; 6 hours (Level A).  <br>3. EXTEND Trial <span class=\"citation\">(Campbell et al., NEJM 2019;380:1795&ndash;1803)</span>  <br>   &ndash; Perfusion-imaging&ndash;guided alteplase 4.5&ndash;9 hours post-onset improves functional outcome (adjusted OR 1.75; 95% CI 1.02&ndash;3.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Middle cerebral artery occlusion is most common; infarct location dictates deficits (e.g., contralateral hemiparesis, aphasia if dominant hemisphere). Penumbral tissue in MCA territory is salvageable with timely reperfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic cascade: energy failure \u2192 ionic pump dysfunction \u2192 cytotoxic edema \u2192 excitotoxicity \u2192 free radical injury. tPA restores perfusion before irreversible cell death.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Immediate neurological assessment (NIHSS).  <br>2. Noncontrast head CT to exclude hemorrhage and large established infarct.  <br>3. Laboratory studies (glucose, coagulation).  <br>4. Vascular imaging (CTA) if endovascular therapy considered.  <br>5. Initiate tPA if within 4.5 hours and no contraindications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT hyperdense vessel sign suggests thrombus.  <br><span class=\"list-item\">\u2022</span> CT perfusion: defines core vs penumbra for extended-window decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Alteplase: 0.9 mg/kg (max 90 mg), 10% bolus over 1 minute, remainder over 60 minutes. Monitor for bleeding; avoid antithrombotics for 24 hours post-infusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Acute reperfusion therapy questions frequently test time windows, exclusion criteria (e.g., minor non-disabling stroke), and distinguishing between pharmacologic (tPA) and mechanical (thrombectomy) approaches. Stroke vignettes often require NIHSS interpretation and CT- vs CTA-based decisions.</div></div></div></div></div>"}, {"id": 100023148, "question_number": "434", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke management hinges on rapid identification of vessel occlusion and penumbral tissue. Core principles include:  <br><span class=\"list-item\">\u2022</span> Noncontrast CT to exclude hemorrhage (time\u2010critical &ldquo;door\u2010to\u2010CT&rdquo;).  <br><span class=\"list-item\">\u2022</span> CT angiography (CTA) of head and neck to localize large\u2010vessel occlusions (LVOs) and assess arterial anatomy for thrombectomy candidacy.  <br><span class=\"list-item\">\u2022</span> Carotid Doppler and echocardiography study extracranial stenosis and cardioembolic sources but are secondary in the hyperacute phase.  <br><span class=\"list-item\">\u2022</span> MRI brain (DWI/FLAIR) refines infarct age and extent but is less accessible in the initial evaluation window.  <br>Thus, once noncontrast CT is done, emergent CTA is the next step to guide reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. MRI brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Although diffusion\u2010weighted MRI defines infarct core and penumbra, it is time\u2010consuming, less available emergently, and not required before reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that MRI always supersedes CT in stroke; in hyperacute phase, CT/CTA is faster and sufficient.  <br><br>C. Carotid Doppler ultrasound  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates only extracranial carotid bifurcation; cannot assess intracranial circulation or vertebrobasilar anatomy critical for thrombectomy.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating carotid stenosis detection with comprehensive vascular imaging; CTA offers full cervicocerebral evaluation.  <br><br>D. Echocardiogram  <br><span class=\"list-item\">\u2022</span> Incorrect: Key for detecting atrial thrombus or PFO but impacts long\u2010term secondary prevention, not immediate reperfusion strategy.  <br><span class=\"list-item\">\u2022</span> Misconception: Prioritizing cardioembolic workup over vessel imaging; delays time\u2010sensitive clot retrieval.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CTA (Correct)</th><th>MRI Brain</th><th>Carotid Doppler</th><th>Echocardiogram</th></tr></thead><tbody><tr><td>Primary Use</td><td>Detect LVO, arterial anatomy</td><td>Tissue viability, infarct dating</td><td>Extracranial carotid stenosis</td><td>Cardiac source of emboli</td></tr><tr><td>Speed</td><td><5 minutes</td><td>20&ndash;45 minutes</td><td>10&ndash;20 minutes</td><td>30&ndash;60 minutes</td></tr><tr><td>Coverage</td><td>Intracranial + extracranial vessels</td><td>Brain parenchyma</td><td>Extracranial carotids only</td><td>Heart chambers & valves</td></tr><tr><td>Role in Hyperacute Stroke</td><td>Guides thrombectomy</td><td>Limited emergent role</td><td>Secondary post\u2010acute evaluation</td><td>Secondary prevention</td></tr><tr><td>Sensitivity for LVO</td><td>High (&ge;95%)</td><td>Moderate (requires MRA sequence)</td><td>None for intracranial occlusion</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Obtain &ldquo;CT/CTA combo&rdquo; in the same scanner session to minimize door\u2010to\u2010reperfusion time.  <br><span class=\"list-item\">\u2022</span> CTA head and neck can be performed without delaying IV tPA; contrast bolus is timed after noncontrast CT.  <br><span class=\"list-item\">\u2022</span> Check renal function but do not delay CTA in patients with unknown creatinine if no history of severe renal disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering carotid ultrasound before CTA, delaying identification of intracranial LVO.  <br>2. Over\u2010relying on MRI DWI/FLAIR mismatch in hyperacute settings, prolonging door\u2010to\u2010needle time.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2018 Guidelines (Class I, Level A): Recommend CTA immediately after noncontrast CT for suspected LVO.  <br><span class=\"list-item\">\u2022</span> ESO (European Stroke Organization) 2021 Guidelines: Advise CTA head and neck within 20 minutes of initial CT in all suspected large\u2010vessel strokes (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 rule out hemorrhage.  <br>2. CTA head & neck \u2192 identify LVO, stenosis, vascular anatomy.  <br>3. IV tPA &plusmn; mechanical thrombectomy based on CTA findings.  <br>4. Subsequent MRI, carotid Doppler, echocardiography for etiologic classification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use bolus tracking to optimize arterial phase in CTA.  <br><span class=\"list-item\">\u2022</span> Recognize &ldquo;clot\u2010sign&rdquo; as filling defect in M1/M2 segments; distinguishes thrombus from calcified plaque.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular imaging sequences are frequently tested as rapid\u2010fire questions in stroke modules, often emphasizing the order: noncontrast CT \u2192 CTA \u2192 reperfusion therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The correct answer is A. CTA. This is supported by current clinical evidence and practice guidelines.</div></div></div></div></div>"}, {"id": 100023149, "question_number": "356", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Carotid endarterectomy (CEA) is a vascular surgery aimed at reducing ipsilateral ischemic stroke risk by physically removing atherosclerotic plaque from the carotid bifurcation and proximal internal carotid artery. Key concepts:  <br><span class=\"list-item\">\u2022</span> Atherosclerotic plaque in the carotid bulb can ulcerate or shed emboli, causing cortical or subcortical infarcts.  <br><span class=\"list-item\">\u2022</span> Surgical plaque removal restores luminal diameter and improves cerebral perfusion.  <br><span class=\"list-item\">\u2022</span> Timing and patient selection (symptomatic status, degree of stenosis, perioperative risk) are critical for benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option A correctly defines CEA. In the landmark North American Symptomatic Carotid Endarterectomy Trial <span class=\"citation\">(NASCET, 1991)</span>, patients with 70&ndash;99% symptomatic stenosis who underwent CEA had a 17% absolute risk reduction in ipsilateral stroke at 2 years (number needed to treat = 6). The subsequent AHA/ASA 2014 guideline (Class I, Level of Evidence A) recommends CEA within 2 weeks for symptomatic patients with 70&ndash;99% stenosis and considers it (Class IIa, LOE B) in asymptomatic patients with &ge;60% stenosis if perioperative stroke/death risk is <3%. The procedure involves arteriotomy at the bifurcation, endarterectomy of the diseased intima, and patch angioplasty or primary closure. By contrast, Option B (ICH management) utilizes craniotomy or minimally invasive hematoma evacuation; Option C (MCA stenting) is an endovascular approach for intracranial atherosclerosis; Option D describes anticoagulation, not plaque removal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intracerebral hemorrhage management  <br><span class=\"list-item\">\u2022</span> Why incorrect: ICH is managed medically (blood pressure control, reversal of coagulopathy) or surgically by clot evacuation, not by plaque removal.  <br><span class=\"list-item\">\u2022</span> Misconception: Confusing &ldquo;endarterectomy&rdquo; with &ldquo;evacuation&rdquo; in hemorrhagic stroke.  <br><span class=\"list-item\">\u2022</span> Differentiator: CEA treats ischemic risk via arterial plaque removal; ICH procedures remove hematoma.<br><br>C. Placement of a stent in the MCA  <br><span class=\"list-item\">\u2022</span> Why incorrect: Endarterectomy is open surgical, not endovascular stenting of intracranial vessels.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any vessel intervention (&ldquo;endar-&rdquo;) with stenting.  <br><span class=\"list-item\">\u2022</span> Differentiator: MCA stenting addresses intracranial atherosclerosis; CEA targets extracranial carotid plaques.<br><br>D. Pharmacological anticoagulation to dissolve clots  <br><span class=\"list-item\">\u2022</span> Why incorrect: Anticoagulants (e.g., warfarin, DOACs) prevent or treat thromboembolism but do not remove fixed plaque.  <br><span class=\"list-item\">\u2022</span> Misconception: Thinking &ldquo;endarterectomy&rdquo; implies &ldquo;enter&rdquo; or &ldquo;anti&rdquo;-carotid therapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Pharmacotherapy alters coagulation; CEA is mechanical plaque excision.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature/Parameter</th><th>Carotid Endarterectomy (A)</th><th>ICH Evacuation (B)</th><th>MCA Stenting (C)</th><th>Anticoagulation (D)</th></tr></thead><tbody><tr><td>Modality</td><td>Open surgical removal of plaque</td><td>Craniotomy or minimally invasive</td><td>Endovascular stent deployment</td><td>Systemic administration of anticoagulants</td></tr><tr><td>Primary Indication</td><td>Symptomatic/asymptomatic carotid stenosis</td><td>Large hematoma with mass effect</td><td>Intracranial atherosclerotic disease</td><td>Cardioembolic stroke prevention/treatment</td></tr><tr><td>Mechanism</td><td>Intimal plaque excision and patch angioplasty</td><td>Hematoma evacuation</td><td>Luminal scaffolding</td><td>Inhibition of clotting cascade</td></tr><tr><td>Timing</td><td>Within 2 weeks of TIA/stroke if symptomatic</td><td>Emergent (hours)</td><td>Elective or acute revascularization</td><td>As indicated by stroke subtype</td></tr><tr><td>Evidence Base</td><td>NASCET, ECST trials; AHA/ASA guidelines</td><td>STICH trials</td><td>SAMMPRIS trial</td><td>WARSS, RE-LY trials</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Optimal benefit in symptomatic carotid stenosis occurs when CEA is performed within 2 weeks of the index TIA/stroke.  <br><span class=\"list-item\">\u2022</span> Perioperative stroke/death risk must be <3% in asymptomatic patients to justify CEA benefit.  <br><span class=\"list-item\">\u2022</span> Antiplatelet therapy (aspirin) is continued perioperatively; dual antiplatelet therapy may be used briefly in high-risk scenarios.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing endarterectomy (plaque excision) with endovascular thrombectomy or stenting.  <br>2. Believing CEA is indicated for hemorrhagic stroke or intracerebral hemorrhage&mdash;misapplication of the term &ldquo;evacuation.&rdquo;</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Prevention of Stroke in Patients With Stroke and TIA: Class I, LOE A recommendation for CEA in symptomatic patients with 70&ndash;99% stenosis within 2 weeks.  <br><span class=\"list-item\">\u2022</span> European Society for Vascular Surgery (ESVS) 2023 Guidelines: Recommend CEA (Level I, LOE A) for symptomatic internal carotid stenosis &ge;50% performed within 14 days of symptom onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The carotid bifurcation at C3&ndash;C4 gives rise to the internal carotid artery, which supplies the anterior circulation via the ophthalmic, anterior cerebral, and middle cerebral arteries&mdash;regions vulnerable to hypoperfusion and embolic infarction in stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque comprises lipid core, fibrous cap, and calcification. Plaque rupture exposes thrombogenic materials, leading to in situ thrombosis or artery-to-artery embolization, causing cortical or subcortical ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Duplex ultrasonography to screen for carotid stenosis.  <br>2. Confirm percentage stenosis with CT angiography or MR angiography.  <br>3. Assess symptomatic status and perioperative risk.  <br>4. Multidisciplinary evaluation to determine CEA candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Peak systolic velocity >230 cm/s on duplex suggests &ge;70% ICA stenosis.  <br><span class=\"list-item\">\u2022</span> CT angiography provides high-resolution assessment of plaque morphology and calcification.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Aspirin (81&ndash;325 mg daily) before and after CEA reduces perioperative thromboembolic risk.  <br><span class=\"list-item\">\u2022</span> Statin therapy stabilizes plaque and is continued perioperatively.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Carotid endarterectomy is a frequently tested topic in stroke prevention modules, often contrasting surgical versus endovascular strategies for extracranial carotid disease.</div></div></div></div></div>"}, {"id": 100023150, "question_number": "479", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2021</span>] &bull; The internal carotid artery (ICA) is enveloped by sympathetic fibers; an intimal tear leads to intramural hematoma, vessel narrowing, and disruption of oculosympathetic outflow, causing ipsilateral Horner&rsquo;s syndrome (ptosis, miosis, anhidrosis).  <br>&bull; Dissection often presents acutely with focal weakness from thromboembolic stroke in the MCA distribution alongside oculosympathetic signs.  <br>&bull; CT angiography (CTA) is first-line for cervical artery dissection, revealing a &ldquo;string sign,&rdquo; tapering lumen, double lumen, or intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>ICA dissection uniquely accounts for the combined presentation of acute focal weakness and ipsilateral ptosis. The oculosympathetic fibers ascend along the ICA adventitia; an intimal flap with false lumen formation compresses true lumen flow and disrupts sympathetic innervation <span class=\"citation\">(Schievink WI, Lancet <span class=\"evidence\">Neurol 2001</span>)</span>. According to the 2018 AHA/ASA guidelines on Stroke Prevention in Patients with Stroke and Transient Ischemic Attack (Class I, Level A), CTA is recommended to confirm cervical artery dissection. Sensitivity and specificity exceed 90% when high-resolution CTA is performed <span class=\"citation\">(Provias J, et al., <span class=\"evidence\">Stroke 2019</span>)</span>. The combination of vascular imaging showing tapered stenosis and clinical Horner&rsquo;s syndrome distinguishes ICA dissection from pure ischemic stroke or neuromuscular disorder.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Myasthenia gravis  <br>  &ndash; MG causes fatigable weakness and ptosis but spares pupils and lacks acute vessel narrowing on CTA. Misconception: conflating neuromuscular junction fatigue with oculosympathetic disruption.  <br>C. Brain tumor  <br>  &ndash; Neoplastic lesions evolve subacutely and produce mass effect on parenchyma, not focal carotid stenosis with intramural hematoma. Imaging shows mass with contrast enhancement, not lumen tapering.  <br>D. Stroke  <br>  &ndash; &ldquo;Stroke&rdquo; denotes parenchymal infarct; it explains weakness but not ptosis via sympathetic pathway interruption or CTA findings of vessel dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>Myasthenia Gravis</th><th>Brain Tumor</th><th>Stroke</th></tr></thead><tbody><tr><td>Onset</td><td>Acute (hours)</td><td>Fluctuating, worsens with use</td><td>Insidious (weeks&ndash;months)</td><td>Acute (minutes&ndash;hours)</td></tr><tr><td>Imaging (CTA)</td><td>Tapered stenosis, intimal flap, double lumen</td><td>Normal</td><td>Mass lesion with enhancement</td><td>No vessel abnormality (unless occlusion)</td></tr><tr><td>Ptosis</td><td>Present (Horner&rsquo;s syndrome)</td><td>Present (fatigable)</td><td>Possible if CN compression</td><td>Absent unless brainstem involvement</td></tr><tr><td>Pupillary involvement</td><td>Miosis (small pupil)</td><td>Normal</td><td>Variable</td><td>Variable</td></tr><tr><td>Pathophysiology</td><td>Intimal tear, intramural hematoma</td><td>Autoimmune AChR blockade</td><td>Neoplastic growth</td><td>Thromboembolism or hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Always assess pupil size and reactivity in acute ptosis; miosis points to Horner&rsquo;s syndrome and vascular etiology.  <br>&bull; CTA is the preferred initial imaging for suspected cervical artery dissection; MRA/DSA reserved if CTA equivocal.  <br>&bull; Antithrombotic therapy (antiplatelet or anticoagulant) should be initiated promptly to prevent recurrent stroke (CADISS trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing oculomotor nerve palsy (ptosis with dilated pupil) with Horner&rsquo;s syndrome (ptosis with miosis).  <br>2. Assuming acute weakness plus ptosis is myasthenia gravis without evaluating pupils or vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA Stroke Prevention <span class=\"evidence\">Guidelines 2018</span>: Recommends CTA or MRA for suspected cervical artery dissection (Class I, Level A).  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs anticoagulant therapy in preventing stroke recurrence after cervical artery dissection (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The oculosympathetic pathway originates in the hypothalamus, descends to the ciliospinal center (C8&ndash;T2), exits as preganglionic fibers to the superior cervical ganglion, then ascends along the ICA adventitia to the pupil dilator muscle. Disruption at the ICA level produces ptosis, miosis, and anhidrosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear permits blood into the medial layer, creating an intramural hematoma. This false lumen compresses the true lumen, causing ischemia via flow restriction or artery-to-artery embolism, and interrupts perivascular sympathetic fibers.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: acute hemiparesis + ipsilateral ptosis/miosis  <br>2. Neurological exam: spect for Horner&rsquo;s signs  <br>3. CTA of head and neck: assess for intimal flap, luminal narrowing  <br>4. MRA/DSA if CTA inconclusive  <br>5. Initiate antithrombotic therapy; consider vascular surgery if expansion/pseudoaneurysm</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>CTA signs of dissection:  <br>&bull; &ldquo;String sign&rdquo;&mdash;tapered lumen appearance  <br>&bull; Double lumen/intimal flap  <br>&bull; Pseudoaneurysm formation at dissection site</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Antithrombotic management:  <br>&bull; Aspirin 75&ndash;325 mg daily or oral anticoagulation (e.g., warfarin INR 2&ndash;3) for 3&ndash;6 months (CADISS protocol).  <br>&bull; Blood pressure control to reduce shear stress on vessel wall.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2021</span> exam. Vascular dissections with Horner&rsquo;s syndrome and acute ischemia are high-yield on board exams, often tested via CTA/MRA image interpretation and distinguishing oculosympathetic disruption from neuromuscular etiologies.</div></div></div></div></div>"}, {"id": 100023151, "question_number": "500", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] Carotid artery dissection involves an intimal tear allowing blood to enter the vessel wall, forming an intramural hematoma that can narrow or occlude the lumen. Key points:  <br>&bull; Anatomy: The cervical segment of the ICA is vulnerable to stretching and compression during blunt trauma.  <br>&bull; Pathophysiology: Intramural hematoma or flap formation predisposes to flow limitation and thrombus formation.  <br>&bull; Clinical setting: Young patients lacking atherosclerotic risk factors who sustain high\u2010energy trauma (e.g., MVA) frequently develop traumatic dissection leading to ischemic stroke.  <br>(Word count: ~85)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic carotid dissection is the predominant cause of ICA occlusion in young trauma victims. Blunt cervical trauma stretches the ICA against bony structures (e.g., C1 transverse process), causing an intimal tear and subsequent intramural hematoma. A meta-analysis <span class=\"citation\">(Biffl et al., J <span class=\"evidence\">Trauma 2002</span>)</span> reports cervical artery dissections in 1&ndash;3% of blunt trauma patients, with up to 64% causing stroke. Current AHA/ASA 2018 guidelines recommend CTA or MRA of head/neck for all high\u2010risk trauma patients to detect dissections early (Class I, Level B). The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> supports antithrombotic therapy post-dissection to prevent recurrent ischemia. In contrast, thrombosis, embolism, and atherosclerosis are far less plausible in this demographic and context.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Thrombosis  <br>&bull; Incorrect: In situ thrombosis usually occurs over an atherosclerotic plaque in older patients.  <br>&bull; Misconception: Equating any occlusion with primary thrombus formation rather than traumatic intimal injury.  <br>&bull; Differentiator: Thrombosis lacks the radiographic intimal flap and is rare without plaque.<br><br>C. Embolism  <br>&bull; Incorrect: Embolic stroke implies a distant source (e.g., cardiac) which is unsupported by trauma history and normal cardiac evaluation.  <br>&bull; Misconception: Assuming all acute infarcts are embolic.  <br>&bull; Differentiator: Emboli produce multifocal infarcts in varied vascular territories, not a localized ICA cut\u2010off.<br><br>D. Atherosclerosis  <br>&bull; Incorrect: Atherosclerotic occlusion develops over years, seen in older individuals with risk factors (hypertension, hyperlipidemia).  <br>&bull; Misconception: Overattributing vascular events to atherosclerosis, even in young patients.  <br>&bull; Differentiator: Lack of plaque on imaging and absent risk profile.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Dissection</th><th>Thrombosis</th><th>Embolism</th><th>Atherosclerosis</th></tr></thead><tbody><tr><td>Patient profile</td><td>Young, trauma</td><td>Older, plaque risk factors</td><td>Any age, cardiac risk (AF, MI)</td><td>Middle\u2010aged/elderly with RFs</td></tr><tr><td>Pathogenesis</td><td>Intimal tear \u2192 intramural bleed</td><td>Clot over plaque</td><td>Thrombus travels from heart/vessel</td><td>Plaque buildup \u2192 lumen narrowing</td></tr><tr><td>Imaging hallmark</td><td>Intimal flap, &ldquo;double lumen&rdquo;</td><td>Filling defect within normal wall</td><td>Abrupt cutoff without flap</td><td>Irregular wall thickening, calcified</td></tr><tr><td>Onset in trauma</td><td>Immediate/subacute</td><td>Unrelated to trauma</td><td>Unrelated to trauma</td><td>Chronic progression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In any young trauma patient with stroke symptoms, obtain emergent CTA/MRA of the neck to rule out carotid or vertebral dissection.  <br>2. Look for the &ldquo;crescent sign&rdquo; (T1 hyperintense intramural hematoma) on fat\u2010suppressed MRI.  <br>3. Early anticoagulation or antiplatelet therapy reduces recurrent stroke risk post-dissection (CADISS trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing acute post-traumatic stroke to fat embolism rather than vascular injury.  <br>2. Overlooking subtle neck pain or Horner syndrome, early signs of carotid dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA (2018): Recommend vascular imaging (CTA/MRA) in blunt cerebrovascular injury&mdash;Class I, Level B.  <br>&bull; ESO (European Stroke Organisation) Guidelines (2019): Endorse either antiplatelet or anticoagulant therapy for extracranial carotid dissection based on patient tolerance&mdash;Level A.  <br>&bull; CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference between antiplatelet vs anticoagulant therapy for preventing stroke recurrence post-dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA&rsquo;s course through the carotid canal and its fixation at the skull base make it susceptible to stretch and shear forces during hyperextension or lateral neck movement, leading to intimal tears at the C1&ndash;C2 level.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to track between vessel wall layers, creating a false lumen. The expanding hematoma narrows the true lumen, precipitating ischemia by flow reduction or distal thromboembolism.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect dissection in trauma with focal deficits or neck pain.  <br>2. Perform CTA/MRA angiography of neck vessels.  <br>3. Confirm intimal flap or intramural hematoma on imaging.  <br>4. Initiate antithrombotic therapy and neurology consultation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; CTA: &ldquo;String sign&rdquo; or tapered stenosis.  <br>&bull; MRI/MRA: T1\u2010weighted fat-suppressed sequences show intramural hematoma as hyperintense crescent.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Carotid dissection is a high\u2010yield topic in trauma and stroke modules; examinees should recognize imaging features of dissection and differentiate from other stroke etiologies.</div></div></div></div></div>"}, {"id": 100023152, "question_number": "191", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Horizontal conjugate gaze is controlled by the frontal eye fields (FEFs; Brodmann area 8) in each frontal cortex, which send excitatory projections to the contralateral paramedian pontine reticular formation (PPRF) and abducens nucleus. A unilateral cortical lesion of the FEF abolishes its drive to the opposite PPRF, leaving the intact FEF unopposed; eyes therefore rest ipsilesionally (toward the lesion). In contrast, pontine (brainstem) lesions disrupt the ipsilateral PPRF directly, causing eyes to deviate contralesionally (away from the lesion). Rapid recognition of these opposing patterns is a cornerstone of acute stroke localization and guides emergent imaging and reperfusion decisions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ipsilateral gaze deviation in hemispheric stroke reflects loss of contralateral FEF input. Robinson and Fuchs <span class=\"citation\">(J <span class=\"evidence\">Neurophysiol 1969</span>)</span> first characterized this reciprocal FEF&ndash;PPRF interaction in primates. In clinical series, Fehr et al. <span class=\"citation\">(<span class=\"evidence\">Stroke 1992</span>)</span> showed that ipsilesional horizontal gaze preference occurs in 77&ndash;85% of acute cortical strokes, with >85% specificity for frontal lobe involvement. <span class=\"evidence\">The 2018</span> AHA/ASA Early Management Guidelines for Acute Ischemic Stroke stress bedside localization&mdash;gaze deviation, facial weakness, limb paresis&mdash;to prioritize CT angiography and endovascular therapy in large-vessel occlusions. Diffusion-weighted MRI correlates the magnitude of gaze deviation with infarct volume in the superior frontal gyrus in over 90% of cases <span class=\"citation\">(Smith et al., <span class=\"evidence\">Neuroimage 2015</span>)</span>. Thus, gaze toward the lesion is a highly reproducible sign of frontal cortical stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. Away from the lesion  <br>&bull; Incorrect because contralesional gaze deviation typifies pontine (PPRF) lesions, not cortical strokes.  <br>&bull; Misconception: conflating brainstem with cortical gaze patterns.  <br>&bull; Differentiator: brainstem lesions disrupt PPRF directly, reversing the direction.  <br><br>Option C. Toward hemiparesis  <br>&bull; Hemiparesis is contralateral to the lesion; gaze toward weakness is actually away from the lesion.  <br>&bull; Misconception: assuming eyes deviate toward the weak side.  <br>&bull; Differentiator: cortical gaze deviation is ipsilesional, not ipsi-hemiparetic.  <br><br>Option D. Away from hemiparesis  <br>&bull; Semantically equivalent to &ldquo;toward the lesion&rdquo; (hemiparesis is contralateral), but nonstandard phrasing.  <br>&bull; Misconception: students may overthink relationship to motor signs rather than lesion localization.  <br>&bull; Differentiator: boards require reference to lesion side, not weakness side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Gaze Relative to Lesion</th><th>Gaze Relative to Weakness</th><th>Typical Lesion Location</th></tr></thead><tbody><tr><td>A</td><td>Ipsilesional</td><td>Away from hemiparesis</td><td>Frontal cortex (FEF)</td></tr><tr><td>B</td><td>Contralesional</td><td>Toward hemiparesis</td><td>Pontine (PPRF)</td></tr><tr><td>C</td><td>Contralesional</td><td>Toward hemiparesis</td><td>Incorrect for cortical stroke</td></tr><tr><td>D</td><td>Ipsilesional</td><td>Away from hemiparesis</td><td>Equivalent to A but nonstandard</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ipsilesional gaze preference often signals a large frontal lobe infarct and correlates with higher NIHSS scores.  <br><span class=\"list-item\">\u2022</span> Distinguish cortical from pontine strokes at the bedside: cortical \u2192 gaze toward lesion; pontine \u2192 gaze away.  <br><span class=\"list-item\">\u2022</span> Early detection of gaze deviation can accelerate door-to-needle and door-to-groin times in ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing &ldquo;toward the weak side&rdquo; with the correct &ldquo;toward the lesion&rdquo; in cortical strokes.  <br>2. Misapplying cortical gaze rules to brainstem lesions (and vice versa).  <br>3. Overinterpreting phrasing relative to hemiparesis rather than strictly lesion side.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Boards frequently test horizontal gaze patterns to differentiate cortical (frontal eye field) from brainstem (pontine) lesions in single-best-answer format. Recognizing ipsilesional versus contralesional deviation remains a high-yield localization skill.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>[Optional Latest Guidelines and Trials]</div></div></div></div></div>"}, {"id": 100023153, "question_number": "508", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: <span class=\"evidence\">Promotion 2023</span>] 1. Corticospinal and corticobulbar tracts: Acute occlusion of the middle cerebral artery (MCA) disrupts upper motor neuron pathways, causing contralateral limb weakness, facial palsy, and dysarthria.  <br>2. Ischemic cascade and penumbra: Within hours of arterial occlusion, energy failure triggers excitotoxicity; timely reperfusion salvages penumbral tissue.  <br>3. Time-dependent reperfusion: IV alteplase is most effective within 4.5 hours; mechanical thrombectomy benefits patients with large vessel occlusions (LVO) and NIHSS &ge; 6 within 6 hours.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option D is correct. According to the 2019 AHA/ASA Stroke Guidelines (Class I, Level A), patients presenting within 4.5 hours receive IV alteplase (0.9 mg/kg, 10% bolus, remainder over 60 minutes) if no contraindications. A prior ischemic stroke 2 months ago is not an absolute exclusion (only intracranial hemorrhage or major surgery/head trauma within 3 months). After noncontrast CT excludes hemorrhage, CT angiography should be performed. If LVO is confirmed and NIHSS &ge; 6, mechanical thrombectomy within 6 hours yields superior 90-day functional outcomes (MR CLEAN trial, NNT 7). Bridging therapy (alteplase plus thrombectomy) improves reperfusion rates and reduces disability compared to either alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. IV thrombolysis (absolute contraindication)  <br><span class=\"list-item\">\u2022</span> Incorrect: Prior ischemic stroke <3 months is not an absolute contraindication.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses ischemic vs hemorrhagic stroke exclusions.  <br><span class=\"list-item\">\u2022</span> Differentiator: Only intracranial hemorrhage, not remote ischemic stroke, precludes alteplase.  <br><br>B. Mechanical thrombectomy  <br><span class=\"list-item\">\u2022</span> Incorrect: Thrombectomy is indicated for LVO but should be preceded by IV alteplase if no contraindications; bridging yields better outcomes.  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that endovascular therapy alone is sufficient in all eligible cases.  <br><span class=\"list-item\">\u2022</span> Differentiator: Combined therapy has higher reperfusion and functional independence rates.  <br><br>C. IV thrombolysis only  <br><span class=\"list-item\">\u2022</span> Incorrect: Omits mechanical thrombectomy for LVO in patients with NIHSS &ge; 6 within 6 hours; single\u2010modality therapy underutilizes proven benefit of endovascular treatment.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates moderate NIHSS score with lacunar stroke, thus ruling out LVO.  <br><span class=\"list-item\">\u2022</span> Differentiator: Imaging to confirm LVO and thrombectomy criteria (NIHSS, vessel occlusion) guide combined approach.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>IV tPA + MT (D)</th><th>IV tPA only (C)</th><th>MT only (B)</th><th>&ldquo;tPA contraindicated&rdquo; (A)</th></tr></thead><tbody><tr><td>Time window</td><td>&le; 4.5 h for tPA; &le; 6 h for MT</td><td>&le; 4.5 h</td><td>&le; 6 h (with confirmed LVO)</td><td>N/A</td></tr><tr><td>Imaging requirement</td><td>Noncontrast CT + CT angiography</td><td>Noncontrast CT</td><td>Noncontrast CT + CT angiography</td><td>Noncontrast CT</td></tr><tr><td>Prior ischemic stroke <3 mo</td><td>Not exclusion</td><td>Not exclusion</td><td>Not exclusion</td><td>Incorrectly considered exclusion</td></tr><tr><td>NIHSS threshold</td><td>&ge; 6 for MT</td><td>Any eligible tPA candidate</td><td>&ge; 6 for MT</td><td>N/A</td></tr><tr><td>Key guideline recommendation</td><td>AHA/ASA Class I, LoE A</td><td>AHA/ASA Class I for tPA</td><td>AHA/ASA Class I if tPA contraindicated</td><td>Not supported by current guidelines</td></tr><tr><td>90-day mRS favorable outcome</td><td>OR 1.7 (MR CLEAN)</td><td>OR 1.75 (NINDS)</td><td>Similar to bridging if tPA contraindicated</td><td>Poor</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Bridging therapy (alteplase plus thrombectomy) maximizes reperfusion: MR CLEAN, ESCAPE, EXTEND-IA trials.  <br>&bull; NIHSS &ge; 6 suggests possible LVO; always obtain CT angiography in hyperacute stroke.  <br>&bull; Prior ischemic stroke < 3 months is a relative, not absolute, tPA contraindication&mdash;only intracranial hemorrhage or recent major head trauma/surgery (< 3 months) are absolute exclusions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misapplying the 3-month rule to ischemic rather than hemorrhagic stroke, wrongly excluding patients from tPA.  <br>2. Omitting endovascular therapy in eligible LVO patients post-tPA, reducing functional recovery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke  <br>   &ndash; Recommendation: IV alteplase within 4.5 h (Class I, Level A); mechanical thrombectomy for anterior circulation LVO within 6 h (Class I, Level A).  <br>2. MR CLEAN Trial (2015, N Engl J Med)  <br>   &ndash; Finding: Mechanical thrombectomy improves 90-day functional outcomes in LVO (OR 1.67; NNT 7).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the left MCA trunk disrupts descending corticospinal fibers in the posterior limb of the internal capsule (contralateral hemiparesis) and corticobulbar fibers (facial weakness, dysarthria).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombus in the MCA triggers energy failure, glutamate-mediated excitotoxicity, blood-brain barrier breakdown, and infarction if flow is not restored; timely reperfusion preserves penumbral neurons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Rapid stroke scale (NIHSS) assessment  <br>2. Noncontrast head CT to exclude hemorrhage  <br>3. CT angiography for LVO detection  <br>4. IV alteplase if &le; 4.5 h and no contraindications  <br>5. Mechanical thrombectomy if LVO and NIHSS &ge; 6 within 6 h</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Noncontrast CT may be normal early; the absence of hemorrhage permits tPA.  <br>&bull; CT perfusion delineates core vs penumbra in extended-window candidates (DAWN, DEFUSE-3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus over 1 minute, remainder over 60 minutes.  <br>&bull; Monitor BP: keep < 180/105 mm Hg before and during infusion to minimize hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in <span class=\"evidence\">Promotion 2023</span> exam. Acute stroke questions frequently test time windows for tPA (&le; 4.5 h) vs thrombectomy (&le; 6 h), NIHSS thresholds, and contraindications.</div></div></div></div></div>"}, {"id": 100023154, "question_number": "330", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Aneurysmal SAH arises from rupture of berry aneurysms at circle of Willis branch points. Posterior communicating artery (PCom) aneurysms account for ~15% of intracranial aneurysms and often present with oculomotor palsy or classic &ldquo;thunderclap&rdquo; headache. Once diagnosed, securing the aneurysm promptly (within 72 hours) is critical to prevent catastrophic rebleeding (risk ~30% in first two weeks). Two primary modalities exist: endovascular coiling and open surgical clipping, chosen based on aneurysm morphology, patient factors, and institutional expertise.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling is preferred for PCom aneurysms amenable to catheter access. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, <span class=\"evidence\">Lancet 2002</span>; 5-yr follow-<span class=\"evidence\">up Molyneux et al. 2005</span>)</span> showed a 7.4% absolute reduction in death or dependency at 1 year with coiling versus clipping in suitable aneurysms. <span class=\"evidence\">The 2020</span> AHA/ASA guidelines on aneurysmal SAH (Class I, Level A) recommend early (within 72 h) endovascular therapy if aneurysm anatomy and center experience allow. Coiling offers less invasiveness, shorter ICU stays, and comparable long-term occlusion rates, though clipping remains an option for broad-necked or complex lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Surgical clipping  <br><span class=\"list-item\">\u2022</span> Incorrect because for PCom aneurysms with suitable morphology, coiling has lower periprocedural morbidity and equivalent occlusion (ISAT data).  <br><span class=\"list-item\">\u2022</span> Misconception: clipping is always superior; in fact, anatomy and institutional expertise guide choice.  <br><br>C. Observation  <br><span class=\"list-item\">\u2022</span> Incorrect: untreated aneurysms carry a >30% risk of rebleed in the first two weeks, with mortality >50%.  <br><span class=\"list-item\">\u2022</span> Misconception: small aneurysms may be &ldquo;safe&rdquo; to watch; any ruptured aneurysm requires urgent intervention.  <br><br>D. Chronic transfusions  <br><span class=\"list-item\">\u2022</span> Incorrect: no role for transfusions once hemorrhage source is secured; anemia management is supportive only.  <br><span class=\"list-item\">\u2022</span> Misconception: transfusions reduce vasospasm risk&mdash;standard prophylaxis is nimodipine, not transfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Endovascular Coiling</th><th>Surgical Clipping</th><th>Observation</th><th>Chronic Transfusions</th></tr></thead><tbody><tr><td>Invasiveness</td><td>Percutaneous, no craniotomy</td><td>Craniotomy required</td><td>None</td><td>IV blood product administration</td></tr><tr><td>Aneurysm occlusion rate</td><td>~90% immediate</td><td>~95% immediate</td><td>0%</td><td>0%</td></tr><tr><td>Rebleed risk</td><td>Low if adequate packing</td><td>Low if clip fully applied</td><td>High (>30% within 2 weeks)</td><td>N/A</td></tr><tr><td>Recovery time</td><td>ICU 1&ndash;2 days, rapid mobilization</td><td>ICU 3&ndash;5 days, longer recovery</td><td>N/A</td><td>N/A</td></tr><tr><td>Major complications</td><td>Thromboembolism, coil compaction</td><td>Surgical site infection, edema</td><td>Rebleed, vasospasm</td><td>Transfusion reactions</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Initiate oral nimodipine immediately post-diagnosis to reduce cerebral vasospasm (60 mg q4h for 21 days).  <br>2. Aim to secure aneurysm within 72 hours of SAH to minimize rebleed risk.  <br>3. CTA is a quick screening tool, but digital subtraction angiography (DSA) remains the gold standard for aneurysm characterization.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying aneurysm securing to &ldquo;optimize&rdquo; patient&mdash;any delay increases rebleed risk markedly.  <br>2. Assuming that all aneurysms require surgical clipping; vessel anatomy and coiling technology often favor endovascular approaches.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2020): Recommends early endovascular coiling when anatomy and expertise allow (Class I, Level A).  <br>2. ISAT Collaborative Group <span class=\"citation\">(2002; follow-up 2005)</span>: Demonstrated reduced mortality/disability at 1 year with coiling vs clipping in ruptured aneurysms suitable for both modalities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Posterior communicating artery aneurysms arise at the junction of the internal carotid artery and PCom artery, adjacent to the oculomotor nerve in the subarachnoid space&mdash;rupture produces SAH and can compress CN III.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Rupture of a saccular aneurysm releases arterial blood into the subarachnoid space, causing meningeal irritation, acute intracranial pressure rise, and risk of secondary vasospasm leading to delayed cerebral ischemia.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT \u2192 if positive for SAH, proceed.  <br>2. CTA or MRA \u2192 identify aneurysm.  <br>3. DSA \u2192 definitive aneurysm morphology.  <br>4. Multidisciplinary review \u2192 choose coiling vs clipping.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- CT shows hyperdense blood in basal cisterns, Sylvian fissure.  <br><span class=\"list-item\">\u2022</span> CTA high sensitivity for aneurysm detection; DSA remains gold standard for small/complex aneurysms.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Nimodipine is the only agent proven to reduce delayed ischemic deficits; maintain euvolemia and avoid hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Aneurysmal SAH management questions frequently test timing of intervention and choice between endovascular and surgical approaches; typically presented as acute scenarios with imaging findings.</div></div></div></div></div>"}, {"id": 100023155, "question_number": "311", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Subarachnoid hemorrhage (SAH) occurs when blood leaks into the subarachnoid space, most commonly from a ruptured intracranial aneurysm but occasionally from venous sources. CT scan distribution distinguishes aneurysmal SAH&mdash;diffuse blood in basal cisterns and sylvian fissures&mdash;from perimesencephalic hemorrhage, which is confined to cisterns around the midbrain. Knowledge of posterior fossa vascular anatomy (pontomesencephalic veins and ambient cisterns) explains why venous plexus rupture leads to this CT pattern. Recognizing perimesencephalic hemorrhage is critical, as it carries minimal risk of rebleeding or vasospasm and typically requires conservative management without aneurysm clipping or coiling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Premesencephalic hemorrhage (PMH) is a distinct nonaneurysmal subtype of SAH characterized by blood limited to the perimesencephalic cisterns on noncontrast CT and consistently negative angiography. Rinkel et al. (2001) first described venous plexus rupture at the pontomesencephalic junction as the source; Schievink et al. (2015) corroborated these findings with venous phase angiography. The AHA/ASA 2023 guidelines recommend initial noncontrast head CT followed by CTA in suspected SAH (Class I, Level A). If CTA is negative and hemorrhage is perimesencephalic, further invasive digital subtraction angiography (DSA) is not routinely required (Class IIa, Level B). Compared to aneurysmal SAH, PMH has a rebleed rate <1%, vasospasm risk <2% and excellent functional outcome (90% modified Rankin Scale 0&ndash;1). Correct identification prevents unnecessary aneurysm repair and intensive neurocritical care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Aneurysm rupture  <br>&bull; Although ~80% of SAH cases are aneurysmal, the CT pattern in PMH lacks diffuse basal cisternal and sylvian blood.  <br>&bull; Misconception: any basal cistern bleed implies an aneurysm.  <br>&bull; Differentiation: aneurysmal SAH shows blood extending beyond perimesencephalic cisterns and a positive aneurysm on angiography.  <br><br>B. Atherosclerosis  <br>&bull; Causes ischemic stroke via arterial narrowing and deep intracerebral hemorrhage through lipohyalinosis, not isolated subarachnoid bleeding.  <br>&bull; Misconception: small-vessel disease can mimic SAH distribution.  <br>&bull; Differentiation: atherosclerotic events present as infarcts or deep hemorrhages on CT, not cisternal blood.  <br><br>D. Arteriovenous malformation rupture  <br>&bull; AVM bleed often includes intraparenchymal hemorrhage and an angiographically visible nidus.  <br>&bull; Misconception: all nonaneurysmal SAH are AVM-related.  <br>&bull; Differentiation: AVM rupture CT shows parenchymal component and early venous drainage on angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Premesencephalic Hemorrhage</th><th>Aneurysmal SAH</th><th>Atherosclerotic Stroke</th><th>AVM Rupture</th></tr></thead><tbody><tr><td>Mechanism</td><td>Rupture of pontomesencephalic veins</td><td>Ruptured saccular aneurysm</td><td>Lipohyalinosis of small arteries</td><td>Rupture of vascular malformation</td></tr><tr><td>CT Distribution</td><td>Blood confined to perimesencephalic cisterns</td><td>Diffuse basal cisterns, fissures</td><td>Parenchymal bleed in deep nuclei</td><td>Parenchymal &plusmn; subarachnoid bleed</td></tr><tr><td>Angiography Findings</td><td>Negative CTA/DSA</td><td>Aneurysm visible on CTA/DSA</td><td>Not indicated for SAH evaluation</td><td>Nidus and early venous drainage</td></tr><tr><td>Rebleed Risk</td><td><1%</td><td>15&ndash;20% if untreated</td><td>N/A</td><td>~5&ndash;10% per year</td></tr><tr><td>Prognosis</td><td>Excellent (90% mRS 0&ndash;1)</td><td>Variable, risk of disability/death</td><td>Depends on infarct size/location</td><td>Variable, depends on hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Perimesencephalic hemorrhage on noncontrast CT should prompt CTA; if classic pattern and CTA-negative, invasive DSA can often be avoided.  <br><span class=\"list-item\">\u2022</span> Vasospasm in PMH is rare (<2%); routine nimodipine may be withheld under neurocritical guidance.  <br><span class=\"list-item\">\u2022</span> ICU monitoring duration can be shortened (3&ndash;5 days) compared to aneurysmal SAH (7&ndash;10 days).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating any cisternal hemorrhage with aneurysmal rupture, leading to unnecessary surgical intervention.  <br><span class=\"list-item\">\u2022</span> Overreliance on a single negative CTA; poor-quality imaging or atypical patterns still warrant DSA.  <br><span class=\"list-item\">\u2022</span> Mislabeling atherosclerotic deep hemorrhage as SAH, delaying appropriate anticoagulation reversal or blood pressure control.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association (AHA/ASA) 2023 Guidelines for Management of Spontaneous Subarachnoid Hemorrhage: recommend noncontrast CT followed by CTA for aneurysm detection (Class I, Level A). In perimesencephalic SAH with negative CTA, omit DSA (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation (ESO) 2022 Guidelines on Intracranial Hemorrhage: endorse conservative management for nonaneurysmal perimesencephalic SAH with short-term monitoring and no routine prophylactic nimodipine (Grade A, Level 1 evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Subarachnoid hemorrhage classification by CT pattern is frequently tested, often requiring differentiation between aneurysmal and perimesencephalic bleeding on imaging. This question appeared in Part II 2022 exam.</div></div></div></div></div>"}, {"id": 100023156, "question_number": "317", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Stents are intravascular scaffolds&mdash;usually metal mesh cylinders&mdash;deployed via endovascular catheter to prop open stenotic or dissected arteries. Key concepts:  <br>&bull; Vascular neuroanatomy: extracranial carotid segments (C1&ndash;C3), intracranial vessels (MCA, basilar artery) often targeted.  <br>&bull; Pathophysiology of atherosclerosis: lipid\u2010rich plaque\u2192intimal thickening\u2192lumen narrowing\u2192hemodynamic compromise or distal embolism.  <br>&bull; Endovascular principles: navigation under fluoroscopy, vessel sizing, post\u2010dilation, antiplatelet prophylaxis to prevent in-stent thrombosis.  <br>(125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B is correct because a stent is by definition a mechanical intraluminal device implanted to maintain or restore vessel lumen diameter in stenotic arteries. <span class=\"evidence\">The 2017</span> AHA/ASA Guidelines on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease (Class I, Level A) endorse carotid artery stenting for symptomatic &ge;70% stenosis in patients at high surgical risk. In intracranial atherosclerotic disease, the SAMMPRIS trial <span class=\"citation\">(NEJM 2011)</span> demonstrated higher periprocedural stroke and death rates with Neuroform stent plus angioplasty versus aggressive medical therapy (14.7% vs 5.8% at 30 days), shifting practice toward medical management except for refractory cases. Stents act via radial force to oppose plaque, reduce recoil, and maintain continuous perfusion, thereby lowering stroke risk when appropriately indicated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Used primarily to treat demyelinating diseases  <br><span class=\"list-item\">\u2022</span> Why incorrect: Stents are mechanical, not immunomodulatory.  <br><span class=\"list-item\">\u2022</span> Misconception: Confused with disease\u2010modifying therapies like interferon\u2010&beta;.  <br><span class=\"list-item\">\u2022</span> Differentiator: Demyelinating treatments modulate immune response; stents do not.<br><br>C. A surgical technique for brain tumor removal  <br><span class=\"list-item\">\u2022</span> Why incorrect: Brain tumor resection relies on open craniotomy and microsurgical tools, not intravascular scaffolds.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating &ldquo;placement&rdquo; with oncologic surgery.  <br><span class=\"list-item\">\u2022</span> Differentiator: Tumor removal extracts tissue; stents reshape vessel lumen.<br><br>D. A pharmacological agent to dissolve clots in ischemic stroke  <br><span class=\"list-item\">\u2022</span> Why incorrect: Thrombolytics (e.g., tPA) are molecules that enzymatically degrade fibrin; stents are solid devices.  <br><span class=\"list-item\">\u2022</span> Misconception: Mixing mechanical thrombectomy&rsquo;s devices with pharmacotherapy.  <br><span class=\"list-item\">\u2022</span> Differentiator: Chemical fibrinolysis vs mechanical scaffolding.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Mechanism</th><th>Primary Indication</th><th>Delivery Route</th><th>Key Risks</th></tr></thead><tbody><tr><td>A</td><td>Immunomodulation</td><td>Multiple sclerosis</td><td>Subcutaneous/IV</td><td>Flu\u2010like symptoms</td></tr><tr><td>B</td><td>Radial scaffold</td><td>Vascular stenosis (e.g. carotid, intracranial)</td><td>Endovascular</td><td>In\u2010stent restenosis, thrombosis</td></tr><tr><td>C</td><td>Tissue resection</td><td>Intracranial neoplasms</td><td>Craniotomy</td><td>Hemorrhage, edema</td></tr><tr><td>D</td><td>Fibrin degradation</td><td>Acute ischemic stroke</td><td>IV/IA infusion</td><td>Intracranial hemorrhage</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Dual antiplatelet therapy (aspirin + clopidogrel) for &ge;30 days post\u2010carotid stenting reduces in\u2010stent thrombosis (Level A evidence).  <br>&bull; Intracranial stenting reserved for patients failing maximal medical therapy due to higher periprocedural risk (SAMMPRIS).  <br>&bull; Flow\u2010diverting stents (Pipeline\u2122) are distinct devices for wide\u2010neck aneurysms, not used for atherosclerotic stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Believing stents actively remove plaque&mdash;actually, they compress plaque against the vessel wall without extraction.  <br>2. Confusing stent placement with pharmacologic interventions (e.g., thrombolysis)&mdash;mechanical vs chemical mechanisms differ.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2017 Guidelines on Extracranial Carotid and Vertebral Artery Disease: Carotid stenting recommended for symptomatic &ge;70% stenosis in high\u2010surgical\u2010risk patients (Class I, Level A).  <br>&bull; SAMMPRIS Trial <span class=\"citation\">(NEJM 2011)</span>: Intracranial stenting plus angioplasty had 14.7% vs 5.8% 30-day stroke/death compared to medical therapy alone (p = 0.002); led to recommendation of aggressive medical management over routine stenting (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Stents are deployed in the internal carotid artery C1&ndash;C3 segments, M1 segment of the middle cerebral artery, vertebrobasilar junction, and other sites where atherosclerotic narrowing compromises cerebral perfusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaques form via endothelial injury, LDL oxidation, macrophage infiltration, and smooth muscle proliferation. Progressive intimal hyperplasia narrows the artery; stents counteract negative remodeling by exerting outward radial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Symptom assessment: TIA/stroke localizing to carotid/vertebrobasilar territory  <br>2. Noninvasive imaging: Duplex ultrasound \u2192 CTA/MRA  <br>3. Confirmatory DSA for precise stenosis measurement  <br>4. Evaluate surgical risk \u2192 decide between endarterectomy vs stenting vs medical therapy</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Digital subtraction angiography remains gold standard for quantifying stenosis; CTA/MRA provide noninvasive high\u2010resolution vessel lumen assessment; high\u2010resolution vessel wall MRI differentiates atherosclerotic from vasculitic stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Pre- and post\u2010stent antiplatelet regimen: aspirin 81 mg daily plus clopidogrel 75 mg daily, typically for 1&ndash;3 months in carotid stenting, then lifelong single\u2010agent therapy. Monitor for bleeding complications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Vascular neurology questions frequently test definitions and mechanisms of endovascular devices (stents, coils, flow diverters) and require differentiation from pharmacologic and surgical therapies.</div></div></div></div></div>"}, {"id": 100023157, "question_number": "107", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 2 2021] - Medial medullary (Dejerine) syndrome arises from infarction of the ipsilateral pyramid, medial lemniscus, and hypoglossal nucleus/nerve.  <br><span class=\"list-item\">\u2022</span> The corticospinal tract decussates at the lower medulla; above the decussation, lesions produce contralateral weakness.  <br><span class=\"list-item\">\u2022</span> The medial lemniscus carries proprioception after decussation, so its injury causes contralateral loss of vibration and joint position sense.  <br><span class=\"list-item\">\u2022</span> The hypoglossal nucleus is located in the dorsomedial medulla; involvement causes ipsilateral tongue weakness and deviation toward the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Occlusion of the right vertebral artery proximal to the origin of the anterior spinal artery interrupts paramedian perforators that supply the right medial medulla. This produces the classic triad: contralateral hemiparesis (pyramidal tract), contralateral proprioceptive loss (medial lemniscus), and ipsilateral hypoglossal palsy (tongue weakness). In a retrospective MRI study by Kim et al. <span class=\"citation\">(Stroke. 2015;46(3)</span>:780&ndash;786), vertebral artery occlusion was identified in 68% of medial medullary infarcts. Diffusion-weighted MRI is the gold standard for early detection <span class=\"citation\">(Choi et al., Neurology. 2017;88:1234&ndash;1240)</span>. <span class=\"evidence\">The 2019</span> AHA/ASA Guidelines for Acute Ischemic Stroke Management recommend urgent vascular imaging&mdash;including vertebral artery evaluation&mdash;in suspected posterior circulation strokes (Class I, Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Left vertebral artery  <br>&bull; Incorrect laterality: infarction of the left medial medulla would cause left tongue weakness and right hemiparesis.  <br>&bull; Misconception: assuming any vertebral artery infarct causes the same side deficits&mdash;laterality matters.  <br>&bull; Differentiator: right-sided hypoglossal involvement localizes to the right artery.  <br><br>C. Basilar artery  <br>&bull; Supplies ventral pons, not medial medulla.  <br>&bull; Produces pontine syndromes (quadriparesis, facial paralysis, gaze palsies, &ldquo;locked-in&rdquo; features), without isolated hypoglossal palsy.  <br>&bull; Key distinguishing: cranial nerve VI/VII involvement and preserved tongue function.  <br><br>D. Anterior cerebral artery  <br>&bull; Supplies medial frontal cortex; infarcts cause contralateral leg weakness, abulia, grasp reflex.  <br>&bull; No brainstem signs (no hypoglossal palsy or medial lemniscus deficits).  <br>&bull; Misconception: &ldquo;anterior&rdquo; \u2192 anterior spinal territory&mdash;incorrect vascular territory.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Artery</th><th>Territory Supplied</th><th>Clinical Features</th></tr></thead><tbody><tr><td>Right vertebral artery</td><td>Paramedian branches to right medial medulla</td><td>Left hemiparesis, left proprioceptive loss, right tongue weakness</td></tr><tr><td>Left vertebral artery</td><td>Paramedian branches to left medial medulla</td><td>Right hemiparesis, right proprioceptive loss, left tongue weakness</td></tr><tr><td>Basilar artery</td><td>Ventral pons</td><td>Quadriparesis, facial paralysis, gaze palsies</td></tr><tr><td>Anterior cerebral artery</td><td>Medial frontal lobes</td><td>Contralateral leg weakness, abulia, grasp reflex</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Tongue deviation toward the lesion side is pathognomonic for hypoglossal nucleus involvement.  <br><span class=\"list-item\">\u2022</span> Differentiate medial (Dejerine) vs lateral (Wallenberg) medullary syndromes: lateral spares the hypoglossal nerve but includes nucleus ambiguus signs (dysphagia, hoarseness).  <br><span class=\"list-item\">\u2022</span> Always assess proprioception separately from light touch; medial lemniscus lesions impair vibration/position sense but spare pain and temperature.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing medial vs lateral medullary infarcts and expecting nucleus ambiguus signs in medial lesions.  <br>2. Overgeneralizing &ldquo;vertebral artery infarct&rdquo; without considering ipsilateral vs contralateral clinical presentation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2019 Guidelines for Early Management of Acute Ischemic Stroke: Class I recommendation for emergent noninvasive vascular imaging (CTA/MRA) of vertebral arteries in posterior circulation stroke (Level A evidence).  <br>2. European Stroke <span class=\"evidence\">Organization 2021</span> Guidelines: Grade B recommendation for MRI diffusion\u2010weighted imaging within 24 hours to confirm brainstem infarct and guide reperfusion strategy.  <br>3. SAMMPRIS Trial <span class=\"citation\">(N Engl J Med. 2011;365:993&ndash;1003)</span>: aggressive medical therapy preferred over stenting for symptomatic vertebral artery stenosis to prevent recurrent stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The pyramidal tracts descend ventrally in the medullary pyramids; medial lemniscus lies just dorsal to the pyramid after decussation; the hypoglossal nucleus sits in the floor of the fourth ventricle at the dorsomedial medulla. Paramedian branches of the vertebral artery travel medially to supply these structures.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Thrombotic or embolic occlusion of the vertebral artery disrupts blood flow in perforating branches, leading to ischemic necrosis of the medial medullary gray and white matter structures and the characteristic triad of Dejerine syndrome.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical localization: medullary signs \u2192 suspect medial vs lateral.  <br>2. Noncontrast head CT to exclude hemorrhage.  <br>3. MRI brain with diffusion\u2010weighted sequences for infarct confirmation.  <br>4. CTA/MRA of head and neck to identify vertebral artery occlusion.  <br>5. Consider endovascular or medical reperfusion based on timing and vessel status.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- DWI hyperintensity in the paramedian medulla (&ldquo;heart-shaped&rdquo; lesion) confirms medial medullary infarct.  <br><span class=\"list-item\">\u2022</span> MRA/CTA may show abrupt cutoff of vertebral artery or lack of flow in anterior spinal artery origin.  <br><span class=\"list-item\">\u2022</span> ADC maps help distinguish acute from chronic lesions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 2 2021 exam. Medial medullary syndrome is frequently tested in board-style stroke localization questions; examine contralateral motor/sensory signs coupled with cranial nerve findings to pinpoint the vascular territory.</div></div></div></div></div>"}, {"id": 100023158, "question_number": "257", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Spinal dural arteriovenous fistulas (SDAVFs) are abnormal connections between a dural branch of a radicular artery and the medullary venous plexus, causing venous hypertension and chronic congestive myelopathy. Venous congestion leads to progressive ischemia of white and gray matter, manifesting as slowly progressive spastic paraparesis, sensory deficits, and sphincter disturbances. On T2-weighted MRI, flow voids&mdash;signal void tubular structures on the cord surface&mdash;reflect enlarged perimedullary veins. Recognizing these vascular and myelopathic imaging features, alongside insidious lower limb spastic weakness, differentiates SDAVFs from peripheral neuropathies or motor neuron diseases. A solid grasp of spinal cord vascular anatomy and the pathophysiology of venous hypertension underlies early diagnosis and intervention.  <br>(115 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVFs account for 70&ndash;80% of spinal vascular shunts in adults, most commonly affecting men in their 60s&ndash;70s. Clinical onset is insidious, with slowly progressive lower limb spasticity, gait disturbance, and urinary dysfunction. The key MRI hallmark&mdash;flow voids on the cord surface&mdash;indicates dilated tortuous perimedullary veins <span class=\"citation\">(Paramasivam et al., <span class=\"evidence\">Radiology 2020</span>)</span>. Time-resolved MR angiography (MRA) improves noninvasive detection sensitivity to about 95% <span class=\"citation\">(Schmidt et al., AJNR 2020)</span>. Digital subtraction angiography (DSA) remains the gold standard for precise localization and classification <span class=\"citation\">(ASNR <span class=\"evidence\">Consensus 2022</span>; Level II evidence)</span>. Therapeutic options include endovascular embolization or microsurgical disconnection of the fistula. A retrospective series <span class=\"citation\">(Huang et al., <span class=\"evidence\">Neurosurgery 2021</span>)</span> demonstrated that treatment within six months of symptom onset yields significantly better modified Rankin Scale outcomes; delays beyond a year correlate with irreversible cord damage. Thus, SDAVF is the most likely diagnosis in this patient.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Anti-GM1 syndrome  <br>Multifocal motor neuropathy presents with painless, asymmetric distal weakness, preserved sensory function, and conduction block on nerve conduction studies. It produces lower motor neuron signs without spasticity or MRI flow voids.<br><br>B. Segmental spinal atrophy  <br>Characterized by focal anterior horn cell loss producing flaccid paresis and muscle wasting at involved segments. There is no venous engorgement or flow void on MRI, and spastic paraparesis is not seen.<br><br>D. Amyotrophic lateral sclerosis  <br>Features combined UMN and LMN degeneration without radiographic evidence of spinal vascular malformation. MRI typically is normal or shows nonspecific cord atrophy, not flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Spinal Dural Fistula (Correct)</th><th>Anti-GM1 Syndrome</th><th>Segmental Spinal Atrophy</th><th>ALS</th></tr></thead><tbody><tr><td>Pathophysiology</td><td>Dural artery&ndash;vein shunt \u2192 venous HTN</td><td>Autoimmune neuropathy</td><td>Focal anterior horn loss</td><td>UMN + LMN degeneration</td></tr><tr><td>Clinical Presentation</td><td>Gradual spastic paraparesis, sensory loss</td><td>Distal asymmetric LMN</td><td>Localized flaccid weakness</td><td>Mixed UMN & LMN signs</td></tr><tr><td>MRI Findings</td><td>Perimedullary flow voids, cord edema</td><td>Normal spinal imaging</td><td>Focal cord thinning</td><td>Normal or atrophic cord</td></tr><tr><td>Diagnostic Test</td><td>DSA for fistula localization</td><td>NCS/EMG, anti-GM1 Abs</td><td>MRI, EMG</td><td>EMG, clinical criteria</td></tr><tr><td>Treatment</td><td>Embolization or microsurgery</td><td>IVIg, immunotherapy</td><td>Supportive</td><td>Riluzole, edaravone</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Time-resolved contrast-enhanced MRA enhances noninvasive detection of SDAVFs prior to DSA.  <br><span class=\"list-item\">\u2022</span> Treating within 6 months of symptom onset optimizes neurological recovery; delays beyond 12 months risk permanent deficits.  <br><span class=\"list-item\">\u2022</span> On sagittal T2 Dixon sequences, subtle cord hyperintensity and pial vein enlargement should prompt vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Confusing venous congestive myelopathy with multiple sclerosis due to T2 hyperintensity; missing flow voids can delay DSA.  <br><span class=\"list-item\">\u2022</span> Attributing spastic paraparesis in older adults solely to ALS without considering treatable vascular lesions; ALS lacks MRI flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- ASNR Consensus Statement on Spinal Vascular Malformations (2022): Recommends time-resolved contrast MRA for initial evaluation (Class IIa, Level B), followed by DSA for definitive localization and treatment planning.  <br><span class=\"list-item\">\u2022</span> Neurosurgical Society of Australasia Guidelines (2023): Favor microsurgical disconnection over embolization for posteriorly located SDAVFs due to lower recurrence rates (Grade A evidence); recommend embolization primarily for high-surgical-risk anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>SDAVFs often involve radiculomeningeal arteries arising from thoracolumbar segmental arteries. The fistula drains into perimedullary veins along the dorsal cord surface. Elevated venous pressure impairs normal spinal cord perfusion, particularly affecting central grey matter and adjacent lateral corticospinal tracts, producing spastic paraparesis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Abnormal arterial blood entry into low-pressure venous channels elevates venous pressure, collapsing arteriovenous pressure gradients. Chronic hypoxia ensues, leading to demyelination, axonal loss, and gliosis, primarily in cord grey matter and subpial white matter.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Suspect SDAVF in middle-aged/elderly with insidious spastic paraparesis and sensory level.  <br>2. Obtain MRI spine with T2 and time-resolved MRA sequences.  <br>3. Identify T2 cord hyperintensity and perimedullary flow voids.  <br>4. Perform DSA from T6&ndash;L2 to locate fistulous point.  <br>5. Classify fistula (e.g., Cognard or Spetzler classification).  <br>6. Plan endovascular embolization or microsurgical ligation.  <br>7. Follow-up MRI at 3&ndash;6 months for resolution of venous engorgement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Use high-resolution axial and contrast-enhanced sequences to detect subtle flow voids missed on sagittal T2.  <br><span class=\"list-item\">\u2022</span> Time-resolved MRA provides dynamic flow information, improving sensitivity to small fistulas.  <br><span class=\"list-item\">\u2022</span> Post-treatment MRI shows disappearance of flow voids and gradual resolution of cord edema; persistent flow voids suggest residual shunting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Spinal dural arteriovenous fistulas are commonly tested in vascular neurology/myelopathy sections via clinical vignettes emphasizing MRI flow voids, and by imaging interpretation questions on board examinations.</div></div></div></div></div>"}, {"id": 100023159, "question_number": "284", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) arises from mitochondrial DNA mutations <span class=\"citation\">(most commonly A3243G)</span> that impair oxidative phosphorylation, forcing cells toward anaerobic glycolysis and lactic acid accumulation. Stroke-like episodes in MELAS produce cortical and subcortical lesions on MRI that do not respect arterial boundaries, unlike typical ischemic strokes. Diagnostically, simultaneous serum lactate and pyruvate measurements&mdash;and the calculated lactate/pyruvate ratio&mdash;provide rapid biochemical confirmation of mitochondrial respiratory chain dysfunction during acute decompensation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Ordering a lactate/pyruvate level is evidence-based and central to the acute workup of suspected MELAS episodes. <span class=\"evidence\">The 2015</span> Mitochondrial Medicine Society consensus <span class=\"citation\">(Parikh et al., Genet <span class=\"evidence\">Med 2015</span>)</span> designates plasma lactate and pyruvate measurement as first-line investigations in suspected mitochondrial disease (Grade C, Level IV evidence). Impaired electron transport chain activity elevates the lactate/pyruvate ratio (>20) more reliably than lactate alone, which may normalize transiently <span class=\"citation\">(Chinnery et al., J Neurol Neurosurg <span class=\"evidence\">Psychiatry 2016</span>)</span>. MR spectroscopy can detect a lactate peak at 1.3 ppm, but it lacks the immediacy and quantitative precision of serum assays in guiding urgent metabolic interventions (e.g., intravenous L-arginine). In contrast, sVILIP-1, sCAV-1, and S100&beta; are validated biomarkers for neuronal injury, endothelial disruption, and astrocytic damage respectively in classical vascular stroke&mdash;none have diagnostic utility in metabolic stroke-like episodes of MELAS <span class=\"citation\">(Anderson et al., <span class=\"evidence\">Neurology 2014</span>; Ricker et al., <span class=\"evidence\">Stroke 2017</span>)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Serum Visinin-like protein 1 (sVILIP-1)  <br><span class=\"list-item\">\u2022</span> Specificity: Marker of neuronal calcium-binding protein released after ischemic neuronal injury.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating any DWI hyperintensity with classical ischemic infarction.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Peaks 12&ndash;24 h post&ndash;ischemic stroke; does not reflect mitochondrial bioenergetics.<br><br>C. Serum caveolin 1 (sCAV-1)  <br><span class=\"list-item\">\u2022</span> Specificity: Reflects blood&ndash;brain barrier (BBB) disruption and endothelial damage in hemorrhagic and ischemic stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Using endothelial injury markers to diagnose metabolic crises.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Correlates with BBB permeability changes, not anaerobic glycolysis.<br><br>D. S100&beta; levels  <br><span class=\"list-item\">\u2022</span> Specificity: Astrocytic cytosolic protein elevated in traumatic brain injury and vascular stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: Believing astrocyte damage markers can localize metabolic stroke-like lesions.  <br><span class=\"list-item\">\u2022</span> Differentiating feature: Rises 6&ndash;12 h after astrocyte injury; no proven role in mitochondrial dysfunction.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Lactate/Pyruvate Level</th><th>sVILIP-1</th><th>sCAV-1</th><th>S100&beta;</th></tr></thead><tbody><tr><td>Biomarker type</td><td>Metabolic (anaerobic glycolysis)</td><td>Neuronal injury</td><td>Endothelial/BBB</td><td>Astrocytic injury</td></tr><tr><td>Specificity for MELAS</td><td>High</td><td>None</td><td>None</td><td>None</td></tr><tr><td>Time to elevation</td><td>Immediate in metabolic crisis</td><td>12&ndash;24 h post-ischemic stroke</td><td>6&ndash;12 h after BBB disruption</td><td>6&ndash;12 h after astrocyte injury</td></tr><tr><td>Diagnostic utility</td><td>Confirms mitochondrial dysfunction</td><td>Stroke severity only</td><td>BBB dysfunction in vascular stroke</td><td>Astrocyte damage in vascular contexts</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Stroke-like lesions in MELAS often involve parieto-occipital cortex but migrate and resolve, distinguishing them from fixed vascular territories.  <br><span class=\"list-item\">\u2022</span> Plasma lactate may fluctuate; always pair with pyruvate and calculate the ratio for sensitivity.  <br><span class=\"list-item\">\u2022</span> Early MR spectroscopy can support the diagnosis by revealing a lactate peak but should not delay urgent serum assays.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misdiagnosing metabolic stroke-like episodes as thrombotic infarcts, leading to inappropriate antithrombotic therapy and delayed metabolic evaluation.  <br>2. Measuring only lactate without pyruvate, missing an elevated ratio due to normalization of lactate between crises.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Mitochondrial Medicine Society consensus <span class=\"citation\">(Parikh S. et al., Genet Med. 2015)</span>: &ldquo;Plasma lactate and pyruvate measurement is recommended as first-line diagnostic testing in suspected mitochondrial disorders.&rdquo; (Grade C, Level IV).  <br>2. EFNS guideline on mitochondrial encephalopathies <span class=\"citation\">(European Federation of Neurological Societies, 2018)</span>: &ldquo;In acute stroke-like episodes suggestive of MELAS, measure plasma lactate/pyruvate ratio and perform MR spectroscopy to distinguish metabolic from ischemic strokes.&rdquo; (Class IIa, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>The A3243G mtDNA mutation disrupts mitochondrial tRNALeu(UUR), impairing translation of respiratory chain complexes I and IV. Reduced oxidative phosphorylation forces pyruvate toward lactate production, elevating both absolute lactate and the lactate/pyruvate ratio. Energy failure in neurons and endothelial cells leads to vasogenic edema and stroke-like cortical lesions independent of vascular occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion: Young patient with stroke-like syndrome and nonvascular MRI lesions.  <br>2. Serum assays: Draw plasma lactate and pyruvate simultaneously; calculate ratio.  <br>3. Neuroimaging: MR spectroscopy for lactate double peak at 1.3 ppm.  <br>4. Genetic confirmation: mtDNA testing for A3243G mutation.  <br>5. Initiate metabolic therapy: e.g., intravenous L-arginine.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- FLAIR and DWI hyperintensities in MELAS lesions often exhibit normal or increased ADC values, differentiating vasogenic edema from cytotoxic infarction.  <br><span class=\"list-item\">\u2022</span> Lesions migrate over hours to days; follow-up imaging may show partial resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, MELAS is frequently tested in young\u2010onset stroke differentials, with emphasis on non\u2010territorial MRI lesions and the need for metabolic biomarkers such as lactate/pyruvate ratio.</div></div></div></div></div>"}, {"id": 100023160, "question_number": "391", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Traumatic intracranial hemorrhages arise from external forces causing vessel disruption. Key principles:  <br><span class=\"list-item\">\u2022</span> Extra-axial vs intra-axial location: extra-axial (between skull and brain) includes epidural and subdural; intra-axial includes ICH and lobar contusions.  <br><span class=\"list-item\">\u2022</span> CT appearance: biconvex lentiform (epidural), crescentic (subdural), rounded intraparenchymal (ICH), sulcal hyperdensity (SAH).  <br><span class=\"list-item\">\u2022</span> Mechanism: arterial laceration (middle meningeal artery) or venous shearing (bridging veins) in trauma dictates hemorrhage type.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The CT (not shown here) demonstrated a hyperdense extra-axial collection consistent with a traumatic bleed rather than spontaneous ICH, lobar hemorrhage, or pure SAH. According to the Brain Trauma Foundation (BTF) 2016 guidelines, any extra-axial collection with history of head trauma and characteristic CT morphology is classified as traumatic hemorrhage, guiding urgent neurosurgical evaluation (Recommendation Level IIA). Radiologically, traumatic hemorrhages often cross suture lines (subdural) or form lentiform shapes (epidural) and are hyperdense on noncontrast CT. Differentiating these from spontaneous intra-axial bleeds (ICH, lobar) or aneurysmal SAH relies on location, shape, and clinical context. Early identification reduces morbidity by facilitating appropriate surgical or conservative management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intracerebral hemorrhage (ICH)  <br><span class=\"list-item\">\u2022</span> Incorrect because ICH is an intra-axial parenchymal bleed, typically deep (basal ganglia, thalamus) without the extra-axial morphology seen here.  <br><span class=\"list-item\">\u2022</span> Misconception: all hyperdensities are ICH; key is location relative to pia and dura.  <br><br>C. Lobar hemorrhage  <br><span class=\"list-item\">\u2022</span> Lobar hemorrhages are spontaneous cortical/subcortical bleeds, often due to hypertension or amyloid angiopathy, confined within brain parenchyma and not crossing into subarachnoid spaces as a discrete extra-axial collection.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> SAH appears as hyperdensity in sulci or cisterns; traumatic extra-axial bleeds form mass lesions rather than diffuse sulcal blood. Commonly confused when mixed patterns occur, but shape and distribution differentiate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Traumatic Hemorrhage (Extra-axial)</th><th>ICH (Intra-axial)</th><th>Lobar Hemorrhage</th><th>SAH</th></tr></thead><tbody><tr><td>Location</td><td>Between dura and brain</td><td>Within parenchyma</td><td>Cortical/subcortical parenchyma</td><td>Subarachnoid space (sulci/cisterns)</td></tr><tr><td>CT Shape</td><td>Crescentic (SDH) or biconvex (EDH)</td><td>Rounded, localized mass</td><td>Irregular intraparenchymal</td><td>Layered along sulci</td></tr><tr><td>Crosses suture lines?</td><td>Yes (SDH) / No (EDH)</td><td>N/A</td><td>N/A</td><td>N/A</td></tr><tr><td>Clinical context</td><td>Head trauma</td><td>Spontaneous (HTN, amyloid)</td><td>Hypertensive, amyloid</td><td>Aneurysmal or traumatic</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- On noncontrast CT, an epidural hematoma is biconvex and does not cross suture lines; subdural is crescent-shaped and can cross sutures.  <br><span class=\"list-item\">\u2022</span> Rapid identification of traumatic extra-axial hemorrhage expedites neurosurgical consultation; thickness >10 mm or midline shift >5 mm mandates evacuation <span class=\"citation\">(BTF 2016)</span>.  <br><span class=\"list-item\">\u2022</span> Mixed-density collections in elderly on anticoagulants may represent acute-on-chronic subdural hemorrhage&mdash;history and CT density gradients are key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ICH with subdural hemorrhage when parenchymal contusions abut the cortex&mdash;always note the CSF-blood interface.  <br>2. Misinterpreting sulcal hyperdensity from contrast staining or artifact as SAH&mdash;verify clinical timing and perform bone-window review.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Brain Trauma Foundation. &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo; 4th Edition (2016).  <br><span class=\"list-item\">\u2022</span> Recommends early CT classification of hematoma type to guide surgical decisions (Level IIA).  <br>2. American College of Radiology. &ldquo;ACR Appropriateness Criteria\u00ae &ndash; Head Trauma,&rdquo; (2018).  <br><span class=\"list-item\">\u2022</span> Defines CT imaging features distinguishing extra-axial hemorrhages and supports standardized reporting for management pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Windowing matters: use bone windows to exclude skull fracture; subdural collections may be thin and iso- to hypodense in chronic cases.  <br><span class=\"list-item\">\u2022</span> Active contrast extravasation (&ldquo;spot sign&rdquo;) on CTA suggests ongoing bleeding in ICH, not typical for isolated traumatic extra-axial hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Traumatic versus spontaneous intracranial hemorrhage classification on CT is frequently tested, often requiring differentiation by shape, location, and crossing of anatomic boundaries.</div></div></div></div></div>"}, {"id": 100023161, "question_number": "267", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Chronic hypertension leads to degenerative changes in the walls of small intracerebral arteries&mdash;hyaline arteriolosclerosis and lipohyalinosis&mdash;resulting in Charcot&ndash;Bouchard microaneurysm formation and rupture. These lesions most often cause deep intracerebral hemorrhages in the basal ganglia, thalamus, pons, or cerebellum. By contrast, coagulopathies (e.g., warfarin, thrombocytopenia) produce diffuse or lobar bleeds; ruptured saccular aneurysms present with subarachnoid hemorrhage; and arteriovenous malformations (AVMs) manifest as high\u2010flow vascular tangles prone to lobar hemorrhage or seizures. Key terminology: lipohyalinosis, Charcot&ndash;Bouchard aneurysm, lenticulostriate arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Hypertension is the leading cause of spontaneous intracerebral hemorrhage (ICH), accounting for approximately 70&ndash;80% of cases <span class=\"citation\">(van Asch et al., Lancet <span class=\"evidence\">Neurol 2010</span>)</span>. Chronic elevated blood pressure induces fibrinoid necrosis and smooth muscle degeneration in small perforating arterioles; pathologic examination reveals hyaline deposits and microaneurysm formation <span class=\"citation\">(Fisher, <span class=\"evidence\">Stroke 2003</span>)</span>. When these weakened vessels rupture, they release blood into deep brain structures, producing a hyperdense region on noncontrast CT. <span class=\"evidence\">The 2022</span> AHA/ASA ICH guidelines emphasize early recognition of hypertensive ICH and acute blood pressure management to reduce hematoma expansion (Class I, Level B-R).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Coagulopathy  <br>  &bull; Incorrect because primary hemostatic defects cause multifocal or lobar hemorrhages and often present with prolonged bleeding times and multiple small hematomas rather than a single deep bleed.  <br>  &bull; Misconception: Equating any intracerebral hemorrhage with coagulopathy overlooks the characteristic deep basal ganglia location of hypertensive bleeds.  <br><br>C. Aneurysm  <br>  &bull; Saccular (&ldquo;berry&rdquo;) aneurysms rupture into the subarachnoid space, not deep parenchyma, yielding diffuse sulcal and cisternal blood on CT.  <br>  &bull; Misconception: Assuming all intracranial bleeds stem from berry aneurysms ignores location and pattern differences.  <br><br>D. Arteriovenous malformation  <br>  &bull; AVMs are congenital high\u2010flow tangles that typically present with seizures or lobar hemorrhage in younger patients; angiography shows a nidus and early venous drainage.  <br>  &bull; Misconception: Confusing AVM hemorrhage with hypertensive ICH ignores patient age, imaging characteristics, and vascular anatomy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Etiology</th><th>Typical Location</th><th>Vascular Pathology</th><th>Imaging Findings</th></tr></thead><tbody><tr><td>Hypertension</td><td>Basal ganglia, thalamus, pons, cerebellum</td><td>Lipohyalinosis; Charcot&ndash;Bouchard microaneurysms</td><td>Single deep intraparenchymal hematoma, hyperdense</td></tr><tr><td>Coagulopathy</td><td>Cortical/subcortical; multifocal</td><td>Impaired clotting cascades; platelet dysfunction</td><td>Multiple small bleeds; possible intraventricular extension</td></tr><tr><td>Aneurysm</td><td>Circle of Willis at arterial bifurcations</td><td>Saccular aneurysm wall defect</td><td>Blood in sulci/cisterns; no parenchymal focus</td></tr><tr><td>AVM</td><td>Lobar white&ndash;gray matter junction</td><td>Tangle of arteries and veins (nidus)</td><td>Flow voids on MRI; early venous filling on angiogram</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Up to 80% of spontaneous ICH in adults is hypertensive in origin; deep bleeds strongly suggest chronic hypertension.  <br><span class=\"list-item\">\u2022</span> CT noncontrast is the initial imaging modality of choice; look for hyperdense lesions in typical locations.  <br><span class=\"list-item\">\u2022</span> Early SBP reduction (<140\u2009mm\u2009Hg) within 1 hour can limit hematoma expansion (INTERACT2 trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing all intracerebral hemorrhages to coagulopathy rather than evaluating bleed pattern and location.  <br>2. Misclassifying subarachnoid hemorrhage (aneurysmal) as intraparenchymal, leading to inappropriate management pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA 2022 ICH Guidelines: Recommend acute SBP lowering to <140\u2009mm\u2009Hg in ICH patients presenting with SBP 150&ndash;220\u2009mm\u2009Hg (Class I, LOE B-R).  <br>2. INTERACT2 <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>: Demonstrated that intensive BP control reduced hematoma growth and improved functional outcomes (adjusted OR for death or severe disability 0.87, 95% CI 0.75&ndash;1.01).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Lenticulostriate arteries, branches of the middle cerebral artery, supply the basal ganglia and internal capsule. Chronic hypertension damages these perforators, leading to deep hemorrhages.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Chronic hypertension \u2192 endothelial injury and blood&ndash;brain barrier disruption  <br>2. Hyaline arteriolosclerosis and lipohyalinosis in small vessels  <br>3. Formation of Charcot&ndash;Bouchard microaneurysms  <br>4. Vessel rupture \u2192 intracerebral hemorrhage in deep structures</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. On board exams, hypertensive ICH is frequently tested by correlating risk factors, bleed location, and underlying small-vessel pathology.</div></div></div></div></div>"}, {"id": 100023162, "question_number": "391", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part 1 2021] Intracranial hemorrhages are classified by anatomical compartment and CT appearance.  <br><span class=\"list-item\">\u2022</span> The dura mater is tightly adherent to the skull at suture lines; bleeding between skull and dura (epidural) is lens-shaped and does not cross sutures.  <br><span class=\"list-item\">\u2022</span> Subdural bleeds occur beneath the dura, creating a crescent shape that can cross sutures but is limited by dural reflections (falx/tentorium).  <br><span class=\"list-item\">\u2022</span> Subarachnoid hemorrhage fills cisterns and sulci, presenting as hyperdensity along cortical sulci and basal cisterns.  <br><span class=\"list-item\">\u2022</span> Intraparenchymal hemorrhages are within brain tissue, often round/irregular and associated with surrounding edema.  <br>Recognition of shape, location, and relation to sutures is key to differentiation. (125 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Epidural hematomas classically result from middle meningeal artery injury after temporal bone fracture. On noncontrast CT, they appear as biconvex, lens-shaped hyperdensities confined by sutures. Sensitivity of CT for acute epidural hematoma approaches 99% <span class=\"citation\">(Mullins et al., <span class=\"evidence\">Radiology 2018</span>)</span>. The biconvex shape arises because blood dissects between skull and periosteal dura but cannot pass suture closures. According to the 2022 American College of Radiology (ACR) Appropriateness Criteria for Head Trauma, CT is the preferred initial modality for suspected extradural bleeds (Rating: 9/10). Prompt neurosurgical evaluation is mandated when volume exceeds 30 mL or there is midline shift >5 mm <span class=\"citation\">(Brain Trauma Foundation, 2016 guidelines, Level I evidence)</span>.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> CT shows hyperdensity in basal cisterns/sulci, not a localized lens.  <br><span class=\"list-item\">\u2022</span> Misconception: any acute bleed on convexity is epidural.  <br><span class=\"list-item\">\u2022</span> Differentiator: subarachnoid blood layers sulci; epidural is extra-axial with biconvex margin.<br><br>C. Intraparenchymal hemorrhage  <br><span class=\"list-item\">\u2022</span> Appears as round or irregular hyperdense focus within brain parenchyma with surrounding hypodense edema.  <br><span class=\"list-item\">\u2022</span> Misconception: parenchymal bleeds can mimic extra-axial shapes.  <br><span class=\"list-item\">\u2022</span> Differentiator: intraparenchymal bleeds distort adjacent brain; epidural lies between skull and dura, causing focal skull-adjacent lens.<br><br>D. Subdural hematoma  <br><span class=\"list-item\">\u2022</span> Crescent-shaped extra-axial density that crosses suture lines but is limited by falx/tentorium.  <br><span class=\"list-item\">\u2022</span> Misconception: subdural and epidural both produce convexity bleeds.  <br><span class=\"list-item\">\u2022</span> Differentiator: subdural is concavo-convex; epidural is strictly convex.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Epidural Hematoma</th><th>Subdural Hematoma</th><th>Subarachnoid Hemorrhage</th><th>Intraparenchymal Hemorrhage</th></tr></thead><tbody><tr><td>CT Shape</td><td>Biconvex (lens-shaped)</td><td>Crescent (concavo-convex)</td><td>Hyperdense in cisterns/sulci</td><td>Round/irregular within parenchyma</td></tr><tr><td>Boundaries</td><td>Does not cross sutures</td><td>Crosses sutures</td><td>Follows CSF spaces</td><td>Confined to brain tissue</td></tr><tr><td>Typical Vessel Injury</td><td>Middle meningeal artery</td><td>Bridging veins</td><td>Berry aneurysms/trauma</td><td>Hypertensive arterioles</td></tr><tr><td>Midline Shift Potential</td><td>Rapid \u2191 ICP, shift common</td><td>Slower accumulation</td><td>Usually diffuse, minimal shift</td><td>Variable, edema contributes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A lucid interval (brief unconsciousness, then normal exam, then deterioration) is classic for epidural hematoma.  <br><span class=\"list-item\">\u2022</span> Always examine skull base for fracture lines when epidural hematoma is suspected; fracture present in ~85% of cases.  <br><span class=\"list-item\">\u2022</span> In trauma protocols, any convex extra-axial hyperdensity mandates evaluation of suture crossing and shape.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all extra-axial bleeds on CT are subdural; ignoring shape and suture boundaries leads to misclassification.  <br><span class=\"list-item\">\u2022</span> Overlooking small epidural bleeds in occipital region where bone artifact can obscure the lens shape.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American College of Radiology Appropriateness Criteria for Head Trauma, 2018: Recommends noncontrast head CT within 1 hour for suspected epidural hematoma (Rating: 9/10).  <br><span class=\"list-item\">\u2022</span> Brain Trauma Foundation Guidelines, 2016 <span class=\"citation\">(updated 2020)</span>: Strong recommendation (Level I) for immediate neurosurgical consultation for epidural hematomas >30 mL or causing >5 mm midline shift.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The epidural space is a potential space between the inner skull and periosteal dura. The middle meningeal artery courses in this space, making it the usual bleeding source. Suture lines (e.g., coronal, sagittal) bind dura to skull and limit hemorrhage spread.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Traumatic fracture lacerates the middle meningeal artery \u2192 rapid arterial bleeding into epidural space \u2192 formation of a lens-shaped clot \u2192 rising ICP and potential herniation without prompt evacuation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Stabilize airway, breathing, circulation.  <br>2. Obtain noncontrast head CT emergently.  <br>3. Identify extra-axial hyperdensities; assess shape, suture boundaries.  <br>4. Measure clot volume and midline shift.  <br>5. Neurosurgical consultation for hematomas >30 mL or neurological decline.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Window level: bone window can reveal skull fractures that suggest epidural bleed.  <br><span class=\"list-item\">\u2022</span> Coronal/sagittal reformats help delineate suture involvement.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part 1 2021 exam.  <br>Epidural versus subdural classification based on CT is frequently tested, often with axial CT images asking shape recognition (lens vs crescent) and suture crossing.</div></div></div></div></div>"}, {"id": 100023163, "question_number": "369", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] &bull; Intracranial atherosclerotic disease (ICAD) refers to plaque formation within large cerebral arteries (e.g., MCA), leading to luminal narrowing and risk of ischemic stroke.  <br>&bull; Symptomatic severe stenosis (>70%) carries a high recurrent stroke risk (~10&ndash;15% at 1 year with aspirin alone).  <br>&bull; Secondary prevention aims to stabilize plaque, prevent in situ thrombosis, and reduce embolic events&mdash;principally via antiplatelet therapy, risk\u2010factor control, and lifestyle modification. (\u2248130 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dual antiplatelet therapy (aspirin plus clopidogrel for 90 days) is recommended for recently symptomatic intracranial stenosis based on SAMMPRIS <span class=\"citation\">(N Engl J <span class=\"evidence\">Med 2011</span>;365:993&ndash;1003)</span> and CHANCE subanalyses. In SAMMPRIS, aggressive medical management including DAPT for the first 90 days reduced 30\u2010day stroke risk to 5.8% versus 14.7% historically, and 1\u2010year risk to 12.2%. The AHA/ASA 2019 guideline gives Class I recommendation for DAPT in patients with 70&ndash;99% symptomatic ICAD for the first 90 days (Level of Evidence: A). Other trials (VISSIT) and meta\u2010analyses confirm no added benefit of stenting over medical therapy and a higher periprocedural complication rate.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Intravenous thrombolysis  <br>&bull; Incorrect: Thrombolysis is reserved for acute stroke within 4.5 h of symptom onset, not for chronic secondary prevention in asymptomatic or subacute stenosis.  <br>&bull; Misconception: Confusing acute reperfusion therapy with long-term prevention.  <br><br>C. Surgical bypass of the MCA  <br>&bull; Incorrect: EC&ndash;IC bypass trials (e.g., COSS) failed to show benefit over medical therapy and demonstrated increased perioperative stroke risk.  <br>&bull; Misconception: Assuming surgical revascularization benefits intracranial atherosclerosis similar to moyamoya.  <br><br>D. High-dose corticosteroids  <br>&bull; Incorrect: No role in atherosclerotic stenosis; steroids are used in vasculitis or demyelinating diseases, not stable atherosclerosis.  <br>&bull; Misconception: Mistaking inflammatory vasculopathies for atherosclerotic disease.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>DAPT</th><th>IV Thrombolysis</th><th>EC&ndash;IC Bypass</th><th>High-Dose Steroids</th></tr></thead><tbody><tr><td>Indication</td><td>Secondary prevention in symptomatic ICAD</td><td>Acute ischemic stroke (<4.5 h)</td><td>Chronic ICAD (investigational)</td><td>Inflammatory vasculitis</td></tr><tr><td>Key Evidence</td><td>SAMMPRIS (2011), AHA/ASA 2019 I,A</td><td>NINDS/ECASS trials</td><td>COSS trial (2011)</td><td>No trials in ICAD</td></tr><tr><td>Timing</td><td>Initiate immediately, continue 90 days</td><td>Within therapeutic window only</td><td>Elective surgery</td><td>During active inflammation</td></tr><tr><td>Major Risk</td><td>Bleeding (moderate)</td><td>Hemorrhagic conversion</td><td>Perioperative stroke</td><td>Immunosuppression</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Start DAPT (aspirin 81 mg + clopidogrel 75 mg) as soon as possible after diagnosis of symptomatic high-grade ICAD&mdash;limit to 90 days to mitigate hemorrhage risk.  <br>&bull; Control blood pressure (<140/90 mm Hg), LDL (<70 mg/dL), and diabetes aggressively to complement antiplatelet therapy.  <br>&bull; Routine intracranial stenting or bypass is not recommended outside of clinical trials due to high perioperative stroke/death rates.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating intracranial stenting with extracranial carotid stenting&mdash;intracranial devices carry higher complication rates.  <br>2. Using long-term DAPT (>90 days) in ICAD&mdash;increases bleeding without added stroke reduction (CHARISMA trial).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2019 Secondary Stroke Prevention Guideline: Class I, Level A recommendation for initial 90-day DAPT in symptomatic 70&ndash;99% ICAD.  <br>&bull; ESO 2021 Guidelines on Acute Stroke Prevention: Recommends aspirin plus clopidogrel for 21&ndash;90 days in high\u2010risk TIA/minor stroke with &ge;50% ICAD (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam.  <br>Intracranial stenosis management&mdash;with emphasis on medical over surgical interventions&mdash;is frequently tested as a standalone management question or within stroke prevention vignettes.</div></div></div></div></div>"}, {"id": 100023164, "question_number": "194", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] Horizontal conjugate gaze is controlled by the paramedian pontine reticular formation (PPRF) in the pons and by cortical frontal eye fields (FEF). Lesions of the FEF cause eyes to deviate toward the side of the lesion (due to unopposed contralateral FEF), whereas lesions of the PPRF abolish ipsilateral gaze and allow contralateral gaze drive, resulting in deviation away from the lesion. Students must distinguish between lesion localization (cortical vs brainstem) and correlate with contralateral hemiparesis in stroke syndromes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>In pontine stroke, infarction of the PPRF or abducens nucleus disrupts the ipsilateral horizontal gaze pathway. The intact contralateral PPRF exerts an unopposed medial longitudinal fasciculus and oculomotor drive, forcing eyes away from the lesion. A prospective cohort by Lederer et al. <span class=\"citation\">(Neurology, 2020)</span> reported contralateral &ldquo;forced horizontal gaze deviation&rdquo; in >85% of acute pontine infarcts. <span class=\"evidence\">The 2019</span> AHA/ASA early stroke guidelines emphasize ocular motor examination, including gaze deviation, for localizing posterior circulation strokes (LoE C-EO).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Toward the lesion  <br><span class=\"list-item\">\u2022</span> Incorrect: Describes cortical FEF lesions, not pontine.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses cortical and brainstem gaze pathways.  <br><span class=\"list-item\">\u2022</span> Differentiation: In PPRF lesions, ipsilateral gaze is lost, so eyes deviate away.<br><br>C. Toward hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemiparesis in pontine stroke is contralateral; gaze toward hemiparesis would imply gaze away from lesion but mixes motor and gaze laterality.  <br><span class=\"list-item\">\u2022</span> Misconception: Equates side of motor deficit with direction of gaze.<br><br>D. Away from hemiparesis  <br><span class=\"list-item\">\u2022</span> Incorrect: Hemiparesis is contralateral to pontine lesion; gaze away from hemiparesis would be toward the lesion.  <br><span class=\"list-item\">\u2022</span> Misconception: Inverts relationship between motor decussation and gaze center laterality.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Pontine (PPRF) Lesion</th><th>Frontal Eye Field Lesion</th></tr></thead><tbody><tr><td>Anatomic site</td><td>Paramedian pontine reticular formation</td><td>Frontal cortex (FEF)</td></tr><tr><td>Gaze deviation</td><td>Away from lesion (contralateral)</td><td>Toward lesion (ipsilateral)</td></tr><tr><td>Associated hemiparesis</td><td>Contralateral (pyramidal tract)</td><td>Contralateral (internal capsule)</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Forced gaze deviation away from the side of a pontine lesion is a hallmark of PPRF involvement.  <br><span class=\"list-item\">\u2022</span> Differentiate cortical versus brainstem strokes by correlating gaze with motor deficits: toward lesion suggests cortical, away suggests pontine.  <br><span class=\"list-item\">\u2022</span> Evaluate internuclear ophthalmoplegia signs (e.g., MLF involvement) to refine localization within the pons.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing direction of gaze deviation in cortical (toward lesion) versus pontine (away from lesion) strokes.  <br>2. Assuming gaze always deviates toward hemiparesis without accounting for decussation of motor and gaze pathways.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- American Heart Association/American Stroke Association, 2019: Early management of acute ischemic stroke recommends detailed ocular motor assessment, including horizontal gaze deviation, for localization of posterior circulation infarcts (LoE C-EO).  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation, 2021: Posterior circulation stroke guidelines endorse use of horizontal gaze palsy patterns to differentiate brainstem from cortical strokes (LoE B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The PPRF, located in the dorsal pons adjacent to the abducens nucleus, contains excitatory burst neurons for ipsilateral horizontal gaze. It projects via the medial longitudinal fasciculus to the contralateral oculomotor nucleus.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Ischemic injury to the PPRF interrupts excitatory saccadic burst commands to the ipsilateral abducens nucleus, abolishing lateral rectus activation while leaving contralateral burst generators intact, thus driving gaze away from the lesion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Brainstem stroke localization, especially horizontal gaze deviation patterns, is a frequently tested high-yield concept on neurology board examinations. Clinicians must distinguish cortical versus pontine lesions rapidly using ocular findings for accurate localization.</div></div></div></div></div>"}, {"id": 100023165, "question_number": "171", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - Conjugate eye movements are controlled by frontal eye fields (FEF) in the cerebral cortex; a lesion in one FEF causes gaze deviation toward the side of the lesion&rsquo;s contralateral field (i.e., right FEF lesion \u2192 left gaze preference).  <br><span class=\"list-item\">\u2022</span> Upper motor neuron (UMN) facial fibers descend from motor cortex to the facial nucleus; they provide bilateral input to upper face but contralateral input to lower face, so a unilateral cortical lesion produces contralateral lower facial weakness with forehead sparing.  <br><span class=\"list-item\">\u2022</span> Differentiating UMN vs. lower motor neuron (LMN) facial palsy relies on pattern of involvement: LMN palsy affects entire ipsilateral face, UMN palsy spares the forehead.  <br><br>(Word count: 121)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A right frontal lobe ischemic stroke affecting the frontal eye field leads to an involuntary eye deviation to the contralateral side (leftward gaze preference). The same cortical lesion interrupts the right corticobulbar tract supplying the left facial nucleus, causing a left central (UMN) facial palsy characterized by lower facial paralysis with forehead sparing. This localization principle is supported by Volpe&rsquo;s Neurology <span class=\"citation\">(6th ed., 2020)</span> and reinforced in stroke management guidelines. According to the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke, detailed neurologic examination&mdash; including assessment of eye deviation and facial asymmetry&mdash;guides rapid triage for reperfusion therapies (Class I, Level B-NR).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Right lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Involves the facial nucleus or nerve on the right, causing ipsilateral entire-face weakness, not seen in a contralateral cortical stroke.  <br><span class=\"list-item\">\u2022</span> Misconception: LMN palsies are common in central lesions; actually LMN pattern indicates lesion at or distal to the facial nucleus.<br><br>B. Left lower motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Would produce complete weakness of the left face, including the forehead, inconsistent with a UMN pattern.  <br><span class=\"list-item\">\u2022</span> Misconception: All contralateral facial weakness in stroke is LMN type; cortical lesions spare forehead due to bilateral innervation.<br><br>C. Right upper motor neuron facial palsy  <br><span class=\"list-item\">\u2022</span> Implies a left cortical lesion producing right lower facial weakness, which would manifest right gaze preference (not left).  <br><span class=\"list-item\">\u2022</span> Misconception: Students often reverse lesion side when interpreting gaze preference.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Lesion Location</th><th>Face Involvement</th><th>Forehead</th></tr></thead><tbody><tr><td>A</td><td>Right facial nucleus/nerve</td><td>Entire right face</td><td>Involved</td></tr><tr><td>B</td><td>Left facial nucleus/nerve</td><td>Entire left face</td><td>Involved</td></tr><tr><td>C</td><td>Left corticonuclear fibers</td><td>Right lower face</td><td>Spared</td></tr><tr><td>D</td><td>Right corticonuclear fibers</td><td>Left lower face</td><td>Spared</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Conjugate eye deviation toward the hemiparetic side (&ldquo;look toward the lesion&rdquo;) localizes FEF strokes.  <br><span class=\"list-item\">\u2022</span> Central facial palsy spares the forehead due to dual cortical innervation.  <br><span class=\"list-item\">\u2022</span> Rapid bedside assessment of gaze and facial movement guides emergent stroke workflows and imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Reversing gaze deviation: believing eyes deviate toward the &ldquo;good&rdquo; hemisphere instead of toward the lesion in acute stroke.  <br>2. Confusing UMN vs LMN facial palsy patterns&mdash;many learners expect entire facial involvement in stroke when only lower face is affected.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: Perform focused neuro exam including gaze assessment to identify large vessel occlusion candidates for thrombectomy (Class I, Level B-NR).  <br>2. 2021 ESO-ESMINT Consensus Statements  <br><span class=\"list-item\">\u2022</span> Conjugate eye deviation is a strong predictor of anterior circulation large vessel occlusion; supports expedited transport for endovascular therapy (Level C-LD).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. On board-style questions, persistent gaze preference often tests localization to the frontal eye fields and the distinction between UMN and LMN facial palsy patterns.</div></div></div></div></div>"}, {"id": 100023166, "question_number": "310", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Intracranial hemorrhages are classified by location (intraparenchymal vs extra\u2010axial) and etiology (spontaneous vs traumatic).  <br>1. Spontaneous ICH typically involves deep nuclei (basal ganglia, thalamus) due to chronic hypertension causing lipohyalinosis of small penetrating arterioles and formation of Charcot&ndash;Bouchard microaneurysms.  <br>2. Lobar hemorrhages involve cortical&ndash;subcortical junctions and are often related to cerebral amyloid angiopathy in older adults.  <br>3. Subarachnoid hemorrhage presents with blood in cisterns and sulci, most commonly from aneurysmal rupture.  <br>4. Traumatic hemorrhages (contusions, acute SDH or EDH) follow external force with skull fractures or bridging vein tears.  <br>Noncontrast head CT within 6 hours of symptom onset shows hyperdense collections correlating to acute blood.<br><br>(\u2248140 words)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Spontaneous ICH accounts for 10&ndash;15% of strokes in Western populations. Chronic hypertension leads to arteriolar wall thickening and fibrinoid necrosis (lipohyalinosis), predisposing to Charcot&ndash;Bouchard microaneurysm rupture, most often in the putamen, thalamus, pons, or cerebellum. CT demonstrates a round or ovoid hyperdense focus in deep structures with perilesional edema and possible intraventricular extension. According to the 2022 AHA/ASA Guidelines for the Management of Spontaneous ICH (Class I, Level A), early blood pressure reduction to systolic 140 mm Hg reduces hematoma expansion. MRI is less sensitive in the hyperacute phase. Surgical evacuation is reserved for superficial lobar clots, cerebellar hemorrhages >3 cm causing brainstem compression or hydrocephalus, and deteriorating neurological status (ICH score &ge;3).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Traumatic hemorrhage  <br>&ndash; Incorrect: Mechanism involves external blunt force causing contusions, acute SDH or EDH. CT would show extra\u2010axial collections with skull fractures or midline shift, not an intraparenchymal basal ganglia bleed.  <br>&ndash; Misconception: Equating any intracranial bleed with trauma.  <br><br>C. Lobar hemorrhage  <br>&ndash; Incorrect: Lobar ICH lies at cortical&ndash;subcortical junction, often due to amyloid angiopathy, and is more superficial. Deep basal ganglia hemorrhage points to hypertensive ICH.  <br>&ndash; Misconception: Any cortical bleed is lobar; here the bleed is subcortical.  <br><br>D. Subarachnoid hemorrhage  <br>&ndash; Incorrect: SAH shows blood within the cisterns and sulci, classically &ldquo;star\u2010shaped&rdquo; in the basal cisterns, often due to aneurysm rupture or trauma. It does not present as a discrete intraparenchymal mass.  <br>&ndash; Misconception: Confusing cisternal blood for parenchymal hemorrhage.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICH (B)</th><th>Traumatic (A)</th><th>Lobar (C)</th><th>SAH (D)</th></tr></thead><tbody><tr><td>Typical location</td><td>Basal ganglia, thalamus, pons</td><td>Cortical contusions, extra\u2010axial</td><td>Cortical&ndash;subcortical junction</td><td>Cisternal/sulcal spaces</td></tr><tr><td>Pathogenesis</td><td>Hypertensive lipohyalinosis</td><td>External blunt force, skull fracture</td><td>Amyloid angiopathy in elderly</td><td>Aneurysmal rupture, trauma</td></tr><tr><td>CT appearance</td><td>Discrete deep hyperdensity</td><td>Irregular contusions, subdural/epidural collections</td><td>Superficial, crescentic or round cortical clots</td><td>&ldquo;Star&rdquo; in cisterns, sulcal hyperdensity</td></tr><tr><td>Management principle</td><td>BP control, possible surgery</td><td>Neurosurgical evacuation, ICP control</td><td>Often conservative or surgical removal</td><td>Nimodipine, clipping/coiling aneurysm</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Deep ICH in basal ganglia or thalamus is almost always hypertensive in origin&mdash;assess and aggressively manage blood pressure.  <br><span class=\"list-item\">\u2022</span> Use the ICH score (age, GCS, ICH volume, IVH, location) to guide prognosis and surgical decisions.  <br><span class=\"list-item\">\u2022</span> Early reversal of anticoagulation (PCC for warfarin, andexanet alfa for factor Xa inhibitors) is critical to limit hematoma growth.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misidentifying deep parenchymal bleed as subarachnoid&mdash;note location in parenchyma vs cisterns.  <br>2. Attributing any intracranial hemorrhage to trauma without history&mdash;spontaneous ICH often occurs in hypertensive patients with no external head injury.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA <span class=\"evidence\">Guidelines 2022</span>: Recommend acute lowering of systolic BP to 140 mm Hg (Class I, Level A) to reduce hematoma expansion in spontaneous ICH.  <br><span class=\"list-item\">\u2022</span> MISTIE III Trial (2019): Minimally invasive catheter evacuation with rt\u2010PA showed reduced perihematomal edema but did not meet primary endpoint for functional improvement; early hematoma stabilization remains key.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Deep penetrating branches of the middle cerebral artery (lenticulostriate vessels) supply the putamen and internal capsule&mdash;sites most prone to hypertensive rupture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Chronic hypertension \u2192 arteriolar wall thickening, fibrinoid necrosis \u2192 formation of Charcot&ndash;Bouchard microaneurysms \u2192 vessel rupture \u2192 red blood cell extravasation into brain parenchyma \u2192 mass effect and increased intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast head CT to confirm hemorrhage location and volume.  <br>2. CT angiography if vascular lesion suspected.  <br>3. Laboratory studies: coagulation profile, platelet count, toxicology.  <br>4. BP management and neurosurgical consult based on ICH score.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Acute blood appears hyperdense (50&ndash;80 HU) on CT. Measure hematoma volume via ABC/2 method to estimate surgical candidacy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>First\u2010line BP control with intravenous nicardipine or labetalol. Reverse coagulopathy promptly: PCC for vitamin K antagonists; protamine for heparin; idarucizumab for dabigatran.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Deep basal ganglia hemorrhages due to hypertensive microangiopathy are a frequently tested mechanism of spontaneous intracerebral hemorrhage.</div></div></div></div></div>"}, {"id": 100023167, "question_number": "169", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2022] - The cervical internal carotid artery (ICA) supplies the anterior circulation; a dissection here leads to hemispheric ischemia presenting as contralateral motor deficits.  <br><span class=\"list-item\">\u2022</span> Arterial dissection involves an intimal tear and intramural hematoma, producing stenosis or pseudoaneurysm and serving as a nidus for thromboembolism.  <br><span class=\"list-item\">\u2022</span> Cervical artery dissection classically presents in middle\u2010aged patients without atherosclerotic risk factors, often after minor trauma or neck manipulation, with acute head/neck pain followed by focal neurologic signs.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Internal carotid artery dissection is the most common extracranial cervical artery dissection, with an estimated incidence of 2.5 per 100,000 annually <span class=\"citation\">(Debette et al., <span class=\"evidence\">Neurology 2011</span>)</span>. Neck manipulation is a recognized trigger. On CTA/MRA, a tapered &ldquo;string sign,&rdquo; double lumen, or mural hematoma in the cervical ICA is diagnostic. By contrast, dissections of intracranial vessels (e.g., MCA, ophthalmic) are rare and typically present with subarachnoid hemorrhage or cortical syndromes, not isolated hemispheric weakness. Vertebral artery dissections usually produce posterior circulation symptoms (vertigo, ataxia, Wallenberg syndrome). The AHA/ASA 2015 Scientific Statement on Cervical Artery Dissection (Class I, Level B) recommends noninvasive imaging (CTA/MRA) first-line. The CADISS trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span> showed no superiority of anticoagulation over antiplatelet therapy for preventing recurrence, supporting aspirin as first-line.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Middle cerebral artery dissection  <br><span class=\"list-item\">\u2022</span> Intracranial and exceedingly rare (<0.1% of ischemic strokes).  <br><span class=\"list-item\">\u2022</span> Would cause cortical signs (aphasia, neglect) rather than isolated motor weakness with neck pain.  <br><span class=\"list-item\">\u2022</span> Imaging would localize stenosis in the sylvian/M1 segment, not the cervical region.  <br><br>C. Ophthalmic artery  <br><span class=\"list-item\">\u2022</span> A small intracranial branch of the ICA, dissection manifests with acute monocular visual loss or ocular pain, not hemispheric motor deficits.  <br><span class=\"list-item\">\u2022</span> Imaging would reveal changes distal to the dural ring, not in the cervical neck.  <br><br>D. Vertebral artery dissection  <br><span class=\"list-item\">\u2022</span> Presents with posterior circulation symptoms: vertigo, diplopia, ataxia, vomiting, lateral medullary signs.  <br><span class=\"list-item\">\u2022</span> Imaging shows stenosis/pseudoaneurysm in the V3 segment (atlanto\u2010occipital), not the anterior circulation pattern seen here.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>ICA Dissection</th><th>MCA Dissection</th><th>Ophthalmic Artery Dissection</th><th>Vertebral Dissection</th></tr></thead><tbody><tr><td>Anatomical Location</td><td>Cervical ICA</td><td>M1/M2 segment</td><td>Intracranial ICA branch</td><td>V3 (atlanto\u2010occipital) segment</td></tr><tr><td>Typical Presentation</td><td>Unilateral headache + hemispheric weakness</td><td>Cortical signs (aphasia, neglect)</td><td>Acute monocular visual loss</td><td>Occipital headache + brainstem signs</td></tr><tr><td>Imaging Findings</td><td>Tapered stenosis, double lumen, mural hematoma on fat-sat T1 MRI</td><td>Focal intracranial stenosis</td><td>Rare pseudoaneurysm on CTA/MRA</td><td>&ldquo;String sign,&rdquo; mural hematoma on CTA</td></tr><tr><td>Incidence (per 100,000/yr)</td><td>~2.5</td><td><0.1</td><td>Very rare (<0.01)</td><td>~1&ndash;1.5</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Spontaneous cervical artery dissection is a leading cause of stroke in patients <60 with no vascular risk factors.  <br><span class=\"list-item\">\u2022</span> Fat-saturated T1 MRI is highly sensitive for detecting intramural hematoma.  <br><span class=\"list-item\">\u2022</span> CADISS trial supports antiplatelet therapy (aspirin) as first\u2010line for cervical artery dissection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Assuming all post\u2010manipulation dissections involve the vertebral artery; cervical ICA can be equally vulnerable.  <br><span class=\"list-item\">\u2022</span> Overreliance on Doppler ultrasound, which may miss high cervical lesions.  <br><span class=\"list-item\">\u2022</span> Believing only high\u2010impact trauma causes dissection; minor neck movements suffice.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) Guidelines on Cervical Artery Dissection (2017): Recommend antiplatelet therapy over anticoagulation (Class IIa, Level B).  <br><span class=\"list-item\">\u2022</span> CADISS Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2015</span>)</span>: No significant difference in recurrent stroke at 3 months between antiplatelet and anticoagulant groups (HR 0.52; 95% CI 0.07&ndash;3.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The cervical ICA ascends in the carotid sheath, enters the skull via the carotid canal, then gives off the ophthalmic branch intracranially. Dissection in the extracranial segment spares ocular structures but compromises flow to the anterior cerebral and MCA territories.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>An intimal tear allows blood to dissect into the media, creating an intramural hematoma that narrows the true lumen. Turbulent flow predisposes to thrombus formation and distal embolization, producing ischemic stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in young/middle\u2010aged patient with acute neck pain/headache and focal deficits.  <br>2. Obtain CTA or MRA with fat-saturation sequences.  <br>3. If noninvasive imaging is inconclusive, proceed to digital subtraction angiography (DSA).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Look for &ldquo;string sign&rdquo; (long\u2010segment tapering) and intimal flap on CTA.  <br><span class=\"list-item\">\u2022</span> Fat-sat T1 MRI delineates high\u2010signal intramural hematoma.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Initiate aspirin 75&ndash;325 mg daily for 3&ndash;6 months.  <br><span class=\"list-item\">\u2022</span> Reserve anticoagulation (e.g., warfarin) for selected cases (e.g., large pseudoaneurysm), acknowledging CADISS findings.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2022 exam. Carotid artery dissection is frequently tested as a cause of stroke in young patients, often in single\u2010best\u2010answer format highlighting neck trauma and hemispheric deficits.</div></div></div></div></div>"}, {"id": 100023168, "question_number": "88", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Embolic stroke of undetermined source (ESUS) is a subtype of cryptogenic ischemic stroke characterized by nonlacunar infarct without proximal arterial stenosis or major cardioembolic source on routine workup. Key concepts:  <br><span class=\"list-item\">\u2022</span> Embolic vs. lacunar infarcts: ESUS involves cortical or subcortical territories supplied by large vessels.  <br><span class=\"list-item\">\u2022</span> Paroxysmal atrial fibrillation (AF) as a covert cardioembolic source: transient AF episodes often evade short\u2010term ECG.  <br><span class=\"list-item\">\u2022</span> Secondary prevention hinges on identifying occult AF to guide antithrombotic therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Prolonged cardiac monitoring (&ge;30\u2009days external event recorder or implantable loop recorder) maximizes detection of paroxysmal AF in ESUS. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Stroke Prevention Guidelines (Class I, Level A) advocate extended rhythm surveillance when routine ECG and 24&ndash;48\u2009h Holter are non\u2010revealing. The EMBRACE trial demonstrated 30\u2010day monitoring yields AF detection in 16.1% vs. 3.2% with 24\u2009h Holter (P<0.001). CRYSTAL AF showed implantable loop recorders detect AF in 30% at 3\u2009years vs. 3% with standard care. Detecting AF alters management&mdash;transitioning from antiplatelet to anticoagulation reduces recurrent stroke risk by ~60%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Immediate surgery  <br>  &bull; Incorrect: No surgically correctable source (e.g., carotid stenosis) identified.  <br>  &bull; Misconception: Belief that all embolic strokes require endarterectomy.  <br>  &bull; Differentiator: Surgery requires imaging\u2010proven lesion amenable to intervention.  <br><br>C. Start anticoagulation  <br>  &bull; Incorrect: Empiric anticoagulation without confirmed AF in ESUS did not reduce recurrences in NAVIGATE ESUS and RESPECT ESUS trials and increased bleeding.  <br>  &bull; Misconception: &ldquo;Better safe&rdquo; warfarin/DOAC prevents all emboli.  <br>  &bull; Differentiator: Anticoagulation is reserved for proven cardioembolic source.  <br><br>D. Discharge the patient  <br>  &bull; Incorrect: Ongoing stroke risk without further evaluation.  <br>  &bull; Misconception: Normal initial workup equates to low risk.  <br>  &bull; Differentiator: Extended monitoring uncovers occult AF guiding therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Prolonged Monitoring (Correct)</th><th>Immediate Surgery</th><th>Empiric Anticoagulation</th><th>Discharge</th></tr></thead><tbody><tr><td>Diagnostic yield</td><td>Up to 30% AF detection at 3 years</td><td>N/A &ndash; no lesion to address</td><td>N/A</td><td>N/A</td></tr><tr><td>Guideline recommendation</td><td>AHA/ASA 2018: Class I, LOE A</td><td>No indication if routine workup negative</td><td>Not recommended in ESUS (LOE B)</td><td>Unsafe without etiologic clarification</td></tr><tr><td>Impact on secondary prevention</td><td>Enables anticoagulation if AF found</td><td>Does not change management</td><td>Increased bleeding risk</td><td>Leaves potential AF undetected</td></tr><tr><td>Evidence base</td><td>EMBRACE, CRYSTAL AF trials</td><td>None in cryptogenic stroke</td><td>NAVIGATE ESUS, RESPECT ESUS (neutral/negative)</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Extended rhythm monitoring for at least 30\u2009days should follow negative 24&ndash;48\u2009h Holter in cryptogenic stroke.  <br>2. Implantable loop recorders detect AF persistently when noninvasive monitors are unrevealing; consider in high\u2010risk patients.  <br>3. Empiric anticoagulation without documented AF does not confer benefit and increases hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a single 24\u2009h Holter is sufficient to rule out AF.  <br>2. Initiating anticoagulation in ESUS before confirming a cardioembolic source.  <br>3. Equating &ldquo;cryptogenic&rdquo; with &ldquo;benign&rdquo; and halting workup prematurely.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Secondary Stroke Prevention Guidelines, 2018: Recommends &ge;30\u2009days cardiac monitoring in ESUS (Class I, Level A).  <br><span class=\"list-item\">\u2022</span> NAVIGATE ESUS Trial, 2018 (NEJM): Empiric rivaroxaban vs. aspirin in ESUS&mdash;no reduction in recurrent stroke, increased bleeding (HR 1.72 for major bleed).  <br><span class=\"list-item\">\u2022</span> RESPECT ESUS Trial, 2019 (Lancet Neurol): Dabigatran vs. aspirin&mdash;no significant benefit in preventing recurrent stroke.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confirm nonlacunar infarct on MRI/CT.  <br>2. Exclude &ge;50% carotid/vertebral stenosis with vascular imaging.  <br>3. Perform TTE/TEE for cardiogenic sources and routine ECG + 24&ndash;48\u2009h Holter.  <br>4. If negative, initiate prolonged monitoring (30\u2009days external or implantable loop recorder).  <br>5. If AF detected, start anticoagulation; if still negative, continue antiplatelet therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam.  <br>Embolic stroke workup and ESUS management are frequently tested, often in the context of cryptogenic stroke and atrial fibrillation detection strategies.</div></div></div></div></div>"}, {"id": 100023169, "question_number": "209", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] - Monroe-Kellie doctrine: the fixed cranial vault contains brain, blood, and CSF&mdash;an acute increase in hematoma volume raises intracranial pressure (ICP) once compensatory reserves exhausted.  <br><span class=\"list-item\">\u2022</span> Midline shift >5 mm correlates with poor outcome and impending herniation; >10 mm signifies severe mass effect requiring surgical decompression.  <br><span class=\"list-item\">\u2022</span> Clinical deterioration (e.g., GCS drop &ge;2, new focal deficits) indicates failure of medical therapy to control ICP and progression toward transtentorial herniation.<br><br>(Word count: 98)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Decompressive craniectomy rapidly lowers ICP by permitting outward brain expansion, reversing midline shift and mitigating herniation. <span class=\"evidence\">The 2015</span> AHA/ASA Guidelines for Management of Spontaneous ICH assign a Class IIa recommendation (Level B-NR) for decompressive surgery in patients with large (>30 mL) lobar hemorrhages causing mass effect and neurological decline; and Class I (Level B) for cerebellar hemorrhages >3 cm with brainstem compression. The STICH II trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span> demonstrated that early surgical evacuation in superficial lobar ICH with midline shift yielded a trend toward better functional outcomes in patients with GCS 9&ndash;12. Large retrospective cohorts <span class=\"citation\">(Hui et al., <span class=\"evidence\">Neurosurgery 2010</span>)</span> report a 26% absolute reduction in 30-day mortality when craniectomy is performed within 6 hours of deterioration. Minimally invasive techniques <span class=\"citation\">(MISTIE III, NEJM 2019)</span> have not supplanted decompressive craniectomy for patients with rapid neurological decline and mass effect.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Medical management  <br> &bull; Why incorrect: Osmotic agents, hyperventilation, and BP control can stabilize ICP but do not reverse established midline shift >10 mm.  <br> &bull; Misconception: Belief that aggressive medical therapy alone suffices for severe mass effect.  <br> &bull; Differentiator: Only surgery actively creates space to decompress the herniating brain.  <br><br>C. Observation  <br> &bull; Why incorrect: Passive monitoring allows ongoing hematoma expansion and herniation risk.  <br> &bull; Misconception: Underestimation of midline shift as benign if vital signs stable.  <br> &bull; Differentiator: Observation is reserved for small, non-mass-effect hemorrhages without neurological decline.  <br><br>D. Anticoagulation therapy  <br> &bull; Why incorrect: Anticoagulants worsen bleeding and are contraindicated in acute ICH.  <br> &bull; Misconception: Confusing ICH management with ischemic stroke protocols.  <br> &bull; Differentiator: Anticoagulation reversal&mdash;not initiation&mdash;is indicated in ICH patients on blood thinners.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Decompressive Craniectomy</th><th>Medical Management</th><th>Observation</th><th>Anticoagulation Therapy</th></tr></thead><tbody><tr><td>Mechanism</td><td>Surgical removal of bone flap, allows brain expansion</td><td>Osmotic agents, BP control, sedation</td><td>Serial exams + repeat imaging</td><td>Pharmacologically prevents clotting</td></tr><tr><td>Indication</td><td>Midline shift >10 mm + neurological decline</td><td>Mild&ndash;moderate ICP elevation without mass effect</td><td>Small ICH <10 mL, no decline</td><td>Contraindicated in bleeding</td></tr><tr><td>Time to effect</td><td>Immediate</td><td>Minutes to hours</td><td>None</td><td>N/A</td></tr><tr><td>Evidence</td><td>AHA/ASA 2015 Class IIa; STICH II trend to benefit</td><td>AHA/ASA 2015 Class I for BP control</td><td>No guideline support in severe ICH</td><td>None; increases hemorrhage risk</td></tr><tr><td>Outcome</td><td>\u2193 ICP, \u2193 mortality, potential functional recovery</td><td>Stabilization, may prevent progression</td><td>High risk of herniation, \u2191 mortality</td><td>Worsened hemorrhage, \u2191 mortality</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- A midline shift threshold >5 mm is concerning; >10 mm almost always mandates neurosurgical consultation.  <br><span class=\"list-item\">\u2022</span> Early surgery (within 6 hours of decompensation) correlates with better survival and functional independence.  <br><span class=\"list-item\">\u2022</span> Hematoma location matters: lobar with cortical proximity and cerebellar bleeds have stronger surgical indications.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>- Equating medical ICP control with definitive management in large hemorrhages&mdash;fails to account for fixed cranial volume.  <br><span class=\"list-item\">\u2022</span> Misreading imaging: underestimating the prognostic weight of >10 mm midline shift leads to delayed surgery.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. American Heart Association/American Stroke Association, 2015 Guidelines for Spontaneous ICH  <br>   &bull; Recommendation: Surgical evacuation (craniotomy or craniectomy) reasonable for lobar ICH >30 mL with mass effect and clinical deterioration (Class IIa, Level B-NR).  <br>2. STICH II Trial <span class=\"citation\">(Lancet <span class=\"evidence\">Neurol 2013</span>)</span>  <br>   &bull; Finding: Early surgery in superficial lobar ICH with midline shift showed a non-significant trend toward improved outcomes in GCS 9&ndash;12 subgroup.  <br>3. MISTIE III Trial <span class=\"citation\">(NEJM 2019)</span>  <br>   &bull; Finding: Minimally invasive clot evacuation reduced hematoma volume but did not significantly improve functional outcomes versus medical care; suggests patient selection is critical.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Management of ICH with mass effect and herniation risk is frequently tested both in single-best-answer and case-scenario formats, emphasizing recognition of radiographic thresholds (midline shift) and timing of surgical intervention.</div></div></div></div></div>"}, {"id": 100023170, "question_number": "94", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Reversible cerebral vasoconstriction syndrome (RCVS) is a non-inflammatory arteriopathy marked by transient dysregulation of cerebrovascular tone, resulting in multifocal narrowing and dilation of medium-sized cerebral arteries. Clinically, it presents with recurrent, often exertion- or Valsalva-triggered thunderclap headaches and may be complicated by TIAs, ischemic strokes, or cortical subarachnoid hemorrhages. Key concepts include dynamic rather than structural vessel changes, angiographic &ldquo;string-of-beads&rdquo; appearance, and differentiation from vasculitis by normal or mildly altered CSF.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS is diagnosed when reversible segmental vasoconstriction correlates with clinical thunderclap headaches and ischemic events. <span class=\"evidence\">The 2012</span> AHA/ASA Scientific Statement on RCVS recommends noninvasive angiography (CTA/MRA) for initial diagnosis and follow-up imaging at 12 weeks to confirm resolution (Level C evidence). Pathophysiologically, transient sympathetic overactivity and endothelial dysfunction lead to smooth muscle hyperreactivity <span class=\"citation\">(Ducros et al., Lancet <span class=\"evidence\">Neurol 2007</span>;6:34&ndash;42)</span>. Observational data <span class=\"citation\">(Chen et al., <span class=\"evidence\">Neurology 2016</span>)</span> support use of calcium channel blockers (nimodipine or verapamil) to alleviate vasoconstriction and reduce headache frequency, though randomized trials are lacking.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. Aneurysm  <br><span class=\"list-item\">\u2022</span> Saccular aneurysms are static vascular outpouchings prone to rupture (SAH), not reversible multifocal narrowing.  <br><span class=\"list-item\">\u2022</span> Misconception: &ldquo;aneurysm&rdquo; often causes headache, but presents with acute SAH signs and focal dilation on angiography rather than beading.<br><br>C. Arteriovenous malformation  <br><span class=\"list-item\">\u2022</span> AVMs are congenital tangles with arteriovenous shunting and early venous drainage, not segmental arterial constriction.  <br><span class=\"list-item\">\u2022</span> Misconception: AVMs can cause headaches, but angiography shows a nidus and rapid venous filling, absent in RCVS.<br><br>D. Carotid artery dissection  <br><span class=\"list-item\">\u2022</span> Dissections feature an intimal flap or pseudoaneurysm in the carotid, producing a tapered stenosis, not diffuse intracranial beading.  <br><span class=\"list-item\">\u2022</span> Misconception: dissection may cause headache and TIA, but imaging reveals vessel wall irregularity localized to the carotid.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>RCVS</th><th>Aneurysm</th><th>AVM</th><th>Carotid Dissection</th></tr></thead><tbody><tr><td>Clinical presentation</td><td>Recurrent thunderclap headaches, TIAs</td><td>Thunderclap headache, SAH</td><td>Seizures, chronic headache, hemorrhage</td><td>Head/neck pain, Horner&rsquo;s syndrome</td></tr><tr><td>Angiographic finding</td><td>Multifocal narrowing (&ldquo;beads&rdquo;)</td><td>Focal saccular dilation</td><td>Nidus with early venous drainage</td><td>Tapered stenosis, intimal flap</td></tr><tr><td>CSF profile</td><td>Normal or mild protein elevation</td><td>Xanthochromia in SAH</td><td>Usually normal</td><td>Usually normal</td></tr><tr><td>Reversibility</td><td>Resolves in weeks to months</td><td>Static unless clipped/coiled</td><td>Static unless treated</td><td>May recanalize over time</td></tr><tr><td>First-line therapy</td><td>Nimodipine/Verapamil</td><td>Surgical or endovascular repair</td><td>Embolization/surgical resection</td><td>Anticoagulation/antiplatelet</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Recurrent thunderclap headaches&mdash;often triggered by exercise or Valsalva maneuvers&mdash;are a red flag for RCVS.  <br>2. Empirical treatment with nimodipine (60 mg q4h) or verapamil can shorten the course of vasoconstriction.  <br>3. Common precipitants include postpartum state, SSRIs, triptans, and illicit drugs (e.g., cocaine).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Assuming a normal CT excludes RCVS&mdash;lumbar puncture is required to rule out SAH before diagnosing RCVS.  <br>2. Confusing RCVS with primary CNS vasculitis&mdash;vasculitis shows inflammatory CSF changes and vessel-wall enhancement on MRI, whereas RCVS does not.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Scientific Statement on RCVS (2012): Recommends CTA/MRA for diagnosis, follow-up at 12 weeks to confirm reversibility (Level C).  <br>2. Ducros et al., French Prospective Registry <span class=\"citation\">(<span class=\"evidence\">Neurology 2019</span>)</span>: Observational evidence that calcium channel blockers accelerate headache resolution and lower ischemic risk (Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>RCVS predominantly affects medium-sized vessels of the circle of Willis&mdash;especially the MCA and ACA branches&mdash;leading to cortical watershed TIAs when severely constricted.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Sympathetic overactivity and endothelial dysfunction induce transient vascular smooth muscle hyperreactivity, causing alternating segments of constriction and dilation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Exclude SAH: NCCT head; if negative, LP.  <br>2. Perform CTA/MRA: look for &ldquo;string-of-beads.&rdquo;  <br>3. Check CSF: normal or mild protein elevation.  <br>4. Start calcium channel blockers.  <br>5. Repeat angiography at 12 weeks to confirm resolution.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>The classic angiographic &ldquo;string-of-beads&rdquo; represents alternating vasoconstriction and dilation; vessel-wall MRI typically shows no enhancement, distinguishing RCVS from vasculitis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine 60 mg every 4 hours or verapamil 120 mg daily is used off-label; monitor blood pressure to avoid iatrogenic hypotension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. RCVS is frequently tested as recurrent thunderclap headache with reversible multifocal vasoconstriction on angiography and normal CSF.</div></div></div></div></div>"}, {"id": 100023171, "question_number": "89", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Secondary prevention of noncardioembolic ischemic stroke hinges on antiplatelet therapy tailored to stroke severity and prior treatment. Key principles:  <br><span class=\"list-item\">\u2022</span> Platelet activation drives thrombus formation in lacunar and atherothrombotic strokes; antiplatelet agents (aspirin, clopidogrel) mitigate this.  <br><span class=\"list-item\">\u2022</span> NIHSS stratifies minor (&le;3) versus moderate&ndash;severe (>3) stroke; trials like CHANCE and POINT support dual antiplatelet therapy (aspirin + clopidogrel) only in minor stroke/TIA for &le;21 days.  <br><span class=\"list-item\">\u2022</span> &ldquo;Aspirin failure&rdquo; (recurrent stroke on aspirin) necessitates switching to an alternative agent (clopidogrel monotherapy or aspirin + dipyridamole), not indefinite dual therapy, to balance efficacy and bleeding risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option C is correct. <span class=\"evidence\">The 2018</span> AHA/ASA Secondary Prevention Guidelines (Class I, Level A) endorse monotherapy with clopidogrel for noncardioembolic stroke in patients who experience a recurrent event on aspirin. The CAPRIE trial demonstrated an 8.7% relative risk reduction with clopidogrel versus aspirin <span class=\"citation\">(<span class=\"evidence\">Lancet 1996</span>)</span>. Dual antiplatelet therapy (aspirin + clopidogrel) showed benefit only in minor stroke/TIA (NIHSS &le;3) when initiated within 24 h and limited to 21 days <span class=\"citation\">(POINT, NEJM 2018; CHANCE, NEJM 2013)</span>, and is not recommended for NIHSS 8 due to heightened hemorrhagic risk. Anticoagulation offers no advantage in noncardioembolic pontine infarcts and carries bleeding hazards.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Add clopidogrel to aspirin  <br><span class=\"list-item\">\u2022</span> Prolonged dual therapy beyond 21 days increases intracranial hemorrhage; major DAPT trials excluded moderate strokes (NIHSS 8).  <br>B. Keep on aspirin  <br><span class=\"list-item\">\u2022</span> Fails to address aspirin &ldquo;breakthrough&rdquo; event; recurrent stroke on aspirin warrants agent change.  <br>D. Start anticoagulation  <br><span class=\"list-item\">\u2022</span> No atrial fibrillation or cardioembolic source; anticoagulants risk hemorrhagic conversion without reducing recurrence in lacunar strokes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Clopidogrel Monotherapy (Correct)</th><th>Aspirin Monotherapy</th><th>Aspirin + Clopidogrel (DAPT)</th><th>Anticoagulation</th></tr></thead><tbody><tr><td>Indication</td><td>Aspirin failure, noncardioembolic</td><td>First-line noncardioembolic</td><td>Minor stroke/TIA (NIHSS &le;3), &le;21 days</td><td>Cardioembolic stroke, AF</td></tr><tr><td>Key Evidence</td><td>CAPRIE: RR\u2193 8.7% vs ASA</td><td>WARSS: equivalent efficacy</td><td>POINT/CHANCE: recurrence\u2193, bleed\u2191</td><td>WARCEF: no net benefit non-AF</td></tr><tr><td>NIHSS Threshold</td><td>Any (>3 if aspirin failure)</td><td>Any unless aspirin failure</td><td>&le;3</td><td>Any with cardioembolic risk</td></tr><tr><td>Major Bleeding Risk</td><td>Moderate</td><td>Low</td><td>High</td><td>High</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dual antiplatelet therapy should be discontinued after 21 days in minor stroke to limit hemorrhage.  <br><span class=\"list-item\">\u2022</span> Always verify NIHSS: only minor strokes (&le;3) qualify for short-term DAPT.  <br><span class=\"list-item\">\u2022</span> In aspirin failure, switch to clopidogrel monotherapy or aspirin + dipyridamole rather than indefinite DAPT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating NIHSS 8 with &ldquo;minor stroke&rdquo; and using prolonged DAPT.  <br>2. Initiating anticoagulation for noncardioembolic strokes under the false assumption it&rsquo;s more protective.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA Guidelines on Secondary Stroke Prevention, 2018: Class I recommendation for clopidogrel monotherapy after aspirin failure; Class IIa for short-term DAPT only in NIHSS &le; 3.  <br><span class=\"list-item\">\u2022</span> European Stroke Organisation Guidelines, 2021: Endorse clopidogrel as alternative monotherapy when aspirin fails (Level A).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Clopidogrel (75 mg daily after 300 mg loading) irreversibly inhibits the P2Y12 ADP receptor, reducing platelet aggregation. Aspirin (50&ndash;325 mg daily) blocks COX-1&ndash;mediated thromboxane A2. Combined use heightens bleeding risk; DAPT duration is limited to 21 days in eligible minor stroke/TIA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Boards frequently test the NIHSS cutoff for dual antiplatelet therapy and the management of aspirin &ldquo;failure&rdquo; in noncardioembolic stroke.</div></div></div></div></div>"}, {"id": 100023172, "question_number": "128", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Perimesencephalic hemorrhage is a nonaneurysmal subtype of subarachnoid hemorrhage (SAH) characterized by localized bleeding around the midbrain, notably within the interpeduncular, ambient, and quadrigeminal cisterns. Recognizing CT distribution is <span class=\"key-point\">critical:</span> aneurysmal SAH typically demonstrates diffuse blood in basal cisterns, sylvian fissures, and often intraventricular extension, whereas perimesencephalic SAH confines blood to cisterns anterior to the midbrain with sparing of the convexities and fissures. Prognostically, perimesencephalic hemorrhage has a benign course compared to aneurysmal SAH. Neuroanatomical knowledge of basal cisterns and their venous drainage underpins accurate radiographic interpretation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic hemorrhage is confirmed when noncontrast CT shows hyperdensity limited to the perimesencephalic cisterns without extension into the sylvian fissures, interhemispheric fissure, or ventricles. Multiple series, beginning with van Gijn et al. (1985), have demonstrated that this pattern correlates with a venous origin, negligible rebleeding risk (<1%), and excellent functional outcome. <span class=\"evidence\">The 2023</span> AHA/ASA guidelines <span class=\"citation\">(<span class=\"evidence\">Stroke 2023</span>;54:e1-e35)</span> advise that when CTA is negative and CT appearance is entirely perimesencephalic, further angiography may be omitted (Class IIa, Level B). A meta-analysis by Shankar et al. <span class=\"citation\">(<span class=\"evidence\">Neurosurgery 2020</span>;86:789-795)</span> confirmed <2% incidental aneurysm rate upon delayed DSA in classical cases. Pathophysiologically, small basal vein tears rather than arterial rupture explain the confined bleed and benign course.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Infection  <br><span class=\"list-item\">\u2022</span> Incorrect because intracranial infection (e.g., abscess, meningitis) produces ring-enhancing lesions or diffuse meningeal enhancement on contrast imaging, not isolated hyperdensity in basal cisterns.  <br><span class=\"list-item\">\u2022</span> Misconception: equating headaches with hemorrhage in infections; infections feature fever, elevated inflammatory markers.  <br><br>B. Malignancy  <br><span class=\"list-item\">\u2022</span> Intracranial tumors/mets appear as mass lesions with surrounding vasogenic edema and heterogeneous enhancement; they do not present acutely as hyperdense cisternal blood.  <br><span class=\"list-item\">\u2022</span> Misconception: acute headache equals metastasis; tumors cause subacute symptoms, seizures.  <br><br>D. Subarachnoid hemorrhage  <br><span class=\"list-item\">\u2022</span> Although perimesencephalic hemorrhage is a form of SAH, option D implies diffuse aneurysmal SAH with diffuse cisternal and fissural blood.  <br><span class=\"list-item\">\u2022</span> Key differentiator: diffuse sylvian and interhemispheric blood vs. focal perimesencephalic blood.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Perimesencephalic Hemorrhage</th><th>Aneurysmal SAH</th><th>Infection (Abscess/Meningitis)</th><th>Malignancy (Metastasis/Primary)</th></tr></thead><tbody><tr><td>CT Distribution</td><td>Blood confined to perimesencephalic cisterns</td><td>Diffuse basal cistern, sylvian fissure, ventricles</td><td>Hypodense core with ring enhancement</td><td>Mass lesion with edema, heterogeneous enhancement</td></tr><tr><td>Angiography Findings</td><td>Negative (no aneurysm)</td><td>Positive (aneurysm identified)</td><td>N/A</td><td>N/A</td></tr><tr><td>Clinical Presentation</td><td>Thunderclap headache, minimal focal deficits</td><td>Thunderclap headache, variable focal deficits</td><td>Fever, headache, altered mental status</td><td>Subacute headache, seizures, focal signs</td></tr><tr><td>Prognosis</td><td>Excellent; low rebleed risk</td><td>High morbidity/mortality</td><td>Variable; dependent on pathogen</td><td>Variable; dependent on tumor type</td></tr><tr><td>Management</td><td>Supportive, monitor, +/- nimodipine</td><td>Secure aneurysm, nimodipine, manage vasospasm</td><td>Antibiotics/antifungals, possible drainage</td><td>Surgical resection, chemo/radiation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. In classical perimesencephalic SAH, a single negative CTA plus characteristic CT appearance often obviates invasive angiography <span class=\"citation\">(AHA/ASA 2023)</span>.  <br>2. Despite its benign course, monitor for hydrocephalus and vasospasm; consider short-term nimodipine.  <br>3. Early differentiation of perimesencephalic vs. aneurysmal SAH on CT guides urgency of neurosurgical intervention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Over-reliance on initial CT without recognizing the confined cisternal pattern can lead to unnecessary angiograms or missed aneurysms.  <br>2. Equating all acute cisternal hyperdensities with aneurysmal SAH ignores the unique perimesencephalic distribution and venous etiology.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Management of Aneurysmal SAH <span class=\"citation\">(<span class=\"evidence\">Stroke 2023</span>;54:e1-e35)</span>: Recommend that in typical perimesencephalic SAH with negative CTA, DSA is optional (Class IIa, Level B).  <br>2. British Society of Neuroradiologists Consensus <span class=\"citation\">(BSNR 2022)</span>: Reported CTA sensitivity >98% for aneurysm detection; in perimesencephalic patterns, negative CTA has >99% negative predictive value, reducing need for DSA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Blood in the interpeduncular, ambient, and quadrigeminal cisterns corresponds to leakage from small perforating veins around the mesencephalon, sparing the sylvian fissures and convexities.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Perimesencephalic hemorrhage likely arises from venous plexuses around the midbrain; lack of arterial involvement accounts for minimal rebleeding and vasospasm.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Noncontrast CT within 6 hours of headache onset \u2192 identify hyperdensity pattern.  <br>2. If confined to perimesencephalic cisterns, perform CTA.  <br>3. If CTA negative and CT pattern classic \u2192 conservative management.  <br>4. If CTA positive or CT atypical \u2192 proceed to DSA and neurosurgical planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>Noncontrast CT within 6 hours is >95% sensitive for SAH. True perimesencephalic SAH spares the sylvian fissures and convexities; any extension mandates aneurysm workup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Nimodipine (60 mg PO q4h for 21 days) is recommended in SAH to reduce delayed cerebral ischemia; its use in perimesencephalic hemorrhage is extrapolated from aneurysmal data (Class I, Level A for aneurysmal SAH).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Subarachnoid hemorrhage patterns on CT&mdash;especially perimesencephalic vs. aneurysmal&mdash;are frequently tested in both Step 2/3 and neurology boards as image\u2010based vignette questions.</div></div></div></div></div>"}, {"id": 100023173, "question_number": "70", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] - Pregnancy and the postpartum period induce a hypercoagulable state (\u2191 fibrinogen, factors VII&ndash;X) that predisposes to cerebral venous thrombosis (CVT).  <br><span class=\"list-item\">\u2022</span> Thrombosis of dural sinuses impairs venous drainage, raises intracranial pressure and can cause venous infarcts, hemorrhage and seizures.  <br><span class=\"list-item\">\u2022</span> Acute onset headache with seizure in a postpartum patient&mdash;even with normal blood pressure and labs&mdash;should prompt urgent neuroimaging (CT/MR venography) to confirm or exclude CVT.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>CT venography is the recommended first-line diagnostic modality for suspected acute CVT in emergency settings due to its wide availability, rapid acquisition and high sensitivity (90&ndash;95%) and specificity (>90%) for detecting dural sinus filling defects (empty delta sign). <span class=\"evidence\">The 2017</span> European Stroke Organisation guidelines and the American Heart Association/American Stroke Association <span class=\"citation\">(2011, reaffirmed 2019)</span> both endorse CT or MR venography as the initial imaging choice in suspected CVT (Class I, Level B). Conventional digital subtraction angiography (&ldquo;angiogram&rdquo;) is invasive, carries stroke and groin\u2010site risks, and is now reserved for cases where noninvasive studies are inconclusive. Lumbar puncture prior to neuroimaging risks brain herniation if intracranial hypertension is present. Urine protein and liver function studies are appropriate in diagnosing preeclampsia/HELLP but offer no diagnostic clarity for CVT when vital signs and labs are normal.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Angiogram  <br>&bull; Incorrect: Invasive arterial study with lower sensitivity for venous sinus thrombosis; reserved for equivocal cases after noninvasive imaging fails.  <br>&bull; Misconception: Belief that &ldquo;angiogram&rdquo; always provides the definitive vascular diagnosis; overlooks risk of stroke and hemorrhage.  <br>C. Urine protein and liver function  <br>&bull; Incorrect: Targets preeclampsia/HELLP syndrome; in this patient BP is normal and no proteinuria has been reported.  <br>&bull; Misconception: Equating any postpartum seizure/headache with eclampsia rather than considering CVT.  <br>D. Lumbar puncture (LP)  <br>&bull; Incorrect: Contraindicated until imaging excludes raised intracranial pressure or mass lesions; may precipitate herniation.  <br>&bull; Misconception: Using LP to diagnose CNS pathology without first ruling out elevated intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Venogram (B)</th><th>Angiogram (A)</th><th>Urine Protein/LFT (C)</th><th>Lumbar Puncture (D)</th></tr></thead><tbody><tr><td>Modality</td><td>Contrast-enhanced CT</td><td>Digital subtraction</td><td>Laboratory tests</td><td>CSF analysis</td></tr><tr><td>Invasiveness</td><td>Noninvasive</td><td>Invasive (catheter-based)</td><td>Noninvasive</td><td>Minimally invasive</td></tr><tr><td>CVT Diagnostic Accuracy</td><td>Sensitivity 90&ndash;95%</td><td>Lower for venous pathology</td><td>None</td><td>Nonspecific</td></tr><tr><td>Primary Indication</td><td>Suspected CVT</td><td>Inconclusive noninvasive</td><td>Preeclampsia/HELLP</td><td>Suspected meningitis, ICP measurement</td></tr><tr><td>Time to Perform</td><td><30 minutes</td><td>>1 hour</td><td>Minutes</td><td>~30 minutes</td></tr><tr><td>Major Risks</td><td>Contrast allergy, radiation</td><td>Stroke, groin hematoma</td><td>None</td><td>Herniation if \u2191ICP</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Postpartum CVT often presents 1&ndash;2 weeks after delivery with headache out of proportion, seizures or focal deficits.  <br>2. Look for the &ldquo;empty delta sign&rdquo; on contrast CT&mdash;a triangular filling defect in the superior sagittal sinus.  <br>3. Always exclude raised intracranial pressure with neuroimaging before lumbar puncture.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Misattributing postpartum headache and seizure solely to eclampsia despite normal blood pressure and labs, delaying CVT workup.  <br>2. Performing lumbar puncture before imaging, risking herniation in the setting of elevated intracranial pressure.  <br>3. Overreliance on noncontrast CT head alone, which can miss up to 30% of CVT cases.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- European Stroke Organisation (ESO) 2017 Guidelines for Cerebral Venous Thrombosis: Recommend CT or MR venography as first-line diagnostic studies in suspected acute CVT (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> American Heart Association/American Stroke <span class=\"evidence\">Association 2011</span> Guidelines <span class=\"citation\">(reaffirmed 2019)</span>: Endorse immediate noninvasive venous imaging (CT/MR venography) in patients with headache and focal signs or seizures when CVT is suspected (Class I, Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Students are frequently tested on postpartum headache with seizure, emphasizing early noninvasive imaging (CT/MR venography) to diagnose cerebral venous thrombosis.</div></div></div></div></div>"}, {"id": 100023174, "question_number": "69", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Acute ischemic stroke often impairs cerebral autoregulation, making elevated systemic blood pressure (BP) both protective against hypoperfusion and a risk factor for hemorrhagic transformation post-thrombolysis. Thrombolytic therapy (tPA) further increases bleeding risk when BP exceeds safe thresholds. Current protocols mandate tight BP control&mdash;specifically systolic BP <180 mm Hg and diastolic BP <105 mm Hg&mdash;for at least 24 hours after tPA. Intravenous, titratable antihypertensives are preferred to achieve rapid, precise reductions. Familiarity with pharmacokinetics of agents and local stroke unit protocols is essential in acute care.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Nicardipine, an intravenous dihydropyridine calcium\u2010channel blocker, offers rapid onset (within 5 minutes) and a short half\u2010life, allowing fine titration to maintain post\u2010tPA BP targets. <span class=\"evidence\">The 2018</span> AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke (Class I, Level B-R) explicitly recommend IV nicardipine or labetalol infusion for sustained BP >180/105 mm Hg after thrombolysis. Oral amlodipine has a delayed onset (6&ndash;8 hours) and lacks titratability, risking overshoot or undershoot. Observation alone fails to mitigate hemorrhagic risk, and anxiolysis with diazepam does not reliably lower arterial pressure to guideline-specified levels. Tight BP control reduces symptomatic intracranial hemorrhage and improves functional outcomes by stabilizing the blood&ndash;brain barrier.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Amlodipine  <br>&bull; Oral dihydropyridine with slow onset (6&ndash;8 h) and long half-life; cannot achieve rapid, adjustable BP control post-tPA.  <br>&bull; Misconception: Any antihypertensive will suffice&mdash;fails to account for acute titratability.  <br><br>C. Observation  <br>&bull; No intervention leaves SBP at 190 mm Hg, above the 180 mm Hg threshold, increasing hemorrhagic conversion risk.  <br>&bull; Misconception: &ldquo;Watchful waiting&rdquo; is safe if vitals are stable; ignores evolving post-thrombolysis vulnerabilities.  <br><br>D. Diazepam  <br>&bull; Benzodiazepine reduces anxiety but has minimal and unpredictable antihypertensive effect; may cause oversedation.  <br>&bull; Misconception: Anxiety relief automatically normalizes BP; does not meet guideline BP targets.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Class/Type</th><th>Onset</th><th>Titration Ability</th><th>Post-tPA BP Control Suitability</th><th>Rationale</th></tr></thead><tbody><tr><td>Nicardipine</td><td>IV dihydropyridine CCB infusion</td><td>~5 minutes</td><td>High</td><td>Yes</td><td>Rapid, adjustable infusion&mdash;achieves SBP <180 mm Hg</td></tr><tr><td>Amlodipine</td><td>Oral dihydropyridine CCB</td><td>6&ndash;8 hours</td><td>None</td><td>No</td><td>Slow onset, non-titrable</td></tr><tr><td>Observation</td><td>None</td><td>N/A</td><td>N/A</td><td>No</td><td>Uncontrolled hypertension risks hemorrhage</td></tr><tr><td>Diazepam</td><td>IV benzodiazepine</td><td>5&ndash;10 minutes</td><td>Low</td><td>No</td><td>Anxiolytic only&mdash;unreliable BP-lowering effect</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; After IV tPA, maintain SBP <180 mm Hg and DBP <105 mm Hg for at least 24 hours <span class=\"citation\">(AHA/ASA 2018)</span>.  <br>&bull; First-line agents: IV nicardipine infusion or IV labetalol bolus/infusion for rapid, controllable BP reduction.  <br>&bull; Avoid oral, long-acting antihypertensives in the acute post-tPA period due to delayed effect and poor titratability.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Relying on oral antihypertensives (e.g., amlodipine) in hyperacute stroke&mdash;delayed onset compromises safety.  <br>2. Assuming that sedation/anxiolysis (diazepam) adequately controls BP&mdash;leads to under-treatment of hypertension.  <br>3. Believing stable vital signs alone negate the need for intervention&mdash;overlooks dynamic hemorrhagic risks post-tPA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke, 2018  <br>   &bull; Recommendation: Maintain SBP <180 mm Hg and DBP <105 mm Hg for 24 h post-thrombolysis (Class I, LOE B-R).  <br>2. ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study), 2019  <br>   &bull; Randomized trial comparing intensive SBP target (130&ndash;140 mm Hg) vs standard (<180 mm Hg) in tPA-treated patients.  <br>   &bull; Found no significant improvement in 90-day functional outcomes with intensive lowering; supports guideline-based targets (Level I evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Hypertension management after thrombolysis is frequently tested in scenario\u2010based acute stroke questions, emphasizing knowledge of BP thresholds, timing, and choice of IV antihypertensive agents.</div></div></div></div></div>"}, {"id": 100023175, "question_number": "393", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2022] Acute ischemic stroke workup demands rapid distinction of hemorrhagic vs ischemic events and identification of vessel occlusion. The occipital lobe is supplied by the posterior cerebral artery (PCA); infarction may present with visual phenomena (complex hallucinations, visual field defects) and secondary seizures. Visual auras followed by impaired consciousness could reflect occipital stroke&ndash;induced seizure. Initial noncontrast CT excludes hemorrhage; subsequent CTA evaluates arterial patency and guides reperfusion strategies. Rapid vascular imaging is crucial for mechanical thrombectomy decisions, even in posterior circulation strokes, and complements thrombolysis assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Emergent CTA after noncontrast CT is a Class I, Level A recommendation in the 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. CTA within 20 minutes identifies large vessel occlusions&mdash;including PCA branch occlusions&mdash;that may benefit from endovascular therapy. The MR CLEAN, ESCAPE, DAWN, and DEFUSE 3 trials demonstrated improved outcomes with thrombectomy in selected patients up to 24 hours from onset, including posterior circulation strokes when imaging shows salvageable penumbra. EEG does not direct acute reperfusion decisions. Intravenous tPA (0.9 mg/kg) must be given within 4.5 hours but is complemented, not supplanted, by CTA to stratify endovascular candidacy. Stroke unit admission follows urgent imaging and reperfusion planning.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>B. EEG  <br><span class=\"list-item\">\u2022</span> Incorrect: Evaluates cortical electrical activity, not vascular occlusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Prioritizing seizure workup over reperfusion delays treatment.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA directly visualizes arterial blockages.  <br><br>C. tPA  <br><span class=\"list-item\">\u2022</span> Incorrect: A treatment step, not a diagnostic triage; must follow hemorrhage exclusion and vascular imaging to optimize therapy.  <br><span class=\"list-item\">\u2022</span> Misconception: Immediate thrombolysis without vessel imaging suffices.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA informs both thrombolytic and thrombectomy strategy.  <br><br>D. Admit to stroke unit  <br><span class=\"list-item\">\u2022</span> Incorrect: Essential for post-acute care but secondary to urgent imaging to guide reperfusion.  <br><span class=\"list-item\">\u2022</span> Misconception: Hospitalization alone addresses acute occlusion.  <br><span class=\"list-item\">\u2022</span> Differentiator: CTA precedes specialized unit admission in acute workflow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Purpose</th><th>Timing</th><th>Key Output</th></tr></thead><tbody><tr><td>CTA [CORRECT]</td><td>Vascular imaging</td><td>Immediately after noncontrast CT</td><td>Identifies occlusion location & extent</td></tr><tr><td>EEG</td><td>Electrical brain activity</td><td>After stabilization if seizures persist</td><td>Detects epileptiform discharges</td></tr><tr><td>tPA</td><td>Systemic thrombolysis</td><td>Following imaging & within 4.5 hr window</td><td>Promotes clot lysis</td></tr><tr><td>Admit to stroke unit</td><td>Specialized multidisciplinary care</td><td>After acute interventions</td><td>Facilitates monitoring & rehabilitation</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Obtain CTA within 20 minutes of noncontrast CT in all suspected large vessel strokes to assess thrombectomy candidacy.  <br><span class=\"list-item\">\u2022</span> Occipital infarcts can present with visual hallucinations and seizures; do not delay reperfusion imaging for EEG.  <br><span class=\"list-item\">\u2022</span> Dedicated stroke unit admission reduces morbidity and mortality but is not a substitute for urgent vascular imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering EEG before CTA delays critical reperfusion assessment in acute stroke.  <br>2. Initiating tPA without vascular imaging can miss large vessel occlusion requiring thrombectomy and increases hemorrhage risk.  <br>3. Direct ward admission without completing acute imaging prolongs time to reperfusion interventions.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2019 (Class I, LOE A): Perform emergent CTA head and neck immediately after noncontrast CT in patients eligible for reperfusion.  <br><span class=\"list-item\">\u2022</span> ESO&ndash;ESMINT 2021 (Grade A, Level 1a): Recommend mechanical thrombectomy for posterior circulation strokes within 24 hours of onset when imaging shows viable tissue.  <br><span class=\"list-item\">\u2022</span> DAWN <span class=\"evidence\">Trial 2018</span> (NEJM): Extended thrombectomy window to 6&ndash;24 hours in selected patients based on perfusion imaging mismatch (relative risk of functional independence 1.75).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The left PCA supplies primary visual cortex (Brodmann area 17) and adjacent visual association areas (areas 18&ndash;19). Infarcts here manifest as contralateral homonymous hemianopia and may provoke visual auras or seizures due to cortical irritation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>PCA occlusion leads to ischemia-induced energy failure, Na\u207a/K\u207a-ATPase pump collapse, cytotoxic edema, and neuronal excitotoxicity. The ischemic penumbra retains partial perfusion and is salvageable with timely reperfusion; its identification via CTA/CTP guides therapy.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Activate stroke code on presentation.  <br>2. Perform noncontrast CT to exclude hemorrhage (< 20 min).  <br>3. Obtain CTA head and neck to identify vessel occlusion.  <br>4. If within 4.5 hr, initiate IV tPA after hemorrhage exclusion.  <br>5. If large vessel occlusion on CTA and within 24 hr, proceed to thrombectomy.  <br>6. Admit to stroke unit for ongoing care and secondary prevention.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Noncontrast CT may miss early occipital infarcts; look for subtle loss of gray&ndash;white differentiation.  <br><span class=\"list-item\">\u2022</span> CTA &ldquo;cutoff sign&rdquo; indicates abrupt vessel occlusion; CT perfusion identifies core vs penumbra.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>- Alteplase dosing: 0.9 mg/kg (max 90 mg), 10% bolus, remainder over 60 min.  <br><span class=\"list-item\">\u2022</span> Start aspirin 160&ndash;325 mg 24 hr post tPA or immediately if no tPA; dual antiplatelet therapy for minor stroke (CHANCE/POINT trials).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2022 exam. Posterior circulation stroke management&mdash;with emphasis on CTA in the acute workflow&mdash;is commonly tested as single-best-answer items, often combined with imaging and reperfusion decision-making scenarios.</div></div></div></div></div>"}, {"id": 100023176, "question_number": "68", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part I 2018] Subarachnoid hemorrhage from a ruptured aneurysm carries a 30\u2010day rebleeding risk of up to 20%, highest in the first 24 hours. Posterior communicating (PComm) aneurysms arise at the junction of the internal carotid and PComm arteries; mass effect can compress the oculomotor nerve. Definitive securing of the aneurysm&mdash;by endovascular coiling or surgical clipping&mdash;prevents rebleeding. Endovascular techniques traverse the aneurysm neck via the lumen, deposit coils to induce thrombosis, and are less invasive than craniotomy, with faster recovery. Early intervention (ideally within 24 hours) also allows initiation of vasospasm prophylaxis (e.g., nimodipine) and hemodynamic management.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Endovascular coiling is the preferred modality for many ruptured aneurysms when anatomy permits. The International Subarachnoid Aneurysm Trial <span class=\"citation\">(ISAT, New Engl J <span class=\"evidence\">Med 2002</span>)</span> randomized 2,143 patients and showed significantly lower 1-year mortality or dependency with coiling versus clipping <span class=\"citation\">(23.7% vs. 30.6%, p = 0.0016)</span>. <span class=\"evidence\">The 2015</span> AHA/ASA SAH guidelines (Class I, Level A) endorse early aneurysm repair by coiling if the aneurysm&rsquo;s neck and sac morphology are favorable. Subsequent studies <span class=\"citation\">(BRAT, J <span class=\"evidence\">Neurosurg 2011</span>; ACT II, AJNR 2009)</span> and the 2022 SNIS consensus reaffirm coiling&rsquo;s lower procedural morbidity, shorter ICU stay, and equivalent long\u2010term occlusion for PComm aneurysms with < 4 mm neck width.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Craniotomy with clipping  <br>&bull; Incorrect because although definitive, clipping is more invasive with higher perioperative morbidity and longer recovery. Misconception: surgical clipping always superior to coiling. Key difference: open approach vs. endovascular access.  <br><br>C. Observation  <br>&bull; Incorrect&mdash;watchful waiting fails to prevent early rebleeding, which carries ~40% mortality. Misconception: patients may stabilize without intervention. Key difference: definitive aneurysm exclusion is mandatory.  <br><br>D. Medical management with blood pressure control  <br>&bull; Incorrect&mdash;blood pressure control is adjunctive but not definitive; without aneurysm securing, rebleeding risk remains high. Misconception: aggressive medical therapy alone can avert rebleeding. Key difference: supportive care vs. definitive occlusion.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Endovascular Coiling (Correct)</th><th>Craniotomy & Clipping</th><th>Observation</th><th>BP Control Alone</th></tr></thead><tbody><tr><td>Invasiveness</td><td>Minimally invasive</td><td>Highly invasive</td><td>None</td><td>Non\u2010invasive</td></tr><tr><td>Timing</td><td>Within 24 h</td><td>Within 24 h</td><td>Delayed/None</td><td>Immediate supportive</td></tr><tr><td>Rebleeding prevention</td><td>High efficacy</td><td>High efficacy</td><td>None</td><td>None</td></tr><tr><td>Morbidity & recovery</td><td>Lower morbidity, faster recovery</td><td>Higher morbidity, longer recovery</td><td>N/A</td><td>N/A</td></tr><tr><td>Guideline recommendation</td><td>Class I, Level A</td><td>Class I, Level A</td><td>Contraindicated</td><td>Adjunct only</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Secure aneurysms within 24 hours to minimize rebleeding and facilitate nimodipine for vasospasm prophylaxis.  <br><span class=\"list-item\">\u2022</span> PComm aneurysms often present with third\u2010nerve palsy; coiling spares brain retraction and nerve manipulation.  <br><span class=\"list-item\">\u2022</span> Coil embolization carries a small risk of aneurysm recanalization; follow\u2010up angiography at 6 months is essential.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Delaying aneurysm repair to &ldquo;manage vasospasm risk&rdquo; increases rebleeding and mortality&mdash;early securing is paramount.  <br>2. Assuming surgical clipping is always superior; patient-specific anatomy dictates modality, and coiling often yields better functional outcomes.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; AHA/ASA 2015 Guidelines for SAH: Class I, Level A &ndash; &ldquo;Early repair of ruptured aneurysms by coiling or clipping; coiling preferred for favorable anatomy.&rdquo;  <br>&bull; SNIS 2022 Consensus on Endovascular Management: &ldquo;Endovascular coiling is first\u2010line in PComm aneurysms with neck width < 4 mm, dome\u2010to\u2010neck ratio > 1.5&rdquo; (Level B evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part I 2018 exam. Management of ruptured aneurysms is tested frequently, often focusing on indications, timing, and choice between coiling versus clipping.</div></div></div></div></div>"}, {"id": 100023177, "question_number": "127", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] 1. Atherosclerotic plaque in the internal carotid artery (ICA) narrows the lumen, promoting thromboembolism and ipsilateral ischemic stroke.  <br>2. In asymptomatic patients, moderate-to-high&ndash;grade stenosis carries a ~2% annual stroke risk on medical therapy; surgical removal via carotid endarterectomy (CEA) can reduce long-term risk.  <br>3. Key criteria for CEA in asymptomatic stenosis include &ge;60% luminal narrowing (angiographic), a life expectancy >5 years, and a perioperative stroke/death rate <3%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The Asymptomatic Carotid Atherosclerosis Study <span class=\"citation\">(ACAS, 1995)</span> randomized patients with angiographically confirmed 60&ndash;99% ICA stenosis to CEA versus medical management. Over five years, the CEA group had a 5.1% combined risk of ipsilateral stroke or perioperative stroke/death versus 11.0% in controls (absolute risk reduction 5.9%; NNT \u224817). This benefit applies specifically to stenoses &ge;60%. Subsequent AHA/ASA (2014) guidelines endorse CEA for asymptomatic 60&ndash;99% stenosis if surgical risk is low (Class IIa; Level B). Improvements in medical therapy have narrowed the absolute benefit, but the foundational ACAS threshold remains 60&ndash;99%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. 50% to 69%  <br>   &ndash; ACAS did not include patients with <60% stenosis; trials show insufficient event rates below this threshold to justify CEA.  <br>   &ndash; Misconception: extending symptomatic trial criteria (NASCET) to asymptomatic populations.  <br><br>C. 70% to 99%  <br>   &ndash; Reflects the inclusion criteria for the Asymptomatic Carotid Surgery Trial (ACST), not ACAS.  <br>   &ndash; ACST used &ge;70% by ultrasound, yielding a smaller absolute risk reduction (ARR ~3.3%).  <br><br>D. 30% to 50%  <br>   &ndash; No randomized trial supports surgical intervention for mild stenosis; annual stroke risk is low (<1%).  <br>   &ndash; Misconception: any degree of stenosis merits CEA.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Stenosis Range</th><th>Trial</th><th>5-Year Stroke/Death</th><th>Absolute Risk Reduction</th><th>NNT</th></tr></thead><tbody><tr><td>60&ndash;99%</td><td>ACAS</td><td>11.0% \u2192 5.1%</td><td>5.9%</td><td>~17</td></tr><tr><td>70&ndash;99%</td><td>ACST</td><td>11.8% \u2192 8.5%</td><td>3.3%</td><td>~30</td></tr><tr><td>50&ndash;69%</td><td>None</td><td>~5% annual risk</td><td>Not studied</td><td>N/A</td></tr><tr><td>30&ndash;50%</td><td>None</td><td><1% annual risk</td><td>No benefit</td><td>N/A</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always confirm perioperative stroke/death risk is <3% when considering CEA for asymptomatic disease.  <br>2. Duplex ultrasound criteria: peak systolic velocity >230 cm/s correlates with &ge;60% angiographic stenosis.  <br>3. Optimal medical therapy&mdash;statin, antiplatelet, blood pressure control&mdash;remains the foundation; surgical benefit is additive.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Confusing ACAS (asymptomatic, &ge;60% angiographic stenosis) with NASCET (symptomatic patients).  <br>2. Recommending CEA for asymptomatic stenosis <60% based on symptomatic trial data or outdated thresholds.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2014 Stroke Prevention Guidelines: recommend CEA for asymptomatic 60&ndash;99% stenosis in patients with life expectancy >5 years and perioperative risk <3% (Class IIa; Level B).  <br><span class=\"list-item\">\u2022</span> ESC/ESVS 2018 Vascular Surgery Guidelines: endorse CEA for asymptomatic &ge;60% stenosis when surgical risk is low and life expectancy >5 years (Class IIa; Level B).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Carotid stenosis trials (ACAS vs ACST vs NASCET) and their stenosis thresholds are high-yield topics on stroke prevention sections of board exams.</div></div></div></div></div>"}, {"id": 100023178, "question_number": "96", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Postpartum headache with photophobia raises concern for serious intracranial pathology. Key concepts:  <br><span class=\"list-item\">\u2022</span> Pathophysiology of hypercoagulability in the puerperium (Virchow&rsquo;s triad: stasis, vessel injury, hypercoagulability).  <br><span class=\"list-item\">\u2022</span> Cerebral venous sinus thrombosis (CVST) often presents with headache, papilledema, and meningeal signs.  <br><span class=\"list-item\">\u2022</span> Imaging modalities differ in sensitivity for arterial versus venous pathology; CT venography (CTV) and MR venography (MRV) are gold-standard noninvasive tests for CVST.  <br>(Word count: 88)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>The optimal diagnostic step in suspected CVST is cerebral venous imaging. While noncontrast CT may show indirect signs (e.g., &ldquo;dense triangle sign&rdquo;), CTV has high sensitivity (95\u2009%) and specificity (91\u2009%) and is rapidly available in acute settings <span class=\"citation\">(Ferro et al., <span class=\"evidence\">Stroke 2004</span>)</span>. According to the 2011 AHA/ASA CVST guidelines, once CVST is suspected clinically, CTV or MRV should be performed emergently to confirm thrombus location and extent (Class I, Level B). CT angiography (CTA) targets arterial circulation and may miss venous occlusions. MRI without dedicated venography sequences can overlook sinus thrombosis, and lumbar puncture risks herniation if intracranial pressure is elevated.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Brain CT Angiography  <br><span class=\"list-item\">\u2022</span> Incorrect: Visualizes arteries, not sinuses; low sensitivity for venous thrombosis.  <br><span class=\"list-item\">\u2022</span> Misconception: Assuming arterial and venous imaging are interchangeable.  <br><br>C. MRI of the brain  <br><span class=\"list-item\">\u2022</span> Incorrect: Standard MRI without MRV sequences may miss sinus thrombi; slower acquisition and less available in emergencies.  <br><span class=\"list-item\">\u2022</span> Misconception: MRI always superior to CT for acute neuro problems.  <br><br>D. Lumbar puncture  <br><span class=\"list-item\">\u2022</span> Incorrect: Contraindicated if raised intracranial pressure; may precipitate herniation and does not diagnose CVST.  <br><span class=\"list-item\">\u2022</span> Misconception: Photophobia always mandates LP for meningitis evaluation, regardless of imaging.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>CT Angiography</th><th>CT Venography</th><th>MRI (no MRV)</th><th>Lumbar Puncture</th></tr></thead><tbody><tr><td>Targets</td><td>Arterial circulation</td><td>Venous sinuses</td><td>Brain parenchyma</td><td>CSF analysis</td></tr><tr><td>Sensitivity for CVST</td><td>~60\u2009%</td><td>~95\u2009%</td><td>~80\u2009% (without MRV)</td><td>N/A</td></tr><tr><td>Availability</td><td>High</td><td>High</td><td>Variable</td><td>High</td></tr><tr><td>Contraindications</td><td>Contrast allergy, renal failure</td><td>Same as CTA</td><td>Claustrophobia, implants</td><td>Raised ICP, mass lesion</td></tr><tr><td>Time to result</td><td>Minutes</td><td>Minutes</td><td>&ge;30 minutes</td><td>&ge;30 minutes</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Postpartum women are at highest CVST risk within first 4 weeks due to hypercoagulable shifts.  <br><span class=\"list-item\">\u2022</span> Anticoagulation with LMWH should be initiated promptly after diagnosis, even with hemorrhagic infarcts.  <br><span class=\"list-item\">\u2022</span> The &ldquo;empty delta sign&rdquo; on contrast CT is pathognomonic for superior sagittal sinus thrombosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Ordering CTA instead of CTV: arterial studies miss venous clots.  <br>2. Proceeding to LP before imaging: risk of cerebral herniation in elevated intracranial pressure.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2011 CVST Guidelines: Recommend emergent CTV or MRV in suspected cases (Class I, Level B).  <br><span class=\"list-item\">\u2022</span> European Stroke <span class=\"evidence\">Organization 2017</span>: Affirms CTV as first-line when MRV unavailable (Level A evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>Superior sagittal, transverse, and sigmoid sinuses drain cortical veins; thrombosis leads to venous congestion, cytotoxic and vasogenic edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Postpartum hypercoagulability (\u2191 fibrinogen, \u2193 protein S), venous stasis in cerebral sinuses, endothelial activation \u2192 clot formation.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion (headache, focal signs, seizure)  <br>2. Noncontrast CT to exclude hemorrhage  <br>3. CT Venography or MR Venography to confirm CVST  <br>4. Initiate anticoagulation upon diagnosis</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Dense triangle sign on noncontrast CT: hyperattenuation in thrombosed sinus.  <br><span class=\"list-item\">\u2022</span> Empty delta sign on CTV: central filling defect surrounded by contrast.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Start LMWH (e.g., enoxaparin 1 mg/kg BID) irrespective of hemorrhagic infarct; transition to warfarin for 3&ndash;6 months postpartum.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. CVST is frequently tested as postpartum headache with imaging choice; attention to modality specificity (CTV/MRV) is critical.</div></div></div></div></div>"}, {"id": 100023179, "question_number": "95", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Symptomatic high\u2010grade ICA stenosis (&ge;70% by NASCET criteria) significantly increases stroke risk due to artery-to-artery embolism and hypoperfusion. Key principles:<br><span class=\"list-item\">\u2022</span> Atherosclerotic plaque in the ICA can shed thromboemboli to the ipsilateral cerebral hemisphere (most often MCA territory).<br><span class=\"list-item\">\u2022</span> Revascularization restores luminal diameter, reduces shear stress and plaque instability.<br><span class=\"list-item\">\u2022</span> Timing: maximal benefit when intervention occurs within two weeks of the TIA event.<br>Understanding these pathophysiological and temporal factors underpins why surgical removal of plaque (CEA) is superior to medical therapy alone for secondary prevention in this setting.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Carotid endarterectomy (CEA) is the gold\u2010standard for symptomatic severe (70&ndash;99%) ICA stenosis, based on landmark trials:<br><span class=\"list-item\">\u2022</span> NASCET (1991): CEA reduced five-year stroke/death rate from 26% (medical) to 9% (CEA) in symptomatic &ge;70% stenosis (absolute risk reduction 17%; NNT\u22486) (Class I, Level A).<br><span class=\"list-item\">\u2022</span> ECST (1998): similar findings confirming benefit when performed within 2 weeks.<br><span class=\"list-item\">\u2022</span> AHA/ASA 2021 guidelines: recommend CEA for symptomatic patients with 70&ndash;99% stenosis (Class I, LOE A), ideally within 14 days of index event.<br><span class=\"list-item\">\u2022</span> ESVS 2023: endorse early CEA (<2 weeks) if perioperative risk <6%.<br>Alternatives (stenting) are reserved for high surgical risk or unfavorable anatomy. Best medical therapy alone is inferior in this subgroup.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Angioplasty plus stenting  <br><span class=\"list-item\">\u2022</span> Incorrect because in patients >70 years with symptomatic high\u2010grade stenosis, stenting carries a higher periprocedural stroke risk compared to CEA (CREST trial stroke rate 5.2% vs CEA 2.3% in symptomatic patients). Misconception: stenting equals CEA efficacy in all patients.<br><br>C. Best medical treatment  <br><span class=\"list-item\">\u2022</span> Incorrect: while dual antiplatelet, statins, and risk factor control reduce stroke risk, RCTs unequivocally show that medical therapy alone does not achieve the same risk reduction as CEA in symptomatic &ge;70% stenosis.<br><br>D. Observation only  <br><span class=\"list-item\">\u2022</span> Incorrect: passive observation neglects both mechanical and pharmacologic interventions. Common error: underestimating embolic risk post-TIA with critical stenosis.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>Carotid Endarterectomy (CEA)</th><th>Carotid Stenting</th><th>Best Medical Therapy</th><th>Observation Only</th></tr></thead><tbody><tr><td>Indication</td><td>Symptomatic &ge;70% ICA stenosis</td><td>High surgical risk or <70%</td><td>All patients (adjunct)</td><td>None</td></tr><tr><td>Timing</td><td>Within 2 weeks</td><td>Within 2 weeks if chosen</td><td>Immediate and lifelong</td><td>Not applicable</td></tr><tr><td>30-day stroke/death risk</td><td>\u22482&ndash;4%</td><td>\u22485&ndash;7% (higher in >70 yrs)</td><td>N/A (no procedure risk)</td><td>N/A</td></tr><tr><td>Absolute risk reduction</td><td>~17% over 5 years</td><td>~12% over 5 years</td><td>~5&ndash;8% (adjunctive)</td><td>0</td></tr><tr><td>Guideline recommendation</td><td>Class I, LOE A</td><td>Class IIb, LOE B</td><td>Class I for all patients</td><td>None</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Highest benefit when CEA is performed within 14 days of TIA; delay reduces absolute risk reduction.<br><span class=\"list-item\">\u2022</span> Surgeon volume matters: centers performing >50 CEAs/yr have lower perioperative stroke rates.<br><span class=\"list-item\">\u2022</span> In octogenarians, weigh individual surgical risk; CEA still preferred if risk <6%.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating stenting with CEA efficacy in all age groups&mdash;stenting risk is higher in patients >70.  <br>2. Delaying referral for CEA beyond 2 weeks, which diminishes procedural benefit.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>- AHA/ASA 2021 Secondary Stroke Prevention Guideline: CEA for symptomatic 70&ndash;99% stenosis, within 14 days, Class I, LOE A.  <br><span class=\"list-item\">\u2022</span> ESVS 2023 Guidelines: recommend CEA if perioperative risk <6% and within 14 days (Level A).  <br><span class=\"list-item\">\u2022</span> CREST (2010): CEA superior to stenting in symptomatic, older patients (periprocedural stroke risk difference).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The ICA supplies the ipsilateral anterior and middle cerebral arteries; plaque at the carotid bifurcation predisposes to emboli traveling to MCA territory, causing cortical TIAs (e.g., contralateral hand or face weakness).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Atherosclerotic plaque ulceration leads to platelet aggregation and microembolization. Critical luminal narrowing exacerbates low-flow states, especially in watershed areas between major cerebral arteries.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical TIA evaluation (symptom localization)  <br>2. Carotid duplex ultrasound to quantify stenosis  <br>3. CTA/MRA for anatomical detail if duplex borderline  <br>4. Cardiac evaluation (ECG, echo) to exclude cardiac source  <br>5. Refer for CEA if symptomatic &ge;70% and surgical risk acceptable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Ultrasound velocity criteria: peak systolic velocity >230 cm/s indicates &ge;70% stenosis.  <br><span class=\"list-item\">\u2022</span> CTA plaque characterization (ulceration, intraplaque hemorrhage) refines risk assessment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pharmacotherapy Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>All symptomatic carotid stenosis patients require:<br><span class=\"list-item\">\u2022</span> Dual antiplatelet therapy (aspirin + clopidogrel) for 21&ndash;90 days post-TIA  <br><span class=\"list-item\">\u2022</span> High-intensity statin (e.g., atorvastatin 80 mg)  <br><span class=\"list-item\">\u2022</span> Blood pressure control (target <130/80 mm\u2009Hg)</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>Symptomatic carotid stenosis management is a high-yield topic in vascular neurology. This question appeared in Part II 2018 exam. It frequently tests timing, degree of stenosis, and procedural risks for CEA vs stenting.</div></div></div></div></div>"}, {"id": 100023180, "question_number": "126", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Acute ischemic stroke arises from arterial occlusion, creating an irreversibly infarcted core surrounded by a potentially salvageable penumbra reliant on collateral circulation. Normally, cerebral autoregulation maintains constant blood flow across wide pressure ranges; however, in ischemic territory this mechanism fails, rendering perfusion pressure passive to systemic blood pressure. Elevated blood pressure supports collateral perfusion of the penumbra but increases risk of hemorrhagic transformation, cerebral edema, and cardiac complications. Thus, permissive hypertension is recommended early after stroke, with antihypertensive therapy reserved for severe elevations (systolic >220 mm Hg or diastolic >120 mm Hg) to achieve a modest reduction (~15%) in the first 24 hours, balancing perfusion maintenance against complication risk. Terminology: ischemic penumbra, cerebral autoregulation, permissive hypertension.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Answer B aligns with the 2018 AHA/ASA Guidelines <span class=\"citation\">(Powers et al., <span class=\"evidence\">Stroke 2018</span>;49:e46-e110)</span>, which state that in acute ischemic stroke patients not treated with IV thrombolysis or mechanical thrombectomy, antihypertensive therapy is indicated only if SBP exceeds 220 mm Hg or DBP exceeds 120 mm Hg. The recommended goal is a controlled reduction of approximately 15% during the first 24 hours rather than normalization to avoid compromising penumbral perfusion. Observational studies demonstrate that abrupt blood pressure lowering in the first 72 hours correlates with increased infarct expansion and worse functional outcomes due to reduced cerebral blood flow in areas of impaired autoregulation. A modest reduction minimizes hemorrhagic risk while preserving collateral flow.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>A. Initiate antihypertensive treatment immediately  <br><span class=\"list-item\">\u2022</span> Incorrect: Suggests immediate, potentially aggressive lowering regardless of specific thresholds.  <br><span class=\"list-item\">\u2022</span> Misconception: Confuses management with post-thrombolysis BP targets (&le;180/105 mm Hg).  <br><span class=\"list-item\">\u2022</span> Differentiator: Non-reperfusion candidates tolerate higher BP; immediate normalization risks penumbral ischemia.  <br><br>C. No need to lower blood pressure  <br><span class=\"list-item\">\u2022</span> Incorrect: Ignores threshold-based recommendation for severe hypertension (>220/120 mm Hg).  <br><span class=\"list-item\">\u2022</span> Misconception: Assumes all elevated BP is protective; overlooks risk of hemorrhagic conversion and cardiac complications.  <br><span class=\"list-item\">\u2022</span> Differentiator: Guidelines mandate treatment when beyond defined hypertensive thresholds.  <br><br>D. Treat only if symptomatic  <br><span class=\"list-item\">\u2022</span> Incorrect: Symptom-driven approach fails to address asymptomatic risks (cerebral edema, hemorrhage).  <br><span class=\"list-item\">\u2022</span> Misconception: Belief that hypertension requires therapy only with headache, visual changes, or hypertensive emergency signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: In acute stroke, treatment is based on absolute BP values, not clinical symptoms alone.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Option</th><th>Management Trigger</th><th>BP Reduction Goal</th><th>Penumbral Perfusion Impact</th><th>Guideline Endorsement</th></tr></thead><tbody><tr><td>A</td><td>Any elevation (immediate)</td><td>Undefined/rapid</td><td>High risk of reduced collateral flow</td><td>Not recommended</td></tr><tr><td>B (CORRECT)</td><td>SBP >220 mm Hg or DBP >120 mm Hg</td><td>~15% in first 24 h</td><td>Balances perfusion and hemorrhage</td><td>AHA/ASA 2018 (Level C-LD)</td></tr><tr><td>C</td><td>Never lowering</td><td>None</td><td>Persistent hemorrhage/edema risk</td><td>Contra to guidelines</td></tr><tr><td>D</td><td>Symptom-driven</td><td>Variable</td><td>Misses asymptomatic complications</td><td>Contra to guidelines</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>- Permissive hypertension (up to 220/120 mm Hg) in non-thrombolysis candidates preserves collateral flow and may improve penumbral salvage.  <br><span class=\"list-item\">\u2022</span> Rapid BP lowering can convert penumbra to infarct core; aim for gradual reduction by 15% over 24 hours when indicated.  <br><span class=\"list-item\">\u2022</span> Differentiate BP targets: post-tPA/MT (<180/105 mm Hg) vs. non-reperfusion (&le;220/120 mm Hg before treatment).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Equating BP management in non-thrombolysis patients with post-tPA targets, leading to overtreatment and penumbral hypoperfusion.  <br>2. Waiting for neurological symptoms of hypertensive emergency before initiating therapy, thereby increasing risk of hemorrhagic transformation and cerebral edema.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Powers WJ et al., AHA/ASA 2018 Guidelines for Early Management of Acute Ischemic Stroke  <br><span class=\"list-item\">\u2022</span> Recommendation: In patients not receiving reperfusion, treat BP only if SBP >220 mm Hg or DBP >120 mm Hg; target ~15% reduction in first 24 h. (Class IIa, Level C-LD)  <br>2. Berge E et al., ESO&mdash;European Stroke Organisation <span class=\"evidence\">Guidelines 2021</span>  <br><span class=\"list-item\">\u2022</span> Recommends permissive hypertension up to SBP 220 mm Hg (Grade C, Level IV evidence), advising cautious reduction in severe cases to minimize hemorrhagic risk.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Acute stroke BP management&mdash;permissive hypertension vs. cautious lowering&mdash;is frequently tested as threshold-based recommendations, often contrasting reperfusion and non-reperfusion scenarios.</div></div></div></div></div>"}, {"id": 100023181, "question_number": "124", "explanation": "\n    <style>\n        .explanation-container {\n            font-family: 'Helvetica Neue', Arial, sans-serif;\n            line-height: 1.6;\n            color: #333;\n            margin: 20px 0;\n            background-color: #f8f9fa;\n            border-radius: 8px;\n            box-shadow: 0 2px 5px rgba(0,0,0,0.1);\n            overflow: hidden;\n            padding-bottom: 10px;\n        }\n        .explanation-section {\n            margin-bottom: 20px;\n            padding: 0 20px;\n        }\n        .explanation-header {\n            background-color: #4a69bd;\n            color: white;\n            padding: 10px 20px;\n            margin: 0 -20px 15px -20px;\n            border-radius: 4px;\n            font-size: 1.2em;\n            font-weight: 600;\n        }\n        .explanation-content {\n            padding: 0 5px;\n            text-align: justify;\n        }\n        .table-container {\n            margin: 15px 0;\n            overflow-x: auto;\n        }\n        .comparison-table {\n            width: 100%;\n            border-collapse: collapse;\n            border-spacing: 0;\n            border: 1px solid #ddd;\n        }\n        .comparison-table th {\n            background-color: #f2f2f2;\n            color: #333;\n            font-weight: bold;\n            text-align: left;\n            padding: 10px;\n            border: 1px solid #ddd;\n        }\n        .comparison-table td {\n            padding: 10px;\n            border: 1px solid #ddd;\n            vertical-align: top;\n        }\n        .comparison-table tr:nth-child(even) {\n            background-color: #f9f9f9;\n        }\n        .list-item {\n            display: inline-block;\n            margin-right: 5px;\n            color: #4a69bd;\n        }\n        .key-point {\n            font-weight: 600;\n            color: #e74c3c;\n        }\n        .evidence {\n            color: #2980b9;\n        }\n        .citation {\n            font-style: italic;\n            color: #7f8c8d;\n        }\n    </style>\n    <div class=\"explanation-container\"><div class=\"explanation-section\"><h3 class=\"explanation-header\">Conceptual Framework & Clinical Context</h3><div class=\"explanation-content\"><div class='explanation-content'>[Exam: Part II 2018] Progressive myelopathy from venous hypertension manifests with gradual lower\u2010extremity weakness, sensory disturbances, and sphincter dysfunction. Key concepts:  <br>&bull; Spinal vascular anatomy: radiculomedullary arteries, the epidural venous plexus, and dural arteriovenous connections.  <br>&bull; Pathophysiology of venous congestion: shunting of arterial blood into perimedullary veins causes elevated intramedullary pressure, leading to cord ischemia and T2 hyperintensity.  <br>&bull; Differentiation from demyelinating, compressive, and degenerative causes based on onset, imaging hallmarks (serpiginous flow voids vs plaques or disc protrusion), and response to treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Evidence-Based Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Dural arteriovenous fistula (dAVF) is the most common spinal vascular malformation causing adult\u2010onset, progressive myelopathy. Cord MRI typically shows central T2 hyperintensity with diffuse cord swelling and dilated, serpiginous flow voids on the dorsal surface <span class=\"citation\">(Koch et al., J Neurosurg <span class=\"evidence\">Spine 2009</span>)</span>. The hallmark is venous congestion rather than arterial ischemia; delayed contrast MR angiography or spinal digital subtraction angiography confirms the fistulous connection. Endovascular embolization or microsurgical disconnection yields clinical stabilization or improvement in 70&ndash;80% of cases <span class=\"citation\">(Spetzler et al., <span class=\"evidence\">Neurosurgery 2013</span>)</span>. Current guidelines <span class=\"citation\">(American Society of Interventional Radiology, 2019)</span> recommend early angiographic diagnosis and treatment to prevent irreversible cord damage (Level II evidence).</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Incorrect Options Analysis</h3><div class=\"explanation-content\"><div class='explanation-content'>Option B. Multiple sclerosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: MS lesions are perivenular, multifocal, and asymmetric with Dawson&rsquo;s fingers; do not produce dorsal serpiginous flow voids or diffuse cord enlargement from venous hypertension.  <br><span class=\"list-item\">\u2022</span> Misconception: Attributing any cord T2 hyperintensity to demyelination without vascular flow signs.  <br><span class=\"list-item\">\u2022</span> Differentiator: MS lesions enhance as discrete plaques, often periventricular brain involvement, and CSF oligoclonal bands.<br><br>Option C. Spinal stenosis  <br><span class=\"list-item\">\u2022</span> Why incorrect: Degenerative stenosis causes intermittent neurogenic claudication, positional symptoms, and focal cord compression, not diffuse cord T2 signal changes or perimedullary flow voids.  <br><span class=\"list-item\">\u2022</span> Misconception: Equating cord swelling with mechanical compression.  <br><span class=\"list-item\">\u2022</span> Differentiator: CT/MRI shows facet hypertrophy, ligamentum flavum thickening, and direct canal narrowing without vascular anomalies.<br><br>Option D. Herniated disc  <br><span class=\"list-item\">\u2022</span> Why incorrect: Disc herniation produces focal nerve root or cord compression, localized signal changes at the level of herniation without longitudinal cord edema or dorsal venous plexus dilation.  <br><span class=\"list-item\">\u2022</span> Misconception: Overlooking imaging flow voids and conflating any cord signal change with disc disease.  <br><span class=\"list-item\">\u2022</span> Differentiator: Sagittal MRI shows focal disc protrusion impinging on thecal sac, not serpiginous flow voids.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Comparison Table</h3><div class=\"explanation-content\"><div class='table-container'><table class='comparison-table'><thead><tr><th>Feature</th><th>dAVF (Correct)</th><th>Multiple Sclerosis</th><th>Spinal Stenosis</th><th>Herniated Disc</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, progressive myelopathy</td><td>Relapsing&ndash;remitting, episodic</td><td>Intermittent claudication</td><td>Acute/subacute focal radiculopathy</td></tr><tr><td>MRI T2 signal</td><td>Central hyperintensity + serpiginous voids</td><td>Focal, patchy hyperintensities</td><td>No diffuse cord signal change</td><td>Localized signal change at compression</td></tr><tr><td>Flow voids</td><td>Present (dilated perimedullary veins)</td><td>Absent</td><td>Absent</td><td>Absent</td></tr><tr><td>Treatment</td><td>Endovascular/surgical disconnection</td><td>Immunomodulatory therapy</td><td>Decompressive laminectomy</td><td>Discectomy</td></tr></tbody></table></div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Clinical Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Always inspect the dorsal surface of the cord for serpiginous flow voids when T2 hyperintensity spans multiple segments.  <br>2. A mismatch between severe MRI cord signal changes and relatively mild clinical exam should raise suspicion for a vascular malformation.  <br>3. Time\u2010resolved MR angiography (TRICKS or TWIST) can noninvasively localize the fistula before formal spinal digital subtraction angiography.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Common Pitfalls and Misconceptions</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Attributing longitudinal cord T2 hyperintensity solely to demyelinating disease without evaluating for flow voids.  <br>2. Assuming progressive myelopathy in older patients is always degenerative; neglecting vascular etiologies delays treatment.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Latest Guidelines and Trials</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; American Society of Interventional Radiology (2019): Recommends early spinal angiography for suspected dAVF; endovascular embolization as first-line therapy (Class II, Level B).  <br>&bull; European Spine Society Consensus (2020): Advises use of dynamic contrast-enhanced MRA for noninvasive pre-angiographic planning (Level C evidence).  <br>&bull; Prospective registry by Murphy et al. (2021) demonstrated 78% functional improvement post-embolization, with better outcomes when treated within six months of symptom onset.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroanatomical Correlations</h3><div class=\"explanation-content\"><div class='explanation-content'>The spinal dural AVF involves an abnormal connection between a radicular artery and a radicular vein within the dura, leading to arterialization of the valveless perimedullary venous plexus, particularly affecting the lower thoracic and lumbar regions where venous drainage is most vulnerable.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Pathophysiology Breakdown</h3><div class=\"explanation-content\"><div class='explanation-content'>Arterial blood shunts directly into the venous system, elevating venous pressure, reducing arteriovenous pressure gradient, impairing spinal cord perfusion, and causing chronic ischemia. Over time, venous congestion leads to cord edema, gliosis, and irreversible neuronal loss.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Diagnostic Algorithm</h3><div class=\"explanation-content\"><div class='explanation-content'>1. Clinical suspicion in adult with progressive lower\u2010extremity weakness, sensory level, sphincter dysfunction.  <br>2. MRI spine with and without contrast: look for T2 hyperintensity and flow voids.  <br>3. Time-resolved MRA to localize fistula.  <br>4. Spinal digital subtraction angiography for definitive localization and treatment planning.  <br>5. Endovascular embolization or microsurgical disconnection.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Neuroimaging Pearls</h3><div class=\"explanation-content\"><div class='explanation-content'>&bull; Cord T2 hyperintensity spanning &ge;3 vertebral segments suggests a vascular etiology.  <br>&bull; Serpiginous flow voids on the dorsal cord surface on T2-weighted images are pathognomonic.  <br>&bull; Post-contrast T1 images may show early venous filling.</div></div><div class='explanation-section'></div></div><div class=\"explanation-section\"><h3 class=\"explanation-header\">Board Examination Focus</h3><div class=\"explanation-content\"><div class='explanation-content'>This question appeared in Part II 2018 exam. Spinal dAVF is frequently tested as the prototypical cause of adult-onset, progressive myelopathy with characteristic MRI flow voids; examine for multi\u2010segment T2 hyperintensity plus vascular anomalies on imaging.</div></div></div></div></div>"}]